Final Programme Esmo2022 PDF

09.09.
2022
10:15 - 11:45 Type: Industry Satellite Symposium 7.2.E - Évry
Title: Mirati Therapeutics, Inc. - Advancing Tailored Therapies in Auditorium
NSCLC and KRASG12C-Driven Tumors
Chair(s): Fabrice Barlesi, FR

10:15 - 10:20 Welcome and Introduction
F. Barlesi, Gustave Roussy - Cancer Campus, Villejuif, FR

10:20 - 10:40 Unmet Needs and Recent Advances for NSCLC
J. Naidoo, Beaumont Hospital, Dublin, IE

10:40 - 11:00 Emerging Therapies to Overcome CPI Resistance in NSCLC

11:00 - 11:30 New Perspectives with Targeted Options for KRAS -Driven Tumors
S. Gadgeel, Henry Ford Cancer Institute-Henry Ford Health, Detroit, US

11:30 - 11:40 Q&A
F. Barlesi1, J. Naidoo2, S. Gadgeel3, 1Gustave Roussy - Cancer Campus, Villejuif, FR,

2Beaumont Hospital, Dublin, IE, 3Henry Ford Cancer Institute-Henry Ford Health,
Detroit, US

11:40 - 11:45 Summary & Close

Last update: 09-09-2022 11:42:18am Programme

10:15 - 11:45 Type: Industry Satellite Symposium 7.1.D -
Title: Deciphera Pharmaceuticals - From clinical trial to clinical Dijon
practice: novel strategies for treating patients with advanced GIST Auditorium
Chair(s): Peter Reichardt, DE

10:15 - 10:20 Welcome and introduction
P. Reichardt, Helios Klinikum Berlin-Buch, Berlin, DE

10:20 - 10:40 Clinical update in advanced GIST
A. Le Cesne, Gustave Roussy - Cancer Campus, Villejuif, FR

10:40 - 11:00 Scope of treatment through progressive lines in metastatic GIST: stable disease
and QoL
A. Italiano, Institute Bergonié, Bordeaux, FR

11:00 - 11:20 Management of treatment to progression: radiologic progression vs clinical
benefit

11:20 - 11:45 Discussion and conclusions



10:15 - 11:45 Type: Industry Satellite Symposium 7.3.G -
Title: Novartis - Guiding Through Oesophageal Cancer: Expert Grenoble
Insights on the Patient Journey From Diagnosis to Treatment Auditorium
Chair(s): Sylvie Lorenzen, DE

10:15 - 10:20 Welcome and Programme Overview
S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

10:20 - 10:30 Diagnosis and Staging of a Patient With Oesophageal Cancer
H. Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, NL

10:30 - 10:35 Panel Case Discussion
S. Lorenzen1, A. Adenis2, H. Van Laarhoven3, 1Klinikum Rechts der Isar - Technische

Universitaet Muenchen, Munich, DE, 2ICM - Institut du Cancer de Montpellier,

Montpellier, Cedex 5, FR, 3Academic Medical Center, University of Amsterdam,
Amsterdam, NL

10:35 - 10:50 Biomarker Testing in Oesophageal Cancer

10:50 - 11:00 Panel Discussion

Amsterdam, NL

11:00 - 11:15 First-line Treatment Option in Oesophageal Cancer
A. Adenis, ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR



Amsterdam, NL

11:30 - 11:45 Q&A Session


Amsterdam, NL


10:15 - 11:45 Type: Industry Satellite Symposium 7.3.H -
Title: PeerView Oncology - Targeting HER2-Low Expression in Breast Honfleur
Cancer: Evaluating the Evidence, Challenges, and Opportunities for Auditorium
Expanding Treatment Benefit to More Patients
Chair(s): Aleix Prat, ES

A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

10:20 - 10:40 Understanding the Foundational Concepts of HER2-Low Breast Cancer:
Challenges and Opportunities of an Evolving Definition
P. Tarantino, Dana Farber Cancer Institute, Boston, US

10:40 - 11:00 Extending Anti-HER2 Therapy Benefits to a Larger Population of Patients:
Emerging Evidence, Implementation in Clinical Practice, and Future Directions
S. Modi, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

11:00 - 11:20 Unveiling the Biology of HER2-Low Breast Cancer: Insights From Genomics,
Transcriptomics, and Opportunities With Evolving Testing Approaches

11:20 - 11:40 Exploring the Nuances of HER2-Targeted Treatment Selection for Patients With
HER2-Low Breast Cancer: Expert Insights Into Implications for Practice and
Team-Based Approaches to Individualizing Patient Care
A. Prat1, P. Tarantino2, S. Modi3, 1Hospital Clinic y Provincial de Barcelona, Barcelona,

ES, 2Dana Farber Cancer Institute, Boston, US, 3MSKCC - Memorial Sloan Kettering
Cancer Center, New York, US

11:40 - 11:45 Summary, Reflections, and Key Takeaways


10:15 - 11:45 Type: Industry Satellite Symposium 7.3.O - Orléans
Title: Bristol Myers Squibb - GI Cancer and Immuno-Oncology Auditorium
Today: Best Practice and Clinical Challenges
Chair(s): Myriam Chalabi, NL; Ian Chau, GB

M. Chalabi, Netherlands Cancer Institute, Amsterdam, NL

10:20 - 10:40 Current Status of I-O for Treating CRC

10:40 - 11:00 Treating Gastric Cancer Today: I-O-focused Update
K. Muro, Aichi Cancer Center Hospital, Nagoya, JP

11:00 - 11:20 Emerging Treatments for Esophageal Cancer: First-Line Metastatic Disease and
Earlier Stages
E. Samalin-Scalzi, ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR

11:20 - 11:40 Roundtable Case Discussion, Q&A, and Summary
I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton,

GB

11:40 - 11:45 Close

GB


10:15 - 11:45 Type: Industry Satellite Symposium 7.3.Q -
Title: ACE Oncology - Navigating Treatment Decisions in Advanced Quimper
NSCLC: Update on Molecular Testing and New Targeted Treatment Auditorium
Options
Chair(s): Julien Mazieres, FR

10:15 - 10:22 Welcome, introduction, and warm-up quiz
J. Mazieres, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR

10:22 - 10:38 Fine-tuning molecular profiling in advanced NSCLC
F. Länger, Hannover Medical School, Hannover, DE

10:38 - 10:54 Update on new targeted treatment options for patients with specific NSCLC
subtypes
N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto,

CA

10:54 - 11:10 Tackling resistance to targeted therapy
J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

11:10 - 11:25 Treatment decision-making: An interactive case discussion

11:25 - 11:33 Quiz questions revisited

11:33 - 11:43 Q&A
J. Mazieres1, N. Leighl2, J. Vansteenkiste3, F. Länger4, 1Centre Hospitalier Universitaire

de Toulouse - Hopital Larrey, Toulouse, FR, 2UHN - University Health Network - Princess

Margaret Cancer Center, Toronto, CA, 3University Hospitals Leuven - Campus
Gasthuisberg, Leuven, BE, 4Hannover Medical School, Hannover, DE

11:43 - 11:45 Pearls for practice


12:00 - 13:45 Type: Opening session 6.P - Paris Auditorium
Title: Opening session

12:00 - 12:18 Welcome and Presidential address
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

12:18 - 12:22 Scientific Co-Chair addresses
F. André1, C. Swanton2, 1Gustave Roussy - Cancer Campus, Villejuif, FR, 2Francis Crick

Institute, London, GB

12:22 - 12:35 Presentation of ESMO awards 2020 and 2021
A. Psyrri, Attikon University Hospital, Haidari, GR

12:35 - 12:52 ESMO Award 2022 - Is oncology complex or simple?
K. Fizazi, Institut Gustave Roussy, Villejuif, Cedex, FR

12:52 - 13:09 ESMO Award for Translational Research 2022 - Making sense of cancer evolution
for patient benefit
S. Turajlic, The Royal Marsden Hospital - Chelsea, London, GB

13:09 - 13:26 ESMO Women for Oncology Award 2022 - Gender gap and women’s rights: One
step forward, two steps back?!
F. Cardoso, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT

13:26 - 13:43 ESMO Lifetime Achievement Award 2022 - Renal cancer: A model for oncology
training
B. Escudier, Gustave Roussy - Cancer Campus, Villejuif, FR

13:43 - 13:45 Closure of the Opening Ceremony


14:00 - 15:30 Type: Special symposium 4.A - Antibes
Title: Are novel immunotherapeutics and targeted treatments Auditorium
going to transform the management of CRC?
Chair(s): Clara Montagut Viladot, ES; Andrea Sartore Bianchi, IT

14:00 - 14:05 Introduction and scientific background
C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

14:05 - 14:20 Targeting the uncommon molecular alterations
A. Sartore Bianchi, Università degli Studi di Milano, Milan, IT

14:20 - 14:35 Drugging KRAS in CRC: where do we stand?
R. Dienstmann, Grupo Oncoclinicas, Sao Paulo, BR

14:35 - 14:50 Immunomodulatory strategies for non-MSI-H metastatic colorectal cancer

G. Argiles Martinez, Memorial Sloan Kettering Cancer Center, New York, US

14:50 - 15:05 Neoadjuvant immunotherapy in CRC: where do we go from here?

15:05 - 15:10 Conclusions and perspectives
A. Sartore Bianchi, Università degli Studi di Milano, Milan, IT

15:10 - 15:30 Discussion

14:00 - 15:30 Type: Educational session 4.B - Brest
Title: Updates in the standard of care of metastatic breast Auditorium
cancer
Chair(s): Lisa Carey, US; Shaheenah Dawood, AE

14:00 - 14:25 ER+ HER2 - advanced breast cancer
S. Johnston, London, GB

14:25 - 14:50 HER2+ advanced breast cancer

14:50 - 15:15 Triple negative advanced breast cancer
L. Carey, Chapel Hill, NC, US



14:00 - 15:30 Type: Educational session 7.1.C - Cannes
Title: Using molecular data that impacts clinical Auditorium
practice
Chair(s): Elena Castro Marcos, ES; Gerhardt Attard, GB

14:00 - 14:25 Matching a molecular readout to a novel therapeutic
M. Lolkema, Erasmus MC - University Medical Center, Rotterdam, NL

14:25 - 14:50 Neuroendocrine disease: Molecular data and new models
H. Beltran, Boston, MA, US

14:50 - 15:15 Is germline testing needed and does it impact treatment decisions?
E. Castro Marcos, Hospital Universitario 12 de Octubre, Madrid, ES


14:00 - 15:30 Type: Proffered Paper session 7.2.F - Fécamp
Title: Proffered Paper session: Gynaecological Auditorium
cancers
Chair(s): Jonathan Ledermann, GB; Alexandra Leary, FR

14:00 - 14:10 LBA29 - Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-
ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in
patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
I. Ray-Coquard1, A. Leary2, S. Pignata3, C. Cropet1, A.J. Gonzalez Martin4, G. Bogner5, H.

Yoshida6, I. Vergote7, N. Colombo8, J. Maenpaa9, F. Selle10, B. Schmalfeldt11, G.
Scambia12, E.M. Guerra Alia13, C. Lefeuvre-Plesse14, A. Belau15, A. Lortholary16, M.
Gropp-Meier17, E. Pujade-Lauraine18, P. Harter19, 1Centre Léon Bérard, and GINECO,
Lyon, FR, 2Institut Gustave Roussy, and GINECO, Villejuif, FR, 3Istituto Nazionale Tumori
‘Fondazione G Pascale’, IRCCS, and MITO, Napoli, IT, 4Clínica Universidad de Navarra,
and GEICO, Madrid, ES, 5Paracelsus Medical University Salzburg, and AGO Au,
Salzburg, AT, 6Saitama Medical University International Medical Center, and GOTIC,
Saitama, JP, 7University Hospital Leuven, Leuven Cancer Institute, and BGOG, Leuven,
BE, 8University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS Milan, and

MANGO, Milan, IT, 9Tampere University and University Hospital, and NSGO, Tampere,
FI, 10Groupe Hospitalier Diaconesses Croix Saint-Simon, and GINECO, Paris, FR,
11Universitätsklinikum Hamburg-Eppendorf, and AGO, Hamburg, DE, 12U.O. di
Ginecologia Oncologica - Fondazione Policlinico Universitario Gemelli Università

Cattolica del Sacro Cuore di Roma, and MITO, Rome, IT, 13Hospital Universitario Ramón
y Cajal, and GEICO, Madrid, ES, 14Centre Eugène Marquis, and GINECO, Rennes, FR,
15Universitätsmedizin Greifswald, Frauenklinik and Frauenarztpraxis Dr. Belau, and
AGO, Greifswald, DE, 16Centre Catherine de Sienne, Hopital privé du Confluent, and
GINECO, Nantes, FR, 17Onkologie Ravensburg, and AGO, Ravensburg, DE, 18ARCAGY
Research, Paris, FR, 19Kliniken Essen-Mitte, and AGO, Essen, DE

14:10 - 14:20 517O - Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with
newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm)
who received maintenance olaparib in the SOLO1/GOG-3004 trial
P. Disilvestro1, S. Banerjee2, N. Colombo3, G. Scambia4, B.-G. Kim5, A. Oaknin6, M.

Friedlander7, A. Lisyanskaya8, A. Floquet9, A. Leary10, G. Sonke11, C. Gourley12, A.
Oza13, A.J. Gonzalez Martin14, C. Aghajanian15, W. Bradley16, C. Mathews1, J.
Mcnamara17, E. Lowe18, K. Moore19, 1Women & Infants Hospital, Providence, US, 2The
Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB,
3University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, IT, 4Università
Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, IT,

5Sungkyunkwan University School of Medicine, Seoul, KR, 6Vall d'Hebron University
Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, 7University of New
South Wales Clinical School, Prince of Wales Hospital, Randwick, AU, 8St Petersburg City
Oncological Dispensary, Saint-Petersburg, RU, 9Institut Bergonié, Comprehensive Cancer
Centre and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens,
Bordeaux, FR, 10Institut Gustave-Roussy and Groupe d’Investigateurs Nationaux pour
l’Etude des Cancers Ovariens, Villejuif, FR, 11The Netherlands Cancer Institute,
Amsterdam, NL, 12Cancer Research UK Scotland Centre, University of Edinburgh,
Edinburgh, GB, 13Princess Margaret Cancer Centre, Toronto, CA, 14Clinica Universidad
de Navarra, Madrid, ES, 15Memorial Sloan Kettering Cancer Center, New York, US,
16Froedtert and the Medical College of Wisconsin, Milwaukee, US, 17AstraZeneca,
Cambridge, GB, 18AstraZeneca, Gaithersburg, US, 19Stephenson Oklahoma Cancer

Center, Oklahoma City, US

14:20 - 14:30 518O - Overall survival results from ARIEL4: A phase III study assessing
rucaparib vs chemotherapy in patients with advanced, relapsed ovarian
carcinoma and a deleterious BRCA1/2 mutation
A. Oza1, A. Lisyanskaya2, A. Fedenko3, A. De Melo4, Y. Shparik5, I. Bondarenko6, N.

Colombo7, D. Lorusso8, D. Cibula9, R.L. Póka10, A. Oaknin11, T. Safra12, B. Maćkowiak-
Matejczyk13, L. Ma14, D. Thomas15, K. Lin15, K. Mclachlan15, S. Goble15, R. Kristeleit16,
1Princess Margaret Cancer Centre, University Health Network, Toronto, CA, 2Saint
Petersburg City Oncological Dispensary, Saint Petersburg, RU, 3N.N. Blokhin Russian
Cancer Research Center, Moscow, RU, 4Instituto Nacional de Câncer - Hospital do
Câncer II, Rio de Janeiro, BR, 5Lviv Regional Oncology Dispensary, Lviv, UA,
6Dnipropetrovsk Medical Academy, Dnipro, UA, 7University of Milan-Bicocca and
European Institute of Oncology (IEO) IRCCS, Milan, IT, 8Fondazione Policlinico
Universitario Gemelli IRCCS and Catholic University of Sacred Heart, Rome, IT, 9First
Faculty of Medicine, Charles University and General University Hospital, Prague, CZ,
10Clinical Center, University of Debrecen, Debrecen, HU, 11Vall d'Hebron Institute of
Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital
Campus, Barcelona, ES, 12Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel
Aviv University, Tel Aviv, IL, 13Bialostockie Centrum Onkologii im. Marii Sklodowskiej-
Curie,, Białostockie, PL, 14Rocky Mountain Cancer Centers, Lakewood, US, 15Clovis
Oncology, Inc., Boulder, US, 16Guy’s and St Thomas’ NHS Foundation Trust, London, GB

14:30 - 14:40 Invited Discussant LBA29, 517O and 518O
J. Ledermann, UCL Cancer Institute - UCL - London's Global University, London, GB

14:40 - 14:50 Q&A

14:50 - 15:00 LBA30 - Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with
platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with
platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
J.E. Kurtz1, E. Pujade-Lauraine2, A. Oaknin3, L. Belin4, I. Tsibulak5, D. Cibula6, I.

Vergote7, O. Rosengarten8, M. Rodrigues9, N. De Gregorio10, J. Martinez-Garcia11, P.
Pautier12, M.A. Mouret Reynier13, F. Selle14, V. D'Hondt15, F. Joly Lobbedez16, E. Bultot
Boissier17, A. Floquet18, P.-E. Heudel19, F. Heitz20, 1Service d'Oncologie médicale,
Strasbourg, FR, 2RESEARCH, Paris, FR, 3Medical Oncology, Barcelona, ES, 4Hôpital Pitié
Salpêtrière, Département de Santé Publique, Unité de Recherche Clinique PSL-CFX ,
CIC-1901, Paris, FR, 5Gynecology & Obstetrics Department, Innsbruck, AT, 6Department
of Obstetrics and Gynecology, Prague, CZ, 7Department of Gynecology, Leuven, BE,

8Oncology department, Jerusalem, IL, 9Medical Oncology, Paris, FR, 10Oncology
department, Heilbronn, DE, 11Medical Oncology department, El Palmar, ES, 12Medicine

Dept., Villejuif, Cedex, FR, 13Oncology department, Clermont-Ferrand, FR, 14Oncology
department, Paris, FR, 15Medical Oncology, Montpellier, Cedex, FR, 16Medical oncology
department, Caen, Cedex, FR, 17Oncology department, PARIS, FR, 18Medical Oncology
Dept, Bordeaux, FR, 19Oncology department, Lyon, FR, 20Charité - Universitätsmedizin
Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin,
and Berlin Institute of Health, BERLIN, DE

15:00 - 15:10 LBA31 - Randomized phase III trial of maintenance chemotherapy with tegafur-
uracil versus observation following concurrent chemoradiotherapy for locally
advanced cervical cancer, GOTIC-002 LUFT trial
K. Fujiwara1, S. Nishio2, K. Yamamoto3, H. Fujiwara4, H. Itagaki5, T. Nagai6, H. Takano7,

S. Yamaguchi8, A. Kudoh9, Y. Suzuki10, T. Nakamoto11, M. Kamio12, K. Kato13, K.
Nakamura14, K. Takehara15, H. Yahata16, H. Kobayashi17, M. Saito18, K. Ushijima2, K.
Hasegawa1, 1Saitama Medical University International Medical Center, Saitama, JP,
2Kurume University School of Medicine, Kurume, JP, 3Yokohama City University, School
of Medicine, Yokohama, JP, 4Jichi Medical University Hospital, Shimotsuke, JP, 5University
of Tsukuba, Tsukuba, JP, 6Saitama Medical Center, Saitama Medical University, Saitama,

JP, 7Jikei University Kashiwa Hospital, Kashiwa, JP, 8Hyogo Cancer Center, Akashi, JP,
9Tottori University Hospital, Yonago, JP, 10Saitama Cancer Center, Kita-Adachi-gun, JP,
11Ryukoku University, Otsu, JP, 12Kagoshima Medical Center, Kagoshima, JP, 13Kitasato
University, Sagamihara City, JP, 14Gunma Prefectural Cancer Center, Ota, JP, 15Shikoku
Cancer Center, Matsuyama, JP, 16Graduate School of Medical Sciences, Kyushu
University, Fukuoka, JP, 17Kagoshima University, Kagoshima, JP, 18Jikei University School
of Medicine, Tokyo, JP

15:10 - 15:20 Invited Discussant LBA30 and LBA31
M.R. Mirza, Rigshospitalet, Copenhagen, DK

15:20 - 15:30 Q&A


14:00 - 15:30 Type: Special symposium 7.1.D - Dijon Auditorium
Title: Exploiting synthetic lethality: The next
generation
Chair(s): Timothy Yap, US; Violeta Serra, ES

T. Yap, The University of Texas M. D. Anderson Cancer Center, Houston, US

14:05 - 14:20 Next generation synthetic lethal target discovery using high-throughput CRISPR
technology
M. Garnett, Wellcome Trust Sanger Institute, Cambridge, GB

14:20 - 14:35 Modern translational correlatives for synthetic lethality trials
V. Serra, Barcelona, ES

14:35 - 14:50 Clinical development of next generation DDR agents for molecularly-selected
tumours
T. Yap, The University of Texas M. D. Anderson Cancer Center, Houston, US

14:50 - 15:05 Exploiting synthetic lethality for non-DDR approaches in the clinic
S. Martin, London,

V. Serra, Barcelona, ES



14:00 - 15:30 Type: Educational session 7.3.G - Grenoble Auditorium
Title: Ultra-rare sarcoma: Navigating an endless
sea
Chair(s): Silvia Stacchiotti, IT; Herbert Ho Fung Loong, HK

14:00 - 14:25 The role of molecular biology in defining new entities
I.-M. Schaefer, Brigham and Women's Hospital, Boston, US

14:25 - 14:50 New drugs for ultrarare sarcoma
S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

14:50 - 15:15 Advocating for patients with ultra-rare cancer
H. Leonard, EHE Rare Cancer Charity, Kingston-Upon-Thames, GB


14:00 - 15:30 Type: Special symposium 7.3.H - Honfleur
Title: How the tumour microenvironment affects outcome Auditorium
and therapy response?
Chair(s): Adil Daud, US; Alessandra Curioni, CH

A. Curioni, USZ - University Hospital Zürich, Zurich, CH

14:10 - 14:25 Organ-specific tumour microenvironment
A. Daud, San Francisco, CA, US

14:25 - 14:40 The role of B cell/TLS
C. Sautes-Fridman, Centre de Recherche des Cordeliers, Paris, FR

14:40 - 14:55 Immune signatures in the tumour microenvironment
K. Litchfield, UCL Cancer Institute - UCL - London's Global University, London, GB

A. Daud, San Francisco, CA, US



14:00 - 15:30 Type: Educational session 7.3.O - Orléans Auditorium
Title: Advances in non-cutaneous melanoma
Chair(s): Sapna Patel, US; Teresa Troiani, IT

14:00 - 14:25 Uveal melanoma
S. Patel, MD Anderson Cancer Center, Houston, US

14:25 - 14:50 Mucosal melanoma
J. Hassel, NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE

14:50 - 15:15 Acral melanoma
M. Carlino, Westmead, AU


14:00 - 15:30 Type: Proffered Paper session 7.3.Q - Quimper Auditorium
Title: Proffered Paper session: CNS tumours
Chair(s): Giuseppe Minniti, IT; Dieta Brandsma, NL

14:00 - 14:10 277O - The ReSPECT-GBM™ phase I/IIa trial of rhenium-186
nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery
(CED) and planned phase IIb trial
A. Brenner1, W. Phillips2, A. Bao3, M.H. Hedrick4, J. Michalek2, N. Lafrance4, T. Patel5, J.

Weinberg6, J. Floyd7, 1Institute for Drug Development Cancer Therapy Research Center,
San Antonio, US, 2UTHSCSA - University of Texas Health Science Center at San Antonio,
San Antonio, US, 3The University Hospital Cleveland Medical Center, Cleveland, US,
4Plus Therapeutics, Austin, US, 5UT Southwestern Medical Center, Dallas, US, 6The
University of Texas MD Anderson Cancer Center, Houston, US, 7UT Health San Antonio,
San Antonio, US

14:10 - 14:20 278O - Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor)
plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab
and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295
J. Campian1, O. Butt2, J. Huang3, J. Luo3, Y. Tao3, R. Strowd4, D. Hissim4, S. Kizilbash1, C.

Abraham3, G. Ansstas2, T. Johanns2, A. Kim2, M. Ciorba2, M. Chheda2, 1Mayo Clinic,
Rochester, US, 2Washington University School of Medicine in St. Louis - Siteman Cancer
Center, St. Louis, US, 3Washington University School of Medicine in St. Louis, St. Louis,
US, 4Wake Forest University Comprehensive Cancer Center, Winston-Salem, US

14:20 - 14:30 Invited Discussant 277O and 278O
G. Minniti, University of Siena, Siena, IT

14:30 - 14:40 Q&A


14:40 - 14:50 279O - ctDNA detection in cerebrospinal fluid and concordance with the primary
tumor in a multicenter prospective study of patients with glioma
S. Cabezas-Camarero1, R. Pérez-Alfayate1, V. García-Barberán1, M. Gandía2, P. García-

Feijóo2, I. López-Cade1, I. Casado-Fariñas1, N. Cerón1, M. Sotelo Lezama3, P. Pérez

Segura1, 1Hospital Clinico Universitario San Carlos, Madrid, ES, 2Hospital Universitario
La Paz, Madrid, ES, 3Hospital Maria Auxiliadora, Lima, PE

14:50 - 15:00 280O - Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed
glioblastoma patients with unmethylated MGMT promoter status: Final phase II
study results
P. Wen1, J. De Groot2, J. Battiste3, S. Goldlust4, D. Damek5, B. Ellingson6, J. Garner7, J.

Friend7, J. Simpson7, A. Olivero8, T. Cloughesy9, 1Dana Farber Cancer Institute, Boston,
US, 2The University of Texas M. D. Anderson Cancer Center, Houston, US, 3Stephenson
Cancer Center/University of Oklahoma, Oklahoma City, US, 4John Theurer Cancer Center
- Hackensack University Medical Center, Hackensack, US, 5UCHealth Cancer Care -

Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, 6UCLA
Brain Tumor Imaging Laboratory, David Geffen School of Medicine, University of
California Los Angeles, Los Angeles, US, 7Kazia Therapeutics Limited, Sydney, AU,
8Olivero Consulting, Half Moon Bay, US, 9Ronald Reagan UCLA Medical Center
University of California, Los Angeles, US

F. De Vos, UMC - University Medical Center Utrecht, Utrecht, NL

15:10 - 15:20 Q&A


14:00 - 15:30 Type: Special symposium 7.3.T - Toulouse
Title: How diagnostic tools impact therapy of Auditorium
haematological malignancies
Chair(s): Lars Bullinger, DE

14:00 - 14:15 Acute myeloid leukaemia
L. Bullinger, Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE

14:15 - 14:30 PET: New applications
M. Mayerhoefer, New York, NY, US

14:30 - 14:45 Molecular classification of aggressive lymphoma
F. Jardin, Rouen, FR

14:45 - 15:00 Will circulating tumour DNA have a role in treatment decisions?
F. Scherer, University Medical Center Freiburg, Freiburg im Breisgau, DE

L. Bullinger, Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE



14:00 - 15:30 Type: Patient Advocacy session 7.3.M - Marseille
Title: The impact of COVID-19 on patients with cancer: Auditorium
Lessons learnt and pathway for the future
Chair(s): Christopher Curtis, GB; Tanja Spanic, SI

14:00 - 14:15 The impact of COVID-19 pandemic on cancer patients and early diagnosis - Time
to act!
M. Lawler, Queen's University Belfast, Belfast, GB

14:15 - 14:30 The impact of COVID-19 on patient-physician communication and the role of
telemedicine
I. Ratosa, Institute of Oncology Ljubljana, Ljubljana, SI

14:30 - 14:45 The impact of COVID-19 on surgery
F. Rimareix, Institut Gustave Roussy, Villejuif, Cedex, FR

14:45 - 15:00 The impact of COVID-19 on advocacy networks
L. Makaroff, Fight Bladder Cancer, Chinnor, GB

15:00 - 15:15 COVID-19 and the pathway for the future to support patients with cancer
C. Curtis, Chris Curtis Consultant Ltd, Blackpool, GB


15:25 - 15:30 Conclusion


14:00 - 15:30 Type: Special session 7.3.U - Urval
Title: 5-year impact of new registered indications on the Auditorium
ESMO-MCBS
Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL

14:00 - 14:05 Introduction
E.G.E. De Vries, Groningen, NL

14:05 - 14:30 Five years of FDA approvals (2017-2022): A report from the ESMO-MCBS
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

14:30 - 14:55 Long term follow-up on single arm registration studies: what have we learned?
B. Gyawali, KAHS - Karnali Academy of Health Sciences, Chandannath, NP

14:55 - 15:20 ICI landscape in solid tumours: what are the scores, are there differences and
why?
L. Castelo-Branco, ESMO - European Society for Medical Oncology, Lugano, CH

15:20 - 15:30 Conclusions and Q&A


14:00 - 15:30 Type: Young Oncologist session 7.3.L - Lyon
Title: ON-SITE ONLY: Young Oncologist Mentorship sessions

14:00 - 14:00 Table 1: Clinical oncology
M. Lambertini1, A. Prat2, 1IRCCS AOU San Martino - IST-Istituto Nazionale per la

Ricerca sul Cancro, Genova, IT, 2Hospital Clinic y Provincial de Barcelona, Barcelona, ES

14:00 - 14:00 Table 2: Clinical oncology
S. Braga1, E. Connolly2, 1José de Mello Saúde, Lisbon, PT, 2Chris O'Brien Lifehouse,

Camperdown, AU

14:00 - 14:00 Table 3: Translational research
S. Turajlic1, A. Matikas2, 1The Royal Marsden Hospital - Chelsea, London, GB,

2Karolinska Institutet, Huddinge, SE

14:00 - 14:00 Table 4: Translational research
C.B. Westphalen1, M. Kfoury2, 1LMU Klinikum der Universität München, Munich, DE,
2Institut Gustave Roussy, Villejuif, Cedex, FR

14:00 - 14:00 Table 5: Becoming an early phase trial oncologist
N. Cook, R. Pihlak, The Christie NHS Foundation Trust, Manchester, GB

14:00 - 14:00 Table 6: The role of clinician scientist
M.E. Elez Fernandez1, R. Sanchez Bayona2, 1Vall d'Hebron University Hospital,

Barcelona, ES, 2Hospital Universitario 12 de Octubre, Madrid, ES

14:00 - 14:00 Table 7: The role of clinician-scientist
C. Serrano1, K.H.J. Lim2, 1Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center,

Barcelona, ES, 2The Francis Crick Institute, London, GB

14:00 - 14:00 Table 8: Policy making and public health
A. Ilbawi1, E. Mariamidze2, 1WHO - World Health Organization, Geneva, CH, 2Todua

Clinic, Tbilisi, GE


15:45 - 17:30 Type: Special session 7.3.U -
Title: 7th ESMO Designated Centres of Integrated Oncology and Urval
Palliative Care and Awards Session: Where are we going and what’s Auditorium
next
Chair(s): Stein Kaasa, NO; Gudrun Kreye, AT

S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

15:50 - 16:05 Designated Centres Survey: Education, research, programme development –
Final results
G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT

16:05 - 16:20 My Path: improving the content, quality and cost-effectiveness of cancer
treatment

16:20 - 16:35 Financial toxicity and out of pocket cost for supportive care medications among
cancer patients
R. Giusti, AOU Sant'Andrea, Rome, IT


17:00 - 17:10 Conclusion and next steps

17:10 - 17:30 Designated Centre and Palliative Care Fellowship Awards

16:00 - 17:30 Type: Proffered Paper session 4.B - Brest Auditorium
Title: Proffered Paper session: Breast cancer, metastatic
Chair(s): Peter Schmid, GB; Sibylle Loibl, DE

16:00 - 16:10 LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a
nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-
advanced breast cancer (ABC)
M. Goetz1, M. Toi2, J. Huober3, J. Sohn4, O. Tredan5, I.H. Park6, M. Campone7, S.C.

Chen8, L. Manso Sanchez9, S. Paluch-Shimon10, G. Van Hal11, A. Shahir11, H. Iwata12, S.
Johnston13, 1Mayo Clinic, Rochester, US, 2Kyoto University Hospital, Kyoto, JP,
3Kantonsspital St. Gallen, St. Gallen, CH, 4Yonsei University, Seoul, KR, 5Centre Léon
Bérard, Lyon, FR, 6Korea University College of Medicine, Seoul, KR, 7ICO Institut de

Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, 8Chang Gung Medical
Foundation- Taipei Chang Gung Memorial Hospital, Taipei City, TW, 9Hospital
Universitario 12 de Octubre, Madrid, ES, 10Hadassah University Hospital - Ein Kerem,
Jerusalem, IL, 11Eli Lilly and Company, Indianapolis, US, 12Aichi Cancer Center Hospital,

Nagoya, JP, 13Royal Marsden Hospital, London, GB

16:10 - 16:20 LBA16 - Dalpiciclib plus letrozole or anastrozole as first-line treatment for
HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial
B. Xu1, Q.Y. Zhang2, P. Zhang1, Z. Tong3, T. Sun4, W. Li5, Q. Ouyang6, X. Hu7, Y. Cheng8,
M. Yan9, Y. Teng10, Y. Pan11, X. Yan12, Y. Wang13, W. Xie14, X. Zeng15, S. Jiang16, N.
Bayaxi16, X. Zhu16, 1National Cancer Center/National Clinical Research Center for
Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
Medical College, Beijing, CN, 2Harbin Medical University Cancer Hospital, Harbin, CN,
3Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, 4Cancer Hospital
of China Medical University/Liaoning Cancer Hospital, Shenyang, CN, 5The First

Hospital of Jilin University, Changchun, CN, 6Hunan Cancer Hospital, Changsha, CN,
7Fudan University Shanghai Cancer Center, Shanghai, CN, 8Jilin Cancer Hospital,
Changchun, CN, 9Henan Breast Cancer Center/the affiliated Cancer Hospital of

Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, 10The First Affiliated
Hospital of China Medical University, Shenyang, CN, 11Anhui Provincial Hospital, Hefei,
CN, 12West China Hospital, Sichuan University, Chengdu, CN, 13Sun Yat-Sen Memorial
Hospital, Sun Yat-Sen University, Guangzhou, CN, 14Guangxi Medical University Cancer
Hospital, Nanning, CN, 15Chongqing University Cancer Hospital/Chongqing Cancer
Hospital, Chongqing, CN, 16Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai, CN

16:20 - 16:30 LBA76 - Overall survival (OS) results from the phase III TROPiCS-02 study of
sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in
patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
H. Rugo1, A. Bardia2, F. Marmé3, J. Cortés4, P. Schmid5, D. Loirat6, O. Tredan7, E.

Ciruelos8, F. Dalenc9, P. Gomez Pardo10, K. Jhaveri11, R. Delaney12, T. Valdez12, H.
Wang12, W. Verret12, S. Tolaney13, 1University of California-San Francisco, Helen Diller
Family Comprehensive Cancer Center, San Francisco, US, 2Massachusetts General
Hospital Cancer Center, Harvard Medical School, Boston, US, 3Medical Faculty
Mannheim, Heidelberg University, Department of Obstetrics and Gynaecology,
Mannheim, DE, 4International Breast Cancer Center (IBCC), Pangaea Oncology,
Quirosalud Group, Madrid & Barcelona, Spain, Universidad Europea de Madrid, Faculty
of Biomedical and Health Sciences, Department of Medicine, Madrid, ES, 5Barts Cancer
Institute, Queen Mary University of London, London, GB, 6Institut Curie, Paris, FR,
7Centre Léon Bérard, Lyon, FR, 8Hospital Universitario 12 de Octubre, Madrid, ES,
9Institut Claudius Régaud, Toulouse, FR, 10Hospital Universitari Vall D'Hebron,
Barcelona, ES, 11Memorial Sloan-Kettering Cancer Center (MSKCC), New York, US,
12Gilead Sciences, Inc., Foster City, US, 13Dana-Farber Cancer Institute, Harvard
Medical School, Boston, US

16:30 - 16:40 Invited Discussant LBA15, LBA16 and LBA76
M. Bellet Ezquerra, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona,

ES

16:40 - 16:50 Q&A

16:50 - 17:00 210O - Mutational signature analysis reveals patterns of genomic instability

linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition
(CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-)
metastatic breast cancer (MBC)
A. Marra1, A. Gazzo1, A. Gupta1, P. Selenica1, E. Da Silva1, F. Pareja1, X. Pei1, Y. Zhu1, P.

Razavi1, A. Safonov1, E. Ferraro1, R. Harris2, N. Riaz1, J. Reis-Filho1, S. Chandarlapaty1,

1Memorial Sloan Kettering Cancer Center, New York, US, 2University of Minnesota,
Minneapolis, US

17:00 - 17:10 LBA17 - Primary endpoint results of SYNERGY, a randomized phase II trial, first-
line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with
or without the anti-CD73 antibody oleclumab in patients with advanced or
metastatic triple-negative breast cancer (TNBC)
L. Buisseret1, D. Loirat2, P. Aftimos3, K. Punie4, C. Maurer5, V. Debien1, A. Goncalves6, F.

Ghiringhelli7, D. Taylor8, F. Clatot9, T. Van Den Mooter10, J.-M. Ferrero11, H. Bonnefoi12,
J.-L. Canon13, F. Duhoux14, F. Bazan15, P. Kristanto16, E. De Azambuja17, M. Ignatiadis16,
M. Piccart16, 1Institute Jules Bordet, Brussels, BE, 2Institut Curie, Paris, FR, 3Institute
Jules Bordet, Bruxelles, BE, 4Leuven Cancer Institute, University Hospitals Leuven,
Leuven, BE, 5Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf;
University of Cologne, Cologne, DE, 6Institut Paoli-Calmettes, Marseille, FR, 7Centre
Georges-François Leclerc (Dijon), Dijon, FR, 8CHU-UCL-Namur - Site Sainte-Elisabeth,
Namur, BE, 9Centre Henri Becquerel, Rouen, FR, 10GZA Ziekenhuizen Campus Sint-
Augustinus, Antwerp, BE, 11Centre Antoine Lacassagne, Nice, FR, 12Institut Bergonié,
Bordeaux, FR, 13Grand Hopital de Charleroi - Site Notre Dame, Charleroi, BE,
14Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE, 15CHRU
Besancon - Hopital Jean Minjoz, Besancon, FR, 16Institut Jules Bordet, Université Libre
de Bruxelles (ULB), Brussels, BE, 17Institute Jules Bordet, Université Libre de Bruxelles
(ULB), Bruxelles, BE

17:10 - 17:20 Invited Discussant 210O and LBA17
P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine

and Dentistry, London, GB

17:20 - 17:30 Q&A


Title: Adjuvant and perioperative therapy for non-colorectal Auditorium
GI cancers: Latest status
Chair(s): Elizabeth Smyth, GB; Lam Chan, HK

16:00 - 16:25 Gastroesophageal cancer
E. Smyth, Addenbrooke's Hospital, Cambridge, GB

16:25 - 16:50 Hepatobiliary cancer
J. Knox, Toronto, ON, CA

16:50 - 17:15 Pancreatic cancer
T. Conroy, Vandoeuvre-lès-Nancy, FR


16:00 - 17:30 Type: Educational session 7.2.E - Évry
Title: Perioperative strategies in high-risk and oligometastatic Auditorium
renal cell (RCC) and urothelial cancers (UC)
Chair(s): Elizabeth Plimack, US; Enrique Grande, ES

16:00 - 16:25 Management of high-risk UC: Latest data
J. Bellmunt, Boston, US

16:25 - 16:50 Management of high-risk RCC: Latest data
J. Larkin, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

16:50 - 17:15 Management of oligometastatic renal and urothelial cancers: Incorporating best
practices
E. Plimack, Fox Chase Cancer Center - Main Campus, Philadelphia, US


Title: Proffered Paper session: Investigational Auditorium
immunotherapy
Chair(s): John Haanen, NL; Evan Lipson, US

16:00 - 16:10 LBA37 - A randomized, multicentric phase II study of preoperative nivolumab
plus relatlimab or nivolumab in patients with resectable non-small cell lung
cancer (NEOpredict-Lung)
M. Schuler1, K. Cuppens2, T. Ploenes3, M. Vanbockrijck2, M. Wiesweg1, K. Darwiche3, A.

Schramm1, B. Maes2, B. Hegedus4, H.-U. Schildhaus1, H. Hautzel1, D. Theegarten1, P.
Baas5, K. Hartemink5, B. Du Pont2, C. Aigner3, 1University Hospital Essen, Essen, DE,
2Jessa Hospital, Hasselt, BE, 3University Medicine Essen – Ruhrlandklinik, Essen, DE,
4University Medicine Essen - Ruhrlandklinik, Essen, DE, 5Netherlands Cancer
Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:10 - 16:20 Invited Discussant LBA37
E. Lipson, Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center,

Baltimore, US

16:20 - 16:30 Q&A

16:30 - 16:40 LBA38 - BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6
CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in
patients with CLDN6-positive advanced solid tumours
A. Mackensen1, J. Haanen2, C. Koenecke3, W. Alsdorf4, E. Wagner-Drouet5, D.

Heudobler6, P. Borchmann7, C. Bokemeyer4, S. Klobuch2, E. Smit2, F. Müller1, A.
Desuki5, F. Lüke6, E. Wiegert8, C. Flemmig9, C. Schulz-Eying9, B. Rengstl9, L.
Preussner9, Ö. Türeci9, U. Sahin9, 1University Hospital Erlangen, Erlangen, DE,
2Netherlands Cancer Institute, Amsterdam, NL, 3Hannover Medical School, Hannover,
DE, 4University Medical Center Hamburg-Eppendorf, Hamburg, DE, 5University Medical

Center Mainz, Mainz, DE, 6University Hospital Regensburg, Regensburg, DE, 7University
Hospital of Cologne, Cologne, DE, 8Bexon Clinical Consulting, Montclair, US, 9BioNTech
SE, Mainz, DE

16:40 - 16:50 728O - Results from phase I dose escalation of IMC-F106C, the first PRAME
× CD3 ImmTAC bispecific protein in solid tumors
O. Hamid1, T. Sato2, D. Davar3, M. Callahan4, F. Thistlethwaite5, R. Aljumaily6, M.

Johnson7, H.-T. Arkenau 8, E. Ileana Dumbrava9, B. Izar10, H.A. Chen11, S. Marshall12, Y.
Yuan12, M. Deo13, S. Stanhope14, L. Collins15, R. Mundy13, S. Abdullah13, J. Lopez16, 1A
Cedars Sinai Affiliate, Los Angeles, US, 2Thomas Jefferson Univ Hospital, Philadelphia,
US, 3University of Pittsburgh Cancer Institute, Pittsburgh, US, 4Memorial Sloan
Kettering Cancer Center, New York, US, 5The Christie NHS Foundation Trust,
Manchester, GB, 6University of Oklahoma, Oklahoma City, US, 7Sarah Cannon Research
Institute-Cancer Centre, Nashville, US, 8Sarah Cannon Research Institute SCRI UK,
London, GB, 9The University of Texas M. D. Anderson Cancer Center, Houston, US,
10Columbia University Medical Center, New York, US, 11University of California Davis
Comprehenvise Cancer Center, Sacramento, US, 12Immunocore LLC, Rockville, US,

13Immunocore LLC, Conshohocken, US, 14Immunocore Ltd, Abingdon-on-Thames, GB,
15Immunocore Limited, Abingdon-on-Thames, GB, 16The Royal Marsden Hospital NHS
Foundation Trust, Sutton, GB

16:50 - 17:00 Invited Discussant LBA38 TBC and 728O
D. Braun, Yale University School of Medicine - Yale Cancer Center, New Haven, US

17:00 - 17:15 Q&A

16:00 - 17:30 Type: Educational session 7.1.D - Dijon
Title: Emerging treatment strategies for non-metastatic Auditorium
NSCLC
Chair(s): Mariano Provencio Pulla, ES; Kersti Oselin, EE

16:00 - 16:25 Perioperative targeted therapy for early-stage NSCLC
H. Wakelee, Stanford University, Stanford, US

16:25 - 16:50 Perioperative immunotherapy for early-stage NSCLC
M. Provencio Pulla, University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES

16:50 - 17:15 Pathologic assessment post neo-adjuvant treatment
S. Dacic, Pennsylvania, PA, US


16:00 - 17:30 Type: Educational session 7.3.G - Grenoble
Title: New discoveries in cancer using single cell and Auditorium
spatial technologies
Chair(s): Göran Jönsson, SE; Sherene Loi, AU

16:00 - 16:25 Single cell genomics to understand cancer evolution
C. Curtis, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford,

US

16:25 - 16:50 Single cell pathology using spatial proteomics
R. Casanova, UZH - Universität Zürich, Zurich, CH

16:50 - 17:15 Spatial gene expression and mapping tumor morphology
G. Jönsson, Lund University, Lund, SE



16:00 - 17:30 Type: Special session 7.3.O -
Title: ESMO in collaboration with MASCC- Emerging toxicities to Orléans
targeted therapies: Management strategies and future directions Auditorium
Chair(s): Maryam Lustberg, US; Ines Vaz Luis, FR

I. Vaz Luis, Institut Gustave Roussy, Villejuif, Cedex, FR

16:05 - 16:20 Safety management of Antibody-Drug-Conjugates     
M. Lustberg, Yale University School of Medicine, New Heaven, US

16:20 - 16:35 Immune-check point inhibitors: From acute to long term toxicities  
O. Lambotte, CHU de Bicêtre, Le Kremlin Bicetre, FR

16:35 - 16:50 New oral targeted therapies: Main toxicities, improve management to increase
adherence

16:50 - 17:05 How to step up systems to better learn and manage new toxicities?   
A. Charalambous, Cyprus University of Technology - Nursing Science, Limassol, CY

17:05 - 17:25 Panel discussion on safety management of new anticancer drugs with case
discussion and Q&A

17:25 - 17:30 Conclusions


16:00 - 17:30 Type: Special symposium 7.3.T -
Title: Challenging the use of small cell lung cancer as a Toulouse
paradigm for extrapulmonary neuroendocrine carcinoma Auditorium
Chair(s): Emily Bergsland, US; Halfdan Sorbye, NO

H. Sorbye, Haukeland Universitetssykehus, Bergen, NO

16:05 - 16:20 Clinical and molecular features distinguish small cell lung carcinoma from
extrapulmonary NEC
E. Bergsland, UCSF - University of California San Francisco - Parnassus Campus, San

Francisco, US

16:20 - 16:35 Treatment of gastroenteropancreatic NEC
H. Sorbye, Haukeland Universitetssykehus, Bergen, NO

16:35 - 16:50 Neuroendocrine prostate cancer (NEPC): A model for phenotypic plasticity
F. Demichelis, University of Trento, Trento, IT

16:50 - 17:05 Gynaecological NEC
M. Frumovitz, Houston, TX, US

E. Bergsland, UCSF - University of California San Francisco - Parnassus Campus, San

Francisco, US



Title: Patient Advocates and their expertise: How to Auditorium
get involved
Chair(s): Natacha Bolanos Fernandez, ES; Ananda Plate, DE

16:00 - 16:15 The importance of patients’ involvement in the decision-making process
B. Ryll, Melanoma Patient Network Europe MPNE, Uppsala, SE

16:15 - 16:30 How to interact with policymakers
A. Cardone, Pancreatic Cancer Europe (PCE), Brussels, BE

16:30 - 16:45 How to grow your network
A. Plate, Patvocates, Munich, DE

16:45 - 17:00 How to get funding
J. Fratczak Kazana, Alivia - Fundacja Onkologiczna Osób Mlodych (Alivia - Young People
Cancer Foundation), Warsaw, PL




16:15 - 17:15 Type: Multidisciplinary session 7.3.H - Honfleur Auditorium
Title: Plenty of choices in rectal cancer
Chair(s): Gerard Beets, NL

16:15 - 16:20 Presentation of case/condition
G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE

16:20 - 16:35 Are we in the era of total neoadjuvant treatment?
G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE

16:35 - 16:50 Role, timing and duration of neo-adjuvant (chemo)radiotherapy
K. Haustermans, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg,

Leuven, BE

16:50 - 17:05 The surgeon’s perspective: TME, local excision or watch and wait?
G. Beets, The Netherlands Cancer Institute, Amsterdam, NL


16:15 - 17:15 Type: Special session 7.3.Q - Quimper Auditorium
Title: Special session: Ovarian cancer Consensus
Chair(s): Anna Fagotti, IT; Jonathan Ledermann, GB

16:15 - 16:20 Clinical case 1
M. Kfoury, Institut Gustave Roussy, Villejuif, Cedex, FR

16:20 - 16:35 Case 1 Discussant
A. Fagotti, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT

16:35 - 16:45 Case 1 Discussion / Q&A

16:45 - 16:50 Clinical case 2
M. Kfoury, Institut Gustave Roussy, Villejuif, Cedex, FR

16:50 - 17:05 Case 2 Discussant
J. Ledermann, UCL Cancer Institute - UCL - London's Global University, London, GB

17:05 - 17:15 Case 2 Discussion / Q&A


17:30 - 18:30 Type: Young Oncologist session Networking Hub
Title: ON-SITE ONLY: Young Oncologists Vesalius Talk
Chair(s): Maria Kfoury, FR; Teresa Amaral, DE; Elene Mariamidze, GE

17:30 - 17:40 Introduction by the Chairs

17:40 - 18:30 Panel discussion
T.S.K. Mok1, P. Vuylsteke2, M. Garassino3, A. Leary4, 1Prince of Wales Hospital - Li Ka

Shing Specialist Clinics, Sha Tin, HK, 2University of Botswana, Gaborone, BW,
3University of Chicago Department of Medicine - Section of Hematology/Oncology,
Chicago, US, 4Institut Gustave Roussy, Villejuif, Cedex, FR

18:00 - 19:30 Type: Industry Satellite Symposium 7.2.E - Évry
Title: Gilead and Kite Oncology - CAR T-cell therapy: The next Auditorium
frontier in immuno-oncology
Chair(s): Mohamad Mohty, FR; Jean-Philippe Spano, FR

18:00 - 18:08 Building the foundations of CAR T-cell therapy
M. Mohty1, J.-P. Spano2, 1Hopital Saint-Antoine, Paris, FR, 2Hopital Pitié Salpetrière AP-

HP, Paris, FR

18:08 - 18:28 CAR T-cell therapy: Pioneering the way in haematological malignancies
A. Sureda, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals),

Barcelona, ES

18:28 - 18:43 Expanding the reach of CAR T
M. Mohty, Hopital Saint-Antoine, Paris, FR

18:43 - 19:07 New avenues for CAR technology
F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

19:07 - 19:15 Exploring CARs in solid tumours and closing remarks
J.-P. Spano, Hopital Pitié Salpetrière AP-HP, Paris, FR

19:15 - 19:30 Q&A
J.-P. Spano1, M. Mohty2, A. Sureda3, F. Thistlethwaite4, 1Hopital Pitié Salpetrière AP-HP,

Paris, FR, 2Hopital Saint-Antoine, Paris, FR, 3ICO - Institut Català d'Oncologia

l'Hospitalet (Hospital Duran i Reynals), Barcelona, ES, 4The Christie NHS Foundation
Trust, Manchester, GB


18:00 - 19:30 Type: Industry Satellite Symposium 7.1.D - Dijon
Title: Servier - Interpreting real-world data to better manage Auditorium
patients with metastatic colorectal cancer
Chair(s): Julien Taieb, FR


J. Taieb, Hopital European George Pompidou, Paris, FR

18:10 - 18:25 Is there a need for real-world data?
C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

18:25 - 18:40 Real-world data in mCRC
M. Koopman, UMC - University Medical Center Utrecht, Utrecht, NL

18:40 - 18:55 Patient insights and perspectives on real-world data
F. Marti, The Christie NHS Foundation Trust, Manchester, GB

18:55 - 19:10 Optimization and management of treatment in mCRC
D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE

19:10 - 19:30 Conclusion and Q&A


18:00 - 19:30 Type: Industry Satellite Symposium 7.3.G -
Title: PeerView Oncology - SERDs at the Inflection Point in Grenoble
Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Auditorium
Establishing New Standards of Care, and Improving Patient
Outcomes With Novel ER-Targeting Therapies
Chair(s): Javier Cortés, ES

J. Cortés, Hospital Ruber Internacional, Madrid, ES

18:05 - 18:25 Modern Approaches in the Treatment of ER+/HER2- Breast Cancer:
Understanding the Biology and Foundational Concepts
F.C. Bidard, Institut Curie, Paris, FR

18:25 - 18:45 ER+/HER2- Breast Cancer Pre-Treated With EndocrineTherapy as an Inflection
Point: Unmet Needs and Novel Rational Treatment Strategies

18:45 - 19:05 Emerging Options in the Treatment of ER+/HER2- Breast Cancer: The Expanding
Evidence Base on Oral SERDs and Other ER-Targeting Agents
A. Bardia, Massachusetts General Hospital Cancer Center, Harvard Medical School,

Boston, US

19:05 - 19:30 Accelerating Progress in the Treatment of Previously Treated ER+HER2- Breast
Cancer With Novel Therapies: Translating Research Advances to Improvements
in Practice
J. Cortés1, A. Bardia2, F.C. Bidard3, 1Hospital Ruber Internacional, Madrid, ES,

2Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US,
3Institut Curie, Paris, FR

18:00 - 19:30 Type: Industry Satellite Symposium 7.3.H - Honfleur
Title: F. Hoffman-La Roche LTD - Navigating the possibilities Auditorium
of personalised healthcare in oncology
Chair(s): Allan Hackshaw, GB

18:00 - 18:10 A guide to the expanding possibilities in personalised healthcare
A. Hackshaw, Cancer Research UK & University College London Cancer Trials Centre,

London, GB

18:10 - 18:25 Cancer of unknown primary: Making the unknown known
A. Krämer, DKFZ - German Cancer Research Center, Heidelberg, DE

18:25 - 18:35 Panel discussion: Progress in personalised healthcare
A. Hackshaw1, A. Krämer2, J.-Y. Blay 3, C. Alessi4, W. Minnaard5, 1Cancer Research UK &

University College London Cancer Trials Centre, London, GB, 2DKFZ - German Cancer
Research Center, Heidelberg, DE, 3Centre Léon Bérard, Lyon, FR, 4HIMSS - Healthcare
Information and Management Systems Society, London, GB, 5Missie Tumor Onbekend,
NL

18:35 - 18:50 Staying at the frontier of comprehensive genomic profiling and liquid biopsy
J.-Y. Blay , Centre Léon Bérard, Lyon, FR

18:50 - 19:05 The value of real-world data for augmenting personalised healthcare at several
levels

London, GB

19:05 - 19:25 Panel discussion: Putting the possibilities into practice
A. Hackshaw1, J.-Y. Blay 2, A. Krämer3, C. Alessi4, W. Minnaard5, 1Cancer Research UK &

University College London Cancer Trials Centre, London, GB, 2Centre Léon Bérard,
Lyon, FR, 3DKFZ - German Cancer Research Center, Heidelberg, DE, 4HIMSS -
Healthcare Information and Management Systems Society, London, GB, 5Missie Tumor
Onbekend, NL


London, GB


18:00 - 19:30 Type: Industry Satellite Symposium 7.3.O -
Title: Janssen-Cilag International NV - Catching it early, getting it Orléans
right: optimal disease and patient management from biomarkers to Auditorium
treatment selection for bladder cancer
Chair(s): Maria De Santis, DE; Thomas Powles, GB

M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE

18:05 - 18:25 Patient case presentation and discussion: From the pathologist's and urologists'
perspectives
M. De Santis1, T. Powles2, E. Comperat3, S.F. Shariat3, 1Charité - Universitätsmedizin

Berlin, Berlin, DE, 2St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB,
3MedUni Wien - Medical University of Vienna, Vienna, AT

18:25 - 18:45 Patient case analysis: how do we select the best treatment in challenging cases?


18:45 - 19:10 Treatment selection and managing patients safety: a discussion on the treatment
landscape


19:10 - 19:25 Audience Q&A


19:25 - 19:30 Summary and close
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB


18:00 - 19:30 Type: Industry Satellite Symposium 7.3.Q - Quimper
Title: Merck - From complex to simple: The journey to strategic Auditorium
sequencing in the management of mCRC
Chair(s): Marc Van Den Eynde, BE

M. Van Den Eynde, Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE

18:05 - 18:25 One step closer: Treatment sequencing in RAS wt mCRC

18:25 - 18:45 Going the extra mile: Building in an additional line of treatment with ≥3L
rechallenge
C. Parseghian, MD Anderson Cancer Center, Houston, US

M. Van Den Eynde1, C. Parseghian2, T. Price3, 1Institut Roi Albert II - Cliniques

universitaires St-Luc, Brussels, BE, 2MD Anderson Cancer Center, Houston, US, 3The
Queen Elizabeth Hospital - Emergency Department, Woodville, AU

18:55 - 19:15 The next steps forward: Co-targeting KRAS G12C mt mCRC
T. Price, The Queen Elizabeth Hospital - Emergency Department, Woodville, AU

M. Van Den Eynde1, C. Parseghian2, T. Price3, 1Institut Roi Albert II - Cliniques

universitaires St-Luc, Brussels, BE, 2MD Anderson Cancer Center, Houston, US, 3The
Queen Elizabeth Hospital - Emergency Department, Woodville, AU

19:25 - 19:30 Meeting close


10.09.2022
Title: Antibody-drug conjugates to transform outcome of Auditorium
patients with metastatic breast cancer
Chair(s): Eva Ciruelos, ES; Aditya Bardia, US

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

08:35 - 08:50 Antibody-drug conjugates: Constructs and targets
B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR

08:50 - 09:05 ADCs for patients with triple negative breast cancer: Moving towards
combinations with I-O and agents targeting DDR

Boston, US

09:05 - 09:20 Which impact of Her2-directed ADCs?
I. Krop, Yale University School of Medicine - Yale Cancer Center, New Haven, US

09:20 - 09:35 Finding the right population and combination to develop ADCs in patients with
HR+/Her2- mBC
K. Jhaveri, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES



08:30 - 10:00 Type: Special symposium 4.B - Brest
Title: Progress in the identification of new immune Auditorium
targets
Chair(s): Sebastian Kobold, DE; Sergio Quezada, GB

S. Quezada, London, GB

08:40 - 08:55 Novel immune checkpoints
P. Sharma, Houston, TX, US

08:55 - 09:10 Cytokines
S. Kobold, LMU Klinikum der Universität München, Munich, DE

09:10 - 09:25 Targeting regulatory T cells

09:25 - 09:40 Vaccines
P. Ott, Dana Farber Cancer Institute, Boston, US



08:30 - 09:50 Type: Proffered Paper session 7.1.C - Cannes Auditorium
Title: Proffered Paper session 1: GI, upper digestive
Chair(s): Angela Lamarca, ES; Lam Chan, HK

08:30 - 08:40 LBA34 - Primary results from the phase III LEAP-002 study: Lenvatinib plus
pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced
hepatocellular carcinoma (aHCC)
R. Finn1, M. Kudo2, P. Merle3, T. Meyer4, S. Qin5, M. Ikeda6, R. Xu7, J. Edeline8, B.-Y.

Ryoo9, Z. Ren10, A.-L. Cheng11, P. Galle12, S. Kaneko13, H. Kumada14, A. Wang15, K.
Mody16, L. Dubrovsky15, A. Siegel17, J. Llovet18, 1University of California, Los Angeles,
Los Angeles, US, 2Kindai University - Faculty of Medicine, Osaka, JP, 3Hôpital de la Croix-
Rousse, Lyon, FR, 4Royal Free Hospital-Royal Free London NHS Foundation Trust,
London, GB, 5Cancer Center of Nanjing, Jinling Hospital Nanjing University of Chinese
Medicine, Nanjing, CN, 6National Cancer Center Hospital East, Kashiwa, JP, 7Hunan
Cancer Hospital, Changsha, CN, 8Centre Eugene - Marquis, Rennes, FR, 9Asan Medical
Center - University of Ulsan College of Medicine, Seoul, KR, 10Zhongshan Hospital
Affiliated to Fudan University, Shanghai, CN, 11NTUH - National Taiwan University
Hospital, Taipei City, TW, 12Universitätsmedizin der Johannes Gutenberg-Universität

Mainz, Mainz, DE, 13Kanazawa University, Kanazawa, JP, 14Toranomon Hospital, Minato-
ku, JP, 15Merck & Co., Inc., Rahway, US, 16Eisai Inc., Nutley, US, 17Merck & Co. Inc.,
Rahway, US, 18Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New
York, NY, USA & August Pi i Sunyer Biomedical Research Institute-Hospital Clinic,
University of Barcelona, Catalonia, Spain, Barcelona, ES

08:40 - 08:50 LBA35 - Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line
therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase
III trial
S. Qin1, L. Chan2, S. Gu3, Y. Bai4, Z. Ren5, X. Lin6, Z. Chen7, W. Jia8, Y. Jin9, Y. Guo10, A.
Sultanbaev11, M. Pazgan-Simon12, M. Pisetska13, X. Liang14, C. Chen14, Z. Nie14, L.
Wang14, A.-L. Cheng15, A. Kaseb16, A. Vogel17, 1Nanjing University of Chinese Medicine,
Nanjing, CN, 2The Chinese University of Hong Kong Medical Center, Sha Tin, HK,
3Hunan Cancer Hospital, Changsha, CN, 4The Affiliated Tumor Hospital of Harbin
Medical University, Harbin, CN, 5Zhongshan Hospital Affiliated to Fudan University,

Shanghai, CN, 6Fujian Medical University Union Hospital, Fuzhou, CN, 7The Second
Affiliated Hospital of Anhui Medical University, Hefei, CN, 8The First Affiliated Hospital
of USTC/ Anhui Provincial Hospital, Hefei, CN, 9Sichuan Cancer Center, School of
Medicine, University of Electronic Science and Technology of China, Chengdu, CN,
10Nanfang Hospital, Southern Medical University, Guangzhou, CN, 11Republican Clinical
Oncological Dispensary of the Ministry of Health of the Republic of Bashkortostan, Ufa,

RU, 12Wroclaw Medical University, and Centrum Badań Klinicznych P.Napora, Wroclaw,
PL, 13Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv, UA,
14Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN, 15National Taiwan
University Hospital, Taipei City, TW, 16The University of Texas M. D. Anderson Cancer
Center, Houston, US, 17Hannover Medical School, Hannover, DE

R.K. Kelley, UCSF - University of California San Francisco - Parnassus Campus, San

Francisco, US

09:00 - 09:15 Q&A

09:15 - 09:25 LBA36 - Final analysis of RATIONALE-301: Randomized, phase III study of
tislelizumab versus sorafenib as first-line treatment for unresectable
hepatocellular carcinoma
S. Qin1, M. Kudo2, T. Meyer3, R. Finn4, A. Vogel5, Y. Bai6, Y. Guo7, Z. Meng8, T. Zhang9, T.

Satoh10, A. Hiraoka11, D. Marino12, E. Assenat13, L. Wyrwicz14, M. Calvo Campos15, K.
Hsing-Tao 16, F. Boisserie17, S. Li17, Y. Chen18, A. Zhu19, 1Nanjing University of Chinese
Medicine, Nanjing, CN, 2Kindai University Faculty of Medicine, Osaka, JP, 3Royal Free
Hospital NHS Trust and UCL Cancer Institute, London, GB, 4University of California Los
Angeles, Los Angeles, US, 5Hepatology and Endocrinology, Hannover Medical School,
Hannover, DE, 6Harbin Medical University Cancer Hospital, Harbin, CN, 7Nanfang
Hospital, Southern Medical University, Guangzhou, CN, 8Fudan University Shanghai
Cancer Hospital, Shanghai, CN, 9Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, CN, 10Osaka University, Osaka, JP,
11Ehime Prefectural Central Hospital, Matsuyama, JP, 12Ordine Mauriziano Hospital,

Turin, IT, 13Montpellier University Hospital, Montpellier, FR, 14Maria Sklodowska-Curie
National Cancer Research Institute, Warsaw, PL, 15Institut Català d'Oncologia,
Barcelona, ES, 16Chi Mei Medical Center, Tainan, TW, 17BeiGene, Ltd., Ridgefield Park,
US, 18BeiGene (Beijing) Co., Ltd., Beijing, CN, 19Massachusetts General Hospital Cancer
Center, Boston, MA, United States; Jiahui International Cancer Center, Jiahui Health,
Shanghai, CN

L. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

09:35 - 09:50 Q&A

08:30 - 10:00 Type: Mini Oral session 7.2.E - Évry Auditorium
Title: Mini Oral session 1: Gynaecological cancers
Chair(s): Susana Banerjee, GB; Iain McNeish, GB; Robert Coleman, US

08:30 - 08:35 519MO - Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of
cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival
analysis
A. Oaknin1, B. Monk2, L. Polastro3, A. Cristina De Melo4, H.S. Kim5, Y.M. Kim6, A.

Lisyanskaya7, V. Samouëlian8, D. Lorusso9, F. Damian10, C.-L. Chang11, S. Takahashi12,
D. Ramone13, B. Maćkowiak-Matejczyk14, J. Li15, S. Jamil15, M. Mathias15, M. Fury15, K.
Tewari16, 1Vall d'Hebron University Hospital, Barcelona, ES, 2University of Arizona and
Creighton University, Phoenix, US, 3Institut Jules Bordet, Anderlecht, BE, 4Brazilian
National Cancer Institute, Rio de Janeiro, BR, 5Seoul National University College of
Medicine, Seoul, KR, 6Asan Medical Center, University of Ulsan, Seoul, KR, 7St.
Petersburg State Budgetary Healthcare Institution “City Oncological Dispensary”, St.
Petersburg, RU, 8Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, CA,
9Division of Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS,
Rome, IT, 10Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto
Alegre, BR, 11Mackay Memorial Hospital, Taipei, TW, 12Cancer Institute Hospital of
Japanese Foundation for Cancer Research, Tokyo, JP, 13Barretos Cancer Hospital (Pio XII
Foundation), Sao Paulo, BR, 14Białostockie Centrum Onkologii, Białostockie, PL,
15Regeneron Pharmaceuticals, Inc., Tarrytown, US, 16University of California, Irvine, US

08:35 - 08:40 LBA32 - Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined
with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer
(phase II): Safe and effective in both PD-L1 positive and negative
S. Lee1, M.-C. Lim2, Y.M. Kim3, J.H. No4, B.-G. Kim5, C.H. Cho6, S.H. Kim7, D.H. Jeong8,
J.-K. Lee9, J.S. Park10, Y.-J. Choi10, K.O. Jeon10, J.W. Woo10, Y.C. Sung10, S. Hur1, 1The
Catholic University of Korea - College of Medicine, Seoul, KR, 2National Cancer Center,
Goyang-si, Gyeonggi-do, KR, 3Asan Medical Center, Seoul, KR, 4Seoul National University

Bundang Hospital, Seongnam, KR, 5Samsung Medical Center, Seoul, KR, 6Dongsan
Medical Center, Daegu, KR, 7Severance Hospital - Yonsei University College of Medicine,
Seoul, KR, 8Inje University Busan Paik Hospital, Busan, KR, 9Korea University Guro
Hospital, Seoul, KR, 10Genexine, Inc., Seoul, KR

08:40 - 08:45 520MO - Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in
patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in
checkmate 358
A. Oaknin1, K. Moore2, T. Meyer3, J.L. González4, L. Devriese5, A. Amin6, C. Lao7, V.

Boni8, W. Sharfman9, J.C. Park10, M. Tahara11, S. Topalian9, M. Magallanes Maciel12, A.
Molina Alavez13, A. Khan14, C. Copigneaux14, M. Lee14, C. Garnett-Benson14, X. Wang14,
R. Naumann6, 1Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall
d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES, 2Stephenson Cancer
Center, Oklahoma City, US, 3University College London, London, GB, 4Clinica
Universidad de Navarra, Madrid, ES, 5Universitair Medisch Centrum Utrecht, Utrecht,

NL, 6Levine Cancer Institute, Atrium Health, Charlotte, US, 7Rogel Cancer Center at the
University of Michigan, Ann Arbor, US, 8START Madrid, Centro Integral Oncológico Clara
Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, 9Johns Hopkins Bloomberg–
Kimmel Institute for Cancer Immunotherapy, Baltimore, US, 10Massachusetts General
Hospital, Boston, US, 11National Cancer Center Hospital East, Kashiwa, JP, 12Centro
Oncológico Internacional, Ciudad de Mexico, MX, 13Centro de Atención e Investigación
Clínica en Oncología, Merida, MX, 14Bristol Myers Squibb, Princeton, US

08:45 - 09:00 Invited Discussant 519MO, LBA32 and 520MO
R. Coleman, US Oncology Research, The Woodlands, US

09:00 - 09:05 521MO - Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell
gynaecological cancer (CCGC): Phase II PEACOCC trial
R. Kristeleit1, A. Clamp2, C. Gourley3, R. Roux4, M. Hall5, M.-J. Devlin6, R. Nirsimloo7, V.

Kounnis8, L. Hughes9, N. Counsell10, L. Farrelly10, R. Miller11, 1Guy's and St Thomas'
NHS Foundation Trust, London, GB, 2The Christie NHS Foundation Trust, Manchester,
GB, 3Cancer Research UK Edinburgh Centre, Edinburgh, GB, 4Churchill Hospital,
Oxford, GB, 5Mount Vernon Cancer Centre, Northwood, GB, 6QMUL - Queen Mary

University of London - Charterhouse Square, London, GB, 7ECC - Edinburgh Cancer
Centre - SCAN, Edinburgh, GB, 8Churchill Hospital - Oxford University Hospitals NHS
Foundation Trust, Oxford, GB, 9UCL - University College London, London, GB, 10Cancer
Research UK & University College London Cancer Trials Centre, London, GB, 11UCLH -
University College London Hospitals NHS Foundation Trust, London, GB

09:05 - 09:10 522MO - Preliminary results of sintilimab (Sin)+bevacizumab (Bev) in
recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-
arm, phase II trial
X. Liu1, B. Xia2, W. Zhang1, L. Sun3, C. Feng1, Y. Huang4, Y. Gao5, J. Jiang6, G. Li7, Q.

Gao1, 1Tongji Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan, CN, 2The First Affiliated Hospital of USTC, University of Science and
Technology of China, Hefei, CN, 3Chinese Academy of Medical Sciences and Peking
Union Medical College, Beijing, CN, 4Hubei Cancer Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, CN, 5Peking University Cancer
Hospital and Institute, Beijing, CN, 6Qilu Hospital of Shandong University, Jinan, CN,
7Union Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan, CN

09:10 - 09:25 Invited Discussant 521MO and 522MO

S. Banerjee, The Royal Marsden Hospital - Chelsea, London, GB

09:25 - 09:30 523MO - Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody)
monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-
escalation analysis
E. Van Nieuwenhuysen1, D. O'Malley2, R. O'Cearbhaill3, K. Moore4, E. Hamilton5, O.

Yeku6, S. Bouberhan6, J.Y. Hou7, S.-Y. Yoo 8, J. Brouwer-Visser 8, H.K. Cheung8, M.
Peterman8, P. Goncalves8, T. Schmidt8, M. Zhu8, I. Lowy8, T. Rowlands8, T. Uldrick8, E.
Miller8, J. Liu9, 1University Hospitals Leuven, Leuven, BE, 2The Ohio State University,
The James Cancer Center, Columbus, US, 3Memorial Sloan Kettering Cancer Center and
Weill Cornell Medical College, New York, US, 4Stephenson Cancer Center, University of
Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Oklahoma City, US,
5Sarah Cannon Research Institute Tennessee Oncology, Nashville, US, 6Massachusetts
General Hospital, Boston, US, 7Columbia University Medical Center, New York, US,
8Regeneron Pharmaceuticals, Inc., Tarrytown, US, 9Dana Farber Cancer Institute,
Boston, US

09:30 - 09:35 524MO - Glucocorticoid receptor expression and activity in a phase II ovarian
cancer trial of the glucocorticoid receptor modulator relacorilant in combination
with nab-paclitaxel
D. Lorusso1, A. Greenstein2, S. Wadekar2, I.C. Tudor2, H. Hunt2, B. Guyer2, 1Fondazione

Policlinico Universitario Gemelli IRCCS and Catholic University of Sacred Heart, Rome,
IT, 2Corcept Therapeutics, Menlo Park, US

I. Mcneish, London, GB


08:30 - 10:00 Type: Educational session 7.3.M - Marseille
Title: The Universal Health Coverage (UHC) dilemma: Can Auditorium
we afford to pay for what we want?
Chair(s): E.G. Elisabeth de Vries, NL; Dario Trapani, US


08:35 - 08:50 ESMO ANMS 2.0 survey about access to cancer medicines
D. Trapani, Dana Farber Cancer Institute, Boston, US

08:50 - 09:05 ESMO’s economic model
P. Kanavos, The London School of Economics and Political Science, London, GB

09:05 - 09:20 WHO pricing guidelines to improve access to medicines
K. Tay-Teo, WHO - World Health Organization, Geneva, CH

09:20 - 09:35 The patient perspective
B. Ryll, Melanoma Patient Network Europe MPNE, Uppsala, SE




08:30 - 10:00 Type: Special symposium 7.3.U - Urval Auditorium
Title: Current and future perspectives in SCLC
Chair(s): Fiona Blackhall, GB; Lauren Byers, US

F. Blackhall, Manchester, GB

08:35 - 08:50 Transcriptomic and immune landscape in SCLC
L. Byers, Houston, TX, US

08:50 - 09:05 Immunotherapy in the current management of SCLC
F. Blackhall, Manchester, GB

09:05 - 09:20 Controversies in SCLC radiotherapy treatment
B.H. Gronberg, Trondheim, NO

09:20 - 09:35 Future perspectives
T. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, US

L. Byers, Houston, TX, US



08:30 - 09:30 Type: Young Oncologist session 7.3.R - Rennes Auditorium
Title: Young Oncologist Boxing session
Chair(s): Kok Haw Jonathan Lim, GB; Pawel Sobczuk, PL

08:30 - 08:40 Pro: Tumor mutional burden as a tumor agnostic biomarker?
A. Marabelle, Institut Gustave Roussy, Villejuif, FR

08:40 - 08:50 Contra: Tumor mutional burden as a tumor agnostic biomarker?
A. Addeo, HUG - Hopitaux Universitaires de Geneve, Geneva, CH

08:50 - 09:00 Discussion led by chairs

09:00 - 09:10 Pro: Medical oncology in 21st century – general or cancer type specialist?
A. Awada, Institute Jules Bordet, Brussels, BE

09:10 - 09:20 Contra: Medical oncology in 21st century: General or cancer type specialist?
J. Barriuso, The Christie NHS Foundation Trust, Manchester, GB

09:20 - 09:30 Discussion led by chairs


08:30 - 10:00 Type: EONS session 7.3.S - Strasbourg Auditorium
Title: Welcome to the EONS15 conference
Chair(s): Johan De Munter, BE

08:30 - 08:35 Welcome to EONS15 the conference
J. De Munter, UZ Gent - Universitair Ziekenhuis Gent, Gent, BE

08:35 - 08:40 Welcome from Association Française des Infirmier(e)s de Cancérologie – French
Oncology Nurses Society
P. Dielenseger, Institut Gustave Roussy, Villejuif, Cedex, FR

08:40 - 09:00 World Code against Cancer Framework: Evidence-based recommendations for
cancer prevention
C. Espina, IARC - International Agency for Research on Cancer, Lyon, FR

09:00 - 09:20 Psycho-oncology in cancer care: Current state and future directions
L. Fallowfield, Brighton and Sussex Medical School - University of Sussex, Brighton, GB

09:20 - 09:40 My Survival Story: What we can learn from each other to get through cancer
M. Inderbitzin, My Survival Story Foundation, Zurich, CH

09:40 - 09:50 EONS Awards: Lifetime Achievement Award and RECaN Award

09:50 - 10:00 Q&A and discussion


09:00 - 10:00 Type: Controversy session 7.2.F - Fécamp Auditorium
Title: Does hyperprogression exist?
Chair(s): Marleen Kok, NL

09:00 - 09:05 Introduction by the Chair
M. Kok, Netherlands Cancer Institute, Amsterdam, NL

09:05 - 09:06 Polling 1 (led by chair)

09:06 - 09:21 Pro: Does hyperprogression exist?
C. Ottensmeier, University of Liverpool - School of Medicine, Liverpool, GB

09:21 - 09:36 Contra: Does hyperprogression exist?
C. Le Tourneau, Paris, FR


09:37 - 09:57 Q&A

09:00 - 10:00 Type: Multidisciplinary session 7.1.D - Dijon Auditorium
Title: Management of adrenocortical carcinoma
Chair(s): Alfredo Berruti, IT

A. Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

09:05 - 09:20 The place of surgery, interventional radiology and radiation
A. Frilling, London, GB

09:20 - 09:35 Systemic therapy
E. Baudin, Gustave Roussy - Cancer Campus, Villejuif, FR

09:35 - 09:50 Novel compounds including immunotherapy
M. Kroiss, LMU - Ludwig Maximilians University of Munich, Munich, DE



09:00 - 10:00 Type: Challenge your Expert 7.3.G -
Title: Management of 21st century CRPC after upfront treatment: Grenoble
Men progressing after androgen deprivation and second Auditorium
generation therapies
Chair(s): Cora Sternberg, US

09:00 - 09:15 Presentation by Expert
R. De Wit, Erasmus MC, Rotterdam, NL

09:15 - 10:00 Discussion led by Chair
C. Sternberg, Weill Cornell Medicine - Belfer Research Building, New York, US

09:00 - 10:00 Type: Challenge your Expert 7.3.H - Honfleur
Title: Immunotherapy for lung cancer: The longer the Auditorium
better? The more the better?
Chair(s): Tony S.K. Mok, HK


T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

09:00 - 10:00 Type: Challenge your Expert 7.3.O - Orléans
Title: What every oncologist should know about palliative Auditorium
sedation?
Chair(s): Giovanni Boniolo, IT

N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

G. Boniolo, Ferrara, IT

09:00 - 10:00 Type: Challenge your Expert 7.3.T - Toulouse
Title: Can we cure oligometastatic disease in sarcoma Auditorium
patients?
Chair(s): Armelle Dufresne, FR

A. Gronchi, Milan, IT

A. Dufresne, Centre Léon Bérard, Lyon, FR


Title: Slicing the pie: Advances in targeted therapy for Auditorium
oncogene-addicted NSCLC
Chair(s): Zofia Piotrowska, US; Jarushka Naidoo, IE


10:20 - 10:35 New therapies and questions for EGFR, Exon 20 and HER2 mutation
Z. Piotrowska, MGH - Massachusetts General Hospital, Boston, US

10:35 - 10:50 Targeting KRAS: Current knowledge and future directions
A. Calles Blanco, Hospital General Universitario Gregorio Marañon, Madrid, ES

10:50 - 11:05 How to address resistance
J. De Langen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,

Amsterdam, NL

11:05 - 11:20 Where does IO fit in?
R. Hui, Westmead Hospital, Westmead, AU

Z. Piotrowska, MGH - Massachusetts General Hospital, Boston, US


10:15 - 11:45 Type: Proffered Paper session 4.B - Brest
Title: Proffered Paper session 1: GU tumours, non- Auditorium
prostate
Chair(s): Thomas Powles, GB; Rana McKay, US

10:15 - 10:25 LBA66 - IMmotion010: Efficacy and safety from the phase III study of
atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal
cell carcinoma (RCC) at increased risk of recurrence after resection
A. Bex1, R. Uzzo2, J.A. Karam3, V. Master4, F. Donskov5, C. Suárez6, L. Albiges7, B. Rini8,

Y. Tomita9, A. Kann10, G. Procopio11, F. Massari12, M. Zibelman2, I. Antonyan13, M.
Huseni14, D. Basu15, B. Ci14, W. Leung14, O. Khan16, S. Pal17, 1The Royal Free London
NHS Foundation Trust, University College London Division of Surgery and Interventional
Science, London, UK & The Netherlands Cancer Institute, Amsterdam, NL, 2Fox Chase
Cancer Center, Philadelphia, US, 3The University of Texas MD Anderson Cancer Center,
Houston, US, 4Winship Cancer Institute, Emory University School of Medicine, Atlanta,
US, 5Aarhus University Hospital, Aarhus, Denmark & University Hospital of Southern
Denmark, Esbjerg, DK, 6Vall d´Hebron Institute of Oncology (VHIO), Hospital
Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus, Barcelona, ES,
7Gustave Roussy, Université Paris-Saclay, Villejuif, FR, 8Vanderbilt University Medical

Center, Nashville, US, 9Graduate School of Medical and Dental Sciences, Niigata
University, Niigata, JP, 10Hospital Alemão Oswaldo Cruz, São Paulo, BR, 11Fondazione
IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, 12University of Bologna,
Bologna, IT, 13Regional Medical Clinical Center of Urology and Nephrology n.a.
V.I.Shapoval, Kharkiv, UA, 14Genentech, Inc., South San Francisco, US, 15F. Hoffmann-La
Roche Ltd, Welwyn Garden City, GB, 16Roche Products Ltd, Welwyn Garden City, GB,
17City of Hope Comprehensive Cancer Center, Duarte, US

10:25 - 10:35 LBA67 - Phase III randomized study comparing perioperative nivolumab (nivo)
versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing
nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials
Network trial
M. Allaf1, S.E. Kim2, L. Harshman3, D. Mcdermott4, V. Master5, S. Signoretti6, S. Cole7,

H. Moon8, N. Adra9, E. Singer10, J. Gills11, T. Choueiri2, B. Leibovich12, M.D.
Michaelson13, B. Shuch14, P. Lara15, D. Heng16, A. Kapoor17, M. Carducci18, N. Haas19,
1Johns Hopkins University School of Medicine, Boston, US, 2Dana Farber Cancer
Institute, Boston, US, 3Surface Oncology Inc, Cambridge, US, 4Beth Israel Deaconess
Medical Center, Boston, US, 5Emory University - Rollins School of Public Health, Atlanta,
US, 6Brigham and Women's Hospital, Boston, US, 7UTSW - University of Texas
Southwestern Medical Center, Dallas, US, 8Kaiser Permanente - Riverside Medical

Center, Riverside, US, 9Indiana University Simon Cancer Center, Indianapolis, US,
10Rutgers Cancer Institute of New Jersey, New Brunswick, US, 11LSU Healthcare
Network, Metairie Multispeciality Clinic, Metairie, US, 12Mayo Clinic, Rochester, US,
13MGH - Massachusetts General Hospital, Boston, US, 14UCLA - David Geffen School of
Medicine, Los Angeles, US, 15University of California Davis Cancer Center, Sacramento,
US, 16Tom Baker Cancer Centre, Calgary, CA, 17St. Joseph's Healthcare Hamilton,
Hamilton, CA, 18Johns Hopkins University, Baltimore, US, 19Abramson Cancer Center -
University of Pennsylvania, Philadelphia, US


10:45 - 11:00 Q&A

11:00 - 11:10 1735O - PD-L1 expression on immune cells by SP142 co-localises with dendritic
cells and is associated with improved overall survival (OS) with atezolizumab in
patients with untreated metastatic urothelial cancer (mUC)
E. Grande Pulido1, M. Galsky2, R. Van Elzen3, R. Banchereau4, M. Peterson4, C. Sedano4,

H. Koeppen5, H. Li6, A. Bamias7, J. Arranz Arija8, E. Kikuchi9, M. De Santis10, I. Davis11,
I. Mellman4, S. Oh4, P. Williams4, S. Bernhard12, C. Lee12, M. Kockx3, S. Mariathasan4,
1MD Anderson Cancer Center Madrid, Madrid, ES, 2Icahn School of Medicine at Mount
Sinai, New York, US, 3CellCarta, Antwerpen, BE, 4Genentech, Inc., South San Francisco,
US, 5Genentech Inc., South San Francisco, US, 6Hoffmann-La Roche Ltd, Mississauga,
CA, 7National & Kapodistrian University of Athens, Athens, GR, 8Gregorio Maranon
Hospital, Madrid, ES, 9St. Marianna University School of Medicine, Kawasaki, JP,
10Charité Universitätsmedizin, Berlin, Germany & Medical University of Vienna, Vienna,
AT, 11Monash University Eastern Health Clinical School, Box Hill, AU, 12Roche Products

Limited, Welwyn Garden City, GB

11:10 - 11:20 LBA74 - Genomic biomarkers in peripheral blood (PB) from patients (pts)
enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L)
maintenance in advanced urothelial carcinoma (aUC)
T. Powles1, S. Sridhar2, J. Bellmunt3, C. Sternberg4, P. Grivas5, E. Hunter6, M. Dezfouli6,

M. Salter6, R. Powell6, A. Dring6, J. Green6, A. Akoulitchev7, R. Amezquita8, K. Ching9, J.
Pu10, S. Deng9, A. Di Pietro11, C. Davis8, 1Barts Cancer Institute, Experimental Cancer
Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London,
GB, 2Princess Margaret Cancer Centre, University Health Network, Toronto, CA, 3Dana
Farber Cancer Institute, Harvard Medical School, Boston, US, 4Weill Cornell Medicine,
New York, US, 5University of Washington, Fred Hutchinson Cancer Research Center,
Seattle Cancer Care Alliance, Seattle, US, 6Oxford BioDynamics Plc, Oxford, GB, 7Oxford
Biodynamics Plc, Oxford, GB, 8Pfizer, La Jolla, US, 9Pfizer, San Diego, US, 10Pfizer,
Tucson, US, 11Pfizer srl, Milano, IT

R. Mckay, University of California San Diego - UCSD, La Jolla, US

11:30 - 11:45 Q&A


10:15 - 11:45 Type: Special symposium 7.1.C - Cannes
Title: Lessons learned and new horizons and other Auditorium
hepatobiliary/pancreatic malignancies
Chair(s): Angela Lamarca, ES; Arndt Vogel, DE

A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

10:20 - 10:35 Approach to inhibition of activating FGFR2 fusions
F. Facchinetti, Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR

10:35 - 10:50 IDH1 and IDH2
M. Lowery, Trinity College Dublin, Dublin, IE

10:50 - 11:05 The role of immunotherapy and other targeted treatments
A. Vogel, MHH - Medizinische Hochschule Hannover, Hannover, DE

11:05 - 11:20 The role of KRAS inhibitor and other new treatment options in pancreatic cancer
E. O'Reilly, New York, NY, US



10:15 - 11:45 Type: Proffered Paper session 7.2.E - Évry Auditorium
Title: Proffered Paper session: Breast cancer, early stage
Chair(s): Peter Dubsky, CH; Ana Bosch, SE

10:15 - 10:25 133O - Extended adjuvant aromatase inhibition after sequential endocrine
therapy: Final results of the phase III DATA trial
V. Tjan-Heijnen1, S. Lammers1, S. Geurts1, I. Vriens1, A. Swinkels2, C. Smorenburg3, M.

Van Der Sangen4, J. Kroep5, H. De Graaf6, A. Honkoop7, F. Erdkamp8, W. De Roos9, S.
Linn3, A. Imholz10, 1Maastricht University Medical Centre, Maastricht, NL, 2Netherlands
Comprehensive Cancer Organisation (IKNL), Nijmegen, NL, 3Antoni van Leeuwenhoek
Hospital - Netherlands Cancer Institute, Amsterdam, NL, 4Catharina Hospital,
Eindhoven, NL, 5Leiden University Medical Centre, Leiden, NL, 6Medical Centre
Leeuwarden, Leeuwarden, NL, 7Isala Clinics, Zwolle, NL, 8Zuyderland Medical Centre,
Sittard-Geleen, NL, 9Gelderse Vallei Hospital, Ede, NL, 10Deventer Ziekenhuis, Deventer,
NL

10:25 - 10:35 LBA13 - Nivolumab and ipilimumab in early-stage triple negative breast cancer
(TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the

BELLINI trial
M. Kok1, I. Nederlof1, O. Isaeva1, N. Bakker1, M. De Graaf1, R. Salgado2, N. Klioueva3, K.

Van De Vijver4, F. Van Duijnhoven5, E. Kalashnikova6, S. Willingham6, S. Luykx7, C.E.
Loo5, E. Kerver3, G. Sonke5, C. Blank5, R. Mann5, S. Linn5, D. Lambrechts8, H. Horlings1,
1Netherlands Cancer Institute, Amsterdam, NL, 2GZA Ziekenhuizen Campus Sint-
Augustinus, Wilrijk, BE, 3OLVG Hospital, Amsterdam, NL, 4UZ Gent - Universitair
Ziekenhuis Gent, Gent, BE, 5NKI-AVL - Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital, Amsterdam, NL, 6Natera, Inc., Austin, US, 7Tergooi Hospital -
locatie Hilversum, Hilversum, NL, 8VIB-KULeuven, Leuven, BE

L. Del Mastro, IRCCS Ospedale Policlinico San Martino, Genova, IT

10:45 - 11:00 Q&A

11:00 - 11:10 LBA14 - Impact of age, recurrence score (RS) and ovarian function suppression
(OFS) on endocrine response to short preoperative endocrine therapy (ET):
Analysis of ADAPT and ADAPTcycle trials
O. Gluz1, U. Nitz1, M. Christgen2, S. Kuemmel3, M. Braun4, M. Thill5, B. Aktas6, P.

Wimberger7, K. Luedtke-Heckenkamp8, M. Zaiss9, M. Warm10, C. Schumacher11, C.
Schem12, M. Graeser1, A. Hartkopf13, R. Kates14, C. Zu Eulenburg15, P. Schmid16, H.
Kreipe17, N. Harbeck18, 1Evangelical Johanniter Bethesda Clinics and West German
Study Group, Mönchengladbach, DE, 2MHH - Medizinische Hochschule Hannover,
Hannover, DE, 3Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE,
4Rotkreuzklinikum München - Frauenklinik, Munich, DE, 5Kliniken Markus-Krankenhaus,
Agaplesion, Frankfurt am Main, DE, 6Universitätsklinikum Leipzig - Klinik und Poliklinik

für Frauenheilkunde, Leipzig, DE, 7Universitaetsklinikum Carl Gustav Carus Dresden,
Dresden, DE, 8Franziskus-Hospital Harderberg - Niels-Stensen-KlinikenGmbH,
Georgsmarienhütte, DE, 9Praxis für Interdisziplinaere Onkologie, Freiburg im Breisgau,
DE, 10City Hospital Köln-Holweide, Köln, DE, 11St. Elisabeth Krankenhaus Köln-
Hohenlind, Köln, DE, 12Krankenhaus Jerusalem, Hamburg, DE, 13University Clinics
Tuebingen, Tübingen, DE, 14West German Study Group, Moenchengladbach, DE,
15Westdeutsche Studiengruppe GmbH, Mönchengladbach, DE, 16Queen Mary University
of London, London, GB, 17Hannover Medical School, Hannover, DE, 18Ludwig

Maximilians University Hospital of Munich, Munich, DE

11:10 - 11:20 134O - Dose-dense adjuvant chemotherapy in early-stage breast cancer patients:
End-of-study results from a randomised, phase III trial of the Gruppo Italiano
Mammella (GIM)
L. Del Mastro1, F. Poggio1, E. Blondeaux1, S. De Placido2, M. Giuliano3, M. De

Laurentiis4, G. Bisagni5, M. Cantore6, A. Turletti7, C. Nisticò8, Y. Urracci9, O. Garrone10,
C. Bighin1, M. Mansutti11, F. Montemurro12, G. Colantuoni13, M. Lambertini1, L. Boni1,
1IRCCS Ospedale Policlinico San Martino, Genova, IT, 2Azienda Ospedaliera Universitaria
Federico II, Napoli, IT, 3University "Federico II", Napoli, IT, 4Istituto Nazionale Tumori -
IRCCS - Fondazione Pascale, Napoli, IT, 5Azienda Ospedaliera - Arcispedale Santa Maria

Nuova - IRCCS, Reggio Emilia, IT, 6Azienda Ospedaliera Carlo Poma, Mantova, IT, 7POEV
ASL TO1, Torino, IT, 8IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT,

9Ospedale Oncologico "A. Businco", Cagliari, IT, 10Ospedale Maggiore Policlinico -
Fondazione IRCCS Ca' Granda, Milan, IT, 11ASU Friuli Centrale - Ospedale S. Maria della
Misericordia, Udine, IT, 12IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, 13Azienda
Ospedaliera S. Giuseppe Moscati, Avellino, IT

11:20 - 11:30 Invited Discussant LBA14 and 134O
P. Dubsky, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH

11:30 - 11:45 Q&A

10:15 - 11:45 Type: Special symposium 7.2.F - Fécamp
Title: Is heterogeneity the limitation of precision oncology Auditorium
in melanoma?
Chair(s): Caroline Robert, FR; Dirk Schadendorf, DE

C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

10:20 - 10:35 Plasticity: The door for tumour escape?
C. Vallot, Institut Curie, Paris, FR

10:35 - 10:50 Discovery of new metabolic pathways and liabilities in cancer cells
A. Tasdogan, Universitätsklinikum Essen, Essen, DE

10:50 - 11:05 Single cell dynamics
B. Raphael, San Diego, CA, US

11:05 - 11:20 How to target invisible melanoma cells

D. Schadendorf, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE


10:15 - 11:45 Type: Mini Oral session 7.1.D - Dijon Auditorium
Title: Mini Oral session: Head & neck cancer
Chair(s): Ana Martins Ferreira Varges Gomes, PT; Sandra Schmitz, BE; Sjoukje Oosting,

NL

10:15 - 10:20 655MO - Quality of life in patients with p16+ oropharyngeal cancer
receiving accelerated radiotherapy (RT) with either cisplatin or cetuximab in
NRG/RTOG 1016

J. Ringash1, L. Demora2, M. Gillison3, D. Adelstein4, P. Harari5, E. Sturgis6, E. Basch7, S.
Koyfman8, G. Krempl9, D. Blakaj10, J. Bates11, T. Galloway12, C. Jones13, B. Beadle14, P.
Torres-Saavedra2, Q.-T. Le 15, B. Movsas16, 1The Princess Margaret Cancer Centre/UHN
& The University of Toronto, Toronto, CA, 2NRG Oncology Statistics and Data
Management Center, Philadelphia, US, 3MD Anderson Cancer Center, Houston, US,
4Cleveland Clinic - Cancer Center, Cleveland, US, 5University of Wisconsin Carbone
Cancer Center, Madison, US, 6Jamail Specialty Center, Houston, US, 7UNC - The
University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US,
8Cleveland Clinic Main Campus, Cleveland, US, 9University of Oklahoma Health Sciences
Center, Oklahoma City, US, 10OSUCCC - The Ohio State University Comprehensive
Cancer Center - James, Columbus, US, 11Winship Cancer Institute of Emory University,
Atlanta, US, 12Fox Chase Cancer Center - Main Campus, Philadelphia, US, 13Sutter
Cancer Center, Sacramento, US, 14Stanford Cancer Center Palo Alto, Palo Alto, US,
15Stanford University, Stanford, US, 16Henry Ford Cancer Institute-Henry Ford Health,
Detroit, US

10:20 - 10:25 656MO - Phase I study of M6620 (VX-970, berzosertib) in combination with
cisplatin and XRT in patients with locally advanced head and neck squamous cell
carcinoma
A. Bhatia1, Z. Chen2, J. Bruce3, C. Steuer4, D. Zandberg5, J. Riess6, D. Mitchell7, T.

Davis8, M. Patel9, V. Kaur10, S. Arnold11, T. Owonikoko12, 1Yale University School of
Medicine - Yale Cancer Center, New Haven, US, 2UIC - University of Illinois Chicago -
Student Center West, Chicago, US, 3University of Wisconsin Carbone Cancer Center,
Madison, US, 4Winship Cancer Institute of Emory University, Atlanta, US, 5University of
Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Pittsburgh,
US, 6UC Davis Comprehensive Cancer Center, Sacramento, US, 7OSUCCC - The Ohio
State University Comprehensive Cancer Center - James, Columbus, US, 8Norris Cotton
Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, 9Rutgers Cancer
Institute of New Jersey, New Brunswick, US, 10UVA - University of Virginia - School of
Medicine - Division of Hematology & Oncology, Charlottesville, US, 11UK - University of
Kentucky - Markey Cancer Center, Lexington, US, 12University of Pittsburgh and Hillman
Cancer Center, Pittsburgh, US

10:25 - 10:30 657MO - Effectiveness of geriatric assessment-driven interventions on quality of
life for 2 years in older patients with head and neck cancer: Results from the
EGeSOR trial
C. Lafont1, E. Paillaud2, C. Bertolus3, M. Baron4, P. Caillet2, E. Bouvard5, M. Laurent6, D.

Salvan7, L. Chaumette8, L. De Decker Lemarcis9, B. Piot10, B. Barry11, A. Raynaud-
Simon12, E. Sauvaget13, A. Minard14, A. Anota15, H. Panjo16, L. Brugel17, F. Canouï-
Poitrine1, 1Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France; AP-HP,
hôpital Henri-Mondor, Service de Santé Publique, F-94010, Créteil, France, Creteil, FR,
2Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France; AP-HP, Paris Cancer
Institute CARPEM, hôpital Européen Georges Pompidou, département de gériatrie, F-

75015 Paris, France, Creteil, FR, 3AP-HP, Sorbonne université, Hôpital Pitié Salpétrière,
service de chirurgie maxillo-faciale, F-75013 Paris, France, Paris, FR, 4AP-HP, Sorbonne
université, hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Service de Soins de
Suites et de Réadaptation Gériatrique, F-94205 Ivry sur Seine, France, Ivry sur Seine,
FR, 5AP-HP, hôpital Tenon, service de gériatrie, F-75020 Paris, France, Paris, FR, 6Univ
Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France; AP-HP, hôpital Henri-Mondor,
Département de Gériatrie, F-94010 Créteil, France, Creteil, FR, 7Centre Hospitalier Sud
Francilien, Service ORL et cervico-facial, F-91100 Corbeil-Essonnes, France, Corbeil-

Essonnes, FR, 8Centre Hospitalier Sud Francilien, Service de court sejour gériatrique, F-
91100 Corbeil-Essonnes, France, Corbeil-Essonnes, FR, 9Centre Hospitalier Universitaire
de Nantes, service de gériatrie, F-44093 Nantes, France, Nantes, FR, 10Centre
Hospitalier Universitaire de Nantes, service de chirurgie maxillo-faciale et stomatologie,
F-44093 Nantes, France, Nantes, FR, 11AP-HP, Université de Paris, hôpital Bichat,
Service ORL et chirurgie cervico-faciale, F-75018 Paris, France, Paris, FR, 12AP-HP,
Université Paris Cité, hôpital Bichat, service de gériatrie, F-75018 Paris, France, Paris,
FR, 13Groupe Hospitalier Paris-Saint Joseph, service ORL et chirurgie cervico-faciale, F-
75014 Paris, France, Paris, FR, 14Hôpital Léopold Bellan, Service de gériatrie, F- 75014
Paris, France, Paris, FR, 15Clinical Research and Innovation Department & Department
of Human and Social Sciences, Centre Léon Bérard, Lyon, France; French National
Platform Quality of life and Cancer, France, Lyon cedex, FR, 16Université Paris-Saclay,
UVSQ, Inserm, CESP, 94807 Villejuif, France, Villejuif, FR, 17Centre Hospitalier
Intercommunal de Créteil, Service d'ORL et Chirurgie Cervico-faciale, F-94010 Créteil,
France, Créteil, FR

10:30 - 10:45 Invited Discussant 655MO, 656MO and 657MO
S. Oosting, Groningen, NL

10:45 - 10:50 658MO - Pembrolizumab (pembro) vs standard-of-care (SOC) in previously
treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC): 6-year follow-up of KEYNOTE-040
D. Soulieres1, K. Harrington2, C. Le Tourneau3, J.D. Silva4, L. Licitra5, M.-J. Ahn6, A.

Soria Rivas7, J.-P. Machiels8, N. Mach9, R. Mehra10, B. Burtness11, J. Lin12, N. Lerman12,
B. Gumuscu12, E. Cohen13, 1CHUM (Centre Hospitalier de l’Université de Montréal),
Montreal, CA, 2The Institute of Cancer Research, London, GB, 3Institut Curie, Paris, FR,
4Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PT, 5Fondazione
IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, IT, 6Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, 7Hospital
Universitario Ramón y Cajal, Madrid, ES, 8Cliniques Universitaires Saint-Luc, Brussels,
BE, 9Geneva University Hospital, Geneva, CH, 10University of Maryland Greenebaum
Comprehensive Cancer Center, Baltimore, US, 11Yale School of Medicine, New Haven,
US, 12Merck & Co., Inc., Rahway, US, 13Moores Cancer Center, UC San Diego Health, La
Jolla, US

10:50 - 10:55 659MO - Pembrolizumab with or without chemotherapy for first-line treatment
of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC):
5-year results from KEYNOTE-048
M. Tahara1, R. Greil2, D. Rischin3, K. Harrington4, B. Burtness5, G. De Castro Jr.6, A.

Psyrri7, I. Brana8, P. Neupane9, Å. Bratland10, T. Fuereder11, B. Hughes12, R. Mesia
Nin13, N. Ngamphaiboon14, T. Rordorf15, W.Z. Wan Ishak16, J. Lin17, B. Gumuscu17, N.
Lerman17, D. Soulieres18, 1National Cancer Center Hospital East, Kashiwa, JP,
2Paracelsus Medical University Salzburg Cancer Research Institute and Cancer Cluster,
Salzburg, AT, 3Peter MacCallum Cancer Institute University of Melbourne, Melbourne,

AU, 4The Institute of Cancer Research, London, GB, 5Yale School of Medicine, New
Haven, US, 6Instituto do Cancer de Sao Paulo—ICESP, Sao Paulo, BR, 7National and
Kapodistrian University of Athens, Attikon University Hospital, Athens, GR, 8Vall
d’Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES,
9University of Kansas Medical Center, Kansas City, US, 10Oslo University Hospital, Oslo,

NO, 11Medical University of Vienna/General Hospital Vienna, Vienna, AT, 12Royal
Brisbane & Women's Hospital, and University of Queensland, Herston, AU, 13Catalan
Institute of Oncology, Badalona, ES, 14Ramathibodi Hospital, Mahidol University,
Ratchatewi, Bangkok, TH, 15University Hospital, Zurich, CH, 16University Malaya, Kuala
Lumpur, Wilayah Persekutuan, MY, 17Merck & Co., Inc., Rahway, US, 18CHUM, Montréal,
CA

10:55 - 11:00 LBA33 - 5-year overall survival (OS) in patients (pts) with locally advanced
squamous cell carcinoma of the head and neck (LA SCCHN) treated with
xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a
randomized, phase II study
J. Bourhis1, C. Le Tourneau2, B. Calderon3, L. Martin4, C. Sire5, Y. Pointreau6, J.-F.

Ramee7, A. Coutte8, P. Boisselier9, M.-C. Kaminsky-Forrett10, J.-P. Delord11, F. Clatot12, X.
Sun13, J. Villa14, N. Magne15, O. Elicin16, L. Damstrup17, K. Gollmer17, P. Crompton17, Y.
Tao18, 1Centre Hospitalier Universitaire Vaudois, Lausanne, CH, 2Institut Curie, Paris,
FR, 3Avignon-Provence Cancer Institute, Avignon, FR, 4William the Conqueror Center, Le
Havre, FR, 5Hôpital du Scorff , South Brittany Hospital Group, Lorient, FR, 6Institut
Inter-Régional de Cancérologie, Centre Jean Bernard, Le Mans, FR, 7CHD Vendée, La
Roche Sur Yon, FR, 8CHU Amiens Picardie, Amiens, FR, 9Montpellier Cancer Institute,
Val d’Aurelle, Montpellier, FR, 10The Cancer Institute, de Lorraine Alexis Vautrin,
Vandoeuvre-lès-Nancy, FR, 11Institut Claudius Regaud, IUCT-Oncopole, Toulouse, FR,
12Henri Becquerel Centre, Rouen, FR, 13Nord Franche-Comté de Montbéliard and CHRU
de Besançon, Montbéliard, FR, 14CHU Grenoble, Grenoble, FR, 15Institut de

Cancérologie Lucien Neuwirth, Saint Etienne, FR, 16Inselspital, Bern University Hospital,
University of Bern, Bern, CH, 17Debiopharm International SA, Lausanne, CH, 18Institut
Gustave Roussy, Villejuif, FR

11:00 - 11:15 Invited Discussant 658MO, 659MO and LBA33
A. Martins Ferreira Varges Gomes, Centro Hospitalar Universitário do Algarve - Hospital

de Faro EPE-SNS, Faro, PT

11:15 - 11:20 660MO - Molecular targets in salivary gland cancers: A comprehensive genomic
analysis of 1,666 cases
A. Sivapiragasam1, P. Ashok Kumar1, M. Bou Zerdan1, D. Zaccarini1, N. Danziger2, J.

Ross2, 1SUNY Upstate Medical University, Syracuse, US, 2Foundation Medicine, Inc,
Cambridge, US

11:20 - 11:25 654MO - High dimensional immuno-phenotyping of immunotherapy response in
head and neck cancer
K. O'Byrne1, N. Ma2, H. Sadeghirad3, N. Jhaveri2, J. Monkman3, A. Pratapa2, B. Ben

Cheikh2, R. Ladwa1, B. Hughes4, O. Braubach2, A. Kulasinghe5, 1Princess Alexandra
Hospital - Metro South Health, Woolloongabba, AU, 2Akoya Biosciences - East Coast,
Hopkinton, US, 3The University of Queensland, St Lucia, AU, 4Royal Brisbane and
Women's Hospital, Herston, AU, 5University of Queensland, Brisbane, AU

11:25 - 11:30 661MO - Evaluation of the DNA damage response (DDR) network as predictor of
nivolumab efficacy in head and neck squamous cell carcinoma (HNSCC)
P. Economopoulou1, C. Papanikolaou2, A. Spathis1, I. Kotsantis1, N. Gavrielatou3, M.

Anastasiou3, D. Stellas2, I. Panayiotides1, P. Foukas4, V.L. Souliotis2, A. Psyrri1, 1Attikon
University Hospital, Haidari, GR, 2National Hellenic Research foundation, Athens, GR,
3Attikon University Hospital, Athens, GR, 4CHUV - Centre Hospitalier Universitaire
Vaudois, Lausanne, CH

S. Schmitz, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-

Lambert, BE

10:15 - 11:45 Type: Educational session 7.3.G - Grenoble
Title: Insight the new CNS WHO classification: Novel concepts Auditorium
and therapeutic implications for gliomas
Chair(s): Pieter Wesseling, NL; Enrico Franceschi, IT

10:15 - 10:40 Update on diagnosis: Novel concepts of WHO
P. Wesseling, Amsterdam, NL

10:40 - 11:05 Therapeutic implications for gliomas
C. Balana, Badalona, ES

11:05 - 11:30 Are molecular subtypes also radiologic subtypes? Radiogenomic mapping of
brain tumours
M. Smits, Rotterdam, NL


10:15 - 11:45 Type: Proffered Paper session 7.3.O - Orléans
Title: Proffered Paper session: Developmental Auditorium
therapeutics
Chair(s): Alexander Drilon, US; Shivaani Kummar, US

10:15 - 10:25 451O - Preliminary evidence of clinical activity from phase I and Ib trials of the
CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors
A. Scott1, J. Call2, S. Chandana3, E. Borazanci4, G. Falchook5, R. Bordoni6, S. Richey7, A.

Starodub8, V. Chung9, N. Lakhani10, E. Lam11, K. Schaffer12, J. Wang13, G. Shapiro14, J.
Sachdev15, D. Beaupre15, A. Tolcher16, 1University of Arizona Cancer Center, Tucson,
US, 2South Texas Accelerated Research Therapeutics (START), San Antonio, US, 3START
- Midwest, Grand Rapids, US, 4HonorHealth Research Institute, Scottsdale, US, 5Sarah
Cannon Research Institute, denver, US, 6Georgia Cancer Specialists affiliated with
Northside Hospital Cancer Institute, Atlanta, US, 7US Oncology, Inc., Fort Worth, US,

8The Christ Hospital - Hematology & Oncology, Cincinnati, US, 9City of Hope
Comprehensive Cancer Center, Duarte, US, 10START Midwest, Grand Rapids, US,
11UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer
Center, Aurora, US, 12Vanderbilt University Medical Center, Nashville, US, 13Florida
Cancer Specialists & Research Institute - Lake Mary Cancer Center, Lake Mary, US,
14Dana Farber Cancer Institute, Boston, US, 15Biosplice Therapeutics, Inc., SAN DIEGO,

US, 16NEXT OncologyTM, San Antonio, US

10:25 - 10:35 452O - A phase I dose-escalation and expansion study evaluating the safety and
efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with
solid tumours
P. Schoeffski1, N. Yamamoto2, T. Bauer3, M. Patel4, M. Gounder5, J. Geng6, R. Sailer7, G.

Jayadeva7, P. Lorusso8, 1Leuven Cancer Institute, University Hospitals Leuven, Leuven,
BE, 2National Cancer Center Hospital, Tokyo, JP, 3Tennessee Oncology, Nashville, US,
4Florida Cancer Specialists & Research Institute, Sarasota, US, 5Memorial Sloan

Kettering Cancer Center, New York, US, 6Boehringer Ingelheim Pharmaceuticals Inc,
Ridgefield, US, 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE,
8Yale Cancer Center, New Haven, US

10:35 - 10:45 453O - DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable
antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II
study
T. Doi1, M. Patel2, G. Falchook3, T. Koyama4, C. Friedman5, S. Piha-Paul6, M. Gutierrez7,

R. Abdul-Karim8, M. Awad9, D. Adkins10, S. Takahashi11, S. Kadowaki12, B. Cheng13, N.
Ikeda14, A. Laadem14, N. Yoshizuka14, M. Qian14, O. Dosunmu15, H.-T. Arkenau 16, M.
Johnson15, 1National Cancer Center Hospital East, Kashiwa, Chiba, JP, 2Florida Cancer
Specialists & Research Institute, Sarasota, US, 3Sarah Cannon Research Institute,
Denver, US, 4National Cancer Center Hospital, Chuo City, Tokyo, JP, 5Memorial Sloan
Kettering Cancer Center, New York, US, 6The University of Texas, MD Anderson Cancer

Center Anderson Cancer Center, Houston, US, 7Hackensack University Medical Center,
Hackensack, US, 8Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, 9Dana
Farber Cancer Institute, Boston, US, 10Washington University School of Medicine, St
Louis, US, 11Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-
ku, JP, 12Aichi Cancer Center Hospital, Nagoya, JP, 13Daiichi Sankyo Inc., Basking Ridge,
US, 14Daiichi Sankyo, Inc., Basking Ridge, US, 15Sarah Cannon Research Institute,
Nashville, US, 16Sarah Cannon Research Institute, London, GB

10:45 - 10:55 Invited Discussant 451O, 452O and 453O
P. Cassier, Centre Léon Bérard, Lyon, FR

10:55 - 11:05 Q&A

11:05 - 11:15 450O - Initial monotherapy results of a phase I first-in-human study of ULK1/2
inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition
A. Tolcher1, D.S. Hong2, A. Vandross3, R. Amaravadi4, C. Psoinos5, D. Brennan5, M.L.

Sherman5, R. Ruiz-Soto5, L. Viswanathan5, K. Sprott5, F.J. Reu5, C. Weekes6, 1Texas
Oncology-San Antonio Babcock NEXT Oncology, San Antonio, US, 2The University of
Texas MD Anderson Cancer Center, Houston, US, 3Texas Oncology-Austin North NEXT
Oncology, Austin, US, 4Abramson Cancer Center, University of Pennsylvania,
Philadelphia, US, 5Deciphera Pharmaceuticals, LLC, Waltham, US, 6Massachusetts
General Hospital, Boston, US


11:15 - 11:25 454O - A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination
with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant
prostate cancer (mCRPC)
C. Guo1, A. Sharp1, U. Vogl2, I. Colombo2, A. Stathis2, S. Jain3, K. Chandran1, C. Tiu1, A.

Paschalis1, R. Matthews4, I. Figueiredo5, J. Rekowski4, C. Yap4, M. De Los Dolores Fenor
De La Maza6, A. Turner4, H. Badham4, M. Parmar4, F. Raynaud4, A. Alimonti2, J. De
Bono1, 1Institute of Cancer Research and Royal Marsden Hospital, London, GB, 2EOC -

Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI),
Bellinzona, CH, 3Belfast City Hospital - Belfast Health & Social Care Trust, Belfast, GB,
4Institute of Cancer Research, London, GB, 5The Institute of Cancer Research, Sutton,
GB, 6The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB

C.-C. Lin, NTUH - National Taiwan University Hospital, Taipei City, TW

11:35 - 11:45 Q&A

10:15 - 11:45 Type: Proffered Paper session 7.3.T - Toulouse Auditorium
Title: Proffered Paper session: Sarcoma
Chair(s): Breelyn Wilky, US; Tom Wei-Wu Chen, TW

10:15 - 10:25 1482O - A phase III study comparing methotrexate (M), adriamycin (A) and
cisplatin (P) with MAP + ifosfamide (MAP + IF) for the treatment of
osteosarcoma: JCOG0905
H. Hiraga1, R. Machida2, A. Kawai2, Y. Matsumoto3, T. Yonemoto4, Y. Nishida5, A.

Nagano6, K. Ae7, S. Yoshida8, K. Asanuma9, J. Toguchida10, D. Huruta11, R. Nakayama12,
T. Akisue13, T. Hiruma14, T. Morii15, K. Tanaka16, T. Kataoka17, H. Fukuda2, T. Ozaki18,
1National Hospital Organization, Hokkaido Cancer Center, Sapporo, JP, 2NCCH - National
Cancer Center Hospital, Tokyo, JP, 3Graduate School of Medical Sciences, Kyushu
University, Fukuoka, JP, 4Chiba Cancer Center Hospital, Chiba, JP, 5Nagoya University
Hospital, Nagoya, JP, 6Gifu University School of Medicine, Gifu, JP, 7Cancer Institute

Hospotal of JFCR, Tokyo, JP, 8Tohoku University Hospital, Sendai, JP, 9Mie University
Hospital, Tsu, JP, 10Kyoto University, Kyoto, JP, 11Hiroshima University Hospital,
Hiroshima, JP, 12Keio University School of Medicine, Shinjuku-ku, JP, 13Kobe University
Graduate School of Medicine, Kobe, JP, 14Kanagawa Cancer Center, Yokohama, JP,
15Kyorin University Faculty of Medicine, Mitaka, JP, 16Oita University Faculty of
Medicine, Yufu, JP, 17National Cancer Center - Tsukiji Campus, Tokyo, JP, 18Faculty of
Medicine Dentistry and Pharmaceutical Sciences Okayama University, Okayama, JP

10:25 - 10:35 1483O - Results of a phase I/II combination regimen with ipilimumab (I),
nivolumab (N) and trabectedin (T) as first line therapy for advanced
leiomyosarcoma
E. Gordon1, W.A. Tellez2, D. Brigham2, C. Valencia2, S. Chawla3, V. Chua-Alcala2, A.

Moradhkani2, 1Sarcoma Oncology Research Center, Monterey, US, 2Sarcoma Oncology
Center, Santa Monica, US, 3Sarcoma Oncology Research Center, Santa Monica, US


K. Boye, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

10:45 - 11:00 Q&A

11:00 - 11:10 1485O - Percutaneous uterine needle biopsy with microscopic and array-CGH
analyses in patients with suspicious myometrial tumors on MRI: A prospective
study
J. Smadja1, V. Servois1, G. Pierron2, S. El Zein2, E. Laas2, T. Ramtohul2, D. Tzanis2, S.

Watson2, S. Bonvalot2, 1Institut Curie, PARIS, FR, 2Institut Curie, Paris, FR

11:10 - 11:20 1484O - Deep learning predicts patients’ outcome and mutations from
H&E slides in gastrointestinal stromal tumor (GIST)
A. Italiano1, Y. Fu2, M. Karanian3, R. Perret4, A. Camara2, F. Le Loarer4, M. Jean-Denis3,

I. Hostein4, A. Michot4, F. Ducimetiere3, A. Giraud5, J.-B. Courreges4, K. Courtet6, Y.
Laizet6, J.O. Du Terrail2, B. Schmauch2, C. Maussion2, J.-Y. Blay 3, J.M. Coindre4, 1Institute

Bergonié, Bordeaux, FR, 2OWKIN France, Paris, FR, 3Centre Léon Bérard, Lyon, FR,
4Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR,
5Institut Bergonié, Bordeaux, FR, 6Institut Bergonie, Bordeaux, FR

J. Kather, Uniklinik RWTH Aachen, Aachen, DE

11:30 - 11:45 Q&A


Title: Complex technologies for diagnosis: How do we Auditorium
implement and use them globally?
Chair(s): Joaquin Mateo, ES; Christoph Benedikt Westphalen, DE

C.B. Westphalen, LMU Klinikum der Universität München, Munich, DE

10:20 - 10:40 Applying the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

10:40 - 11:00 The ESMO survey on availability and accessibility of biomolecular technologies
in oncology
A. Bayle, Institut Gustave Roussy, Villejuif, Cedex, FR

11:00 - 11:20 Is drug access the bottleneck of precision medicine?
D. Horgan, European Alliance for Personalised Medicine, Brussels, BE




10:15 - 11:45 Type: Special session 7.3.U - Urval Auditorium
Title: De-escalation of treatment in medical oncology
Chair(s): Hendrik van Halteren, NL; Michiel Strijbos, BE

H. Van Halteren, Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL

10:20 - 10:35 An ESMO framework for de-escalation of antineoplastic therapies: Principles and
considerations
D. Trapani, Dana Farber Cancer Institute, Boston, US

10:35 - 10:50 Fundamentals of de-escalation
M. Strijbos, GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE

10:50 - 11:05 The use of biomarkers in de-escalation
A. Stenzinger, University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE

11:05 - 11:20 De-escalation from a patients’ perspective
T. Spanic, Europa Donna Slovenia, Ljubljana, SI

11:20 - 11:35 Challenges in de-escalation trials
H. Van Halteren, Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL

11:35 - 11:45 Discussion and Q&A

10:15 - 11:45 Type: EONS session 7.3.S - Strasbourg
Title: Health promotion, prevention, and Auditorium
screening
Chair(s): Amanda Drury, IE

10:15 - 10:30 EONS focus on cancer prevention
L. Sharp, RCC Stockholm-Gotland, HSF, Stockholm, SE

10:30 - 10:45 Physical activity and cancer
M. Himberg, Turku University Hospital (Tyks), Turku, FI

10:45 - 11:00 Prevention and early detection for hereditary breast and ovarian cancer
syndromes
E. O'Donovan, Hermitage Medical Clinic, Dublin, IE

11:00 - 11:10 CN12 - Impact of diet on immune checkpoint blockade: Nurse-directed dietary
intervention
J. Malo1, M. Benlaïfaoui1, K. Diop1, M. Messaoudene1, W. Belkaid1, A. Elkrief2, N. Blais3,

M. Tehfe3, M. Florescu3, A. Al-Saleh1, A. Leblanc2, V. Marcil4, B. Routy3, C. Richard1,
1Université de Montreal, Montreal, CA, 2McGill University Healthcare Centre, Montreal,
CA, 3CHUM - Centre Hospitalier de l’Université de Montréal, Montreal, CA, 4Research

Centre, Sainte-Justine University Health Center, Montreal, CA

11:10 - 11:20 CN13 - Nutriscore: Nutritional screening in colorectal cancer patients previous
to cancer-specific treatment
R. Legido-Diaz1, L. Raventos1, M. Bellver1, A.R. Gonzalez1, L. Hurtos1, I. Peiró

Martínez2, L. Arribas3, 1ICO - Institut Català d'Oncologia - Hospital Duran i Reynals,
Hospitalet de Llobregat, ES, 2ICO - Institut Català d'Oncologia l'Hospitalet (Hospital
Duran i Reynals), Hospitalet de Llobregat, ES, 3Institut Català D´Oncologia, Barcelona,
ES

11:20 - 11:30 CN15 - Individual factors leading to delay in diagnosis in patients with colorectal
cancer and their illness perceptions
Ü. Ege Tanrıkulu1, S. Kav2, 1Baskent University - Ankara Hospital, Ankara, TR, 2Baskent

University, Ankara, TR

11:30 - 11:40 CN14 - Cancer prevention awareness among Croatian AYA population
N. Dodlek1, S. Islamčević2, J. Miličević2, M. Vukoje2, A. Sajnic2, S. Karabatic3, D. Anić4,

A. Perković2, M. Šušnjara2, T. Ladenhauser5, I. Jelinčić6, 1University Hospital Center
Osijek, Osijek, HR, 2KBC - University Hospital Centre Zagreb, Zagreb, HR, 3KBC Zagreb

- Clinic for Lung Diseases Jordanovac, Zagreb, HR, 4Osijek-Baranja County Health
Center, Osijek, HR, 5KBC Osijek - Clinical Medical Center Osijek, Osijek, HR, 6Faculty for
Medicine and Dental Health Osijek, Osijek, HR



Title: Let’s talk about sex and cancer
Chair(s): Matteo Lambertini, IT

M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul

Cancro, Genova, IT

10:35 - 10:50 Implementing onco-fertility care to allow patient access to fertility preservation

Cancro, Genova, IT

10:50 - 11:05 Sexual health: If you don’t address it, patients don’t ask
S. Bober, Boston, MA, US

11:05 - 11:20 Onco-fertility care is not only fertility preservation: Counseling patients about
pregnancy and contraception
I. Demeestere, Brussels, LU


10:30 - 11:30 Type: Challenge your Expert 7.3.Q - Quimper Auditorium
Title: Treating KRAS mutant tumour
Chair(s): Ben Solomon, AU

10:30 - 10:45 Treating KRAS mutant tumour
J. Downward, London, GB

B. Solomon, Peter MacCallum Cancer Center, Melbourne, AU

11:00 - 11:45 Type: Young Oncologist session 7.3.R - Rennes
Title: Young Oncologist Brunch 1: Integrating Patient Auditorium
Reported Outcomes in clinical practice
Chair(s): Claudia Cardone, IT

11:00 - 11:15 Integrating Patient Reported Outcomes in clinical practice
M. Di Maio, Azienda Ospedaliera Ordine Mauriziano - Presidio Umberto I, Torino, IT

C. Cardone, Instituto Nazionale Tumori—IRCCS Fondazione Pascale, Napoli, IT


12:00 - 12:30 Type: Keynote lecture 4.B - Brest
Title: What is the future of digital medicine for cancer Auditorium
patients?
Chair(s): Fabrice André, FR

12:00 - 12:05 Introduction by the Chair
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

12:05 - 12:30 What is the future of digital medicine for cancer patients?
D. Schrag, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

12:00 - 13:30 Type: EONS Industry Satellite Symposium 7.3.S -
Title: AstraZeneca, Eli Lilly, Novartis - Experience of living with Strasbourg
Early Breast Cancer, treatment and beyond: What are we missing Auditorium
Chair(s): Theresa Wiseman, GB

12:00 - 12:05 Welcome
T. Wiseman, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

12:05 - 12:20 FILM (pre-recorded): How people experience of early breast cancer, impact of
diagnosis and treatment

12:20 - 12:40 Evidence re unmet need for people with early breast cancer in Europe
A. Shewbridge, Private Practice, London, GB

12:40 - 12:55 FILM (pre-recorded): How people experience of early breast cancer, end of
treatment and living well

12:55 - 13:15 Discussion concerning patient film and evidence
M. Van Klinken1, E. Wiseman2, C. Díez De Los Ríos De La Serna3, A. Shewbridge4,

1Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam,

NL, 2AstraZeneca, Northolt, GB, 3Vall d'Hebron University Hospital, Barcelona, ES,
4Private Practice, London, GB

13:15 - 13:25 Recommendations for future practice
M. Van Klinken1, T. Wiseman2, C. Díez De Los Ríos De La Serna3, A. Shewbridge4,

1Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam,

NL, 2The Royal Marsden Hospital - NHS Foundation Trust, London, GB, 3Vall d'Hebron
University Hospital, Barcelona, ES, 4Private Practice, London, GB

13:25 - 13:30 Conclusion remarks


12:00 - 13:00 Type: Special session Networking
Title: ONSITE ONLY: Patient guide: How can cancer affect bone Hub
health? 

12:00 - 13:00 Speaker panel
E. Trigoso Arjona1, N. Dodlek2, C. Ernst-Guenther3, A. Deschamps4, 1Hospital

Universitari i Politècnic La Fe, Valencia, ES, 2KBC Osijek - Clinical Medical Center Osijek,

Osijek, HR, 3Europa Uomo - Bundesverband Prostatakrebs Selbsthilfe e. V. (BPS), Bonn,
DE, 4Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE

13:00 - 14:30 Type: Industry Satellite Symposium 7.2.F -
Title: Incyte Biosciences International Sàrl - Targeting FGFR Fécamp
alterations in cholangiocarcinoma and other solid tumours: A new Auditorium
frontier in personalised medicine
Chair(s): David Malka, FR; Juan Valle, GB

J. Valle, The Christie NHS Foundation Trust, Manchester, GB

13:05 - 13:18 Cholangiocarcinoma: The little-known, rare cancer of the biliary tract
F.G.M. De Braud, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

13:18 - 13:31 The challenges associated with diagnosing intrahepatic cholangiocarcinoma for
targeted therapies

13:31 - 13:44 Optimising molecular profiling and the multidisciplinary team approach in
cholangiocarcinoma

13:44 - 13:58 Clinical practice guidelines for biliary tract cancer: Updates for the management
of patients with locally advanced or metastatic intrahepatic cholangiocarcinoma
D. Malka, Institut Gustave Roussy, Villejuif, Cedex, FR

13:58 - 14:11 Targeting FGFR alterations in cholangiocarcinoma and other solid tumours
A. Hollebecque, Institut Gustave Roussy, Villejuif, Cedex, FR

J. Valle1, D. Malka2, F.G.M. De Braud3, A. Lamarca4, A. Hollebecque2, 1The Christie NHS

Foundation Trust, Manchester, GB, 2Institut Gustave Roussy, Villejuif, Cedex, FR,

3Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 4Hospital Universitario
Fundacion Jimenez Diaz, Madrid, ES

14:29 - 14:30 Closing remarks
D. Malka, Institut Gustave Roussy, Villejuif, Cedex, FR


13:00 - 14:29 Type: Industry Satellite Symposium 7.1.D -
Title: MSD - Navigating through the rapidly evolving treatment Dijon
landscape for GI Cancers - A Clinical & Patient Centric Approach Auditorium
towards implementing Immunotherapy
Chair(s): Michel Ducreux, FR

13:00 - 13:05 Introduction and Welcome
M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

13:05 - 13:20 Moving the Needle in HER2 Positive Gastroesophageal Cancer
Y. Janjigian, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

13:20 - 13:35 Changing GEC Patient Care with IO plus Chemotherapy in First-Line
M. Moehler, Universitätsmedizin Mainz, Mainz, DE

13:35 - 13:47 The IO Revolution of Patient Treatment in HCC
R. Finn, UCLA - David Geffen School of Medicine, Los Angeles, US

13:47 - 13:59 Changing the Treatment Paradigm in First-Line Biliary Tract Cancers

13:59 - 14:09 Treating GI Patients in Europe Based on Tumor Characteristics

14:09 - 14:24 Final Q&A and Discussion Session
M. Ducreux1, Y. Janjigian2, M. Moehler3, R. Finn4, A. Vogel5, 1Gustave Roussy - Cancer

Campus, Villejuif, FR, 2MSKCC - Memorial Sloan Kettering Cancer Center, New York, US,
3Universitätsmedizin Mainz, Mainz, DE, 4UCLA - David Geffen School of Medicine, Los
Angeles, US, 5MHH - Medizinische Hochschule Hannover, Hannover, DE

14:24 - 14:29 Summary and Adjournment


13:00 - 14:30 Type: Industry Satellite Symposium 7.3.G - Grenoble
Title: Pfizer Oncology - Journey through patient care: Long- Auditorium
term experience in advanced breast cancer
Chair(s): Paul Cottu, FR

P. Cottu, Institut Curie, Paris, FR

13:05 - 14:05 Navigating aBC case loads: Balancing evidence with experience
P. Cottu1, N. Harbeck2, N. Turner3, 1Institut Curie, Paris, FR, 2Ludwig Maximilians

University - Grosshadern, Munich, DE, 3 London, GB
14:05 - 14:25 Questions and discussion
P. Cottu1, N. Harbeck2, N. Turner3, 1Institut Curie, Paris, FR, 2Ludwig Maximilians

University - Grosshadern, Munich, DE, 3 London, GB

P. Cottu, Institut Curie, Paris, FR


13:00 - 14:30 Type: ESMO Colloquium 7.3.H -
Title: ESMO Colloquium Supported by Lilly and Thermo Fisher Honfleur
Scientific: The practice and promise of NGS tissue testing for Auditorium
tumour-agnostic precision therapeutics
Chair(s): Vivek Subbiah, US; Javier Hernandez-Losa, ES

J. Hernandez-Losa, Vall d'Hebron University Hospital, Barcelona, ES

13:05 - 13:20 Tumour-agnostic precision therapeutics in molecular oncology: Target versus
tissue context: Evidence for benefit and taxonomy considerations
V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Houston, US

13:20 - 13:35 NGS tissue testing in the search of actionable biomarkers in solid tumours:
When is it indicated?

13:35 - 13:50 Optimally integrating tumour tissue NGS in the care pathway: Preanalytics,
analytics, cost and reimbursement
J. Hernandez-Losa, Vall d'Hebron University Hospital, Barcelona, ES

13:50 - 14:05 The non-small cell lung cancer paradigm in translating NGS information to clear
actionable insights: Standardised reporting, molecular tumour boards and
decision-support systems
O. Gautschi, Luzerner Kantonsspital, Sursee, CH


14:25 - 14:30 Concluding remarks
V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Houston, US


13:00 - 14:30 Type: Industry Satellite Symposium 7.3.O -
Title: GSK - Avant-garde: Reframing the art of first-line Orléans
maintenance therapy to optimise long-term outcomes in advanced Auditorium
ovarian cancer
Chair(s): Gilles Freyer, FR

G. Freyer, Hôpital de la Croix-Rousse, Lyon, FR

13:10 - 13:30 State of the art: What are the most current data and updates to treatment
guidelines for first-line maintenance in ovarian cancer
D. Lorusso, Rome, IT

13:30 - 13:50 The art of treatment selection: Importance and impact of early treatment
planning
C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB

13:50 - 14:20 Articles of individualised treatment: How can we begin to individualise
treatment using biomarkers and available therapies



Title: Janssen-Cilag International NV - Precision approaches in Quimper
EGFR-mutant NSCLC: Optimising outcomes for patients Auditorium
Chair(s): David Planchard, FR; Maria Rosario Garcia Campelo, ES

13:00 - 13:05 Welcome & Introduction
D. Planchard, Institut Gustave Roussy, Villejuif, Cedex, FR

13:05 - 13:15 Updates in precision approaches to the molecular diagnosis of NSCLC
P. Hofman, CHU Nice - Hopital Pasteur, Nice, FR

13:15 - 13:25 Discussion: How can we address diagnostic challenges of NSCLC in clinical
practice?
D. Planchard1, M.R. Garcia Campelo2, S. Popat3, A.-M. Dingemans4, P. Hofman5, 1Institut

Gustave Roussy, Villejuif, Cedex, FR, 2Instituto de Investigación Biomédica de A Coruña
(INIBIC), A Coruña, ES, 3The Royal Marsden Hospital - NHS Foundation Trust, London,
GB, 4Erasmus MC - University Medical Center, Rotterdam, NL, 5CHU Nice - Hopital
Pasteur, Nice, FR

13:25 - 13:40 New and emerging therapies for EGFR-mutant NSCLC
A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

13:40 - 13:50 Discussion: What does the future hold for the management of EGFR-mutant
NSCLC?

Pasteur, Nice, FR

13:50 - 14:00 Emerging treatment options for EGFR exon 20 insertions
S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

14:00 - 14:25 Q&A

Pasteur, Nice, FR

14:25 - 14:30 Key learnings and closing remarks
M.R. Garcia Campelo, Instituto de Investigación Biomédica de A Coruña (INIBIC), A

Coruña, ES


13:00 - 14:30 Type: Industry Satellite Symposium 7.3.T -
Title: Bristol Myers Squibb - The Treatment Paradigm Shift: Toulouse
Unlocking New Chapters with I-O in Thoracic Cancers Auditorium
Chair(s): Virginie Westeel, FR

13:00 - 13:05 Welcome and Introductions
V. Westeel, CHRU Besancon - Hopital Jean Minjoz, Besancon, FR

13:05 - 13:35 Multidisciplinary Conversation: Putting I-O on the Table for Patients with
Resectable NSCLC
J. Spicer, McGill University, Montreal, CA

13:35 - 14:00 Considering the Options: Survivorship in Metastatic NSCLC and Potential
Approaches for I-O–Experienced Patients
V. Westeel, CHRU Besancon - Hopital Jean Minjoz, Besancon, FR

14:00 - 14:15 Making Progress for Patients: How I-O Has Changed Outcomes in Unresectable
MPM
D. Fennell, Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust,

Leicester, GB

14:15 - 14:30 Live Q&A and Closing Remarks
V. Westeel1, J. Spicer2, D. Fennell3, 1CHRU Besancon - Hopital Jean Minjoz, Besancon,

FR, 2McGill University, Montreal, CA, 3Leicester Royal Infirmary - University Hospitals of
Leicester NHS Trust, Leicester, GB


Title: Patient involvement in clinical research: Placing the Auditorium
patient at the centre
Chair(s): Gilliosa Spurrier-Bernard, FR; Jana Pelouchova, CZ

13:00 - 13:15 The importance of joining clinical research to improve cancer research
outcomes
W. Van Der Graaf, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek

Hospital, Amsterdam, NL

13:15 - 13:30 How can patients get involved in clinical trials?
E. Verschuur-Van Der Voort, Dutch Breast Cancer Coalition, Bloemendaal, NL

13:30 - 13:45 How is patient data crucial to advance scientific research?
T. Willgoss, EFPIA - European Federation of Pharmaceutical Industries and Associations,

Brussels, BE

13:45 - 14:00 How can patients’ involvement in clinical trial design save lives?
G. Spurrier-Bernard, MelanomeFrance and Melanoma Patients Network Europe, Teilhet,

FR

14:00 - 14:15 Case study: Patients being involved in clinical research
E. Lacointe Artzner, InfoSarcomes, Rennes, FR




13:00 - 14:30 Type: Industry Satellite Symposium 7.3.U - Urval
Title: Merck Pfizer Alliance - New approaches to optimize Auditorium
treatment outcomes in advanced urothelial carcinoma
Chair(s): Joaquim Bellmunt, US

13:00 - 13:15 Recent milestones in the evolution of Standard of Care treatment in advanced
urothelial carcinoma

13:15 - 13:35 Sequencing anticancer agents across lines of therapy in advanced urothelial
carcinoma
S. Sridhar, UHN - University Health Network - Princess Margaret Cancer Center,

Toronto, CA

13:35 - 13:55 Learnings from real-world data to optimize treatment in advanced urothelial
carcinoma
A. Merseburger, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck,
Lübeck, DE

13:55 - 14:25 Mini-debates on ‘hot topics’ in advanced urothelial carcinoma
J. Bellmunt1, S. Sridhar2, A. Merseburger3, 1 Boston, US, 2UHN - University Health

Network - Princess Margaret Cancer Center, Toronto, CA, 3UKSH - Universitätsklinikum
Schleswig-Holstein - Campus Lübeck, Lübeck, DE



Title: eHealth and digital innovations
Chair(s): Wendy Oldenmenger, NL

13:45 - 14:00 Efficiency of eHealth and digital innovations in cancer care
A. Charalambous, Cyprus University of Technology - Nursing Science, Limassol, CY

14:00 - 14:15 Development and implementation of virtual pre-chemotherapy consultations
C. Oakley, Guy's Hospital, London, GB

14:15 - 14:25 CN1 - Patient-reported symptom monitoring improves health-related quality of
life in lung cancer patients: The SYMPRO-Lung trial
N. Billingy1, V. Tromp1, A. Becker1, R. Hoek1, N. Aaronson2, H.-J. Bogaard1, J.

Hugtenburg1, B. Onwuteaka-Philipsen1, L. Van De Poll-Franse2, J. Belderbos2, C. Van Den
Hurk3, I. Walraven4, 1Amsterdam UMC - Vrije University Medical Centre (VUmc),

Amsterdam, NL, 2NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek
Hospital, Amsterdam, NL, 3IKNL - Netherlands Comprehensive Cancer Organisation,
Utrecht, NL, 4Radboud University Medical Center, Nijmegen, Nijmegen, NL

14:25 - 14:35 CN2 - A public involvement process to enhance diversity in technology clinical
trials
L. Goodwin1, A. Keane2, K. Harrigan2, P. Contributors2, M. Syed Ali2, L. Laverty2, S.

Saeed1, B. Starling2, D. Graham3, 1The Christie NHS Foundation Trust, Manchester, GB,

2The University of Manchester, Manchester, GB, 3Christie Hospital NHS Foundation



14:45 - 16:15 Type: Educational session 4.A - Antibes
Title: Is immunotherapy changing the standard of care in Auditorium
gynaecological cancers?
Chair(s): Ana Oaknin, ES; Alexandra Leary, FR

14:45 - 15:10 Endometrial cancer
D. Lorusso, Rome, IT

15:10 - 15:35 Cervical cancer
A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

15:35 - 16:00 Ovarian cancer
E. Pujade-Lauraine, ARCAGY-GINECO, Paris, FR


14:45 - 16:15 Type: Mini Oral session 7.2.E - Évry Auditorium

Title: Mini Oral session: Breast cancer, metastatic
Chair(s): Shaheenah Dawood, AE; Sung-Bae Kim, KR; Shom Goel, AU

14:45 - 14:50 LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/-
fulvestrant versus trastuzumab plus chemotherapy in patients with HR+,
HER2+ advanced breast cancer (monarcHER): A randomized, open-label,
phase II trial
F. André1, J. Nadal2, H. Denys3, S. Goel4, L. Litchfield5, A. Appiah5, Y. Chen5, S. Tolaney6,

1Gustave Roussy - Cancer Campus, Villejuif, FR, 2Instituto Alexander Fleming, Buenos
Aires, AR, 3UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, 4Peter MacCallum Cancer
Centre, Melbourne, AU, 5Eli Lilly and Company - Global Headquarters, Indianapolis, US,
6Dana Farber Cancer Institute, Boston, US

14:50 - 14:55 LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for
HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
B. Xu1, M. Yan2, F. Ma1, W. Li3, Q. Ouyang4, Z. Tong5, Y. Teng6, S. Wang7, Y. Wang8, C.

Geng9, T. Luo10, J. Zhong11, Q. Zhang12, Q. Liu13, X. Zeng14, T. Sun15, Q. Mo16, F.
Dong17, S. Wu17, X. Zhu17, 1Cancer Hospital Chinese Academy of Medical Sciences and
Peking Union Medical College, Beijing, CN, 2Henan Breast Cancer Center, The Affiliated
Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN,
3The First Hospital of Jilin University, Changchun, CN, 4Hunan Cancer Hospital, The
Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University,

Changsha, CN, 5Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, 6The
First Hospital of China Medical University, Shenyang, CN, 7Sun Yat-sen University

Cancer Center, Guangzhou, CN, 8Shandong Cancer Hospital & Institute, Jinan, CN, 9The
Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang,
CN, 10West China Hospital, Sichuan University, Chengdu, CN, 11The First Affiliated
Hospital of Guangxi Medical University, Nanning, CN, 12Cancer Hospital Harbin Medical
University, Harbin, CN, 13Sun Yat-sen Memorial Hospital, Sun Yat-sen University,

Guangzhou, CN, 14Affiliated Cancer Hospital of Chongqing University, Chongqing, CN,
15Liaoning Cancer Hospital & Institute, Shenyang, CN, 16Guangxi Medical University
Affiliated Tumor Hospital, Nanning, CN, 17Jiangsu Hengrui Pharmaceuticals Co., Ltd.,
Shanghai, CN

S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

15:05 - 15:10 LBA20 - Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv)
for women with locally advanced/metastatic ER+/HER2- breast cancer
(mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on
aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
M. Goetz1, P. Plourde2, D. Stover3, N. Bagegni4, G. Vidal5, A. Brufsky6, H. Rugo7, D.

Portman2, E. Gal-Yam 8, 1Mayo Clinic, Rochester, US, 2Sermonix Pharmaceuticals,
Columbus, US, 3OSUCCC - The Ohio State University Comprehensive Cancer Center -
James, Columbus, US, 4Washington University School of Medicine in St. Louis - Siteman
Cancer Center, St. Louis, US, 5West Cancer Center and Research Institute - East
Campus, Germantown, US, 6Comprehensive Breast Cancer Center, University of
Pittsburgh Medical Center, Pittsburgh, US, 7UCSF Helen Diller Family Comprehensive
Cancer Center, San Francisco, US, 8Chaim Sheba Medical Center, Ramat Gan, IL

15:10 - 15:15 211MO - Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy
(PCET) in patients (pts) with ER+, HER2– locally
advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II,
randomised, open-label acelERA BC study
M. Martin Jimenez1, E. Lim2, M. Chavez Mac Gregor3, A. Bardia4, J. Wu5, Q. Zhang6, Z.

Nowecki7, F. Cruz8, R. Safin9, S.-B. Kim10, C. Schem11, A. Montero12, S. Khan13, R.
Bandyopadhyay14, M. Shivhare15, M. Patre16, J. Martinalbo16, L. Roncoroni16, P. Pérez-
Moreno14, J. Sohn17, 1Hospital General Universitario Gregorio Marañón, Madrid, ES, 2St
Vincent's Clinical School, Darlinghurst, AU, 3MD Anderson Cancer Center, Houston, US,
4Harvard Medical School, Boston, US, 5Fudan University Cancer Institute, Shanghai, CN,
6Harbin Medical University Cancer Hospital, Harbin, CN, 7Maria Skłodowska-Curie

National Research Institute of Oncology, Warsaw, PL, 8De Controle Do Cancer-IBCC
Nucleo De Pesquisa Sao-Camilo, São Paulo, BR, 9Ministry of Health of the Republic of
Tatarstan, Kazan, RU, 10University of Ulsan College of Medicine, Seoul, KR,
11Mammazentrum Hamburg, Hamburg, DE, 12University Hospitals Seidman Cancer
Center, Cleveland, US, 13City Hospital Campus, Nottingham, GB, 14Genentech, Inc.,
South San Francisco, US, 15Roche Products Limited, Welwyn Garden City, GB, 16F.
Hoffmann-La Roche Ltd, Basel, CH, 17Yonsei University College of Medicine, Seoul, KR

15:15 - 15:20 212MO - AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine
treatment of physician’s choice (TPC) in patients (pts) with endocrine-
resistant ER+/HER2− advanced breast cancer (aBC)
S. Tolaney1, A. Chan2, K. Petrakova3, S. Delaloge4, M. Campone5, H. Iwata6, P. Peddi7, P.

Kaufman8, E. De Kermadec9, Q. Liu9, P. Cohen10, G. Paux9, S.-A. Im11, 1Dana Farber
Cancer Institute, Boston, US, 2Curtin University, Perth, AU, 3Masaryk Memorial Cancer
Institute, Brno, CZ, 4Institut Gustave Roussy, Villejuif, FR, 5Institut de cancérologie de

l’Ouest, Saint-Herblain, FR, 6Aichi Cancer Center Hospital, Nagoya, JP, 7Providence Saint

John’s Cancer Institute, Santa Monica, US, 8University of Vermont - Larner College of
Medicine, Burlington, US, 9Sanofi, Cambridge, US, 10Sanofi, Vitry-sur-Seine, FR, 11Seoul
National University Hospital, Seoul National University College of Medicine, Seoul, KR

15:20 - 15:35 Invited Discussant LBA20, 211MO and 212MO
S. Dawood, Mediclinic City Hospital, Dubai, AE

15:35 - 15:40 213MO - Primary endpoint analysis of a randomized phase II of darolutamide or
capecitabine in patients with triple-negative androgen receptor-positive
advanced breast cancer (UCBG3-06 START trial)
M. Arnedos1, A. Goncalves2, M. Pulido3, F. Lerebours4, O. Tredan5, F. Dalenc6, S. Guiu7,

D. Mollon Grange8, L. Teixeira9, C. Levy10, B. Verret11, H. Dawood12, P. Augereau13, L.
Deiana14, S. Ladoire15, E. Carola16, M.A. Mouret Reynier17, C. Guyonneau18, G.
Macgrogan19, H. Bonnefoi19, 1Institute Bergonié, Bordeaux, FR, 2Institute Paoli
Calmettes, Marseille, FR, 3Institut Bergonie, BORDEAUX, FR, 4Hôpital René Huguenin -
Institut Curie, St. Cloud, FR, 5Centre Léon Bérard, Lyon, FR, 6Centre Claudius-Regaud,
Toulouse, FR, 7ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, 8Centre

Hospitalier de Cornouaille - Site de Laennec, Quimper, Cedex, FR, 9Hopital Saint Louis
AP-HP, Paris, FR, 10Centre Francois Baclesse, Caen, FR, 11Gustave Roussy, VILLEJUIF,
FR, 12CHR Orléans, Orléans, FR, 13Centre Paul Papin, Angers, FR, 14CHRU Brest -
Hopital Augustin Morvan, Brest, FR, 15Centre Georges-François Leclerc (Dijon), Dijon,
FR, 16GHPSO, Creil, FR, 17Jean Perrin Center, Clermont-Ferrand, FR, 18Unicancer, Paris,
FR, 19Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux,
FR

15:40 - 15:45 214MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-
positive/human epidermal growth factor receptor 2-negative
(HR+/HER2–) metastatic breast cancer (MBC) by HER2
immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
P. Schmid1, J. Cortés2, F. Marmé3, H. Rugo4, S. Tolaney5, M. Oliveira6, D. Loirat7, K.

Jhaveri8, O.K. Yoon9, M. Motwani9, H. Wang9, R. Delaney9, A. Bardia10, 1Cancer
Research UK Barts Centre - Barts and The London School of Medicine and Dentistry,
London, GB, 2International Breast Cancer Center (IBCC), Quiron Group, Madrid &
Barcelona, Barcelona, ES, 3Heidelberg University, University Hospital Mannheim,
Mannheim, DE, 4University of California San Francisco Helen Diller Family
Comprehensive Cancer Center, San Francisco, US, 5Dana Farber Cancer Institute,
Boston, US, 6Vall d'Hebron Institute of Oncology, Barcelona, ES, 7Institut Curie, Paris,
FR, 8Memorial Sloan Kettering, New York, NY, US, 9Gilead Sciences, Inc., Foster City,
US, 10Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston,
US

15:45 - 15:50 215MO - ICON – a randomized phase IIb study evaluating chemotherapy
combined with ipilimumab and nivolumab in metastatic hormone receptor-
positive breast cancer
J.A. Kyte1, N. Andresen1, C. Quaghebeur2, B. Gilje3, B. Boge4, A. Gombos5, A. Røssevold1,

R. Mathiesen6, E. Borgen7, R.S. Falk8, L. Julsrud7, H.G. Russnes9, O.C. Lingjærde7, B.
Naume1, 1Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, 2CHR -
Centre Hospitalier Régional de Namur, Namur, BE, 3Stavanger University Hospital -

Helse Stavanger HF, Stavanger, NO, 4Sørlandet Hospital HF, Kristiansand, NO, 5Institute

Jules Bordet, Brussels, BE, 6Oslo University Hospital, Ulleval, Oslo, NO, 7Oslo University
Hospital, Oslo, NO, 8Oslo University Hospital - Rikshospitalet, Oslo, NO, 9Oslo University
Hospital - Radiumhospitalet, Oslo, NO

15:50 - 15:55 216MO - A randomized phase II trial of metronomic oral vinorelbine plus
cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or
second-line treatment in patients (pts) with ER+/HER2- metastatic breast
cancer (MBC): The METEORA-II trial (IBCSG 54-16)
E. Munzone1, M. Regan2, S. Cinieri3, E. Montagna1, L. Orlando3, R. Shi2, E. Campadelli4,

L. Gianni5, U. De Giorgi6, C. Bengala7, D. Generali8, E. Collova9, F. Puglisi10, E.
Cretella11, C. Zamagni12, C. Chini13, A. Goldhirsch1, M. Colleoni1, 1IEO - Istituto
Europeo di Oncologia, Milan, IT, 2Dana Farber Cancer Institute, Boston, US, 3Ospedale A.
Perrino, Brindisi, IT, 4Opsedale degli Infermi - AUSL Romagna, Faenza, IT, 5Ospedale
Infermi, Rimini, IT, 6IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino
Amadori, Meldola, IT, 7Ospedale della Misericordia, Grosseto, IT, 8Università di Trieste,
Trieste, IT, 9Ospedale Civile di Legnano, Legnano, IT, 10CRO di Aviano, National Cancer
Institute, IRCCS; Department of Medicine (DAME), University of Udine, Udine, IT,
11Ospedale Centrale di Bolzano ASDAA/SABES, Bolzano, IT, 12IRCCS Azienda-
ospedaliero-universitaria di Bologna, Bologna, IT, 13ASST - Sette Laghi, Varese, IT

15:55 - 16:10 Invited Discussant 213MO, 214MO, 215MO and 216MO
S. Goel, Peter MacCallum Cancer Centre, Melbourne, AU

Title: Proffered Paper session 1: Melanoma and other Auditorium
skin tumours
Chair(s): Caroline Robert, FR; Ryan Sullivan, US

14:45 - 14:55 784O - Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab
(IPI) versus placebo in stage IV melanoma with no evidence of disease (NED):
Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-
center phase II DeCOG trial
D. Schadendorf1, J. Hassel2, M. Fluck3, T. Eigentler4, C. Loquai5, S. Haferkamp6, R.

Gutzmer7, F. Meier8, P. Mohr9, A. Hauschild10, C. Menzer11, F. Kiecker12, E. Dippel13, J.-
C. Simon14, B. Conrad3, C. Garbe15, S. Körner16, J.C. Becker17, L. Zimmer1, E.
Livingstone1, 1University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE,
2NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, 3Fachklinik
Hornheide, Münster, DE, 4Charité – Universitätsmedizin Berlin, Berlin, DE,

5Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, 6UKR -
University Hospital Regensburg, Regensburg, DE, 7Ruhr University Bochum

Medizinische Universitätsklinik, Bochum, DE, 8Universitätsklinikum Carl Gustav Carus
Dresden, Dresden, DE, 9Dermatologic Center Buxtehude, Buxtehude, DE, 10UK-SH
Campus Kiel, Kiel, DE, 11Heidelberg University Hospital, Heidelberg, DE, 12Vivantes
Klinikum Neukoelln, Berlin, DE, 13Klinikum der Stadt Ludwigshafen am Rhein gGmbH,
Ludwigshafen, DE, 14Universitätsklinikum Leipzig Klinik and Poliklinik für
Dermatologie,Venerologie und Allergologie, Leipzig, DE, 15Universitaets-Hautklinik
Tuebingen, Tuebingen, DE, 16University Hospital Heidelberg, Heidelberg, DE, 17DKFZ -
German Cancer Research Center, Heidelberg, DE


14:55 - 15:05 LBA39 - Final 5-year results of the phase II, multicenter, randomized, open-label
trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus
surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a
melanoma (MEL)
R. Dummer1, D. Gyorki2, J. Hyngstrom3, A. Berger4, R. Conry5, L. Demidov6, L. Ning7, T.

Lawrence8, M. Faries9, M. Ross10, 1Universitätsspital Zürich - Klinik für Dermatologie,
Zurich, CH, 2Olivia Newton-John Cancer Centre, Victoria, AU, 3University of Utah Health
- Huntsman Cancer Institute, Salt Lake City, US, 4Rutgers Cancer Institute of New Jersey,
New Brunswick, US, 5University of Alabama at Birmingham - School of Medicine,
Birmingham, US, 6N.N. Blokhin Russian Cancer Research Center, Moscow, RU, 7Parexel
China Co. Ltd., Guangzhou, CN, 8AMGEN (Headquarters) - USA, Thousand Oaks, US,
9The Angeles Clinic and Research Institute, Los Angeles, US, 10MD Anderson Cancer
Center, Houston, US


15:15 - 15:30 Q&A

15:30 - 15:40 LBA40 - Phase II study of multiple LXH254 drug combinations in patients (pts)
with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma
C. Lebbe1, G. Long2, C. Robert3, O. Hamid4, V. Atkinson5, A. Shoushtari6, A. Daud7, O.

Bechter8, D. Schadendorf9, R. Sullivan10, R. Dummer11, J.J. Grob12, N. Lewis13, L. Fan13,
S. Basu13, G. Caponigro13, V. Cooke13, A. Lau13, R. Amaria14, 1Université Paris Cité, AP-
HP Hôpital Saint-Louis, Paris, FR, 2Melanoma Institute Australia, University of Sydney
and Royal North Shore and Mater Hospitals, Sydney, AU, 3Institute Gustave Roussy,
Villejiuf, FR, 4The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Los
Angeles, CA, US, 5Princess Alexandra Hospital, University of Queensland, Brisbane, AU,
6Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York,
US, 7University of California, San Francisco, CA, US, 8University Hospital Leuven,
Leuven, BE, 9University Hospital Essen, Essen, DE, 10Massachusetts General Hospital,
Boston, MA, US, 11University Hospital Zürich, Zurich, CH, 12Timone AP-HM Hospital,
Marseille, FR, 13Novartis Institutes for BioMedical Research, Cambridge, US,
14University of Texas M.D. Anderson Cancer Center, Houston, US

15:40 - 15:50 785O - PIVOT IO 001: First disclosure of efficacy and safety of
bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in
advanced melanoma (MEL)
A. Diab1, H. Gogas2, S. Sandhu3, G. Long4, P. Ascierto5, J. Larkin6, M. Sznol7, F. Franke8,

T.-E. Ciuleanu9, E. Muñoz Couselo10, A. Perfetti11, C. Lebbe12, F. Meier13, B. Curti14, C.
Rojas15, H. Yang16, M. Zhou16, S. Ravimohan16, M. Tagliaferri17, N. Khushanlani18, 1The
University of Texas MD Anderson Cancer Center, Houston, US, 2National and
Kapodistrian University of Athens, Athens, GR, 3Peter MacCallum Cancer Centre,
Melbourne, AU, 4Melanoma Institute Australia, The University of Sydney, Royal North
Shore and Mater Hospitals, Sydney, AU, 5Istituto Nazionale Tumori IRCCS Fondazione G.
Pascale, Naples, IT, 6The Royal Marsden Hospital, London, GB, 7Yale Cancer Center, Yale
University School of Medicine and Smilow Cancer Hospital Yale New Haven Health, New


Haven, US, 8Oncosite Centro de Pesquisa Clínica, Ijui, BR, 9Institutul Prof Dr Ion
Chiricuţă, Cluj-Napoca, RO, 10Vall d’Hebron University Hospital and Vall d’Hebron
Institute of Oncology VHIO, Barcelona, ES, 11Clínica Adventista Belgrano, Buenos Aires,
AR, 12Université Paris Cité, APHP Dermatology and CIC Paris, Paris, FR, 13Skin Cancer
Center at the University Cancer Centre Dresden and National Center for Tumor Diseases
Dresden, University Hospital Carl Gustav Carus, Technische Universität Dresden,
Dresden, DE, 14Providence Portland Medical Center, Portland, US, 15Bradford Hill
Clinical Research Center, Santiago, CL, 16Bristol Myers Squibb, Princeton, US, 17Nektar
Therapeutics, San Francisco, US, 18Moffitt Cancer Center, Tampa, US

O. Michielin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

16:00 - 16:15 Q&A

14:45 - 16:15 Type: Mini Oral session 7.3.O - Orléans
Title: Mini Oral session: Investigational Auditorium
immunotherapy
Chair(s): Inge-Marie Svane, DK; Alessandra Curioni, CH

14:45 - 14:50 729MO - Final results of the first-in-human clinical trial of the GDF-15
neutralizing antibody CTL-002 in combination with nivolumab in subjects with
solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment
I. Melero1, M.J. De Miguel2, G. Alonso Casal3, M.-E. Goebeler4, E. Ramelyte5, E. Calvo6,

E. Garralda3, R. Dummer5, M. Rodríguez-Ruiz7, C.M. Sayehli4, M. Sanmamed7, J.
Ramón8, M.J. Lostes Bardaji3, T. Gromke9, M. Schuler9, P. Fettes10, K. Klar10, C.
Schuberth-Wagner 10, J. Wischhusen11, E. Leo10, 1Clinica Universitaria de Navarra,
Pamplona, ES, 2START MADRID, Hospital Universitario HM Sanchinarro – CIOCC,
Madrid, ES, 3Vall d'Hebron University Hospital, Barcelona, ES, 4UKW - University
Hospital Wuerzburg, Wuerzburg, DE, 5Universitätsspital Zürich - Klinik für
Dermatologie, Zurich, CH, 6HM Sanchinarro University Hospital, Madrid, ES, 7Clinica
Universidad de Navarra, Pamplona, ES, 8HM University Sanchinarro Hospital, Madrid,
ES, 9University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, 10Catalym
GmbH, Martinsried Planegg, DE, 11University of Würzburg, Wuerzburg, DE

14:50 - 14:55 730MO - First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal
antibody antagonist in patients with advanced malignancies
M. Gutierrez1, S.-C. Tang2, J. Powderly3, A. Balmanoukian4, J. Janik5, P. Hoyle5, W. Wei5,

X. Gong5, O. Hamid6, 1Hackensack University Medical Center, Hackensack, US,
2University of Mississippi Medical Center, Jackson, US, 3Carolina BioOncology Institute,

Huntersville, US, 4The Angeles Clinic and Research Institute - West Los Angeles, Los
Angeles, US, 5Incyte Corporation, Wilmington, US, 6The Angeles Clinic and Research
Institute, A Cedars Sinai Affiliate, Los Angeles, CA, US

14:55 - 15:00 731MO - A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101
alone and in combination with pembrolizumab in patients with advanced solid
tumors

G. Hanna1, A. Hernando Calvo2, V. Morris3, R. Carvajal4, P. Paik5, D. Zandberg6, J.
Kaczmar7, L. Niculescu8, R. Reiners8, D. Bohr8, E. Gharakhani8, R. Salazar8, S. Bilic9, P.
Bedard2, 1Dana Farber Cancer Institute, Boston, US, 2UHN - University Health Network -
Princess Margaret Cancer Center, Toronto, CA, 3The University of Texas M. D. Anderson

Cancer Center, Houston, US, 4Columbia University Medical Center College of Physicians
& Surgeons - New York Presbyterian Hospital, New York, US, 5MSKCC - Memorial Sloan
Kettering Cancer Center, New York, US, 6UPMC Hillman Cancer Center, Pittsburgh, US,
7MUSC Health Hollings Cancer Center, Charleston, US, 8Bicara Therapeutics, Inc.,
Cambridge, US, 9Vanadro, LLC., Waukee, US

I.-M. Svane, Herlev and Gentofte Hospital, Herlev, DK

15:15 - 15:20 732MO - The combination of ICT01, a γ9δ2 T cell-activating mAb, plus
pembrolizumab induces a broad antitumor immune response and disease control
in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION
trial
S. Champiat1, M. Wermke2, C. Vicier3, J. De Bono4, C. Jungels5, N. Vey3, N. Kotecki5, K.

Wetzko6, L. Ruhnke2, E. Garralda7, V. Galvao De Aguiar8, P. Lorusso9, A. De Gassart10, E.
Valentin10, P. Brune10, M. Iche11, C. Leparquier11, D. Olive12, A. Marabelle13, P.
Frohna14, 1Gustave Roussy - Cancer Campus, Villejuif, FR, 2Universitaetsklinikum Carl
Gustav Carus Dresden, Dresden, DE, 3IPC - Institut Paoli-Calmettes, Marseille, Cedex,
FR, 4The Institute of Cancer Research and The Royal Marsden Hospital, London, GB,
5Institute Jules Bordet, Brussels, BE, 6Universitätsklinikum Carl Gustav Carus Dresden -

Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, DE, 7Hospital
Universitario Vall d'Hebron, Barcelona, ES, 8Vall d'Hebron University Hospital, Vall
d'Hebron Institute of Oncology (VHIO), Barcelona, ES, 9Yale Cancer Center, New Haven,
US, 10ImCheck Therapeutics SAS, Marseille, Cedex, FR, 11Ilife Consulting, Argenteuil,
FR, 12CRCM centre de recherche en cancérologie de marseille, Marseille, FR, 13Institut
Gustave Roussy, Villejuif, Cedex, FR, 14IMCHECK THERAPEUTICS SAS, Marseille, FR

15:20 - 15:25 733MO - γδT cells are effectors of immune checkpoint blockade in
mismatch repair-deficient colon cancers with antigen presentation defects
J. Van De Haar1, N. De Vries2, V. Veninga1, M. Chalabi1, M. Ijsselsteijn2, M. Van Der

Ploeg2, J. Van Den Bulk2, D. Ruano2, J. Haanen1, T. Schumacher1, L. Wessels1, F. Koning2,
N. De Miranda2, E. Voest1, 1NKI-AVL - Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital, Amsterdam, NL, 2LUMC-Leiden University Medical Center,
Leiden, NL

15:25 - 15:30 734MO - Deep sequencing of the T-cell receptor reveals common and
reproducible CD8 T-cell receptor signatures of response to checkpoint
immunotherapy
R. Watson1, C. Taylor1, O. Tong1, R. Cooper1, I. Nassiri1, E. Jungkurth1, P.K. Sharma1, A.

Verge De Los Aires1, E. Ieremia2, M. Middleton3, B. Fairfax4, 1The MRC Weatherall
Institute of Molecular Medicine Oxford, Oxford, GB, 2Oxford University Hospitals NHS
Foundation Trust, Oxford, GB, 3Churchill Hospital, Oxford, GB, 4University of Oxford,
Oxford, GB



15:45 - 15:50 735MO - Updated safety and efficacy from SURPASS, the phase I trial of ADP-
A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in
previously treated patients with unresectable or metastatic tumors
D.S. Hong1, A. Asch2, E. Calvo3, J. Zugazagoitia4, J. Charlson5, M. Butler6, V. Moreno

Garcia7, A. Cervantes8, B. Van Tine9, D. Lawrence10, M. Johnson11, Q. Lin12, T.
Annareddy12, F. Brophy12, R. Broad13, A. Derrac Soria13, J.-M. Navenot12, J. Saro13, E.
Norry12, J. Clarke14, 1The University of Texas MD Anderson Cancer Center, Houston, US,
2Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City,
US, 3START Madrid-CIOCC, Madrid, ES, 4Hospital Universitario 12 de Octubre, Madrid,

ES, 5Medical College of Wisconsin, Milwaukee, US, 6Princess Margaret Cancer Centre,
Toronto, CA, 7START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, ES,
8University of Valencia, Valencia, ES, 9Washington University School of Medicine, St.
Louis, US, 10Massachusetts General Hospital, Boston, US, 11Sarah Cannon Research
Institute, Nashville, US, 12Adaptimmune, Philadelphia, US, 13Adaptimmune, Abingdon,
Oxfordshire, GB, 14Duke Cancer Center, Durham, US

15:50 - 15:55 736MO - Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy
for the treatment of advanced solid tumors: Clinical benefit associated with
decreases in ctDNA (SLATE-KRAS)
C. Kyi1, A. Spira2, D. Carbone3, M. Johnson4, B. Henick5, B. Johnson6, H. Borghaei7, A.

Mahipal8, J. Hecht9, D. Catenacci10, C.-Y. Liao 11, A. Shergill11, R. Memmott3, C. Presley3,
J. Jaroslavsky12, D. Schenk12, K. Jooss12, A. Ferguson12, J. Goldman9, 1Memorial Sloan
Kettering Cancer Center, New York, US, 2Virginia Cancer Specialist, Fairfax, US, 3The
Ohio State University - OSU Wexner Medical Center, Columbus, US, 4Sarah Cannon
Research Institute-Cancer Centre, Nashville, US, 5Columbia University Medical Center

College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, 6MD
Anderson Cancer Center, Houston, US, 7Fox Chase Cancer Center - Main Campus,
Philadelphia, US, 8Mayo Clinic, Rochester, US, 9UCLA Hematology/Oncology Santa
Monica, Santa Monica, US, 10Catenacci Consulting Ltd, Chicago, IL, US, 11University of
Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US,
12Gritstone bio, Inc., Emeryville, US

15:55 - 16:00 737MO - EpCAM-targeted CAR-T cell therapy in patients with advanced
colorectal and gastric cancers
W. Fang1, T. Luo2, Z. Lu2, H. Zhang1, C. Tong1, S. Wang3, F. Tang3, G. Ai3, 1The First
Affiliated Hospital of ZhejiangUniversity, Hangzhou, CN, 2The First Affiliated Hospital of

Naval Medical University/Changhai Hospital of Shanghai, Shanghai, CN, 3Suzhou
Immunofoco Biotechnology Co., Ltd, Suzhou, CN

A. Curioni, USZ - University Hospital Zürich, Zurich, CH

14:45 - 16:15 Type: Proffered Paper session 7.3.Q - Quimper
Title: Proffered Paper session: Haematological Auditorium
malignancies

Chair(s): Catherine Thieblemont, FR; Thomas Cluzeau, FR

14:45 - 14:55 617O - Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in
combination with azacitidine (AZA) in patients with newly diagnosed higher risk
myelodysplastic syndrome (HR-MDS): Initial clinical results
C. Chang1, Z. Xiao2, Q. Li3, X. Yan4, T. Qin2, H. Tong5, M. Dai6, Y. He7, J. Weng8, J. Li9, S.
Gao10, R. Fu11, X. Wei12, X. Ma13, Y. Zhang13, W. Huang13, Q. Wang13, L. Gu13, Y.
Meng13, A. Zhu13, 1Shanghai Sixth People's Hospital, Shanghai, CN, 2Institute of
Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin,
CN, 3Union Hospital affiliated to Tongji Medical, College of Huazhong University of
Science and Technology, Wuhan, CN, 4The First Affiliated Hospital of China Medical
University, Shenyang, CN, 5the First Affiliated Hospital, Zhejiang University School of

Medicine, Hangzhou, CN, 6Nanfang Hospital of Southern Medical University, Guangzhou,
CN, 7Zhujiang Hospital of Southern Medical University, Guangzhou, CN, 8Guangdong
Provincial People's Hospital, Guangzhou, CN, 9Peking Union Medical College Hospital,
Beijing, CN, 10The First Hospital of Jilin University, Changchun, CN, 11Tianjin Medical
University General Hospital, Tianjin, CN, 12Henan Cancer Hospital/Affiliated Cancer
Hospital of Zhengzhou University, Zhengzhou, CN, 13I-Mab Biopharma Co., Ltd. -
Headquarter, Shanghai, CN

14:55 - 15:05 Invited Discussant 617O
T. Cluzeau, Hopital del l'Archet, Nice, FR

15:05 - 15:15 Q&A

15:15 - 15:25 618O - A phase I study of TRS005: An anti-CD20-MMAE antibody-drug
conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma
Y.-K. Shi1, Z.-M. Li2, Y. Qing3, H. Zhang4, Y. Jia5, H. Jing6, Y. Li7, X. Tong8, H. Liu9, L.
Li10, 1Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital,
Beijing, CN, 2Sun Yat-sen University Cancer Center, Guangzhou, CN, 3cancer hospital
Chinese academy of medical sciences, Beijing, CN, 4TMUCIH - Tianjin Medical University
Cancer Institute and Hospital, Tianjin, CN, 5Affiliated Hospital of Hebei University,
Baoding, CN, 6Peking University Third Hospital, Beijing, CN, 7Henan Cancer
Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, 8Zhejiang
Provincial People’s Hospital, Hangzhou, CN, 9Beijing Hospital, Beijing, CN, 10The First
Affiliated Hospital of Zhengzhou University, Zhengzhou, CN

15:25 - 15:35 619O - shRNA-mediated PD1 gene knock-down anti-CD19 CAR-T cell therapy for
relapsed/refractory b cell malignancies
H. Cen, Q. Ke, Z. Li, D. Zhou, M. Wang, J. Sun, C. Liao, Guangxi Medical University

Affiliated Tumor Hospital and Oncology Medical Center, Nanning, CN

15:35 - 15:45 620O - CART-ddBCMA for multiple myeloma: Interim results from phase I study
M. Frigault1, J. Rosenblatt2, N. Raje1, D. Cook1, M. Gaballa3, E. Emmanuel-Alejandro1, C.

Cornwell4, K. Banerjee4, A. Rotte4, C. Heery4, D. Avigan2, A. Jakubowiak5, M. Bishop5,
1MGH - Massachusetts General Hospital, Boston, US, 2Beth Israel Deaconess Medical

Center, Boston, US, 3Massachusetts General Hospital - Surgical Oncology Division,

Boston, US, 4Arcellx, Gaithersburg, US, 5University of Chicago Medicine, Chicago, US

C. Thieblemont, Hopital Saint Louis AP-HP, Paris, FR

16:00 - 16:10 Q&A

14:45 - 16:15 Type: Mini Oral session 7.3.T - Toulouse Auditorium
Title: Mini Oral session: GI, upper digestive
Chair(s): Maeve Lowery, IE; Florian Lordick, DE; Teresa Macarulla Mercade, ES

14:45 - 14:50 LBA61 - HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line
therapy for gemcitabine-refractory locally advanced or metastatic pancreatic
cancer: A multicentered, randomized, double-blind, parallel-controlled phase III
trial (HR-IRI-APC)
L. Wang1, S. Qin2, Y. Zhou3, S. Zhang4, X. Sun5, Z. Chen6, J. Cui7, P. Zhao8, K. Gu9, Z.

Li10, J. Wang11, X. Chen11, J. Yao12, L. Shen13, J. Zhou13, G. Wang14, Y. Bai15, Q. Wang16,
H. Wang16, 1Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
CN, 2Nanjing Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, CN,
3Zhongshan Hospital Affiliated with Fudan University, Shanghai, CN, 4West China School
of Medicine/West China Hospital of Sichuan University, Chengdu, CN, 5JiangsuCancer

Hospital, Nanjing, CN, 6The Second Affiliated Hospital of anhui Medicel University,
Hefei, CN, 7Bethune First Hospital of Jilin University, Changchun, CN, 8The First
Affiliated Hospital,Zhejiang University School Of Medicine, Hangzhou, CN, 9The First
Affiliated Hospital of Anhui Medical University, Hefei, CN, 10Sun Yat-sen Memorial
Hospital, Sun Yat-sen University, Guangzhou, CN, 11Henan Cancer Hospital, Zhengzhou,
CN, 12The First Affiliated Hospital of Henan University of Science and Technology,
Luoyang, CN, 13Beijing Cancer Hospital, Beijing, CN, 14The First Affiliated Hospital of
USTC, Hefei, CN, 15Harbin Medical University Cancer Hospital, Harbin, CN, 16Jiangsu
Hengrui Pharmaceutical Co., Ltd, Shanghai, CN

14:50 - 14:55 1296MO - PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial
comparing chemotherapy with folfirinox or gemcitabine in locally advanced
pancreatic carcinoma (LAPC)
M. Ducreux1, R. Desgrippes2, Y. Rinaldi3, F. Di Fiore4, R. Guimbaud5, P. Follana6, J.-B.

Bachet7, P. Vanelslander8, T. Lecomte9, O. Capitain10, A. Parzy11, M. Bolliet12, P.-L.
Etienne13, J. Forestier14, F. El Hajbi15, A.L. Bignon Bretagne16, V. Ly Lebrun17, N. De
Sousa Carvalho18, M. Texier19, O. Bouche20, 1Gustave Roussy - Cancer Campus, Villejuif,
FR, 2C.H. Broussais, Saint-Malo, FR, 3Hopital Européen Marseille, Marseille, FR, 4CHU
de Rouen Normandie, Rouen, FR, 5Centre Hospitalier Universitaire de Toulouse - Hopital
Rangueil, Toulouse, FR, 6Centre Anticancer Antoine Lacassagne, Nice, FR, 7Groupe
Hospitalier Pitié Salpetriere, Paris, FR, 8Hôpital Saint Claude, Saint-Quentin, FR, 9CHU
de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, 10Centre Paul Papin, Angers, FR,
11Centre Francois Baclesse, Caen, FR, 12Hopitaux Civils de Colmar, Colmar, FR,
13Hôpital Privé des Côtes d'Armor, Plérin sur mer, FR, 14Hopital Edouard Herriot, Lyon,
FR, 15Centre Oscar Lambret, Lille, FR, 16CHU de Caen - Hopital Cote de Nacre, Caen,
FR, 17CHU Limoges - Hopital Dupuytren, Limoges, FR, 18Unicancer, Paris, Cedex, FR,

19Institut Gustave Roussy, Villejuif, FR, 20CHU de Reims - Hôpital Robert Debré, Reims,
Cedex, FR

14:55 - 15:10 Invited Discussant LBA61 and 1296MO
T. Macarulla Mercade, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center,

Barcelona, ES

15:10 - 15:15 52MO - A randomized phase II trial of durvalumab and tremelIMUmab with
gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin
in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma
(IMMUCHEC)
A. Vogel1, S. Boeck2, O. Waidmann3, M. Bitzer4, P. Wenzel5, S. Belle6, C. Springfeld7, K.

Schulze8, A. Weinmann9, U. Lindig10, C. Trautwein11, T. Dechow12, F. Lammert13, R.
Plentz14, C.-H. Koehne15, V. Kunzmann16, M. Maenz17, M.M. Kirstein1, A. Saborowski1,
1MHH - Medizinische Hochschule Hannover, Hannover, DE, 2LMU - Ludwig Maximilians
University of Munich, Munich, DE, 3Universitätsklinikum Frankfurt (Johannes-Wolfgang

Goethe-Universität), Frankfurt am Main, DE, 4Universitaetsklinikum Tuebingen
Medizinische Universitaetsklinik, Tuebingen, DE, 5Klinikum Rechts der Isar - Technische
Universitaet Muenchen, Munich, DE, 6UMM - Universitaetsklinikum Mannheim,
Mannheim, DE, 7NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE,
8UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE,
9Universitätsmedizin Mainz, Mainz, DE, 10Jena University Hospital, Friedrich-Schiller,
Jena, DE, 11Uniklinik RWTH Aachen, Aachen, DE, 12Onkologie Hamatologie Ravensburg,
Ravensburg, DE, 13UKS - Klinik für Innere Medizin II - Gastroenterologie und
Endokrinologie, Homburg, DE, 14Gesundheit Nord-Klinikverbund Bremen - Klinikum
Bremen Nord, Bremen, DE, 15Klinikum Oldenburg, Oldenburg, DE, 16University Clinic
Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM),
Wuerzburg, DE, 17CORBIN - Clinical Oncology Resources Berlin GmbH, Berlin, DE

15:15 - 15:20 53MO - Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio-
and gallbladder carcinoma previously treated with gemcitabine-based therapies
(NALIRICC – AIO-HEP-0116)
A. Vogel1, P. Wenzel2, G. Folprecht3, P. Schütt4, H. Wege5, A. Kretzschmar6, L.

Jacobasch7, N. Ziegenhagen8, S. Boeck9, S. Kanzler10, J. Mohm11, S. Belle12, D. Pink13, T.
Götze14, E. Goekkurt15, U. Graeven16, M. Schaaf17, M. Kirstein18, A. Saborowski1,
1Hannover Medical School, Hannover, DE, 2University Hospital rechts der Isar, Munich,
DE, 3Universitaetsklinikum Carl Gustav Carus, Dresden, DE, 4Oncodoc GmbH, Gütersloh,
DE, 5University Medical Center Hamburg-Eppendorf, Hamburg, DE, 6Medical Care
Center MVZ Mitte, Leipzig, DE, 7Gemeinschaftspraxis BAG- Joint Practice for Oncology,
Dresden, DE, 8HELIOS Hospital Berlin-Buch, Berlin, DE, 9LMU - Ludwig Maximilians
University of Munich, Munich, DE, 10Leopoldina Hospital, Schweinfurt, DE,
11Onkopraxis, Dresden, DE, 12University of Heidelberg, Mannheim, DE, 13University
Medicine Greifswald, Bad Saarow, DE, 14University Cancer Center Frankfurt- Marburg,
Frankfurt am Main, DE, 15Hematological Oncology, Hamburg, DE, 16Kliniken Maria Hilf -
St. Franziskus Hospital, Mönchengladbach, DE, 17KHNW - Krankenhaus Nordwest
GmbH, Frankfurt am Main, DE, 18University Medical Center Schleswig-Holstein, Campus
Luebeck, Luebeck, DE

15:20 - 15:25 54MO - Quality of life (QoL) and value of health (V-He) in advanced biliary

cancers (ABC) treated with second-line active-symptom-control (ASC) alone or
ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised
phase III, multi-centre, open-label ABC-06 trial
A. Lamarca1, D. Palmer2, H. Wasan3, P. Ross4, Y.T. Ma5, A. Arora6, S. Falk7, R. Gillmore8,

J. Wadsley9, K. Patel10, A. Anthoney11, A. Maravellas12, J. Waters13, C. Hoobs14, T.
Macdonald15, D. Ryder15, J. Ramage16, L. Davies15, J. Bridgewater17, J. Valle15, 1The
Christie NHS Foundation Trust, Manchester, GB, 2The Clatterbridge Cancer Centre NHS
Foundation Trust, Wirral, GB, 3Hammersmith Hospital - Imperial College Healthcare
NHS Trust, London, GB, 4Guy's Hospital, London, GB, 5The University of Birmingham -
Institute for Cancer Studies, Birmingham, GB, 6City Hospital Campus - Nottingham
University Hospitals NHS Trust, Nottingham, GB, 7NHS, Bristol, GB, 8Royal Free

Hospital, London, GB, 9Weston Park Hospital - Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield, GB, 10John Radcliffe Hospital University of Oxford, Oxford,
GB, 11St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, GB,
12Castle Hill Hospital - Hull University Teaching Hospitals NHS Trust, Cottingham, GB,
13Maidstone Hospital - Maidstone and Tunbridge NHS Trust, Maidstone, GB, 14The
Great Western Hospital, Swindon, GB, 15The University of Manchester, Manchester, GB,
16NHS Hampshire Hospitals Foundation Trust - Basingstoke and North Hampshire
Hospital, Basingstoke, GB, 17UCL Cancer Institute - Paul O'Gorman Building, London, GB

15:25 - 15:40 Invited Discussant 52MO, 53MO, 54MO
M. Lowery, Trinity College Dublin, Dublin, IE

15:40 - 15:45 1204MO - PRODIGE 59 - DURIGAST trial: A randomised phase II study
evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus
tremelimumab in second-line treatment of patients with advanced gastric or
gastro-oesophageal junction adenocarcinoma
D. Tougeron1, L. Dahan2, F. El Hajbi3, K. Le Malicot4, L. Evesque5, T. Aparicio6, O.

Bouche7, N. Bonichon Lamichhane8, B. Chibaudel9, A. Angelergues10, A. Bodere11, J.M.
Phelip12, M. Mabro13, P. Artru14, C. Louvet15, 1CHU Poitiers - Jean Bernard Hôpital,
Poitiers, FR, 2AP-HM - CHU La Timone Enfants, Marseille, FR, 3Centre Oscar Lambret,
Lille, FR, 4Fédération Francophone de Cancérologie Digestive, Dijon, FR, 5Centre
Anticancer Antoine Lacassagne, Nice, FR, 6Hopital Saint Louis AP-HP, Paris, FR, 7CHU
de Reims - Hôpital Robert Debré, Reims, Cedex, FR, 8Tivoli Ducos Clinique, Bordeaux,
FR, 9Franco-britanique hospital, paris, FR, 10Groupe Hospitalier Diaconesses Croix Saint
Simon, Paris, FR, 11Saint Malo hospital, Saint Malo, FR, 12CHU Saint Etienne - Hopital
Nord, Saint-Étienne, FR, 13Hopital Foch, Suresnes, FR, 14Hôpital privé Jean Mermoz,
Lyon, FR, 15IMM - Institut Mutualiste Montsouris, Paris, FR

15:45 - 15:50 1205MO - Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of
trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive
(HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ)
cancer who progressed on or after trastuzumab-containing regimen
G. Ku1, M. Di Bartolomeo2, E. Smyth3, I. Chau4, H. Park5, S. Siena6, S. Lonardi7, Z.

Wainberg8, J. Ajani9, J. Chao10, F. Barlaskar11, Y. Kawaguchi11, A. Qin11, J. Singh11, G.
Meinhardt11, E. Van Cutsem12, 1Memorial Sloan Kettering Cancer Center, New York, US,
2Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, 3Cambridge University
Hospitals NHS Foundation Trust, Cambridge, GB, 4The Royal Marsden Hospital, London,
GB, 5Siteman Cancer Center, Washington University, St. Louis, US, 6Università degli

Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda,
Milan, IT, 7Veneto Institute of Oncology IOV-IRCCS, Padova, IT, 8UCLA, Los Angeles, US,
9The University of Texas MD Anderson Cancer Center, Houston, US, 10City of Hope
Medical Center, Duarte, US, 11Daiichi Sankyo, Basking Ridge, US, 12University Hospital
Gasthuisberg, Leuven and KU Leuven, Leuven, BE

F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig,

DE

14:45 - 16:15 Type: Proffered Paper session 7.3.M - Marseille
Title: Proffered Paper session: Policy and preventive Auditorium
strategies
Chair(s): Ravindran Kanesvaran, SG; Christophe Massard, FR

14:45 - 14:55 1312O - From regulating off-label use to creating an environment for drug
repurposing in oncology
S. Van Waalwijk Van Doorn-Khosrovani1, A. Pisters1, E. Breugel2, L. Timmers3, E. Voest4,

H. Bloemendal5, F. Eskens6, M. Wymenga7, 1CZ Health Insurance, Tilburg, NL, 2VGZ
Health Insurance, Eindhoven, NL, 3Dutch National Health Care Institute, Diemen, NL,
4NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam,
NL, 5Radboud University Medical Center, Nijmegen, Nijmegen, NL, 6Erasmus MC -

University Medical Center, Rotterdam, NL, 7Hospital Medisch Spectrum Twente,
Enschede, NL

14:55 - 15:05 1313O - Assessment of investigational new drugs (INDs) approved in USA and
Europe after early phase trials using the ESMO-magnitude of clinical benefit
scale (ESMO-MCBS)
J. Moyers1, D. Benjamin1, D. Brazel2, P. Kumar2, V. Subbiah3, 1UCI Health - University of

California Irvine, Orange, US, 2UC Irvine Medical Center, Orange, US, 3The University of
Texas M. D. Anderson Cancer Center, Houston, US

P. Kanavos, The London School of Economics and Political Science, London, GB

15:15 - 15:25 Q&A

15:25 - 15:35 1314O - Cost-effectiveness of molecularly matched off-label therapies for end-
stage cancer: The MetAction precision medicine study
A. Ree1, G.M. Mælandsmo2, K. Flatmark2, H.G. Russnes2, M. Gómez Castañeda3, E.

Aas3, 1Akershus University Hospital HF, Lorenskog, NO, 2Oslo University Hospital -
Radiumhospitalet, Oslo, NO, 3University of Oslo, Oslo, NO

15:35 - 15:45 1315O - Key learnings from building: A precision cancer medicine
implementation initiative for Norway
K. Tasken1, H.G. Russnes2, E. Aas3, L. Bjorge4, E.S. Blix5, E. Enerly6, L. Fagereng2, Å.

Flobak7, B. Gilje8, B.T. Gjertsen9, T.K. Guren1, J. Heix10, E. Hovig2, R. Hovland9, P.E.
Lonning9, P.M. Mæhle11, H.L. Nilsen12, S. Thoresen13, S. Smeland1, A. Helland14, 1Oslo
University Hospital - The Norwegian Radium Hospital, Oslo, NO, 2Oslo University
Hospital - Radiumhospitalet, Oslo, NO, 3University of Oslo, Oslo, NO, 4Helse Bergen HF,
Bergen, NO, 5University Hospital of North Norway, Tromso, NO, 6Cancer Registry of
Norway, Oslo, NO, 7St. Olavs Hospital HF, Trondheim, NO, 8Stavanger University
Hospital - Helse Stavanger HF, Stavanger, NO, 9Haukeland University Hospital, Bergen,
NO, 10Oslo Cancer Cluster, Oslo, NO, 11Oslo University Hospital, Oslo, NO, 12Akershus
University Hospital HF, Lorenskog, NO, 13Merck AB Norway, Oslo, NO, 14University of
Oslo, Institute of Clinical medicine, Oslo, NO

15:45 - 15:55 1316O - Improved nationwide survival of sarcoma patients 10 years after
establishment of the NETSARC+ reference center network
J.-Y. Blay 1, A. Italiano2, N. Penel3, E. Bompas4, F. Duffaud5, C. Chevreau6, P. Anract7, C.

Perrin8, N. Firmin9, M. Toulmonde10, S. Piperno-Neumann11, S. Watson11, M. Rios12, J.E.
Kurtz13, F. Bertucci14, F. Le Loarer15, C. Chemin1, M. Morelle16, F. Gouin1, A. Le
Cesne17, 1Centre Léon Bérard, Lyon, FR, 2Institute Bergonié, Bordeaux, FR, 3Centre
Oscar Lambret, Lille, FR, 4ICO Institut de Cancerologie de l'Ouest René Gauducheau,
Saint-Herblain, FR, 5CHU La Timone Adultes, Marseille, FR, 6Institut Universitaire du
Cancer -Toulouse- Oncopole, Toulouse, FR, 7Hopital Cochin AP-HP, Paris, FR, 8Centre
Eugene - Marquis, Rennes, FR, 9Icm Val D Aurelle, Montpellier, FR, 10Institute Bergonié -
Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, 11Institut Curie, Paris,
FR, 12Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR,
13CHU Hautepierre, Strasbourg, FR, 14IPC - Institut Paoli-Calmettes, Marseille, FR,
15Institut Bergonie, Bordeaux, FR, 16Center Leon Berard, Lyon, FR, 17Gustave Roussy -
Cancer Campus, Villejuif, FR

C. Massard, Gustave Roussy - Cancer Campus, Villejuif, FR

16:05 - 16:15 Q&A


Title: Elements to build a Molecular Tumour Board
Chair(s): Alice Indini, IT; Michiel Strijbos, BE

M. Strijbos, GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE

14:50 - 15:10 Defining the role of the pathologist in the era of Next Generation Sequencing
G. Pruneri, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:10 - 15:30 Next Generation Sequencing: Power and pitfalls
A. Czarnecka, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw,

PL

15:30 - 15:50 Novel therapeutic targets and tumour agnostic treatment

15:50 - 16:10 Challenges in the clinical application of Molecular Tumour Boards
A. Indini, Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT



15:00 - 16:15 Type: Multidisciplinary session 7.1.C - Cannes
Title: Management of challenging situation in urinary Auditorium
cancers
Chair(s): Robert Huddart, GB

A. Fay, PUCRS - Escola de Medicina, Porto Alegre, BR

15:05 - 15:20 Rare variants of bladder cancer management: The role of radiation therapy
R. Huddart, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB

15:20 - 15:35 Emerging systemic therapies in rare urothelial cancer variants
B. Mcgregor, Boston, MA, US

15:35 - 15:50 The role of systemic therapy in brain metastases from RCC: Targeted therapy
and immunotherapy
S. Negrier, Lyon, FR

15:50 - 16:05 The emerging role of SBRT in treating the primary and distant metastases from
Renal cancer
S. Siva, Melbourne, AU


15:00 - 16:00 Type: Challenge your Expert 7.1.D - Dijon Auditorium
Title: HIPEC for peritoneal carcinomatosis
Chair(s): Cornelis Punt, NL

D. Goéré, Institut Gustave Roussy, Villejuif, Cedex, FR

C. Punt, Utrecht, NL


15:00 - 16:10 Type: Multidisciplinary session 7.3.G - Grenoble
Title: How can we collaborate better as a multidisciplinary Auditorium
team to develop novel therapeutics?
Chair(s): Eric Deutsch, FR

15:00 - 15:15 Can novel radiotherapy techniques pave the way for new combinations?
E. Deutsch, Institut Gustave Roussy, Villejuif, FR

15:15 - 15:30 Building infrastructure in academia for truly translational clinical research:
going from bedside to the bench (reverse translation)
S. Turajlic, The Royal Marsden Hospital - Chelsea, London, GB

15:30 - 15:45 COVID as a catalyst for remodelling approaches to early phase clinical trial
development in a resource challenged environment
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara

Campal, Madrid, ES


Title: Locally advanced N2/stage III NSCLC
Chair(s): Myung-Ju Ahn, KR

M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of

Medicine, Seoul, KR

15:05 - 15:20 Systemic approaches in locally advanced N2/stage III NSCLC: EGFR mutation
versus wildtype

Medicine, Seoul, KR

15:20 - 15:35 Radiotherapy approaches in locally advanced N2/stage III NSCLC
S. Senan, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

15:35 - 15:50 Considerations for staging and surgical intervention
E. Lim, London, GB



15:00 - 16:30 Type: EONS Industry Satellite Symposium 7.3.S -
Title: Bristol Myers Squibb - Cancer Nursing Considerations Strasbourg
for comprehensive care in CAR T-Cell Therapy Auditorium



15:05 - 15:30 CART, IEC, BITE – what does the new technology mean for patients with solid
malignancies
S. Rottey, UZ Gent - University Hospital Ghent, Gent, BE

15:30 - 15:55 Prehab to rehab for patients with CAR T cell therapy – optimising health and
wellbeing
M. De Ruijter, VU University Medical Centre, Amsterdam, NL

15:55 - 16:20 What supportive care do patients need?
M. Hellberg-Nägele, USZ - University Hospital Zürich, Zurich, CH

16:20 - 16:30 Q&A and Conclusion remarks

15:00 - 16:00 Type: Young Oncologist session 7.3.L - Lyon
Title: ON-SITE ONLY: Medical student session
Chair(s): Andres Cervantes, ES

15:00 - 15:15 How to prepare and present your first poster at a congress
P. Sobczuk, Medical University of Warsaw, Warsaw, PL

15:15 - 16:00 Poster walk
K.H.J. Lim1, P. Sobczuk2, R. Sanchez Bayona3, E. Connolly4, M. Kfoury5, 1The Francis

Crick Institute, London, GB, 2Medical University of Warsaw, Warsaw, PL, 3Hospital

Universitario 12 de Octubre, Madrid, ES, 4Chris O'Brien Lifehouse, Camperdown, AU,
5Institut Gustave Roussy, Villejuif, Cedex, FR

16:30 - 18:00 Type: Proffered Paper session 6.P - Paris Auditorium
Title: Presidential Symposium I
Chair(s): Solange Peters, CH; Fabrice André, FR

16:30 - 16:45 LBA1 - Mechanism of action and an actionable inflammatory axis for air
pollution induced non-small cell lung cancer: Towards molecular cancer
prevention
C. Swanton1, W. Hill1, E. Lim2, C. Lee1, C. Weeden2, M. Augustine3, K. Chen4, F.-C.

Kuan5, F. Marongiu6, F. Rodrigues2, H. Cha7, T. Jacks8, M. Luchtenborg9, I. Malanchi1, J.
Downward2, C. Carlsten10, A. Hackshaw11, K. Litchfield12, J. Degregori6, M. Jamal-

Hanjani13, 1Francis Crick Institute, London, GB, 2The Francis Crick Institute, London,
GB, 3UCL - University College London, London, GB, 4Peking University People’s Hospital,
Beijing, CN, 5Chang Gung Medical Foundation - Chiayi Chang Gung Memorial Hospital,
Puzi City, TW, 6UCHealth Cancer Care - Anschutz Medical Campus - University of
Colorado Cancer Center, Aurora, US, 7Samsung Medical Center (SMC) - Sungkyunkwan
University School of Medicine, Seoul, KR, 8Koch Institute For Integrative Cancer
Research at MIT, Cambridge, US, 9Public Health England, London, GB, 10UBC - The
University of British Columbia, Vancouver, CA, 11Cancer Research UK & University
College London Cancer Trials Centre, London, GB, 12UCL Cancer Institute - UCL -
London's Global University, London, GB, 13UCL Cancer Institute - Paul O'Gorman
Building, London, GB

S. Delaloge, Institut Gustave Roussy, Villejuif, FR

16:55 - 17:10 LBA2 - DeFi: A phase III, randomized controlled trial of nirogacestat versus
placebo for progressing desmoid tumors (DT)
B. Kasper1, R. Ratan2, T. Alcindor3, P. Schoeffski4, W. Van Der Graaf5, B. Wilky6, R.

Riedel7, A. Lim8, L.M. Smith8, S. Moody9, S. Attia10, S. Chawla11, G. D'Amato12, N.
Federman13, P. Merriam14, B. Van Tine15, B. Vincenzi16, S. Kummar17, M. Gounder18,
1UMM - Universitaetsklinikum Mannheim, Mannheim, DE, 2MD Anderson Cancer Center,
Houston, US, 3McGill University Health Centre - Glen Site - Royal Victoria Hospital,
Montreal, CA, 4KU Leuven - Laboratory of Experimental Oncology, Leuven, BE, 5NKI-AVL
- Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL,
6University of Colorado Anschutz Medical Campus, Aurora, CO, US, 7Duke Cancer

Center, Durham, US, 8SpringWorks Therapeutics, Stamford, US, 9PharPoint Research,
Inc., Durham, US, 10Mayo Clinic Cancer Center, Phoenix, US, 11Sarcoma Oncology
Research Center, Santa Monica, US, 12Sylvester Comprehensive Cancer Center -
University of Miami, Miami, US, 13UCLA - David Geffen School of Medicine, Los Angeles,
US, 14Dana Farber Cancer Institute, Boston, US, 15Washington University School of
Medicine in St. Louis, St. Louis, US, 16Policlinico Universitario Campus Bio-Medico,
Rome, IT, 17Oregon Health & Science University, Portland, US, 18Memorial Sloan
Kettering Evelyn H. Lauder Breast Center, New York, US

J.-Y. Blay , Centre Léon Bérard, Lyon, FR

17:20 - 17:35 LBA3 - Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab
for advanced melanoma: Results from a multicenter, randomized phase III trial
J. Haanen1, M. Rohaan1, T. Borch2, J. Van Den Berg1, Ö. Met2, M. Geukes Foppen1, J.

Stoltenborg Granhøj2, B. Nuijen1, C. Nijenhuis1, J. Beijnen1, I. Jedema1, M. Van Zon1, I.
Mansfield Noringriis2, R. Kessels1, S. Wilgenhof1, H. Van Thienen1, F. Lalezari1, A. Van
Akkooi1, M. Donia2, I.-M. Svane2, 1Netherlands Cancer Institute, Amsterdam, NL,
2National Center for Cancer Immune Therapy, Herlev, DK


I. Melero, Clinica Universitaria de Navarra, Pamplona, ES


Title: The three “Ws” of early breast cancer Auditorium
management
Chair(s): Evandro de Azambuja, BE; Nadia Harbeck, DE

16:30 - 16:55 Gene expression profiling and chemotherapy: Who to test, which test, and when

16:55 - 17:20 Neo-adjuvant therapy in luminal breast cancer: Who to treat, which regimen,
and what duration?
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

17:20 - 17:45 Adjuvant endocrine therapy: Who needs more than 5 years, which regimen, and
what duration beyond 5 years?
E. De Azambuja, Institute Jules Bordet, Brussels, BE



16:30 - 18:00 Type: Special symposium 7.1.D - Dijon
Title: New avenues for targeting biological mechanisms in Auditorium
sarcoma
Chair(s): Breelyn Wilky, US; Paul Huang, GB

B. Wilky, UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado

Cancer Center, Aurora, US

16:35 - 16:50 Targeting the “crack” DNA damage repair deficiency in sarcomas
P. Huang, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

16:50 - 17:05 Understanding the sarcoma genome
F. Amary, The Royal National Orthopaedic Hospital - RNOH - NHS Trust, Stanmore, GB

17:05 - 17:20 Targeting the epigenetics regulatory machinery in sarcoma

17:20 - 17:35 Defining molecular targets for immunotherapy
B. Wilky, UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado

Cancer Center, Aurora, US


P. Huang, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB


16:30 - 18:00 Type: Mini Oral session 7.3.G - Grenoble
Title: Mini Oral session: Supportive and palliative Auditorium
care
Chair(s): Antonio Di Meglio, FR; Gudrun Kreye, AT; Maryam Lustberg, US

16:30 - 16:35 1425MO - Use of psychosocial services and 1-year mortality among newly
diagnosed and distressed cancer patients: A real-world study
J. Cho1, D. Kang1, S. Kim2, J. Lee2, J.S. Ahn1, 1Samsung Medical Center (SMC) -
Sungkyunkwan University School of Medicine, Seoul, KR, 2SAIHST - Samsung Advanced
Institute for Health Sciences & Technology, SKKU, Seoul, KR

16:35 - 16:40 1554MO - Perspectives of patients with metastatic breast cancer on exercise
interventions: Results from a survey in five European countries
M. Sweegers1, J. Depenbusch2, N. Aaronson1, Y. Wengström3, M. Backman3, N.

Gunasekara4, D. Clauss4, M. Pelaez5, M. Lachowicz6, A. May7, K. Steindorf2, M. Stuiver1,
1NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam,
NL, 2DKFZ - German Cancer Research Center, Heidelberg, DE, 3Karolinska Institute,

Huddlinge, SE, 4German Sport University Cologne, Cologne, DE, 5Onkologikoa
Fundazioa, Donostia, ES, 6Medical University of Gdansk, Gdansk, PL, 7University
Medical Center Utrecht, Utrecht, NL

16:40 - 16:45 1555MO - Effects of exercise on sleep quality and cancer-related fatigue during
neurotoxic chemotherapy
J. Müller1, C. Kreutz2, A. Schneeweiss3, G.M. Haag4, K. Steindorf2, M. Weiler4, J.

Wiskemann1, 1Heidelberg University Hospital - National National Center for Tumor
Diseases (NCT), Heidelberg, DE, 2DKFZ - German Cancer Research Center, Heidelberg,
DE, 3Heidelberg University Hospital and German Cancer Research Center, Heidelberg,
DE, 4Heidelberg University Hospital, Heidelberg, DE

A. Di Meglio, Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR

17:00 - 17:05 1556MO - The iBLAD study: Patient-reported outcomes in bladder cancer during
oncological treatment: A multicenter national randomized controlled trial
G.A. Taarnhøj1, C. Johansen2, A. Carus3, R.H. Dahlrot4, L. Dohn5, H. Lindberg5, H.

Pappot1, 1University Hospital Copenhagen, Rigshospitalet, Copenhagen, DK, 2University
of Copenhagen - Faculty of Health and Medical Sciences, Copenhagen, DK, 3Aalborg
University Hospital, Aalborg, DK, 4Odense University Hospital, Odense, DK, 5Herlev and
Gentofte Hospital, Herlev, DK

17:05 - 17:10 1557MO - Phase II trial evaluating effect of gonyautoxins (GTX), a paralytic
shellfish poisoning (PSP) on objective and subjective symptoms of
chemotherapy-induced peripheral neuropathy (CIPN)
M. Dias1, L. Landeiro2, R. Cunha Guimaraes3, F. Copati4, M. Mano5, F. Souza Lima6, C.

Naurath7, C. Orellana8, F. Rondao9, R. Dienstmann9, J. Canedi9, B. Ferrari9, C.G.
Ferreira1, 1Grupo Oncoclinicas Botafogo, Rio de Janeiro, BR, 2NOB - Nucleo de
Oncologia da Bahia - Grupo Oncoclinicas, Salvador, BR, 3Grupo Oncoclinicas -
Oncocentro, Belo Horizonte, BR, 4UFU - Universidade Federal de Uberlandia - Faculdade
de Medicina (FAMED), Uberlandia, BR, 5Hospital Sirio Libanes - Complexo Hospitalar
Bela Vista, Sao Paulo, BR, 6HUPE - Hospital Universitário Pedro Ernesto - UERJ, Rio de
Janeiro, BR, 7Brazilian National Cancer Institute, Rio de Janeiro, BR, 8Algenis SpA,
Santiago, CL, 9Grupo Oncoclinicas, Sao Paulo, BR

17:10 - 17:15 1558MO - Dissecting sexual health after breast cancer (BC) by longitudinal
assessment of patient reported outcomes
M.A. Franzoi1, M. Aupomerol2, J. Havas1, H. Hang1, A. Di Meglio1, M. Lambertini3, C.

Massarotti3, C. Coutant4, O. Tredan5, F. Joly Lobbedez6, P. Cottu7, D. Soldato3, M.-A.
Mouret8, C. Tarpin9, A. Arnaud10, L. Fasse2, S. Everhard11, A.-L. Martin11, B. Pistilli2, I.
Vaz Luis1, 1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Institut Gustave Roussy,
Villejuif, FR, 3IRCCS Ospedale Policlinico San Martino, Genova, IT, 4Centre Georges
Francois Leclerc, Dijon, FR, 5Medical Oncology, Lyon, FR, 6Centre Francois Baclesse,
Caen, Cedex, FR, 7Institut Curie, Paris, FR, 8Centre Jean PERRIN, Clermont-Ferrand,
Cedex, FR, 9IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, 10Institut Sainte-
Catherine, Avignon, FR, 11UNICANCER, Paris, FR


17:30 - 17:35 LBA70 - COVID-19 in cancer patients: Update from the joint analysis of ESMO-
CoCARE, BSMO, PSMO international databases
E. Romano1, L. Castelo-Branco2, Z. Tsourti3, E. De Azambuja4, S. Gennatas5, J. Oliveira6,

J. Rogado7, M. Sekacheva8, S. Susnjar9, D. Vinal Lozano10, R. Lee11, S. Khallaf12, G.
Dimopoulou13, S. Pradervand14, D. Arnold15, K. Harrington16, O. Michielin17, U. Dafni18,
G. Pentheroudakis2, S. Peters14, 1Institut Curie, Paris, FR, 2ESMO - European Society for
Medical Oncology, Lugano, CH, 3Frontier Science Foundation Hellas, Athens, GR,
4Institute Jules Bordet, Brussels, BE, 5The Royal Marsden Hospital (Chelsea) - NHS
Foundation Trust, London, GB, 6Instituto Portugues de Oncologia do Porto Francisco

Gentil, EPE (IPO-Porto), Porto, PT, 7Hospital Universitario Infanta Leonor, Madrid, ES,
8Sechenov First Moscow State Medical University, Moscow, RU, 9Institute for Oncology
and Radiology of Serbia, Belgrade, RS, 10Hospital Universitario La Paz, Madrid, ES,
11The University of Manchester, Manchester, GB, 12SECI - South Egypt Cancer Institute -
Assiut University, Assiut, EG, 13FSF-H - Frontier Science Foundation Hellas, Athens, GR,
14CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, 15Asklepios Klinik
Altona - Asklepios Kliniken, Hamburg, DE, 16The Royal Marsden/The Institute of Cancer
Research NIHR Biomedical Research Centre, London, GB, 17Centre Hospitalier
Universitaire Vaudois - CHUV, Lausanne, CH, 18National and Kapodistrian University of
Athens, Athens, GR

17:35 - 17:40 1264MO - Development and validation of a unifying pre-treatment decision tool
for intracranial and extracranial metastasis-directed radiotherapy
R. Kowalchuk1, T. Mullikin2, W. Breen1, H. Gits1, M. Florez3, B. De3, W. Harmsen1, P.

Rose1, B. Siontis1, B. Costello1, J. Morris1, J. Lucido1, K. Olivier1, B. Stish1, N. Laack1, S.
Park1, D. Owen1, A. Ghia3, P. Brown1, K. Merrell4, 1Mayo Clinic, Rochester, US, 2Duke
Cancer Center - Duke University Medical Center, Durham, US, 3MD Anderson Cancer
Center, Houston, US, 4Mayo Clinic Cancer Center, Rochester, US

17:40 - 17:45 1265MO - Cause and place of death in older patients with cancer: Results from a
large cohort study using linked clinical and population-based data
V. Depoorter1, K. Vanschoenbeek2, L. Decoster3, H. De Schutter2, P. Debruyne4, I. De

Groof5, D. Bron6, F. Cornelis7, S. Luce8, C. Focan9, V. Verschaeve10, G. Debugne11, C.
Langenaeken12, H. Van Den Bulck13, J.-C. Goeminne14, K. Milisen15, J. Flamaing15, C.
Kenis15, F. Verdoodt2, H. Wildiers16, 1KU Leuven, Leuven, BE, 2Belgian Cancer Registry,
Brussels, BE, 3UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, 4Medical
Technology Research Institute (MTRI), School of Life Sciences, Anglia Ruskin University,
Cambridge, GB, 5AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium
Kankernetwerk, Antwerpen, BE, 6Institute Jules Bordet - ULB, Brussels, BE, 7Cliniques
Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, 8Erasme
University Hospital-(Universite Libre de Bruxelles), Brussels, BE, 9Clinique CHC-
MontLégia, Groupe Santé CHC-Liège, Liège, BE, 10GHdC - Grand Hopital de Charleroi,
Charleroi, BE, 11Centre Hospitalier de Mouscron, Mouscron, BE, 12AZ Klina, Brasschaat,
BE, 13Imelda Hospital, Bonheiden, BE, 14CHU-UCL-Namur, Namur, BE, 15University
Hospitals Leuven – KU Leuven, Leuven, BE, 16University Hospitals Leuven - KU Leuven,
Leuven, BE


16:30 - 17:30 Type: Multidisciplinary session 7.3.H - Honfleur
Title: Treating oligometastatic oesophagogastric Auditorium
cancer
Chair(s): Hanneke van Laarhoven, NL


16:35 - 16:50 The surgical oncologist perspective
R. Van Hillegersberg, UMC - University Medical Center Utrecht, Utrecht, NL

16:50 - 17:05 The radiation oncologist perspective
M. Hawkins, UCL - University College London, London, GB

17:05 - 17:20 The medical oncologist perspective


16:30 - 18:00 Type: Mini Oral session 7.3.U - Urval Auditorium
Title: Mini Oral session: CNS tumours
Chair(s): Enrico Franceschi, IT; Patrick Roth, CH; Monika Hegi, CH

16:30 - 16:35 281MO - Quality of life and neurocognitive function in patients with active brain
metastases of HER2-positive breast cancer treated with trastuzumab-
deruxtecan: Secondary endpoint analysis of the prospective single-arm phase II
TUXEDO-1 trial
A.M. Starzer1, A.S. Berghoff1, J. Furtner1, M. Marhold1, E. Bergen1, S. Roider-Schur2, H.

Forstner1, B. Rottenmanner1, K. Dieckmann1, Z. Bago-Horvath1, G. Widhalm1, A. Ilhan-
Mutlu1, C. Minichsdorfer1, T. Fuereder1, B. Gruenberger3, C. Singer1, A. Weltermann4, R.

Puhr1, M. Preusser1, R. Bartsch1, 1Medical University of Vienna, Vienna, AT, 2St. Joseph's
Hospital, Vienna, AT, 3Landesklinikum Wiener Neustadt, Wiener Neustadt, AT,
4Ordensklinikum Linz Elisabethinen, Linz, AT

16:35 - 16:40 282MO - Brain metastases: Real-life treatment patterns, survival and patient-
reported outcomes – Results from a population-based, prospective study
in 914 patients
O. Yri1, G. Astrup1, A. Karlsson1, Ø. Paulsen2, R. Van Helvoirt3, J.-Å. Lund4, M.-I. Taran5,
M. Jensen Hjermstad1, M. Birketvedt1, E. Bjerkeset1, N. Aass1, S. Kaasa1, 1Oslo
University Hospital, Oslo, NO, 2Sykehuset Telemark HF, Skien, NO, 3Sorlandet Hospital,
Kristiansand, NO, 4Helse More og Romsdal HF, Alesund, NO, 5Sykehuset i Vestfold HF,

Tonsberg, NO

16:40 - 16:45 283MO - Leptomeningeal disease (LMD) in patients (pts) with metastatic
melanoma (MM): Survival analysis of a contemporary cohort
I. Glitza1, C. Saberian1, J. Simon2, S. Duncan1, R. Amaria2, M. Davies1, A. Diab1, J.

Mcquade1, S. Patel1, H. Tawbi1, C. Yee1, M. Wong1, I. Mccutcheon1, D. Milton2, S.

Ferguson1, 1The University of Texas M. D. Anderson Cancer Center, Houston, US,
2University of Texas MD Anderson Cancer Center, Houston, US

E. Franceschi, Ospedale Bellaria Carlo Alberto Pizzardi, Bologna, IT

17:00 - 17:05 284MO - Targeting the tumor microenvironment of glioblastoma multiforme
using a macrophage-based treatment for the local delivery of immune-
therapeutic payload: The TEM-GBM study (NCT03866109)
G. Finocchiaro1, M. Eoli2, F. Farina1, B. Gentner1, A. Capotondo1, E. Anghileri2, M.

Bruzzone3, Q.G. D'Alessandris4, A. Franzin5, P. Ferroli2, F. Gagliardi1, F. Legnani2, S.
Mazzoleni6, A. Olivi4, R. Pallini4, M. Saini2, A. Zambanini6, L. Naldini1, C. Russo7, F.
Ciceri1, 1IRCCS Ospedale San Raffaele, Milan, IT, 2Fondazione IRCCS - Istituto

Neurologico C.Besta, Milan, IT, 3Istituto Neurologico Carlo Besta, Milan, IT, 4Fondazione
Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, 5Fondazione Poliambulanza
Istituto Ospedaliero, Brescia, IT, 6Genenta Science, Milan, IT, 7Genenta Science, New
York, US

17:05 - 17:10 285MO - The combination of lomustine and antibody-based targeted TNF
(L19TNF) as a promising treatment for recurrent glioblastoma
T. Weiss1, T. Look1, E. Puca2, T. Hemmerle2, R. De Luca3, R. Stucchi3, P. Roth4, D. Neri5,

M. Weller4, 1Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH, 2Philogen

S.p.A., Sovicille, IT, 3Philochem AG, Otelfingen, CH, 4USZ - Universitätsspital Zürich -
Klinik für Neurologie, Zurich, CH, 5ETH Zurich - Institut fur Mikrobiologie, Zurich, CH

17:10 - 17:15 286MO - Radiomics-based prediction of lymphocyte infiltration in IDH-wildtype
glioblastoma
M. Mair, J. Leitner, M. Zvonek, H. Windhager, K. Häller, G.J. Kührer, C. Paiato, B. Kiesel,
A. Wöhrer, G. Widhalm, K.-H. Nenning, G. Langs, M. Preusser, J. Furtner, A.S. Berghoff,
Medical University of Vienna, Vienna, AT

M. Hegi, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

17:30 - 17:35 287MO - A phase 0 ‘trigger’ trial of pamiparib in newly
diagnosed and recurrent glioblastoma patients
N. Sanai1, S. Mehta1, Y.-W. Chang 1, J. Jiang2, J. Molloy1, C. Pennington-Krygier1, J.

Harmon1, A. Hong1, J. Wanebo1, W. Kennedy1, M. Garcia1, I. Barani1, W. Yoo1, A.
Tovmasyan1, A.-C. Tien3, J. Li2, 1Barrow Neurological Institute, Phoenix, US, 2Wayne
State University School of Medicine; Barbara Ann Karmanos Cancer Institute, Detroit,
US, 3Barrow Brain and Spine, Phoenix, US

17:35 - 17:40 288MO - Brain-only oligometastatic cancer patients present with longer overall
survival than patients with extracranial involvement
A. Steindl1, A.Z. Ahmadi2, G. Moser1, B. Gatterbauer2, K. Dieckmann3, G. Widhalm2, M.

Hoda3, M. Preusser1, A.S. Berghoff1, 1Medical University of Vienna, Vienna, AT, 2MedUni

Wien - Medical University of Vienna, Vienna, AT, 3Universitätskliniken der MedUni Wien -
AKH Wien, Vienna, AT

17:40 - 17:45 289MO - Next-generation sequencing (NGS) for identifying actionable molecular
alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM)
patients: A large mono institutional experience
M. Padovan1, M. Maccari1, A. Bosio1, S. Vizzaccaro1, I. Cestonaro1, M. Corrà1, M.

Caccese1, G. Cerretti1, M. Fassan2, V. Zagonel1, G. Lombardi1, 1Veneto Institute of
Oncology IOV-IRCCS, Padova, IT, 2University of Padova, Padova, IT

P. Roth, USZ - Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH


Title: Supportive care: Adapting to advances in oncology Auditorium
for better patient outcomes
Chair(s): Mary Tanay, GB

16:45 - 17:00 Supportive care in cancer makes excellent cancer care possible! Recent
developments (MASCC)
E. Tomlins, Southampton General Hospital, Southampton, GB

17:00 - 17:15 Cognition, sleep and the daily functioning of patients with cancer: A time for
multi-modal management interventions
G. Kotronoulas, University of Glasgow, Glasgow, GB

17:15 - 17:25 CN61 - Patients’ experiences of a suppoRted self-manAGeMent
pAThway In breast Cancer (PRAGMATIC): Interview results
L. Matthews1, M. Teoh2, S. May3, C. Zammit4, D. Bloomfield4, M. Kothari5, D. Betal6, R.

Santos5, E. Stewart5, J. Finlay6, K. Nicholson6, D. Elwell-Sutton4, F. Mckinna7, H. Gage8,
S. Bell7, V. Jenkins3, 1University of Sussex, Brighton, GB, 2Ashford and St Peter's NHS
Foundation Trust, Ashford, GB, 3Brighton and Sussex Medical School - University of

Sussex, Brighton, GB, 4University Hospitals Sussex, Brighton, GB, 5St Peter's Hospital -
Ashford and St. Peter's Hospitals NHS Foundation Trust, Chertsey, GB, 6Worthing
Hospital, Worthing, GB, 7Surrey and Sussex Cancer Alliance, Guildford, GB, 8University
of Surrey, Guildford, GB

17:25 - 17:35 CN58 - Mapping the measurement of lymphoma survivors’ unmet needs
and quality of life outcomes: Evidence for a lymphoma-specific questionnaire
V. Boland1, A. Drury2, A.-M. Brady1, 1Trinity College Dublin, Dublin, IE, 2University

College Dublin, Dublin, IE


Title: The loved ones’ perspective and role: Best practices Auditorium
to support cancer caregiver
Chair(s): Tanja Spanic, SI; Vlad Voiculescu, RO

18:15 - 18:30 Caregiver story, the lost voice
A. Hyde, The Swallows Head & Neck cancer Charity, Lincolnshire, GB

18:30 - 18:45 Patients and caregivers are on the same journey but on different tracks: the
importance of family-focused education
G. Graffigna, Università Cattolica del Sacro Cuore, Rome, IT

18:45 - 19:00 Psycho-oncology service caregivers in the UK
A. King, St. Mary's Hospital Imperial College Healthcare NHS Trust, London, GB

19:00 - 19:15 A multidisciplinary approach to support families in managing cancer
repercussions
L. Travado, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT

19:15 - 19:30 Connecting for caregivers’ empowerment
K. Oliver, IBTA - International Brain Tumour Alliance, Tadworth, GB




18:30 - 20:00 Type: Industry Satellite Symposium 7.2.F - Fécamp
Title: Janssen-Cilag International NV - Exploring questions in Auditorium
metastatic prostate cancer
Chair(s): Laura-Maria Krabbe, DE; Gerhardt Attard, GB

L.-M. Krabbe, UKM - University Hospital Muenster, Muenster, DE

18:35 - 18:55 Question 1: How should we manage oligometastatic disease?
J. O'Sullivan, Northern Ireland Cancer Centre - Belfast Health & Social Care Trust,

Belfast, GB

18:55 - 19:15 Question 2: What is the role of chemotherapy alongside hormonal treatments in
mHSPC?
G. Attard1, L.-M. Krabbe2, 1UCL Cancer Institute - UCL - London's Global University,

London, GB, 2UKM - University Hospital Muenster, Muenster, DE

19:15 - 19:55 Question 3: How do we choose treatment options for patients with mCRPC?
E. Efstathiou, The M.D. Anderson Cancer Center, Houston, US

19:55 - 20:00 Close
G. Attard, UCL Cancer Institute - UCL - London's Global University, London, GB


Title: BeiGene Switzerland GmbH - Standard of Care is Not Auditorium
Enough! Talking Immunotherapy Clinical Trials in GI Cancers
Chair(s): Lesley Fallowfield, GB; Elizabeth Smyth, GB

18:30 - 18:35 Welcome to the Conversation

18:35 - 18:45 What Now Doc? A Patient’s Perspective
T. Gašpert, University Hospital KBC Rijeka, Rijeka, HR

18:45 - 19:05 GI Cancers: Checkpoint Inhibitors and Beyond

19:05 - 19:25 Talking With Patients About Clinical Trials: How, What, Why, When and Where?

19:25 - 19:35 Questions about Trials? Connect With your Expert!
E. Smyth1, E. Van Cutsem2, M. Ducreux3, S. Lorenzen4, S. Cascinu5, 1Addenbrooke's

Hospital, Cambridge, GB, 2UZ Leuven - University Hospitals Leuven - Campus
Gasthuisberg, Leuven, BE, 3Gustave Roussy - Cancer Campus, Villejuif, FR, 4Klinikum
Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, 5Azienda Ospedaliero -
Universitaria Policlinico di Modena, Modena, IT

19:35 - 19:40 Chairs’ Conclusions
L. Fallowfield1, E. Smyth2, 1Brighton and Sussex Medical School - University of Sussex,

Brighton, GB, 2Addenbrooke's Hospital, Cambridge, GB

Title: Thermo Fisher Scientific - Connecting patients Auditorium
everywhere to precision oncology
Chair(s): Silvia Novello, IT

18:30 - 18:45 The Evolving Paradigm of Precision Medicine in Lung Cancer: what Oncologist
and Advocacies can do
S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

18:45 - 19:00 Lung Cancer: How do I ask for and use molecular profiling results to guide
everyday treatment decisions?
E. Arriola, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

19:00 - 19:15 Next generation sequencing solution for every laboratory: My experience
B. Bellosillo Paricio, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

19:15 - 19:30 Circulating tumour DNA for monitoring of response to neoadjuvant
chemotherapy in patients with high grade serous ovarian carcinoma
E. Gray, Edith Cowan University, Perth, AU

19:30 - 19:45 Fully automated end to end IVD solution for ultra fast NGS results? Yes, we can
C. Rolando, University of Milan, Milan, IT

19:45 - 20:00 Q&A and closing remarks
S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT


Title: PeerVoice - Contemporary Management of Prostate Cancer: Honfleur
Updated Approaches for Improved Outcomes in nmCRPC and Auditorium
mHSPC
Chair(s): Karim Fizazi, FR

18:30 - 18:35 Welcome, Faculty Introductions, and Overview of Agenda

18:35 - 19:05 State-of-the-Art Interventions in mHSPC: New Evidence, New Expectations
K. Fizazi1, A. Morgans2, B. Tombal3, 1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Dana
Farber Cancer Institute, Boston, US, 3Cliniques Universitaires St. Luc - Université
Catholique de Louvain, Brussels, BE

19:05 - 19:35 Modernising the Standard of Care in nmCRPC: What Are We Waiting For?

19:35 - 19:50 Key Questions and Expert Discussion With Programme Faculty

19:50 - 19:55 Final Remarks, Conclusions, and Closing


Title: Sanofi and Regeneron - Evolving Treatment Roadmap Auditorium
for Advanced and High-risk NMSC
Chair(s): Paolo Ascierto, IT

P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

18:35 - 18:55 Current landscape in the immuno-oncology treatment of patients with NMSC

18:55 - 19:10 How to treat difficult cases with advanced CSCC
D. Rischin, Peter MacCallum Cancer Centre, Melbourne, AU

19:10 - 19:25 How to treat difficult cases with advanced BCC
J.J. Grob, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille,

FR

19:25 - 19:45 What are the remaining unmet needs in clinical management of NMSC?

19:45 - 20:00 Interactive Panel Discussion
P. Ascierto1, D. Rischin2, J.J. Grob3, D. Schadendorf4, 1Istituto Nazionale Tumori - IRCCS -

Fondazione Pascale, Napoli, IT, 2Peter MacCallum Cancer Centre, Melbourne, AU,
3Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR,
4University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

Title: Boehringer Ingelheim International GmbH - Breaking Quimper
Through the Firewall: New Therapeutic Strategies to Disrupt Auditorium
Cancer’s Operating Systems
Chair(s): Martin Reck, DE

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

18:35 - 19:05 Development of an MDM2-p53 Antagonist for STS and Other Indications
P. Schoeffski, KU Leuven - Laboratory of Experimental Oncology, Leuven, BE

19:05 - 19:25 Targeting HER2 and KRAS to Deliver Breakthrough Therapies
E. Smit, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,

Amsterdam, NL

19:25 - 19:45 T-cell Engagers: Change of the Treatment Paradigm in Solid Tumors

19:45 - 19:55 Expert Panel Q&A
M. Reck1, P. Schoeffski2, E. Smit3, 1Krankenhaus Grosshansdorf, Grosshansdorf, DE, 2KU

Leuven - Laboratory of Experimental Oncology, Leuven, BE, 3NKI-AVL - Netherlands
Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

19:55 - 20:00 Closing Remarks


18:30 - 20:00 Type: Industry Satellite Symposium 7.3.T - Toulouse
Title: Pfizer Oncology - Is it time to raise the bar for ALK+ Auditorium
NSCLC patients?
Chair(s): Ben Solomon, AU


18:35 - 18:52 New data and updated expectations for 1L therapy

18:52 - 19:10 Managing AEs and keeping patients on treatment
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

19:10 - 19:27 What next? Options after progression on 2nd and 3rd generation TKIs
N. Girard, Institut Curie, Paris, FR

19:27 - 19:45 The future of ALK+ NSCLC

19:45 - 19:55 Q&A
B. Solomon1, E. Felip2, N. Girard3, 1Peter MacCallum Cancer Center, Melbourne, AU,

2Vall d'Hebron University Hospital, Barcelona, ES, 3Institut Curie, Paris, FR



Title: Medscape Oncology Global - Improving Outcomes in Patients Auditorium
With High-Risk HR+/HER2- EBC: Keeping the Patient Central
Chair(s): Joyce O'Shaughnessy, US

18:30 - 18:35 Welcome and introduction 
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

18:35 - 19:00 How Would You Assess Risk of Recurrence in This Patient With HR+/HER2-
EBC? Patient video will be included
W. Janni, Ulm Medical University, Ulm, DE

19:00 - 19:30 Treatment Considerations for Patients With High-Risk HR+/HER2- EBC: What do
the Latest Data Show?
M. Martin Jimenez, Hospital General Universitario Gregorio Marañon, Madrid, ES

19:30 - 19:55 Keeping the Patient Central: Discussing Adherence and Persistence and the Role
of the MDT Patient
S. Donahue, UCSF - University of California San Francisco, San Francisco, US

19:55 - 20:00 Concluding Remarks
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US


11.09.2022
08:30 - 10:00 Type: Proffered Paper session 4.A - Antibes Auditorium
Title: Proffered Paper session: GU tumours, prostate
Chair(s): Elena Castro Marcos, ES; Karim Fizazi, FR

08:30 - 08:40 LBA62 - Comparison of abiraterone acetate and prednisolone (AAP) or
combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive
prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall
survival (OS) results of 2 randomised phase III trials from the STAMPEDE
protocol
G. Attard1, L. Murphy2, N. Clarke3, W. Cross4, S. Gillessen5, C. Amos2, C. Brawley2, R.

Jones6, C. Pezaro7, Z. Malik8, A. Montazeri9, R. Millman2, A. Cook2, D. Gilbert2, R.
Langley2, C. Parker10, M. Sydes2, L. Brown2, M. Parmar2, N. James11, 1UCL Cancer
Institute - UCL - London's Global University, London, GB, 2UCL, Institute of Clinical
Trials & Methodology, London, GB, 3The Christie and Salford Royal NHS Foundation
Trusts, Manchester, GB, 4University of Leeds - Leeds Institute of Molecular Medicine
(LIMM), Leeds, GB, 5EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico

della Svizzera Italiana (IOSI), Bellinzona, CH, 6Institute of Cancer Sciences, University of
Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, GB, 7Weston Park Hospital -
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, 8The Royal Liverpool
University Hospital - Liverpool University Hospitals NHS Foundation Trust, Liverpool,
GB, 9Clatterbridge Cancer Center, Wirral - NHS Foundation Trust, Metropolitan Borough
of Wirral, GB, 10The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton,
GB, 11ICR - Institute of Cancer Research, London, GB

08:40 - 08:50 1358O - Clinical qualification of transcriptome signatures for advanced prostate
cancer (APC) starting androgen deprivation therapy (ADT) with or without
abiraterone acetate and prednisolone (AAP): An ancillary study of the
STAMPEDE AAP trial
M. Parry1, E. Grist1, C. Brawley2, J. Proudfoot3, L. Mendes1, S. Lall1, A. Hoyle4, A.

Sachdeva4, Y. Liu3, C. Amos5, M. Sydes2, R. Jones6, M. Parmar7, F. Feng8, C. Sweeney9,
N. Clarke10, E. Davicioni3, N. James11, L. Brown12, G. Attard1, 1UCL Cancer Institute -
Paul O'Gorman Building, London, GB, 2Medical Research Council Clinical Trials Unit,
London, GB, 3Veracyte, Inc. - Headquarters, South San Francisco, US, 4The Christie NHS
Foundation Trust, Manchester, GB, 5Cancer Research UK & University College London

Cancer Trials Centre, London, GB, 6MVLS - Medical, Veterinary and Life Sciences
College - University of Glasgow, Glasgow, GB, 7Institute of Clinical Trials and
Methodology-UCL, London, GB, 8JLABS @ MBC BioLabs, San Francisco, US, 9Dana
Farber Cancer Institute, Boston, US, 10The University of Manchester, Manchester, GB,
11ICR - Institute of Cancer Research, London, GB, 12MRC - Medical Research Council
Clinical Trials Unit - University College London (UCL), London, GB

E. Castro Marcos, Hospital Universitario 12 de Octubre, Madrid, ES

09:00 - 09:15 Q&A


09:15 - 09:25 1357O - Biomarker analysis and updated results from the Phase III PROpel trial
of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L)
therapy for patients (pts) with metastatic castration-resistant prostate cancer
(mCRPC)
F. Saad1, A. Armstrong2, A. Thiery-Vuillemin 3, M. Oya4, N. Shore5, G. Procopio6, C.

Arslan7, N. Mehra8, F. Parnis9, E. Brown10, F. Constans Schlurmann11, J.Y. Joung12, M.
Sugimoto13, O. Sartor14, Y.-Z. Liu15, C. Poehlein16, C. Desai17, P.M. Del Rosario17, N.
Clarke18, 1Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de
Montreal, Montreal, CA, 2Duke Cancer Institute Center, Durham, US, 3CHRU Besançon
Hôpital J.Minjoz, Besancon, FR, 4Keio University School of Medicine, Tokyo, JP, 5Carolina
Urologic Research Center, Myrtle Beach, US, 6Istituto Nazionale Per Cura Tumori
Milano, Milan, IT, 7Izmir Economy University Medical Park Hospital, Karsiyaka, TR,
8Radboud Universitair Medisch Centrum, Nijmegen, NL, 9Ashford Cancer Centre
Research, Kurralta Park, AU, 10University Hospital Southampton, Southampton, GB,

11Centre Hospitalier de Cornouaille, Quimper, FR, 12National Cancer Center, Goyang-si,
KR, 13Kagawa University Hospital, Kagawa, JP, 14Tulane Cancer Center, New Orleans,
US, 15Astrazeneca, Cambridge, GB, 16Merck & Co., Inc., Rahway, US, 17AstraZeneca,
Cambridge, GB, 18The Christie and Salford Royal NHS Foundation Trusts, Manchester,
GB

09:25 - 09:35 LBA63 - PRESTO: A phase III, open-label study of androgen annihilation in
patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
R. Aggarwal1, G. Heller2, D. Hillman3, H. Xiao2, J. Picus4, J. Wang5, M.E. Taplin6, T.

Dorff7, L. Appleman8, D. Weckstein9, A. Patnaik10, A. Bryce11, D. Shevrin12, J. Mohler13,
D. Anderson14, A. Rao15, S. Tagawa16, A. Tan17, S. Eggener10, M. Morris18, 1UCSF -
University of California San Francisco - Parnassus Campus, San Francisco, US,
2Memorial Sloan Kettering Cancer Center, New York, US, 3Mayo Clinic - Rochester,
Rochester, US, 4Washington University School of Medicine in St. Louis, St. Louis, US,
5MD Anderson Cancer Center, Houston, US, 6Dana Farber Cancer Institute, Boston, US,
7City of Hope Comprehensive Cancer Center, Duarte, US, 8University of Pittsburgh

Cancer Institute, Pittsburgh, US, 9NH Oncology Hematology PA, Concord, US, 10The
University of Chicago, Chicago, US, 11Mayo Clinic Cancer Center, Phoenix, US,
12NorthShore University HealthSystem-Evanston Hospital, Evanston, US, 13Roswell Park
Comprehensive Cancer Center, Buffalo, US, 14Colorado Springs Health Partners, PC,
Colorado Springs, US, 15Baylor College of Medicine, Houston, US, 16NewYork-
Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, 17Rush University
Medical Center, Chicago, US, 18MSKCC - Memorial Sloan Kettering Cancer Center, New
York, US

J. De Bono, ICR - Institute of Cancer Research, London, GB

09:45 - 10:00 Q&A

08:30 - 10:00 Type: Proffered Paper session 4.B - Brest
Title: Proffered Paper session: Non-metastatic NSCLC and Auditorium
other thoracic malignancies
Chair(s): Nicolas Girard, FR; Noemi Reguart Aransay, ES

08:30 - 08:40 LBA47 - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-
mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated
results from ADAURA
M. Tsuboi1, Y.-L. Wu2, C. Grohe3, T. John4, M. Majem Tarruella5, J. Wang6, T. Kato7, J.

Goldman8, S.-W. Kim 9, C.-J. Yu10, H. Vinh Vu11, G. Mukhametshina12, C. Akewanlop13, F.
De Marinis14, F. Shepherd15, D. Urban16, M. Stachowiak17, A. Bolanos18, X. Huang19,
R.S. Herbst20, 1National Cancer Center Hospital East, Kashiwa, JP, 2Guangdong
Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou,
CN, 3Evangelische Lungenklinik Berlin Buch, Berlin, DE, 4Austin Health, Melbourne, AU,
5Hospital de la Santa Creu i Sant Pau, Barcelona, ES, 6Chinese Academy of Medical
Sciences, Beijing, CN, 7Kanagawa Cancer Center, Asahi Ward, Yokohama, JP, 8University
of California Los Angeles, Los Angeles, US, 9Asan Medical Center, Seoul, KR, 10National
Taiwan University Hospital and National Taiwan University College of Medicine, Taipei,
TW, 11Cho Ray Hospital, Ho Chi Minh City, VN, 12Kazan, Republic of Tatarstan, RU,
13Siriraj Hospital, Bangkok, TH, 14European Institute of Oncology (IEO), IRCCS, Milan,
IT, 15University Health Network, Princess Margaret Cancer Centre, Toronto, CA, 16Sheba
Medical Center, Tel Hashomer, Israel and Sackler Faculty of Medicine, Tel Aviv
University, Tel Aviv, IL, 17AstraZeneca, Warsaw, PL, 18AstraZeneca, Mississauga, CA,
19AstraZeneca, Cambridge, GB, 20Yale School of Medicine and Yale Cancer Center, New
Haven, US

08:40 - 08:50 LBA48 - Community-based mass screening with low-dose CT for lung cancer in
Guangzhou
W. Liang, C.C. Li, J. Li, S. Xiong, B. Cheng, H. Liang, N. Zhong, J. He, The First Affiliated

Hospital of Guangzhou Medical University, Guangzhou, CN


09:00 - 09:15 Q&A

09:15 - 09:25 950O - Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery
in patients with resectable and borderline resectable lung cancer: The
INCREASE trial
I. Bahce1, C. Dickhoff2, F. Schneiders2, J. Veltman2, D. Heineman2, S. Hashemi2, M.

Fransen2, A. Vrijmoet2, I. Houda3, E. Ulas2, P. Van De Ven2, N. Bouwhuis2, L. Meijboom2,
D. Oprea-Lager1, J. Garcia Vallejo2, T. De Gruijl2, T. Radonic2, S. Senan1, 1Amsterdam

UMC - Vrije Universiteit Medical Center (VUmc), Amsterdam, NL, 2Amsterdam UMC -
Vrije University Medical Centre (VUmc), Amsterdam, NL, 3Vrije Universiteit, Amsterdam,
NL

09:25 - 09:35 LBA49 - CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy
in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
E. Garon1, S. Lu2, Y. Goto3, P.R. De Marchi4, L. Paz-Ares5, D. Spigel6, M. Thomas7, J.C.-H.

Yang8, A. Ardizzoni9, F. Barlesi10, S. Khanna11, C. Bossen12, M. Carbini12, A. Yovine12,
B.C. Cho13, 1David Geffen School of Medicine at UCLA/TRIO-US/TRIO-Global Network,
Los Angeles, US, 2Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai,

CN, 3National Cancer Center - Tsukiji Campus, Chuo-ku, JP, 4Oncoclínicas, Rio de Janeiro,
BR, 5Hospital Universitario 12 de Octubre, Madrid, ES, 6Sarah Cannon Research

Institute-Cancer Centre, Nashville, US, 7Thoraxklinik and National Center for Tumor
Diseases at Heidelberg University Hospital, and Translational Lung Research Center
Heidelberg (TLRC-H), German Center for Lung Research (DLZ), Heidelberg, DE,
8NTUCC - National Taiwan University Cancer Center, Taipei City, TW, 9University of
Bologna - Alma Mater Studiorum, Bologna, IT, 10Gustave Roussy, Villejuif, FR, 11Novartis
Pharma S.A.S, Rueil-Malmaison, FR, 12Novartis Pharma AG, Basel, CH, 13Yonsei Cancer
Centre, Yonsei University College of Medicine, Seoul, KR

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

09:45 - 10:00 Q&A

08:30 - 10:00 Type: Special symposium 7.2.E - Évry
Title: Application of novel technologies in head & neck Auditorium
cancer
Chair(s): Ingeborg Tinhofer-Keilholz, DE; Lillian Siu, CA

L. Siu, Princess Margaret Cancer Centre, Toronto, CA

08:35 - 08:50 Multi-omic profiling in H&N cancer: Clinical applications
I. Tinhofer-Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE

08:50 - 09:05 Circulating biomarker assays in individualizing targeted therapy and IO for HN
cancers: ctDNA
R. Galot, Brussels,

09:05 - 09:20 New promising targets on the horizon: HRAS, PI3KCA, NTRK, RET, NOTCH1,
BRAF...etc

09:20 - 09:35 Novel platforms to identify neoantigens in personalised immunotherapy
E. Cohen, Moores Cancer Center - UC San Diego Health, La Jolla, US

I. Tinhofer-Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE



08:30 - 10:00 Type: Special symposium 7.1.D - Dijon Auditorium
Title: Interplay between host biology and treatment
Chair(s): Sandra Demaria, US; Christian Ottensmeier, GB

S. Demaria, Weill Cornell Medical College, New York, US

08:35 - 08:55 Germline make-up and immune landscape/response to immunotherapy
D. Bedognetti, Doha, QA

08:55 - 09:15 Targeting the adenosine immune checkpoint to overcome treatment resistance
J. Stagg, University of Montreal Health Center, Montreal, CA

09:15 - 09:35 Radiotherapy shapes the tumor antigenic repertoire




08:30 - 10:00 Type: Special session 7.3.T -
Title: ESMO adaptation of an existing framework for determining Toulouse
Line of Therapy: A designation ecosystem for oncology practice Auditorium
Chair(s): George Pentheroudakis, CH; Christopher Twelves, GB

08:30 - 08:45 Line of Therapy: Definitions and guidelines
K. Saini, Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB

08:45 - 09:00 Line of Therapy in the curative setting, challenges and solutions: Clinical
vignettes
J. Remon Masip, HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES

09:00 - 09:15 Line of Therapy in the non-curative setting, challenges and solutions: Clinical
vignettes
C. Twelves, St. James's University Hospital, Leeds, GB

09:15 - 09:30 Perspectives from the Investigator: Landscape and impact on clinical research
V. Golfinopoulos, EORTC AISBL/IVZW - European Organisation for Research and

Treatment of Cancer, Brussels, BE

09:30 - 09:45 Perspectives from the regulator: Landscape and unmet needs
O. Tenhunen, Finnish Medicines Agency, Helsinki, FI

09:45 - 09:55 Q&A



Title: The road towards clinical implementation of artificial Auditorium
intelligence (AI) in oncology
Chair(s): Rudolf Fehrmann, NL; Nathalie Lassau, FR

08:30 - 08:50 What is AI?
J. Kather, Uniklinik RWTH Aachen, Aachen, DE

08:50 - 09:05 AI applied to radiology
N. Lassau, Gustave Roussy - Cancer Campus, Villejuif, FR

09:05 - 09:20 AI applied to pathology
E. Golomb, Shaare Zedek Medical Center, Jerusalem, IL

09:20 - 09:40 Key challenges for delivering clinical impact with artificial intelligence
J. Reis-Filho, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

09:40 - 09:55 Perspectives: Which transformations are expected?
R. Fehrmann, UMCG - University Medical Center Groningen, Groningen, NL


08:30 - 10:00 Type: Proffered Paper session 7.3.U - Urval
Title: Proffered Paper session: Supportive and palliative Auditorium
care
Chair(s): Karin Jordan, DE; Matteo Lambertini, IT

08:30 - 08:40 1551O - Factors associated with chemotherapy (CT)-related amenorrhea (CRA)
and its relationship with quality of life (QOL) in premenopausal women with
early breast cancer (BC): Results from the prospective CANTO cohort study
R. Kabirian1, J. Havas1, M.A. Franzoi1, C. Coutant2, O. Tredan3, C. Levy4, P. Cottu5, A.

Dhaini Merimeche6, S. Guillermet7, J.-M. Ferrero8, S. Giacchetti9, T. Petit10, F. Dalenc11,
P. Rouanet12, O. Querel13, A.-L. Martin14, B. Pistilli1, M. Lambertini15, I. Vaz Luis1, A. Di
Meglio1, 1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Centre Georges Francois
Leclerc, Dijon, FR, 3Centre Léon Bérard, Lyon, FR, 4Centre Francois Baclesse, Caen, FR,
5Institut Curie, Paris, FR, 6Institut de Cancérologie de Lorraine - Alexis Vautrin,

Vandoeuvre-lès-Nancy, FR, 7Centre Eugene - Marquis, Rennes, FR, 8Centre Antoine
Lacassagne, Nice, FR, 9Hopital Saint Louis - Groupe Hospitalier La Rochelle-Ré-Aunis, La
Rochelle, FR, 10Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR,
11Centre Claudius-Regaud, Toulouse, FR, 12CRLC Val d'Aurelle, Montpellier, FR,
13Unicancer, Paris, Cedex, FR, 14UNICANCER, Paris, FR, 15IRCCS Ospedale Policlinico
San Martino, Genova, IT

08:40 - 08:50 1263O - Evaluation of weight gain and overall survival of male vs. female
patients with advanced non-small cell lung cancer (NSCLC) receiving first-line
chemotherapy
E. Roeland1, F.J. Fintelmann2, R. Yang3, L. Tarasenko3, T.D. Mcrae3, J. Revkin4, P.

Bonomi5, 1Oregon Health and Science University, Portland, US, 2Massachusetts General

Hospital, Boston, US, 3Pfizer Inc, New York, US, 4Pfizer Inc, Cambridge, US, 5Rush
University Medical Center, Chicago, US

K. Jordan, Ernst von Bergmann Klinikum Potsdam, Potsdam, DE

09:00 - 09:10 Q&A

09:10 - 09:20 1552O - Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial
evaluating the efficacy of hand-cooling and compression in patients undergoing
taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First
results of the prospective, randomized POLAR trial
L. Michel1, P. Romar1, M. Feisst2, D. Hamberger3, D. Schwarz4, E. Kurre1, E. Klein1, M.

Breckwoldt4, A. Priester4, M. Weiler4, K. Smetanay4, C. Fremd1, D. Jäger1, M. Bendszus4,
F. Marmé5, A. Schneeweiss1, 1University Hospital and German Cancer Research Center,

Heidelberg, DE, 2University of Heidelberg, Heidelberg, DE, 3Asklepios-Fachklinikum,
Gauting, DE, 4Heidelberg University Hospital, Heidelberg, DE, 5Heidelberg University,
Mannheim University Hospital, Mannheim, DE

09:20 - 09:30 1553O - Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial
of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic
breast cancer (MBC)
H. Rugo1, P. Schmid2, S. Tolaney3, F. Dalenc4, F. Marmé5, L. Shi6, W. Verret7, M.

Gharaibeh7, A. Bardia8, J. Cortés9, 1University of California San Francisco Helen Diller
Family Comprehensive Cancer Center, San Francisco, US, 2Queen Mary University of
London, London, GB, 3Dana-Farber Cancer Institute, Boston, US, 4Institut Claudius
Regaud, Toulouse, FR, 5Heidelberg University, University Hospital Mannheim,

Mannheim, DE, 6Evidera PPD, Waltham, US, 7Gilead Sciences, Inc., Foster City, US,
8Massachusetts General Hospital Cancer Center, Boston, US, 9International Breast
Cancer Center, Quironsalud Group, Madrid & Barcelona, Spain Universidad Europea de
Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid,
Spain, Barcelona, ES

09:30 - 09:40 217O - Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized
phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of
physician's choice (TPC) in patients (pts) with HER2-low metastatic
breast cancer (MBC)
N. Ueno1, W. Jacot2, T. Yamashita3, J. Sohn4, E. Tokunaga5, A. Prat6, J. Tsurutani7, Y.H.

Park8, H. Rugo9, B. Xu10, F. Cardoso11, Z. Mitri12, R. Mahtani13, K. Dunton14, Y. Wang15,
D. Gambhire15, F. Cottone16, N. Harbeck17, D. Cameron18, S. Modi19, 1The University of
Texas MD Anderson Cancer Center, Houston, US, 2Institut du Cancer de Montpellier,
Montpellier University, INSERM U1194, Montpellier, FR, 3Kanagawa Cancer Center,
Yokohama, JP, 4Yonsei Cancer Center, Yonsei University Health System, Seoul, KR,
5National Hospital Organization (NHO) Kyushu Cancer Center, Fukuoka, JP,
6Translational Genomics and Targeted Therapies in Solid Tumors, Barcelona, ES, 7Showa

University, Shinagawa-ku, JP, 8Samsung Medical Center (SMC) - Sungkyunkwan
University School of Medicine, Seoul, KR, 9UCSF Helen Diller Family Comprehensive
Cancer Center, San Francisco, US, 10Cancer Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College, Beijing, CN, 11Champalimaud Clinical
Center/Champalimaud, Lisbon, PT, 12Oregon Health & Science University, Portland, US,
13Baptist Health Miami Cancer Institute, Miami, US, 14Daiichi Sankyo, Uxbridge, GB,
15Daiichi Sankyo, Basking Ridge, US, 16Daiichi Sankyo, Rome, IT, 17LMU University
Hospital, Munich, DE, 18Institute of Genetics and Cancer, University of Edinburgh,

EDINBURGH, GB, 19Memorial Sloan Kettering Cancer Center, New York, US

G. Velikova, St. James's University Hospital, Leeds, GB

09:50 - 10:00 Q&A

Title: YO Fellowship Session: Despite COVID-19 the ESMO Auditorium
Fellowship programme did not stop and research continued
Chair(s): Teresa Amaral, DE; Evandro de Azambuja, BE

E. De Azambuja, Institute Jules Bordet, Brussels, BE

08:35 - 08:55 ESMO Research Fellowship Programme: Supporting young oncologists and
enhancing careers for more than 30 years

08:55 - 09:10 Best paper derived from an ESMO Fellowship
E. Ghisoni, UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges,

CH

09:10 - 09:25 Best Fellowship project
B. Pellegrino, Azienda Ospedaliero-Universitaria di Parma, Parma, IT

09:25 - 09:55 ESMO Fellowship awards ceremony (Research Fellowship, José Baselga, Best
Exam)
T. Amaral1, E. De Azambuja2, 1Skin Cancer Clinical Trials Center, University of

Tuebingen, Tübingen, DE, 2Institute Jules Bordet, Brussels, BE

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE


Title: Patient and occupational safety
Chair(s): Gianluca Catania, IT

08:30 - 08:45 Advanced nursing practice in cancer
M. Fowler, Heartlands Hospital - University Hospitals Birmingham NHS Foundation

Trust, Birmingham, GB

08:45 - 09:00 Can we address the problem of the nurses shortage post COVID-19?
M. Foulkes, Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB

09:00 - 09:15 Cancer nurses and safety around hazardous drugs, outcome of European
Oncology Nursing Society advocacy work
H. Ullgren, Karolinska University Hospital-Solna, Solna, SE

09:15 - 09:25 CN30 - Three stage capacity: Consent process for systemic anti-cancer therapy
F. Barrett1, O. Fitzpatrick1, T. Doyle1, W. Grogan1, D. Mcmahon1, N. Cooley1, A. Murphy1,

M. Conroy1, L. Judge1, J. Naidoo1, R. Mclaughlin1, C. Matassa1, P. Morris1, B. Hennessy1,

M. Breathnach2, K. Egan1, D. O'Doherty1, O. Breathnach1, 1Beaumont RCSI Cancer
Centre, Dublin, IE, 2National University of Ireland - University College Dublin, Dublin, IE

09:25 - 09:35 CN32 - Cancer nurses' experiences and perceptions of potential occupational
exposure to cytotoxic drugs: Systematic review utilising framework analysis
K. Campbell, J. Afseth, M. Dunham, Edinburgh Napier University, Edinburgh, GB

09:35 - 09:45 CN33 - How to work with swiptests in an oncology outpatient ward: An
occupational safety project
A. Stridsberg, S. Wallberg, Karolinska University Hospital-Solna, Solna, SE

09:45 - 09:55 CN31 - Project bedside handover 2022 (a tool for health care professionals to
increase patient participation in bedside report)
L. Matarlo Solvebrand, Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE



09:00 - 10:00 Type: Multidisciplinary session 7.1.C - Cannes
Title: Multidisciplinary management of brain metastases with Auditorium
or without driver oncogene
Chair(s): Rafal Dziadziuszko, PL

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

09:05 - 09:20 Optimizing local treatment for brain metastasis in lung cancer
M. Guckenberger, Zurich, CH

09:20 - 09:35 Role and reliability of systemic treatment for brain metastasis in lung cancer
L. Hendriks, Maastricht, NL

09:35 - 09:50 Molecular features of brain metastasis and considerations for precision
management
P. Brastianos, Massachusetts General Hospital, Boston, US


09:00 - 10:00 Type: Challenge your Expert 7.2.F - Fécamp
Title: Selection of first-line and subsequent treatments Auditorium
in HCC
Chair(s): Robin Katie Kelley, US

A. Forner, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

R.K. Kelley, UCSF - University of California San Francisco - Parnassus Campus, San

Francisco, US

09:00 - 10:00 Type: Challenge your Expert 7.3.G - Grenoble
Title: How to incorporate digital medicine in survivorship Auditorium
care after breast cancer
Chair(s): Ines Vaz Luis, FR

09:00 - 09:15 How to incorporate digital medicine in survivorship care after breast cancer
A. Partridge, Dana Farber Cancer Institute, Boston, US



09:00 - 10:00 Type: Challenge your Expert 7.3.H - Honfleur
Title: Chronic lymphocytic leukemia (CLL): What is the Auditorium
optimal first-line therapy?
Chair(s): Carol Moreno, ES

C.-M. Wendtner, Universitätsklinikum Köln (AöR), Köln, DE

C. Moreno, Barcelona, ES

09:00 - 10:00 Type: Challenge your Expert 7.3.O - Orléans
Title: Should all advanced ovarian cancer patients receive a Auditorium
PARPi in first-line therapy?
Chair(s): Frederik Marmé, DE

D.S. Tan, NUHS - National University Health System, Singapore, SG

F. Marmé, UMM - Universitaetsklinikum Mannheim - Medizinische Fakultaet, Mannheim,

DE

09:00 - 10:00 Type: Challenge your Expert 7.3.Q - Quimper
Title: Germ cell tumors: Prognostic factors, managing poor- Auditorium
risk and progressive/refractory disease
Chair(s): Anja Lorch, CH

G. Baciarello, Azienda Ospedaliera San Camillo Forlanini, Rome, IT

A. Lorch, Zurich, CH

Title: Proffered Paper session 1: GI, lower digestive
Chair(s): Andrea Cercek, US; Marco Gerlinger, GB

10:15 - 10:25 LBA21 - FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients
with initially unresectable colorectal liver metastases (CRLM) and left-sided and
RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch
Colorectal Cancer Group
M. Bond1, K. Bolhuis2, O. Loosveld3, H. Droogendijk4, J.W. De Groot5, M. Hendriks6, B.

De Valk7, M. Liem8, A. Rijken3, K. Verhoef9, J. De Wilt10, K. De Jong11, G. Kazemier2, M.
Van Amerongen12, M. Engelbrecht13, J. Klaase11, A. Komurcu14, M. Lopez-Yurda 15, R.-J.
Swijnenburg2, C. Punt1, 1University Medical Center Utrecht, Utrecht, NL, 2Amsterdam

UMC, Amsterdam, NL, 3Amphia Ziekenhuis, Breda, NL, 4Bravis Ziekenhuis, Roosendaal,
NL, 5Isala, Zwolle, NL, 6Northwest Clinics, Alkmaar, NL, 7Spaarne Hospital, Hoofddorp,
NL, 8Medisch Spectrum Twente, Enschede, NL, 9Erasmus MC, Rotterdam, NL,
10Radboud University Medical Center, Nijmegen, NL, 11UMCG - University Medical
Center Groningen, Groningen, NL, 12Sint Maartenskliniek, Woerden, NL, 13Amsterdam

University Medical Center (UMC), Amsterdam, NL, 14IKNL - Netherlands Comprehensive
Cancer Organisation, Utrecht, NL, 15Netherlands Cancer Institute, Amsterdam, NL

10:25 - 10:35 LBA22 - Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab
followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-
type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
C. Pinto1, A. Orlandi2, N. Normanno3, E. Maiello4, M.A. Calegari2, L. Antonuzzo5, R.

Bordonaro6, M.G. Zampino7, S. Pini8, F. Bergamo9, G. Tonini10, A. Avallone11, T.
Latiano12, G. Rosati13, A. Pazzola14, A. Ballestrero15, A. Zaniboni16, M. Roselli17, S.
Tamberi8, C. Barone2, 1Clinical Cancer Centre Azienda USL – IRCCS di Reggio Emilia,
Reggio Emilia, IT, 2Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome,
IT, 3Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, 4IRCCS
Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, 5Careggi University
Hospital, and Department of Experimental and Clinical Medicine, University of Florence,
Florence, IT, 6Azienda Ospedaliera ARNAS Garibaldi, Catania, IT, 7IEO - Istituto Europeo
di Oncologia, Milan, IT, 8Opsedale degli Infermi - AUSL Romagna, Faenza, IT, 9IOV -
Istituto Oncologico Veneto IRCCS, Padova, IT, 10Policlinico Universitario Campus Bio-
Medico, Rome, IT, 11Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, IT,
12Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT,
13Ospedale San Carlo, Potenza, IT, 14Oncologia Universitaria Sassari, Sassari, IT,
15Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS - DiMI,
Genova, IT, 16Fondazione Poliambulanza, Brescia, IT, 17Policlinico Tor Vergata, Rome, IT


10:45 - 10:55 Q&A

10:55 - 11:05 314O - Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced
colon cancer (HIPECT4): A randomized phase III study
A. Arjona-Sanchez1, M.T. Cano-Osuna1, A. Gutierrez2, J.J. Segura3, E. Perez4, V.

Concepcion5, S. Sanchez6, A. Garcia7, I. Prieto8, P. Barrios Sanchez9, J. Torres10, M.
Ramirez11, A. Prada12, J. Carrasco13, M. Artiles14, P. Villarejo15, G. Ortega16, E. Boldo17,
E. Aranda18, S. Rufian1, 1Hospital Universitario Reina Sofía, Cordoba, ES, 2UAH -
Universidad de Alcalá, Alcalá de Henares, ES, 3Hospital Universitario Son Espases,
Palma de Mallorca, ES, 4Hospital Universitario de Fuenlabrada, Fuenlabrada, ES,
5Hospital Universitario Nuestra Senora de Candelaria, Santa Cruz de Tenerife, ES,
6Hospital General Ciudad Real, Ciudad Real, ES, 7IVO - Fundación Instituto Valenciano
de Oncología, Valencia, ES, 8Hospital Universitario La Paz, Madrid, ES, 9Hospital de Sant
Joan Despi Moisès Broggi, Sant Joan Despí, ES, 10Hospital Torrecardenas, Almeria, ES,
11Hospital Reina Sofia, Murcia, ES, 12Hospital Universitario Badajoz (Hospital Infanta
Cristina), Badajoz, ES, 13Hospital Universitario Regional de Malaga, Malaga, ES,

14Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria,
ES, 15Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, 16MD Anderson
Cancer Center Madrid, Madrid, ES, 17Hospital Provincial de Castellón, Castellón de La
Plana, ES, 18Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
Hospital Universitario Reina Sofía, Córdoba, ES

11:05 - 11:15 LBA23 - Avelumab versus standard second-line treatment chemotherapy in
metastatic colorectal cancer (mCRC) patients with microsatellite instability
(MSI): The SAMCO-PRODIGE 54 randomised phase II trial
J. Taieb1, O. Bouche2, T. André3, E. Barbier4, P. Laurent-Puig5, J. Bez4, C. Toullec6, C.

Borg7, V. Randrian8, L. Evesque9, S. Corbinais10, B. Buecher11, H. Perrier12, F. Di
Fiore13, C. Gallois14, C. Lepage15, F. El Hajbi16, D. Tougeron8, 1Hopital European George
Pompidou, Paris, FR, 2CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR, 3Hopital
Saint-Antoine, Paris, FR, 4Fédération Francophone de Cancérologie Digestive, Dijon, FR,
5Paris Descartes University, Paris, FR, 6 Avignon-Provence Cancer Institute, Avignon, FR,

7CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, 8CHU Poitiers - Jean Bernard
Hôpital, Poitiers, FR, 9Centre Anticancer Antoine Lacassagne, Nice, FR, 10Centre
Francois Baclesse, Caen, FR, 11Institut Curie, Paris, FR, 12Fondation Hôpital Saint
Joseph, Marseille, FR, 13CHU de Rouen Normandie, Rouen, FR, 14Centre de Recherche
des Cordeliers - Université Paris Cité, Paris, FR, 15CHU Dijon, Dijon, FR, 16Centre Oscar
Lambret, Lille, FR

A. Cercek, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

11:25 - 11:35 Q&A

10:15 - 11:45 Type: Educational session 4.B - Brest Auditorium
Title: Non-clear cell renal cell carcinoma: Best practices
Chair(s): Daniel Heng, CA; Cristina Suarez Rodriguez, ES

10:15 - 10:40 Papillary renal cell carcinoma
S. Pal, City of Hope Comprehensive Cancer Center, Duarte, US

10:40 - 11:05 Translocation renal cell carcinoma
G. Malouf, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR

11:05 - 11:30 Sarcomatoid renal cell carcinoma
D. Heng, Tom Baker Cancer Centre, Calgary, CA



10:15 - 11:45 Type: Special session 7.1.C - Cannes Auditorium
Title: ESMO Clinical Practice Guidelines session 1
Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR

10:15 - 10:25 Early breast cancer: Clinical case
C. Valenza, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

10:25 - 10:35 Early breast cancer: Discussant
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

10:35 - 10:45 Early breast cancer: Discussion / Q&A

10:45 - 10:55 Cancer of Unknown Primary site (CUP): Clinical case
R. Pihlak, The Christie NHS Foundation Trust, Manchester, GB

10:55 - 11:05 Cancer of Unknown Primary site (CUP): Discussant
A. Krämer, DKFZ - German Cancer Research Center, Heidelberg, DE

11:05 - 11:15 Cancer of Unknown Primary site (CUP): Discussion / Q&A

11:15 - 11:25 Biliary tract cancer: Clinical case
E. Mariamidze, Todua Clinic, Tbilisi, GE

11:25 - 11:35 Biliary tract cancer: Discussant

11:35 - 11:45 Biliary tract cancer: Discussion / Q&A


10:15 - 11:45 Type: Special symposium 7.2.E - Évry Auditorium
Title: New classification and staging of breast cancer
Chair(s): Carsten Denkert, DE; Barbara Pistilli, FR

B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR

10:20 - 10:35 Rethinking tumor subtype classification: Learning from RNA expression
C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE

10:35 - 10:50 Special subtypes of breast cancer
C. Marchiò, Candiolo, IT

10:50 - 11:05 The microenvironment in early breast cancer: TILS and beyond
S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

11:05 - 11:20 Detecting minimal residual disease for new staging methods
N. Turner, London, GB

C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE


10:15 - 11:45 Type: Mini Oral session 7.2.F - Fécamp Auditorium
Title: Mini Oral session: NSCLC, metastatic
Chair(s): Laura Mezquita, ES; Tony S.K. Mok, HK; Mary O'Brien, GB

10:15 - 10:20 LBA55 - Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant
metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2
DESTINY-Lung02 trial
K. Goto1, K. Sang-We 2, T. Kubo3, Y. Goto4, M.-J. Ahn5, D. Planchard6, D.-W. Kim 7, J.C.-H.
Yang8, T.-Y. Yang 9, K. Pereira10, K. Saxena10, R. Shiga10, Y. Cheng10, M. Aregay10, P.
Jänne11, 1National Cancer Center Hospital East, Kashiwa, JP, 2Asan Medical Center -
University of Ulsan College of Medicine, Seoul, KR, 3Okayama University Hospital,
Okayama, JP, 4National Cancer Center Hospital, Tokyo, JP, 5Samsung Medical Center

Sungkyunkwan University School of Medicine, Seoul, KR, 6Gustave Roussy, Villejuif, FR,
7Seoul National University Hospital, Seoul National University College of Medicine,
Seoul, KR, 8National Taiwan University Hospital, Taipei City, TW, 9Taichung Veterans
General Hospital, Taichung, TW, 10Daiichi Sankyo, Inc., Basking Ridge, US, 11Dana-
Farber Cancer Institute, Boston, US

10:20 - 10:25 LBA56 - MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in

treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II
trial
M.-J. Ahn1, S.-W. Kim 2, E. Carcereny Costa3, L.M. Rodríguez4, J. Oliveira5, M.A. Insa
Molla6, M. Majem7, L. Costa8, W.-C. Su9, K. Lee10, J.C.-H. Yang11, D. Spigel12, E.K.
Cho13, M. D'Arcangelo14, M.R. Garcia Campelo15, A. Delmonte16, P. Mitchell17, I.
Achour17, D. Subramaniam17, E. Felip18, 1Sungkyunkwan University School of Medicine,
Seoul, KR, 2University of Ulsan College of Medicine, Seoul, KR, 3B-ARGO Group,
Badalona, ES, 4Hospital Universitario Virgen de la Victoria, Malaga, ES, 5Portuguese
Oncology Institute of Porto, Porto, PT, 6Hospital Clínico Universitario de Valencia,
Valencia, ES, 7Hospital de la Santa Creu i Sant Pau, Barcelona, ES, 8Hospital de Santa
Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, PT, 9National Cheng Kung
University Hospital College of Medicine, Tainan City, TW, 10Chungbuk National
University, Cheong-ju, KR, 11National Taiwan University Hospital, Taipei City, TW,
12Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, 13Gachon
University, Incheon, KR, 14AUSL di Romagna, Ravenna, IT, 15University Hospital A

Coruna, Madrid, ES, 16Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino
Amadori" - IRCCS, Meldola, IT, 17AstraZeneca, Gaithersburg, US, 18Vall d’Hebron
University Hospital, Barcelona, ES

L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

10:40 - 10:45 LBA57 - Sintilimab plus anlotinib versus platinum-based chemotherapy as first-
line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center,
randomized, phase II study
B. Han1, T. Chu1, Z. Yu2, J. Wang2, Y. Zhao3, X. Mu3, X. Yu4, X. Shi4, Q. Shi5, M. Guan5, C.
Ding6, N. Geng6, 1Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai,
CN, 2The Affiliated Hospital of Qingdao University, Qingdao, CN, 3Henan Cancer
Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, 4Cancer
Hospital Affiliated to the University of Chinese Academy of Sciences, Hangzhou, CN,
5AnHui Chest Hospital, Hefei, CN, 6The Fourth Hospital of Hebei Medical University,
Shijiazhuang, CN

10:45 - 10:50 LBA58 - Sintilimab with or without IBI305 plus chemotherapy in patients with
EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC)
who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second
interim analysis of phase III ORIENT-31 study
S. Lu1, L. Wu2, H. Jian1, Y. Cheng3, Q. Wang4, J. Fang5, Z. Wang5, Y. Hu6, L. Han7, M.

Sun8, L. Miao9, C. Ding10, J. Cui11, K. Wang12, B. Li13, X. Li14, F. Ye15, A. Liu16, Y. Pan17,
S. Cang18, 1Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University,
Shanghai, CN, 2Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya
School of Medicine, Central South University, Changsha, CN, 3Jilin Cancer Hospital,
Changchun, CN, 4Henan Cancer Hospital, Zhengzhou, CN, 5Peking University Cancer
Hospital, Beijing Cancer Hospital, Beijing, CN, 6Hubei Cancer Hospital, Wuhan, CN,
7Xuzhou Central Hospital, Xuzhou, CN, 8Jinan Central Hospital affiliated to Shandong
University, Jinan, CN, 9Nanjing University Medical School affiliated Nanjing Drum Tower
Hospital, Nanjing, CN, 10Hebei Medical University Fourth Affiliated Hospital and Hebei
Provincial Tumor Hospital, Shijiazhuang, CN, 11The First Hospital of Jilin University,
Changchun, CN, 12West China Hospital of Sichuan University, Chengdu, CN, 13Beijing

Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing, CN, 14The First Affiliated Hospital of Zhengzhou University,
Zhengzhou, CN, 15The First Affiliated Hospital of Xiamen University, Xiamen, CN, 16The
Second Affiliated Hospital of Nanchang University, Nanchang, CN, 17Anhui Provincial
Hospital, Hefei, CN, 18Henan Provincial People's Hospital, Zhengzhou, CN

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

11:05 - 11:10 LBA59 - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT)
in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after
median follow-up (mFU) of approximately 4 years (y)
M. Johnson1, B.C. Cho2, A. Luft3, J. Alatorre-Alexander4, S.L. Geater5, K. Laktionov6, S.-

W. Kim7, G. Ursol8, M. Hussein9, F.L. Lim10, C.T. Yang11, L.H. Araujo12, H. Saito13, N.
Reinmuth14, Z. Lai15, H. Mann16, X. Shi17, S. Peters18, E. Garon19, T.S.K. Mok20, 1Sarah
Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, US, 2Yonsei Cancer
Center, Seoul, KR, 3Leningrad Regional Clinical Hospital, Saint-Petersburg, RU, 4Health
Pharma Professional Research, Mexico City, MX, 5Prince of Songkla University, Amphoe
Hat Yai, TH, 6Federal State Budgetary Institution “N.N. Blokhin National Medical
Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N.
Blokhin NMRCO), Moscow, RU, 7Asan Medical Center, University of Ulsan College of
Medicine, Seoul, KR, 8Acinus, Kropyvnytskyi, UA, 9Florida Cancer Specialists - Sarah
Cannon Research Institute, Leesburg, US, 10Queen Mary University of London, London,
GB, 11Chang Gung Memorial Hospital, Taoyuan City, TW, 12Instituto Nacional de Cancer-
INCA, Rio de Janeiro, BR, 13Kanagawa Cancer Center, Yokohama, JP, 14Asklepios Lung
Clinic, Munich-Gauting, DE, 15AstraZeneca, Waltham, US, 16AstraZeneca, Cambridge,
GB, 17AstraZeneca, Gaithersburg, US, 18Centre Hospitalier Universitaire Vaudois,
Lausanne University, Lausanne, CH, 19David Geffen School of Medicine at UCLA, Los
Angeles, US, 20Chinese University of Hong Kong, Hong Kong, HK

11:10 - 11:15 973MO - KEYNOTE-189 5-year update: First-line pembrolizumab (pembro)
+ pemetrexed (pem) and platinum vs placebo (pbo) + pem and
platinum for metastatic nonsquamous NSCLC
M. Garassino1, S. Gadgeel2, G. Speranza3, E. Felip4, E. Esteban Gonzalez5, M. Domine

Gomez6, M. Hochmair7, S. Powell8, H. Bischoff9, N. Peled10, F. Grossi11, R. Jennens12, M.
Reck13, R. Hui14, E. Garon15, T. Kurata16, J.E. Gray17, P. Schwarzenberger18, E. Jensen18,
D. Rodriguez Abreu19, 1Knapp Center for Biomedical Discovery, Chicago, US, 2Henry
Ford Cancer Institute/Henry Ford Health, Detroit, US, 3Hôpital Charles-Le Moyne,
Greenfield Park, CA, 4Vall d'Hebron University, Vall d’Hebron Institute of Oncology
(VHIO), Barcelona, ES, 5Hospital Universitario Central de Asturias, Oviedo, ES, 6Hospital
Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, ES, 7Karl Landsteiner Institute of
Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, 8Sanford Cancer
Center, Sioux Falls, US, 9Thoraxklinik, Heidelberg, DE, 10Shaare Zedek Medical Center,
Jerusalem, IL, 11University of Insubria, Varese, IT, 12Epworth Healthcare, Richmond, AU,
13Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE,
14Westmead Hospital and University of Sydney, Sydney, AU, 15David Geffen School of
Medicine at UCLA, Los Angeles, US, 16Kansai Medical University Hospital, Osaka, JP,
17Moffitt Cancer Center, Tampa, US, 18Merck & Co., Inc., Rahway, US, 19Universidad de
Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES

11:15 - 11:20 974MO - 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy
in squamous non-small cell lung cancer (NSCLC)
S. Novello1, D. Kowalski2, A. Luft3, M. Gumus4, D. Vicente Baz5, J. Mazieres6, J.

Rodriguez Cid7, A. Tafreshi8, Y. Cheng9, K. Lee10, A. Golf11, S. Sugawara12, A.
Robinson13, B. Halmos14, E. Jensen15, P. Schwarzenberger15, M.C. Pietanza15, L. Paz-
Ares16, 1University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, IT,
2Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL,
3Leningrad Regional Clinical Hospital, St Petersburg, RU, 4Istanbul Medeniyet
University, Istanbul, TR, 5Hospital Universitario Virgen Macarena, Seville, ES, 6Hôpital
Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, FR, 7Medica Sur Hospital,
Mexico City, MX, 8Wollongong Private Hospital and Wollongong Oncology, Wollongong,
AU, 9Jilin Cancer Hospital, Changchun, CN, 10Chungbuk National University College of
Medicine, Cheong-ju, KR, 11Universitätsklinikum Tübingen, Tuebingen, DE, 12Sendai
Kousei Hospital, Sendai, Miyagi, JP, 13Kingston General Hospital, Kingston, CA, 14Albert
Einstein College of Medicine, Bronx, US, 15Merck & Co., Inc., Rahway, US, 16Hospital
Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense &
Ciberonc, Madrid, ES

M. O'Brien, The Royal Marsden Hospital - Chelsea, London, GB


Title: Lessons learned and new horizons for treatment of Auditorium
primary brain tumours
Chair(s): Susan Chang, US; Anna Sophie Berghoff, AT

A.S. Berghoff, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

10:20 - 10:35 Emerging role of RANO: From idea to practice
S. Chang, University of California San Francisco, San Francisco, US

10:35 - 10:50 Novel and less conventional treatment strategies
A. Idbaih, Hopital Pitié Salpetrière AP-HP, Paris, FR

10:50 - 11:05 Tailoring treatment according to biology
P. Mischel, Stanford, US

11:05 - 11:20 Targeting IDH mutation

S. Chang, University of California San Francisco, San Francisco, US



10:15 - 11:45 Type: Special session 7.3.H -
Title: In collaboration with EONS: The oncology workforce on Honfleur
the frontline of cancer prevention across Europe Auditorium
Chair(s): Rosa Giuliani, GB; Lena Sharp, SE

R. Giuliani1, L. Sharp2, 1The Clatterbridge Cancer Centre - Aintree, Liverpool, GB, 2RCC

Stockholm-Gotland, HSF, Stockholm, SE

10:20 - 10:35 Cancer prevention at the forefront of the political agenda: The European Union
vision
J.F. Ryan, European Commission - Directorate General Health and Food Safety,

Luxembourg City, LU

10:35 - 10:50 Why cancer prevention? The medical oncologist’s perspective
R. Giuliani, The Clatterbridge Cancer Centre - Aintree, Liverpool, GB

10:50 - 11:05 Implementing cancer prevention: The oncology nurse’s perspective

11:05 - 11:20 Promoting health for all individuals: The patient’s perspective
F. De Lorenzo, ECPC - European Cancer Patient Coalition, Brussels, BE


11:40 - 11:45 Conclusion and closing remarks
R. Giuliani1, A. Sharp2, 1The Clatterbridge Cancer Centre - Aintree, Liverpool, GB,

2Abramson Cancer Center - University of Pennsylvania, Philadelphia, US

10:15 - 11:45 Type: Special symposium 7.3.O - Orléans Auditorium
Title: What’s old is new again
Chair(s): Shivaani Kummar, US; Chia-Chi Lin, TW

S. Kummar, OHSU Knight Cancer Institute - Center for Health and Healing Building 1 -

South Waterfront, Portland, US

10:20 - 10:35 Drugging the undruggable: Next generation KRAS inhibitors
M. Barbacid, Madrid, ES

10:35 - 10:50 Beyond the genome: Novel epigenomic and metabolomic strategies
S. Postel-Vinay, Institut Gustave Roussy, Villejuif, FR

10:50 - 11:05 Break it down: New frontiers in protein degradation and refolding
G. Winter, Vienna, AT

11:05 - 11:20 From cold to hot: Immunotherapy in the genome-driven arena
S. Kummar, OHSU Knight Cancer Institute - Center for Health and Healing Building 1 -

South Waterfront, Portland, US

C.-C. Lin, NTUH - National Taiwan University Hospital, Taipei City, TW


10:15 - 11:45 Type: Mini Oral session 7.3.Q - Quimper Auditorium
Title: Mini Oral session: GU tumours, prostate
Chair(s): Boris Hadaschik, DE; Martijn Lolkema, NL; Nicolas Mottet, FR

10:15 - 10:20 1360MO - Quality of life and patient-relevant endpoints with darolutamide in the
phase III ARASENS study
K. Fizazi1, M. Smith2, M. Hussain3, F. Saad4, C. Sternberg5, E. Crawford6, J. Aragon-

Ching7, S. Thiele8, S. Kapur9, A. Mohamed10, S. Srinivasan10, R. Li10, I. Kuss8, H.
Joensuu11, B. Tombal12, 1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Massachusetts
General Hospital, Boston, US, 3Northwestern University Feinberg School of Medicine,
Chicago, US, 4University of Montreal Hospital Center, Montreal, CA, 5Weill Cornell

Medicine, New York, US, 6University of Colorado, Aurora, US, 7Inova Fairfax Hospital,
Fairfax, US, 8Bayer AG, Berlin, DE, 9Bayer (South East Asia) Pte Ltd, Singapore, SG,
10Bayer HealthCare Pharmaceuticals Inc., Whippany, US, 11Orion Corporation Orion
Pharma, Espoo, FI, 12Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-

Saint-Lambert, BE

10:20 - 10:25 LBA64 - Duration of androgen suppression with post-operative radiotherapy
(DADSPORT): A collaborative meta-analysis of aggregate data

S. Burdett1, D. Fisher1, C. Parker2, M. Sydes1, P. Pommier3, P. Sargos4, D. Spratt5, A.
Kishan6, M. Brihoum7, C. Catton8, S. Chabaud9, N. Clarke10, A. Cook1, I. Latorzeff11, J.
Tierney1, C. Vale1, 1Institute of Clinical Trials and Methodology, London, GB, 2The Royal
Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, 3CRCL - Centre de
recherche en cancerologie de Lyon, Lyon, Cedex, FR, 4Institute Bergonié, Bordeaux, FR,
5Case Western Reserve University / University Hospitals, Cleveland, US, 6Jonsson
Comprehensive Cancer Center at UCLA, Los Angeles, US, 7Unicancer, Paris, Cedex, FR,
8Princess Margaret Cancer Center, Toronto, CA, 9Centre de recherche en cancerologie
de Lyon (CRCL), Lyon, FR, 10The Christie and Salford Royal NHS Foundation Trusts,
Manchester, GB, 11Clinique Pasteur, Toulouse, FR
10:25 - 10:40 Invited Discussant 1360MO and LBA64

N. Mottet, CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR

10:40 - 10:45 1359MO - Differential treatment response with nodal metastases in metastatic
hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden
as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone
acetate and prednisolone (AAP) phase III trials from STAMPEDE
Á. Haran1, Y. Jain2, T. Hambrock2, L. Murphy3, A. Cook3, L. Brown3, A. Hoyle4, A.

Sachdeva2, S.A. Ali1, C. Amos3, M. Sydes3, G. Attard5, M. Parmar3, N. James6, N. Clarke4,
1The University of Manchester, Manchester, GB, 2The Christie NHS Foundation Trust,

Manchester, GB, 3Medical Research Council Clinical Trials Unit (MRC CTU), London, GB,
4The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, 5UCL Cancer
Institute - UCL, London, GB, 6ICR - Institute of Cancer Research, London, GB

10:45 - 10:50 1361MO - 8-month PSA strongly predicts outcomes of men with metastatic
castration-sensitive prostate cancer in the PEACE-1 phase III trial
G. Gravis Mescam1, X. Maldonado2, G. Roubaud3, R.S. Mcdermott4, A. Flechon5, B.

Tombal6, S. Supiot7, D. Berthold8, R. Philippe9, G. Kacso10, F. Calabro'11, J.F. Berdah12,
A. Hasbini13, M. Silva14, A. Thiery-Vuillemin 15, A. Rodriguez-Vida 16, J. Mccaffrey17, H.
Ribault18, S. Foulon19, K. Fizazi20, 1Institut Paoli-Calmettes, Aix-Marseille Université,
CRCM, Marseille, Cedex, FR, 2Vall d’Hebron Institute of Oncology, Barcelona, ES,
3Institute Bergonié, Bordeaux, FR, 4St Vincent's University Hospital and Cancer Trials
Ireland, Dublin, IE, 5Centre Léon Bérard, Lyon, FR, 6Cliniques Universitaires St. Luc -
Université Catholique de Louvain, Brussels, BE, 7ICO Institut de Cancerologie de l'Ouest
René Gauducheau, Saint-Herblain, FR, 8CHUV - Centre Hospitalier Universitaire

Vaudois, Lausanne, CH, 9Centre Azureen Cancerologie, Mougins, FR, 10Amethyst
Radiotherapy Center, luliu Hatienagu of Medicine and Pharmacy, Cluj-Napoca, RO,
11Azienda Ospedaliera San Camillo Forlanini, Rome, IT, 12Clinique Sainte-Marguerite,
Hyères, FR, 13Clinique Pasteur Lanroze, Brest, FR, 14Centre François Baclesse, Caen,
FR, 15CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, 16Hospital del Mar-IMIM
Research Institute, Barcelona, ES, 17The Mater Misericordiae University Hospital,
Dublin, IE, 18Unicancer, Paris, Cedex, FR, 19Gustave Roussy - University of Paris-Saclay-
Oncostat U1018, Villejuif, FR, 20Institut Gustave Roussy, University of Paris Saclay,
Villejuif, Cedex, FR

B. Hadaschik, University Hospital of Essen, Essen, DE

11:05 - 11:10 LBA65 - SAKK 08/14 - IMPROVE Investigation of metformin in patients with
metastatic castration-resistant prostate cancer (mCRPC) in combination with
enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial
C. Rothermundt1, R. Cathomas2, K. Gysel3, N. Fischer4, R. Pereira Mestre5, T.

Hermanns6, S. Rothschild7, N. Mach8, W. Mingrone9, M. Ciriolo10, B. Müller11, A.
Erdmann12, C. Schär3, C. Mamot13, P. Bohanes14, A. Omlin1, S. Bastian2, K. Ribi3, S.
Gillessen15, 1Kantonsspital St. Gallen, St. Gallen, CH, 2Kantonsspital Graubünden, Chur,
CH, 3SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, 4Kantonsspital
Winterthur, Winterthur, CH, 5EOC - Ente Ospedaliero Cantonale, Bellinzona, CH,

6Universitätsspital Zürich, Zurich, CH, 7Universitätsspital Basel, Basel, CH, 8Hopitaux
Universitaires de Geneve, Geneva, CH, 9Kantonsspital Olten, Olten, CH, 10Bürgerspital

Solothurn, Solothurn, CH, 11Luzerner Kantonsspital, Luzern, CH, 12Kantonsspital Baden,
Baden, CH, 13Kantonsspital Aarau, Aarau, CH, 14CCAC 2- Centre de Chimiothérapie Anti-
cancéreuse, Lausanne, CH, 15EOC - Ospedale Regionale Bellinzona e Valli - Istituto
Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

11:10 - 11:15 1362MO - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide
(enza) for patients (pts) with previously treated metastatic castration-resistant
prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
E. Yu1, S.H. Park2, J. Goh3, S.J. Shin4, N. Mehra5, R. Mcdermott6, M.A. Sala Gonzalez7, P.
Fong8, R. Greil9, M. Retz10, J.P. Sade11, Y.-H. Huang12, S. Begbie13, F. Rey14, G.
Kramer15, H. Suzuki16, J. Zhang17, J. Kim17, C. Poehlein17, E. Antonarakis18, 1University
of Washington & Fred Hutchinson Cancer Research Center, Seattle, US, 2Samsung
Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, 3Royal
Brisbane and Women's Hospital, Herston & Queensland University of Technology,
Herston, AU, 4Severance Hospital Yonsei University Health System, Seoul, KR, 5Radboud
University Medical Center, Nijmegen, Nijmegen, NL, 6St Vincents University Hospital,
Dublin, IE, 7Hospital Josep Trueta, Bilbao, ES, 8Auckland City Hospital and University of
Auckland, Auckland, NZ, 9Paracelsus Medical University Salzburg Cancer Research
Institute and Cancer Cluster, Salzburg, AT, 10Rechts der Isar Medical Center, Technical
University Munich, München, DE, 11Instituto Alexander Fleming, Buenos Aires, AR,
12Taipei Veterans General Hospital, Taipei City, TW, 13Port Macquarie Base Hospital, Port
Macquarie, AU, 14Clinica CIDO, Temuco, CL, 15Medical University of Vienna, Vienna, AT,
16Toho University Medical Center Sakura Hospital, Sakura, JP, 17Merck & Co., Inc.,
Rahway, US, 18Johns Hopkins University, Baltimore, US

11:15 - 11:20 1363MO - Cabazitaxel every 2 weeks versus every 3 weeks in older patients with
metastatic castration-resistant prostate cancer (mCRPC): The CABASTY
randomized phase III trial
S. Oudard1, P. Beuzeboc2, E. Voog3, P. Barthelemy4, A. Thiery-Vuillemin 5, M.

Bennamoun6, A. Hasbini7, K. Aldabbagh8, C. Saldana9, E. Sevin10, Y.E. Amela11, G. Von
Amsberg12, N. Houede13, D. Besson14, S. Feyerabend15, M. Boegemann16, D. Pfister17,
M. Schostak18, O. Huillard19, C. Helissey20, 1HEGP - Hopital Europeen Georges-
Pompidou - APHP - University de Paris, Paris, FR, 2Foch Hospital, Suresnes, FR, 3Jean
Bernard Center, Le Mans, FR, 4Institut de Cancérologie Strasbourg Europe, Strasbourg,
FR, 5CHU Jean-Minjoz, Besançon, FR, 6Institute Mutualiste Montsouris, Paris, FR,
7Clinique Pasteur Lanroze, Brest, FR, 8Polyclinique Saint Côme, Compiegne, FR, 9Henri


Mondor Hospital, Paris Est Creteil university, TRePCa, Creteil, FR, 10Centre Maurice
Tubiana, Caen, FR, 11Centre de Cancérologie Les Dentellières, Valenciennes, FR,
12University Hospital Hamburg-Eppendorf, Hamburg, DE, 13Institut de cancérologie du
Gard, Nîmes, FR, 14Centre Armoricain de Radiothérapie et d'Oncologie, Plérin, FR,

15Studienpraxis Urologie, Nürtingen, DE, 16UKM - University Hospital Münster, Münster,
DE, 17Universitaetsklinikum Köln, Koln, DE, 18University Hospital Magdeburg, Otto von
Guericke University Magdeburg, Magdeburg, DE, 19Hopital Cochin AP-HP, Paris, FR,
20Military Hospital Begin, Saint-Mandé, FR

11:20 - 11:25 1364MO - Preliminary phase II results of the CYPIDES study of ODM-208 in
metastatic castration-resistant prostate (mCRPC) cancer patients
K. Fizazi1, A. Bernard-Tessier 1, P. Barthelemy2, T. Utriainen3, G. Roubaud4, A. Flechon5,

J. Van Der Voet6, G. Gravis Mescam7, R. Ratta8, R. Jones9, O. Parikh10, M. Tanner11, C.
Garratt12, L. Nevalaita13, P. Pohjanjousi13, T. Ikonen13, E. Antonarakis14, N. Cook15,
1Institute Gustave Roussy, Villejuif, FR, 2ICANS-Institut de Cancérologie, Strasbourg, FR,
3Helsinki University Central Hospital, Helsinki, FI, 4Institute Bergonié, Bordeaux, FR,
5Centre Léon Bérard, Lyon, FR, 6The James Cook University Hospital, Middlesbrough,

GB, 7IPC - Institut Paoli-Calmettes, Marseille, FR, 8Hopital Foch, Suresnes, FR, 9Velindre
Cancer Centre, Cardiff, GB, 10Royal Preston Hospital-Lancashire Teaching Hospitals
NHS Foundation Trust, Preston, GB, 11Tampere University Hospital (Tays), Tampere, FI,
12Orion Corporation Orion Pharma, Newbury, GB, 13Orion Corporation Orion Pharma,
Espoo, FI, 14Johns Hopkins University, Baltimore, US, 15The Christie NHS Foundation

11:25 - 11:40 Invited Discussant LBA65, 1362MO, 1363MO and 1364MO
M. Lolkema, Erasmus MC - University Medical Center, Rotterdam, NL


10:15 - 11:45 Type: Special session 7.3.T - Toulouse
Title: Sex and gender differences in oncology: From Auditorium
prevention to care
Chair(s): Sabine Oertelt-Prigione, NL; Anna Wagner, CH

10:15 - 10:35 Gender differences in epidemiology and attributable risk factors of non sex-
related cancers
I. Soerjomataram, IARC - International Agency for Research on Cancer, Lyon, FR

10:35 - 10:55 Gender differences in colorectal cancer screening
H. Brenner, DKFZ - German Cancer Research Center, Heidelberg, DE

10:55 - 11:15 Lung cancer biology and outcomes

11:15 - 11:35 Quality-of-life
S. Oertelt-Prigione, Radboud University Medical Center, Nijmegen, Nijmegen, NL


10:15 - 11:45 Type: Educational session 7.3.U - Urval
Title: State-of-the-art: Diagnosis and treatment of Auditorium
gastroenteropancreatic neuroendocrine tumours
Chair(s): Eva Tiensuu Janson, SE; Nicola Fazio, IT

10:15 - 10:40 What oncologists need to know about GEP-NET before commencing therapy
E. Tiensuu Janson, University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE

10:40 - 11:05 Treatment of small intestinal NET
M. Pavel, Universitätsklinik Erlangen, Erlangen, DE

11:05 - 11:30 Treatment of pancreatic NET
N. Fazio, IEO - Istituto Europeo di Oncologia, Milan, IT



Title: Palliative and end-of-life care
Chair(s): Merel van Klinken, NL

10:15 - 10:30 Cultural determinants of end of life
G. Bagcivan, Koc University - School of Nursing, Istanbul, TR

10:30 - 10:45 Gero-oncology integrative view on palliative care
W. Oldenmenger, Erasmus MC Cancer Institute, Rotterdam, NL

10:45 - 11:00 Navigating parental cancer when a mum or dad is at end of life
C. Semple, Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB

11:00 - 11:10 CN24 - The perceptions of healthcare professionals on the provision of palliative
and end-of-life care in prisons
S. Pringle1, G. Kotronoulas2, 1MVLS - Medical, Veterinary and Life Sciences College -

University of Glasgow, Glasgow, GB, 2University of Glasgow, Glasgow, GB

11:10 - 11:20 CN25 - Bereaved parents’ experience of adapting to life after the death
of a parent with cancer who has dependent children
J. Hanna1, C. Semple2, 1Ulster University, Jordanstown, GB, 2Ulster Hospital - South

Eastern Health and Social Care Trust, Dundonald, GB

11:20 - 11:30 CN27 - Exploring the quality of dying and death of patients with cancer
undergoing palliative care (PC)
M. Parara1, S. Katsaragakis2, M. Giannakopoulou2, E. Patiraki2, 1Galilee Palliative Care

Centre, Spata, Attica, GR, 2National and Kapodistrian University of Athens, Athens, GR

11:30 - 11:40 CN23 - The end of life – a topic we avoid: The Croatian National Cancer
Patient Experience Survey
A. Sajnic1, S. Karabatic2, J. Miličević1, I. Lukic Franolic2, N. Dodlek3, F. Seiwerth4, M.

Jakopovic2, 1KBC - University Hospital Centre Zagreb, Zagreb, HR, 2KBC Zagreb - Clinic

for Lung Diseases Jordanovac, Zagreb, HR, 3KBC Osijek - Clinical Medical Center Osijek,
Osijek, HR, 4KBC Zagreb--Jordanovac Clinic for Lung Diseases, Zagreb, HR



10:30 - 11:30 Type: Controversy session 7.3.G - Grenoble
Title: What is the optimal approach to managing intermediate Auditorium
stage HPV positive oropharyngeal carcinoma?
Chair(s): Sandra Schmitz, BE

10:30 - 10:35 Introduction by the chair
S. Schmitz, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-

Lambert, BE


10:36 - 10:51 Induction and de-escalation

10:51 - 11:06 TORS and RT
C. Simon, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH


11:07 - 11:27 Q&A


10:30 - 11:30 Type: Multidisciplinary session 7.3.M - Marseille
Title: Localized extremity STS: Looking beyond Auditorium
surgery
Chair(s): Inga-Marie Schaefer, US

I.-M. Schaefer, Brigham and Women's Hospital, Boston, US

10:35 - 10:50 Isolated limb perfusion
S. Bonvalot, Paris, FR

10:50 - 11:05 RT and radioenhancer: Chemotherapy, TKI and nanoparticles
R.L. Haas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,

Amsterdam, NL

11:05 - 11:20 Risk-based criterion to select for neoadjuvant chemotherapy: Dream or reality?
D. Callegaro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT


Title: Young Oncologist Brunch 2: How to write and respond Auditorium
to a critical peer review

11:00 - 11:15 How to write and respond to a critical peer review
P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES


Cancro, Genova, IT

12:00 - 12:40 Type: Keynote lecture 4.B - Brest
Title: Antigen-focused, biotech-empowered: The promise of Auditorium
antibody and cell-based therapies in cancer
Chair(s): Sherene Loi, AU


12:05 - 12:30 Antigen-focused, biotech-empowered: The promise of antibody and cell-based
therapies in cancer
J. Haanen, T. Schumacher, NKI-AVL - Netherlands Cancer Institute/Antoni van

Leeuwenhoek Hospital, Amsterdam, NL


12:00 - 13:30 Type: EONS Industry Satellite Symposium 7.3.S - Strasbourg
Title: Mundipharma - Pain management in people Auditorium
with cancer
Chair(s): Nikolina Dodlek, HR

12:00 - 12:05 Welcome
N. Dodlek, KBC Osijek - Clinical Medical Center Osijek, Osijek, HR

12:05 - 12:30 Nursing roles in cancer pain management
G. Toumbis, Nicosia General Hospital, Nicosia, CY

12:30 - 12:55 Barriers to pain management in cancer
L. Magee, Papworth Hospital NHS Foundation Trust, Cambridge, GB

12:55 - 13:20 Pain management in home settings
J. Miličević, KBC - University Hospital Centre Zagreb, Zagreb, HR



Title: AstraZeneca - Immunotherapy: the evolving treatment Auditorium
landscape in hepatobiliary cancers
Chair(s): Juan Valle, GB

13:00 - 13:05 Welcome and introduction to hepatobiliary cancers

13:05 - 13:20 The immunogenic landscape of hepatobiliary cancers: rationale for combination
therapy approaches in HCC and BTC

13:20 - 13:35 Therapeutic approaches in unresectable / advanced HCC
G. Abou-Alfa, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

13:35 - 13:45 Case-study discussion of unresectable / advanced HCC
G. Abou-Alfa, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

13:45 - 14:00 Treatment options and prospects for patients with BTC

14:00 - 14:10 Case-study discussion of advanced BTC

14:10 - 14:30 Audience discussion and Q&A


Title: F. Hoffmann-La Roche Ltd - Redefining Lung Cancer Auditorium
Together: Now and Next
Chair(s): Stephen Liu, US

S. Liu, Lombardi Cancer Center Georgetown University, Washington, US

13:05 - 13:10 Patient perspective: Where are we now?
S. Vallone, LuCE, Bern, CH

13:10 - 13:20 Biomarkers in lung cancer: challenges and opportunities
F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

13:20 - 13:40 Immunotherapy, targeted therapy and beyond: navigating options for metastatic
disease
S. Liu1, M. Reck2, 1Lombardi Cancer Center Georgetown University, Washington, US,

2Krankenhaus Grosshansdorf, Grosshansdorf, DE

13:40 - 14:05 Treatment choice in early-stage lung cancer: new insights, new outlooks
M. Reck1, P. Van Schil2, 1Krankenhaus Grosshansdorf, Grosshansdorf, DE, 2UZA -

University Hospital Antwerp, Edegem, BE

14:05 - 14:25 Panel discussion and Q&A
S. Liu1, M. Reck2, F. Penault-Llorca3, P. Van Schil4, S. Vallone5, 1Lombardi Cancer Center

Georgetown University, Washington, US, 2Krankenhaus Grosshansdorf, Grosshansdorf,

DE, 3Jean Perrin Center, Clermont-Ferrand, FR, 4UZA - University Hospital Antwerp,
Edegem, BE, 5LuCE, Bern, CH

S. Liu1, S. Vallone2, 1Lombardi Cancer Center Georgetown University, Washington, US,

2LuCE, Bern, CH

Title: Amgen - Advancing the lung cancer treatment Auditorium
landscape: novel targets for improved patient care
Chair(s): Fabrice Barlesi, FR


13:10 - 13:40 Non-squamous versus squamous NSCLC: actionable and emerging targets
J. Wolf, Universitätsklinikum Köln (AöR), Köln, DE

13:40 - 13:55 Towards a new era of biomarker-driven therapy in SCLC

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

13:55 - 14:10 Expanding treatment opportunities in SCLC: targeting DLL3
S. Champiat, Gustave Roussy - Cancer Campus, Villejuif, FR

F. Barlesi1, J. Wolf2, N. Reguart Aransay3, S. Champiat1, 1Gustave Roussy - Cancer

Campus, Villejuif, FR, 2Universitätsklinikum Köln (AöR), Köln, DE, 3Hospital Clinic y
Provincial de Barcelona, Barcelona, ES


13:00 - 14:30 Type: Industry Satellite Symposium 7.3.H - Honfleur
Title: Ipsen - Disrupting the landscape: the Plus One in Auditorium
RCC and NSCLC
Chair(s): Laurence Albiges, FR

13:00 - 13:05 Welcome & agenda
L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

13:05 - 13:45 Triple, double and monotherapy: what is the sequence for best outcomes?
J. Bedke1, G.A. De Velasco Oria2, S. Pal3, 1Crona Kliniken - Universitätsklinikum

Tübingen, Tübingen, DE, 2Hospital Universitario 12 de Octubre, Madrid, ES, 3City of
Hope Comprehensive Cancer Center, Duarte, US

13:45 - 14:05 Expanding the armamentarium with IO-TKIs combinations – what can be learnt
from RCC for the future of NSCLC?
L. Albiges1, L. Paz-Ares2, S. Pal3, J. Bedke4, G.A. De Velasco Oria2, 1Institut Gustave

Roussy, Villejuif, Cedex, FR, 2Hospital Universitario 12 de Octubre, Madrid, ES, 3City of

Hope Comprehensive Cancer Center, Duarte, US, 4Crona Kliniken - Universitätsklinikum
Tübingen, Tübingen, DE

14:05 - 14:25 Unmet needs in NSCLC: targeting second-line treatment with TKI-IO
L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

14:25 - 14:30 Closing


13:00 - 14:30 Type: ESMO Colloquium 7.3.O -
Title: ESMO Colloquium Supported by Eisai Europe Ltd.: Orléans
Optimising outcomes of patients with advanced renal cancer Auditorium
Chair(s): Toni Choueiri, US; Camillo Guglielmo Porta, IT

T. Choueiri, Dana Farber Cancer Institute, Boston, US

13:10 - 13:25 Biology and prognostication in advanced clear cell renal cell carcinoma (RCC)
V. Gruenwald, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

13:25 - 13:40 State of the art first-line management of patients with advanced RCC
T. Choueiri, Dana Farber Cancer Institute, Boston, US

13:40 - 13:55 The emerging continuum of care in advanced RCC: Second-line and beyond
C.G. Porta, Università degli Studi di Bari Aldo Moro, Bari, IT

13:55 - 14:10 Presentation of two clinical vignettes: Optimising dose-intensity and tolerance
C. Suarez Rodriguez, Vall d'Hebron University Hospital, Barcelona, ES


C.G. Porta, Università degli Studi di Bari Aldo Moro, Bari, IT


Title: Astellas - The maturing treatment landscape of Auditorium
mHSPC
Chair(s): Stephane Oudard, FR

S. Oudard, HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR

13:05 - 13:25 Reap what you sow: Treatments for mHSPC in use today
I. Davis, Eastern Health Clinical School - Monash University, Box Hill, AU

13:25 - 13:45 Forget-me-nots: Unmet needs in mHSPC
S.F. Shariat, MedUni Wien - Medical University of Vienna, Vienna, AT

13:45 - 14:05 The grass is greener: Deciding on the most appropriate initial treatment for
patients with mHSPC
H. Payne, UCLH Foundation Trust, London, GB

14:05 - 14:25 Q&A
S. Oudard1, I. Davis2, H. Payne3, S.F. Shariat4, 1HEGP - Hopital Europeen Georges-

Pompidou - AP-HP, Paris, FR, 2Eastern Health Clinical School - Monash University, Box

Hill, AU, 3UCLH Foundation Trust, London, GB, 4MedUni Wien - Medical University of
Vienna, Vienna, AT

S. Oudard, HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR


Title: Gilead and Kite Oncology - Redefining the Lines of TNBC, Toulouse
Real-world management: improving survival for patients with Auditorium
metastatic TNBC
Chair(s): Suzette Delaloge, FR


13:05 - 13:10 TNBC today: How can we increase survival for a very heterogenous and
aggressive disease?

13:10 - 13:30 Treatment milestones in TNBC and current treatment pathways
A. Gennari, Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara,

IT

13:30 - 14:05 Real-world management of TNBC: incorporating new therapies into clinical
practice
K. Jhaveri1, S. Kuemmel2, 1Memorial Sloan Kettering Evelyn H. Lauder Breast Center,

New York, US, 2Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE

14:05 - 14:25 Key considerations when managing mTNBC patients: Faculty insights and
audience Q&A
S. Delaloge1, A. Gennari2, K. Jhaveri3, S. Kuemmel4, 1Institut Gustave Roussy, Villejuif,

FR, 2Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT,

3Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, 4Kliniken
Essen Mitte Evang. Huyssens-Stiftung, Essen, DE



Title: I am FINE: Frustrated * Isolated * Neglected * Auditorium
Emotional
Chair(s): Christopher Curtis, GB; Natacha Bolanos Fernandez, ES

13:00 - 13:15 Patient’s perspective…Am I fine?
N. Bolanos Fernandez, Lymphoma Coalition, Madrid, ES

13:15 - 13:30 Caregiver’s perspective... Am I fine?
K. Washington, Private Address - Kate Washington, Sacramento, US

13:30 - 13:45 Physician's perspective... Am I fine?
F. Cardoso, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT

13:45 - 14:00 Nurse’s perspective... Am I fine?

14:00 - 14:15 Psycho-oncologist’s perspective
G. Pravettoni, IEO - Istituto Europeo di Oncologia, Milan, IT




Title: Daiichi Sankyo - The Current and Emerging Role of Auditorium
ADCs in Cancer Therapy
Chair(s): Javier Cortés, ES


13:05 - 13:20 Overview of ADC Technology

13:20 - 13:40 Clinical Updates on ADCs in Breast Cancer

13:40 - 14:00 Shifting the Treatment Landscape in Lung Cancer

14:00 - 14:15 The Evolving Treatment Landscape in Gastric Cancer
M. Di Bartolomeo, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

14:15 - 14:30 Q&A
J. Cortés1, S. Modi2, N. Girard3, M. Di Bartolomeo4, 1Hospital Ruber Internacional,

Madrid, ES, 2MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, 3Institut
Curie, Paris, FR, 4Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

Title: Cancer accommodation and disruption in Auditorium
young lives

13:45 - 14:15 A life interrupted: Experiences of living with melanoma
W. Mcinally, J. Brodie, Open University, Edinburgh, GB

14:15 - 14:30 Approach to febrile neutropenia in children and young adolescents


Title: Proffered Paper session: NSCLC, metastatic
Chair(s): Helena A. Yu, US; Rina Hui, AU

14:45 - 14:55 LBA51 - Osimertinib treatment based on plasma T790M monitoring in patients

with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer
Group 1613 APPLE phase II randomized clinical trial
J. Remon Masip1, B. Besse1, S. Ponce Aix2, A. Callejo3, K. Al-Rabi4, R. Bernabe Caro5, L.

Greillier6, M. Majem Tarruella7, N. Reguart Aransay8, I. Monnet9, S. Cousin10, P. Garrido
Lopez11, G. Robinet12, M.R. Garcia Campelo13, A.-C. Madroszyk Flandin14, J. Mazieres15,
Y. Pretzenbacher16, B. Fournier16, A.-M. Dingemans17, R. Dziadziuszko18, 1Institut
Gustave Roussy, Villejuif, FR, 2Hospital Universitario 12 de Octubre, Madrid, ES, 3Vall
d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, 4KHCC - King
Hussein Cancer Center, Amman, JO, 5Hospital Universitario Virgen del Rocio, Seville, ES,
6Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, FR,
7Hospital de la Santa Creu i Sant Pau, Barcelona, ES, 8Hospital Clinic y Provincial de
Barcelona, Barcelona, ES, 9CH Intercommunal de Créteil, Creteil, FR, 10Institut

Bergonie, Bordeaux, FR, 11Hospital Universitario Ramon y Cajal, Madrid, ES, 12CHRU
Brest - Hopital Augustin Morvan, Brest, FR, 13Instituto de Investigación Biomédica de A
Coruña (INIBIC), A Coruña, ES, 14IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR,
15Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, 16EORTC
AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels,

BE, 17Erasmus MC - University Medical Center, Rotterdam, NL, 18Medical University of
Gdansk, Gdansk, PL

14:55 - 15:05 LBA52 - Tepotinib + osimertinib for EGFRm NSCLC with MET
amplification (METamp) after progression on first-line (1L) osimertinib: Initial
results from the INSIGHT 2 study
J. Mazieres1, T.M. Kim2, B.K. Lim3, M. Wislez4, C. Dooms5, G. Finocchiaro6, H. Hayashi7,

C.K. Liam3, J. Raskin8, L.M. Tho9, F. De Marinis10, E. Nadal11, E. Smit12, X. Le13, S.
Brutlach14, A.M. O'Brate Grupp14, S. Adrian14, B. Ellers-Lenz14, N. Karachaliou14, Y.-L.
Wu15, 1Université Paul Sabatier, Toulouse, FR, 2Seoul, Republic of Korea; Department of
Internal Medicine, Seoul National University Hospital, Seoul, KR, 3Faculty of Medicine,
University of Malaya, Kuala Lumpur, MY, 4Hopital Cohin, Assistance Publique – Hôpitaux
de Paris, Paris, FR, 5University Hospitals Leuven, Leuven, BE, 6Humanitas Research

Hospital IRCCS, Rozzano, Milan, IT, 7Kindai University Faculty of Medicine, Osaka-
Sayama, Osaka, JP, 8Antwerp University Hospital (UZA), Edegem, BE, 9Pantai Hospital
Kuala Lumpur, Kuala Lumpur, MY, 10European Institute of Oncology, IRCCS, Milan, IT,
11Catalan Institute of Oncology, L'Hospitalet, Barcelona, ES, 12Netherlands Cancer
Institute, Amsterdam, NL, 13The University of Texas MD Anderson Cancer Center,

Houston, US, 14Merck Healthcare KGaA, Darmstadt, DE, 15Guangdong Provincial
People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

15:05 - 15:15 LBA53 - ELIOS: A multicentre, molecular profiling study of patients (pts) with
epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated
with first-line (1L) osimertinib
Z. Piotrowska1, M.-J. Ahn2, Y.K. Pang3, S.H. How4, S.-W. Kim 5, P.J. Voon6, D. Cortinovis7, J.
De Castro Carpeno8, M. Tiseo9, D. Rodriguez Abreu10, S. Ramalingam11, J. Li12, L.
Servidio12, S. Sadow13, R. Hartmaier14, B.C. Cho15, 1Massachusetts General Hospital,
Boston, US, 2Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul, KR, 3Faculty of Medicine, University of Malaya, Kuala Lumpur, MY, 4Kulliyyah of
Medicine, International Islamic University Malaysia, Kuantan, MY, 5Asan Medical Center,
Seoul, KR, 6Hospital Umum Sarawak, Kuching, MY, 7San Gerardo Hospital, Monza, IT,
8Hospital Universitario La Paz, IdiPAZ, Madrid, ES, 9University of Parma, Parma, Italy

and Medical Oncology Unit, University Hospital of Parma, Parma, IT, 10Gran Canaria
University Hospital, Las Palmas de Gran Canaria, ES, 11The Winship Cancer Institute of
Emory University, Atlanta, US, 12Oncology Business Unit, Global Medical Affairs,
Gaithersburg, US, 13AstraZeneca, Gaithersburg, US, 14AstraZeneca Oncology R&D,
Boston, US, 15Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, KR

15:15 - 15:25 Invited Discussant LBA51, LBA52 and LBA53
H.A. Yu, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

15:25 - 15:35 Q&A

15:35 - 15:45 LBA54 - Three years survival outcome and continued cemiplimab (CEMI) beyond
progression with the addition of chemotherapy (chemo) for patients (pts) with
advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
M. Ozguroglu1, S. Kilickap2, A. Sezer3, M. Gumus4, I. Bondarenko5, M. Gogishvili6, M.

Nechaeva7, M. Schenker8, I. Cicin9, G.F. Ho10, Y. Kulyaba11, M. Dvorkin12, K. Zyuhal13,
R.I. Scheusan14, S. Li15, J.-F. Pouliot15, F. Seebach15, I. Lowy15, G. Gullo15, P. Rietschel15,
1Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, TR, 2Hacettepe
University Cancer Institute, Ankara, TR, 3Baskent Universitesi, Adana, TR, 4S.B. Istanbul
Medeniyet Universitesi - Goztepe Egitim Ve Arastirma Hastanesi, Istanbul, TR,
5Dnipropetrovsk Medical Academy, Dnipro, UA, 6Tbilisi State Medical University and
Ingorokva High Medical Technology University Clinic, Tbilisi, GE, 7Arkhangelsk Regional

Clinical Oncology Dispensary, Arkhangelsk, RU, 8St. Nectarie Oncology Center Craiova,
Craiova, RO, 9Trakya University Rektorlugu, Edirne, TR, 10Pusat Perubatan Universiti
Malaya (PPUM), Kuala Lumpur, MY, 11Medical Center Klinika Manufaktura, Khodosivka
Village, UA, 12BHI of Omsk Region Clinical Oncology Dispensary, Omsk, RU,
13Multiprofile Hospital for Active Treatment - Burgas, Burgas, BG, 14Oncocenter -
Oncologie Clinica SRL, Timisoara, RO, 15Regeneron Pharmaceuticals, Inc., Tarrytown,

US

15:45 - 15:55 972O - Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus
continuation in patients with advanced non-small cell lung cancer (aNSCLC):
Results of the randomized IFCT-1701 phase III trial
G. Zalcman1, A.-C. Madroszyk Flandin2, O. Molinier3, C. Dayen4, T. Egenod5, D.

Debieuvre6, S. Beaucaire-Danel7, A. Dixmier8, E. Pichon9, S. Galland Girodet10, E.
Giroux-Leprieur11, N. Cloarec12, J. Cadranel13, J. Otto14, P. Romand15, A. Langlais16, F.
Morin17, M. Antoine13, V. Westeel18, A.C. Toffart19, 1Université Paris Cité, Paris, FR, 2IPC
- Institut Paoli-Calmettes, Marseille, Cedex, FR, 3Centre Hospitalier Du Mans, Le Mans,
FR, 4Centre Hospitalier de Saint-Quentin, Saint-Quentin, Cedex, FR, 5CHU Limoges -
Hopital Dupuytren, Limoges, FR, 6GHRMSA, Mulhouse, FR, 7Institut Curie, Paris, FR,
8C.H.R. Orleans - La Source, Orleans, FR, 9CHRU Hopitaux de Tours - Hopital
Bretonneau, Tours, cedex, FR, 10Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FR,
11Hopital Ambroise Pare AP-HP - Université Paris Saclay, Boulogne-Billancourt, FR, 12CH
Henri Duffaut, Avignon, FR, 13Hopital Tenon AP-HP, Paris, Cedex, FR, 14Centre Antoine
Lacassagne, Nice, FR, 15Centre Hospitalier Alpes Leman, Contamine-sur-Arve, FR,
16IFCT (Intergroupe Francophone de Cancérologie Thoracique)., Paris, FR, 17French
Cooperative Thoracic Intergroup, Paris, FR, 18CHRU Besancon - Hopital Jean Minjoz,

Besancon, FR, 19CHU Grenoble-Alpes, La Tronche, FR


16:05 - 16:15 Q&A

14:45 - 16:15 Type: Proffered Paper session 4.B - Brest Auditorium
Title: Proffered Paper session 2: GI, upper digestive
Chair(s): Ian Chau, GB; Hanneke van Laarhoven, NL

14:45 - 14:55 1203O - FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction
followed by nivolumab and ipilimumab in patients with previously untreated
advanced or metastatic adenocarcinoma of the stomach or gastroesophageal
junction: Results from the randomized phase II Moonlight trial of the AIO
S. Lorenzen1, P. Thuss-Patience2, G. Folprecht3, J. Riera Knorrenschild4, V. Heinemann5,

E. Goekkurt6, T. Dechow7, T. Ettrich8, K. Luley9, J.-C. Moulin10, U. Lindig11, S.
Angermeier12, O. Waidmann13, D. Pink14, C. Bolling15, S. Junge16, C. Pauligk16, T.
Gaiser17, T. Götze18, S.-E. Al-Batran18, 1Klinikum Rechts der Isar, Technische Universitat,
Munich, DE, 2Charité–Universitätsmedizin Berlin/Campus Virchow Klinikum (CVK),
Berlin, DE, 3Universitaetsklinikum Carl Gustav Carus, Dresden, DE,
4Universitätsklinikum Giessen und Marburg, Marburg, DE, 5LMU Klinikum der
Universität München, Munich, DE, 6Hämatologisch-Onkologische Praxis Eppendorf

(HOPE), Hamburg, DE, 7Onkologie Ravensburg, Ravensburg, DE, 8University Hospital

Ulm, Ulm, DE, 9University Hospital Schleswig-Holstein, Campus Luebeck, Lübeck, DE,
10Ortenau Klinikum Lahr, Lahr/Schwarzwald, DE, 11Jena University Hospital, Jena, DE,
12Klinikum Ludwigsburg, Ludwigsburg, DE, 13Universitätsklinikum Frankfurt (Johannes-
Wolfgang Goethe-Universität), Frankfurt am Main, DE, 14Klinik und Poliklinik für Innere
Medizin C, Hämatologie und Onkologie, Transplantationszentrum, Palliativmedizin,
Universität Greifswald, Bad Saarow, DE, 15Agaplesion Markus Krankenhaus, Frankfurt
am Main, DE, 16Institut für Klinische Krebsforschung IKF, Frankfurt am Main, DE,
17University Medical Center Mannheim, Mannheim, DE, 18Krankenhaus Nordwest,
University Cancer Center Frankfurt, Frankfurt am Main, DE

14:55 - 15:05 Invited Discussant 1203O

GB

15:05 - 15:15 Q&A

15:15 - 15:25 LBA60 - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after
FOLFIRINOX failure or intolerance in metastatic pancreatic ductal
adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 -
GEMPAX UNICANCER study
C. De La Fouchardiere1, D. Malka2, S. Chabaud3, J. Raimbourg4, D. Botsen5, S. Launay6,

L. Evesque7, A. Vienot8, H. Perrier9, M. Jary10, Y. Rinaldi11, C. Coutzac Bergouignan1, J.-

B. Bachet12, C. Neuzillet13, N. Williet14, R. Desgrippes15, G. Brard16, N. Lachaux16, O.
Bouche17, F. Ghiringhelli18, 1Centre Léon Bérard, Lyon, FR, 2Institut Gustave Roussy,
Villejuif, Cedex, FR, 3Centre de recherche en cancerologie de Lyon (CRCL), Lyon, FR,
4ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, 5Institut
Jean Godinot, Reims, FR, 6IPC - Institut Paoli-Calmettes, Marseille, FR, 7Centre
Anticancer Antoine Lacassagne, Nice, FR, 8CHRU Besancon - Hopital Jean Minjoz,
Besancon, FR, 9Fondation Hôpital Saint Joseph, Marseille, FR, 10CHU de Clermont-
Ferrand - Site Estaing, Clermont-Ferrand, Cedex, FR, 11Hopital Européen Marseille,
Marseille, FR, 12Groupe Hospitalier Pitié Salpetriere, Paris, FR, 13Institut Curie, Paris,
FR, 14Hopital Nord, St Priest En Jarez, FR, 15C.H. Broussais, Saint-Malo, FR,
16UNICANCER, Paris, FR, 17CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR,
18University of Burgundy, Genetic and Immunotherapy Medical Institute, Dijon, FR

15:25 - 15:35 Invited Discussant LAB60
H. Wilmink, Amsterdam University Medical Center (UMC) - locatie Academic Medical

Center (AMC), Amsterdam, NL

15:35 - 15:45 Q&A

15:45 - 15:55 LBA12 - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts)
with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-
naïve cholangiocarcinoma (CCA): ReFocus trial
A. Hollebecque1, M. Borad2, L. Goyal3, A. Schram4, J.O. Park5, P. Cassier6, S. Kamath7,

D.T. Wai Meng8, E. Dotan9, R. Kim10, V. Sahai11, D.-Y. Oh 12, C.-Y. Liao 13, M. Millward14,
D. Roda Perez15, C. Ferté16, R. Blakesley16, B. Wolf16, V. Subbiah17, R.K. Kelley18,
1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Mayo Clinic Cancer Center, Scottsdale,
US, 3Massachusetts General Hospital, Boston, US, 4MSKCC - Memorial Sloan Kettering
Cancer Center, New York, US, 5Samsung Medical Center (SMC) - Sungkyunkwan
University School of Medicine, Seoul, KR, 6Centre Léon Bérard, Lyon, FR, 7Taussig
Cancer Center-Cleveland Clinic, Cleveland, US, 8National Cancer Centre Singapore,
Singapore, SG, 9Fox Chase Cancer Center - Main Campus, Philadelphia, US, 10H. Lee
Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, US,
11Michigan Medicine, University of Michigan, Ann Arbor, US, 12Seoul National
University Hospital, Seoul, KR, 13University of Chicago Department of Medicine - Section

of Hematology/Oncology, Chicago, US, 14Linear Clinical Research & University of
Western Australia, Perth, AU, 15Hospital Clinico Universitario de Valencia, Valencia, ES,
16Relay Therapeutics, Inc., Cambridge, US, 17The University of Texas M. D. Anderson
Cancer Center, Houston, US, 18UCSF Helen Diller Family Comprehensive Cancer Center,
San Francisco, US

C. Braconi, BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow

and Clyde, Glasgow, GB

16:05 - 16:15 Q&A


14:45 - 16:15 Type: Special session 7.1.C - Cannes Auditorium
Title: ESMO Clinical Practice Guidelines session 2
Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR

14:45 - 14:55 Bladder cancer: Clinical case
C. Oing, Newcastle University, Newcastle upon Tyne, GB

14:55 - 15:05 Bladder cancer: Discussant

15:05 - 15:15 Bladder cancer: Discussion / Q&A

15:15 - 15:25 Primary CNS lymphoma: Clinical case
D. Alves, Hospital Pedro Hispano - Unidade Local de Saude de Matosinhos EPE - SNS,

Senhora da Hora, PT

15:25 - 15:35 Primary CNS lymphoma: Discussant
A. Ferreri, IRCCS Ospedale San Raffaele, Milan, IT

15:35 - 15:45 Primary CNS lymphoma: Discussion / Q&A

15:45 - 15:55 Metastatic non-small-cell lung cancer: Clinical case
L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

15:55 - 16:05 Metastatic non-small-cell lung cancer: Discussant
L. Hendriks, Maastricht, NL

16:05 - 16:15 Metastatic non-small-cell lung cancer: Discussion / Q&A


14:45 - 16:15 Type: Special symposium 7.2.E - Évry Auditorium
Title: Targeting DNA repair and beyond in ovarian
cancer
Chair(s): Stephanie Lheureux, CA; Clare Scott, AU

C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU

14:50 - 15:05 Can we identify the patients who will most likely benefit through HRD tests?
I. Mcneish, London, GB

15:05 - 15:20 PARPi resistance: What do we know now?
S. Lheureux, University Health Network - Princess Margaret Cancer Center, Toronto, CA

15:20 - 15:35 DNA damage repair: What targeting strategies show promise over and above
PARP inhibition?
C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB

15:35 - 15:50 Other targets beyond DDR in ovarian cancer
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

S. Lheureux, University Health Network - Princess Margaret Cancer Center, Toronto, CA


14:45 - 16:15 Type: Educational session 7.2.F - Fécamp Auditorium
Title: Non-melanoma skin cancers
Chair(s): Reinhard Dummer, CH; Ulrike Leiter-Stoppke, DE

14:45 - 15:10 Merkel cell carcinoma, angiosarcoma & Kaposi
U. Leiter-Stoppke, Universitaets-Hautklinik Tuebingen, Tuebingen, DE

15:10 - 15:35 Basal cell carcinoma
R. Dummer, Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH

15:35 - 16:00 Cutaneous squamous cell carcinoma


14:45 - 16:15 Type: Mini Oral session 7.1.D - Dijon

Title: Mini Oral session: Basic science & translational Auditorium
research
Chair(s): Sarah-Jane Dawson, AU; Marleen Kok, NL; John Stagg, CA

14:45 - 14:50 LBA72 - Unraveling the mechanism of action and resistance to trastuzumab
deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
M.F. Mosele1, A. Lusque2, V. Dieras3, E. Deluche4, A. Ducoulombier5, B. Pistilli6, T.

Bachelot7, F. Viret8, C. Levy9, Y. Pradat1, D. Tran10, N. Droin6, M. Kobayashi11, T.
Kakewaga11, M. Deloger1, B. Job6, M. Jimenez12, M. Lacroix-Triki 13, F. André1, 1Gustave
Roussy - Cancer Campus, Villejuif, FR, 2Institut Claudius Regaud IUCT-O, Toulouse, FR,
3Centre Eugene - Marquis, Rennes, FR, 4CHU Limoges - Hopital Dupuytren, Limoges,

FR, 5Centre Anticancer Antoine Lacassagne, Nice, FR, 6Institut Gustave Roussy, Villejuif,
Cedex, FR, 7Centre Léon Bérard, Lyon, FR, 8IPC - Institut Paoli-Calmettes, Marseille, FR,
9Centre Francois Baclesse, Caen, FR, 10Institut Gustave Roussy - INSERM UMR 981,
Villejuif, FR, 11Daiichi Sankyo Co., Ltd., Tokyo, JP, 12Unicancer, Paris, FR, 13Institut
Gustave Roussy, Villejuif, FR

14:50 - 14:55 904MO - Anthracycline-related cardiotoxicity in breast cancer patients carrying
mutational signature of homologous recombination deficiency (HRD)
L. Incorvaia1, A. Fiorino1, S. Gori2, S. Cinieri3, G. Curigliano4, A. Toss5, L. Cortesi5,

G.R.R. Ricciardi6, R. Chiari7, M. Peri1, C. Brando1, T.D. Bazan Russo1, V. Gristina1, A.
Galvano1, G. Damerino1, I. Carreca1, G. Novo1, G. Badalamenti1, V. Bazan1, A. Russo1,
1University of Palermo, Palermo, IT, 2IRCCS Ospedale Sacro Cuore Don Calabria, Negrar,

IT, 3Ospedale A. Perrino, Brindisi, IT, 4IEO - Istituto Europeo di Oncologia, Milan, IT,
5Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, 6Centro
Oncologico Ospedale Papardo, Messina, IT, 7Azienda Ospedaliera Ospedali Riuniti

Marche Nord, Pesaro, IT

14:55 - 15:00 68MO - Generalization of a deep learning model for HER2 status predictions on
H&E-stained whole slide images derived from 3 neoadjuvant clinical
studies
M. Hägele1, K.-R. Müller2, C. Denkert3, A. Schneeweiss4, B. Sinn5, M. Untch6, M.T. Van

Mackelenbergh7, C. Jackisch8, V. Nekljudova9, T. Karn10, M. Alber11, F. Marmé12, C.
Schem13, E. Stickeler14, P.A. Fasching15, V. Mueller16, K. Weber9, B. Lederer9, S. Loibl9,
F. Klauschen17, 1TU Berlin, BIFOLD – Berlin Institute for the Foundations of Learning
and Data, Berlin, DE, 2Max-Planck-Institut für Informatik, Saarbrücken, BIFOLD – Berlin
Institute for the Foundations of Learning and Data, Berlin, DE, 3Philipps Universität
Marburg und Universitätsklinikum Marburg (UKGM), Marburg, DE,
4Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Heidelberg,
DE, 5Charité Berlin, Berlin, DE, 6Helios Klinikum Berlin-Buch, Berlin, DE,
7Universitätsklinikum Schleswig-Holstein, Kiel, DE, 8Sana Klinikum Offenbach,
Offenbach am Main, DE, 9German Breast Group, Neu-Isenburg, DE, 10Goethe University
Hospital, Frankfurt am Main, DE, 11Charité Berlin, Aignostics GmbH, Berlin, DE,
12Universität Heidelberg, Universitätsfrauenklinik Mannheim, Mannheim, DE,
13Mammazentrum Hamburg, Hamburg, DE, 14Universitaetsklinikum Aachen (UKA),
Aachen, DE, 15Erlangen, Erlangen, DE, 16Universitätsklinikum Hamburg-Eppendorf,

Hamburg, DE, 17German Cancer Consortium (DKTK), Partner Site Berlin, German
Cancer Research Center (DKFZ), Berlin Institute of Health, Berlin, DE


15:00 - 15:05 1661MO - Genomic somatic copy number alterations drive adaptive tumor
immune suppression and primary resistance to anti-PD1 + anti-
angiogenics in pleural mesothelioma
F.-X. Danlos 1, C. Baldini1, M. Texier2, A. Varga1, S. Mouraud3, B. Job1, D. Letourneur3, L.

Cassard1, D. Bredel3, S. Laghouati1, J. Adam1, N. Droin1, A. Parpaleix1, N. Chaput-Gras1,
A. Rabeau4, C. Massard1, J.-C. Soria5, G. Zalcman6, D. Planchard1, A. Marabelle1,
1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Institut Gustave Roussy, Villejuif, FR,
3Institut Gustave Roussy - INSERM, Villejuif, Cedex, FR, 4Centre Hospitalier
Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, 5AMGEN - USA, Thousand

Oaks, US, 6Hopital Bichat - Claude-Bernard AP-HP, Paris, FR

15:05 - 15:20 Invited Discussant LBA72, 904MO, 68MO and 1661MO

15:20 - 15:25 1662MO - Longitudinal analysis of circulating immune cell subsets in melanoma
patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab
(nivo)
R. Simpson1, M. Batten2, E. Shanahan2, I. Pires Da Silva3, J. Versluis4, I. Reijers4, A.

Menzies3, R. Saw3, M. Gonzalez3, K. Shannon3, A. Spillane3, C. Blank4, R. Scolyer3, G.
Long3, 1Melanoma Institute Australia, Sydney, AU, 2University of Sydney, Sydney, AU,
3Melanoma Institute Australia, Wollstonecraft, AU, 4NKI-AVL - Netherlands Cancer

15:25 - 15:30 1663MO - DAV132 prevents antibiotic-induced intestinal microbiota dysbiosis
and maintains anti-PD-1 efficacy: A proof-of-concept in tumor-bearing mice
transplanted with human feces
M. Messaoudene1, N. Saint-Lu2, F. Sablier-Gallis2, S. Ferreira2, C. Le Bescop2, M.

Ponce1, C. Féger3, A. Andremont2, J. De Gunzburg2, B. Routy1, 1CRCHUM - Centre de
recherche du CHUM, Montreal, CA, 2Da Volterra, Paris, FR, 3EMI Biotech, Grenoble, FR

J. Stagg, University of Montreal Health Center, Montreal, CA

15:40 - 15:45 905MO - Synergistic combination of clinical, imaging and DNA methylation
biomarkers improves the classification of pulmonary nodules
J. He1, B. Wang2, J. Tao2, Q. Liu1, M. Peng2, X. Qiu2, Y. Yang2, Z. Ye2, D. Liu3, W. Li3, Z.
Chen2, Q. Zeng1, J. Fan2, W. Liang1, 1The First Affiliated Hospital of Guangzhou Medical

University, Guangzhou, CN, 2Anchordx Medical Co., Ltd, Guangzhou, CN, 3SCU - Sichuan
University - Huaxi Campus, Chengdu, CN

15:45 - 15:50 1664MO - Tumor-naïve methylomes and fragmentomes during
pembrolizumab (P) in metastatic cancer patients
E. Zhao1, E. Sanz Garcia1, Z.(. Liu1, K. Marsh2, A. Abdul Razak1, A. Spreafico1, P.

Bedard1, A. Hansen1, S. Lheureux1, D. Torti2, B. Lam3, T. Pugh1, L. Siu1, 1UHN -
University Health Network - Princess Margaret Cancer Center, Toronto, CA, 2Ontario
Institute for Cancer Research, Toronto, CA, 3Princess Margaret Cancer Centre, Toronto,
CA


15:50 - 15:55 69MO - 5-Hydroxymethycytosine analysis reveals stable epigenetic changes in
tumor tissue that enable cfDNA cancer predictions
F. Feng1, Y. Ning2, Y. Xue2, V. Friedl2, D. Hann2, B. Gibb2, A. Bergamaschi2, G. Guler2, K.

Hazen2, A. Scott2, T. Phillips2, E. Mccarthy2, C. Ellison2, R. Malta2, A. Nguyen2, V.
Lopez2, R. Cavet2, S. Chowdhury2, W. Volkmuth2, S. Levy2, 1UCSF Helen Diller Family
Comprehensive Cancer Center, San Francisco, US, 2Bluestar Genomics, Inc., San Diego,
US

S.-J. Dawson, Peter MacCallum Cancer Centre, Melbourne, AU

Title: Mini Oral session 1: GU tumours, non- Auditorium
prostate
Chair(s): Aly-Khan Lalani, CA; Kate Young, GB; Joaquim Bellmunt, US

14:45 - 14:50 1449MO - Updated efficacy of lenvatinib (LEN) + pembrolizumab
(PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell
carcinoma (aRCC) in the CLEAR study
C.G. Porta1, M. Eto2, R. Motzer3, U. De Giorgi4, T. Buchler5, N. Basappa6, M.J. Mendez

Vidal7, S. Tjulandin8, S.H. Park9, B. Melichar10, T. Hutson11, C. Alemany12, B.
Mcgregor13, C.S. He14, R. Perini15, K. Mody14, J. Mckenzie14, T. Choueiri13, 1University
of Bari 'A. Moro', Bari, IT, 2Kyushu University, Fukuoka, JP, 3Memorial Sloan Kettering
Cancer Center, New York, US, 4IRCCS Istituto Romagnolo per lo Studio dei Tumori
(IRST) Dino Amadori, Meldola, IT, 5Thomayer University Hospital, Prague, CZ, 6Cross
Cancer Institute, University of Alberta, Edmonton, CA, 7Hospital Universitario Reina

Sofía, Maimonides Institute for Biomedical Research of Córdoba, Córdoba, ES, 8N.N.
Blokhin National Medical Research Center for Oncology, Ministry of Health of the
Russian Federation, Moscow, RU, 9Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, KR, 10Palacký University Medical School and Teaching
Hospital, Olomouc, CZ, 11Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Dallas, US, 12AdventHealth Cancer Institute, Orlando, US, 13Dana-Farber Cancer
Institute, Boston, US, 14Eisai Inc., Nutley, US, 15Merck & Co., Inc., Rahway, US

14:50 - 14:55 1450MO - Efficacy of a tailored approach with nivolumab and
nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell
carcinoma: Final results of TITAN-RCC
M.-O. Grimm1, E. Esteban Gonzalez2, P. Barthelemy3, M. Schmidinger4, J. Busch5, B.

Perez Valderrama6, N. Charnley7, M. Schmitz8, U. Schumacher1, G. Baretton9, I. Duran
Martinez10, G.A. De Velasco Oria11, F. Priou12, J.P. Maroto Rey13, L. Albiges14, 1Jena
University Hospital, Friedrich-Schiller University Jena, Jena, DE, 2Hospital Universitario
Central de Asturias, Oviedo, ES, 3Institut de Cancérologie Strasbourg Europe,
Strasbourg, FR, 4Medical University of Vienna, Vienna, AT, 5University Hospital Charité
Berlin, Berlin, DE, 6Hospital Universitario Virgen del Rocío, Seville, ES, 7Royal Preston
Hospital, Preston, GB, 8Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden,
DE, 9University Hospital Carl Gustav Carus, TU Dresden, Dresden, DE, 10Hospital
Universitario Marqués de Valdecilla, IDIVAL, Santander, ES, 11Hospital 12 de Octubre,
Madrid, ES, 12CHD Vendee-Hopital Les Oudairies, La Roche-sur-Yon, FR, 13Hospital de la
Santa Creu I Sant Pau, Barcelona, ES, 14Gustave Roussy Cancer Campus, University of

Paris Sud, Villejuif, FR

K. Young, The Royal Marsden Hospital - Chelsea, London, GB

15:10 - 15:15 LBA75 - RACE IT: A prospective, single arm, multicenter, phase II-trial to assess
safety and efficacy of preoperative RAdiation therapy before radical CystEctomy
combined with ImmunoTherapy in locally advanced urothelial carcinoma of the
bladder (AB 65/18) – first results
S. Schmid1, K. Schiller2, J. Lewerich1, A.K. Seitz3, A. Sauter1, F. Koll1, F. Beckert1, P.

Korn1, P. Maisch4, C. Rödel5, M. Flentje3, T. Wiegel4, S. Combs2, F. Zengerling4, C.
Bolenz4, H. Kuebler3, J. Gschwend1, M. Retz1, 1TUM - Technical University of Munich,
München, DE, 2TUM - Technical University of Munich, Munich, DE, 3UKW - University
Hospital Würzburg, Würzburg, DE, 4Ulm Medical University, Ulm, DE,
5Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am
Main, DE

15:15 - 15:20 1733MO - First results from BladderPath: A randomised trial of MRI versus
cystoscopic staging for newly diagnosed bladder cancer
N. James1, S. Pirrie2, W. Liu3, K. Jefferson4, J. Gallagher2, A. Hughes2, A. Knight5, V.

Nanton6, H. Mintz2, A. Pope2, H. Doyle2, J. Singh2, S. Hafeez1, P. Patel2, J. Catto7, R.
Bryan2, 1ICR - Institute of Cancer Research, London, GB, 2Institute of Cancer and
Genomic Sciences - University of Birmingham, Birmingham, GB, 3The Institute of Cancer
and Genomic Sciences - University of Birmingham, Birmingham, GB, 4University Hospital
Coventry - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB,
5Action on Bladder Cancer, Tetbury, GB, 6University of Warwick, Coventry, GB,
7University of Sheffield Medical School, Sheffield, GB

15:20 - 15:25 1734MO - Hypoxic bladder cancers have a poorer outcome following
hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and
BCON randomised trials
T. Smith1, C. West1, B. Lane1, J. Irlam-Jones1, E. More1, H. Mistry1, P. Hoskin2, S.

Hussain3, E. Hall4, N. Porta4, R. Huddart5, N. James6, A. Choudhury2, 1The University of
Manchester, MANCHESTER, GB, 2University of Manchester and The Christie NHS
Foundation Trust, Manchester, GB, 3University of Sheffield Medical School, Sheffield,
GB, 4ICR - Institute of Cancer Research, Sutton Surrey, GB, 5Royal Marsden Hospital
Institute of Cancer Research, Sutton, GB, 6ICR - Institute of Cancer Research, London,
GB


15:40 - 15:45 1310MO - Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic
penile squamous cell carcinoma (PSCC): An international, multicenter, real-
world study
J. Chahoud1, A. Mustasam1, K. Rose1, P. Spiess1, K. Moses2, V. Master3, B. Nazha4, T.

Zhuang4, A. Schneider1, K. Marchetti5, E. Roussel6, R. Pham7, N. Zacharias7, L.
Pagliaro8, C. Hernandez2, J. Montrose5, C. Alifrangis9, M. Albersen6, C. Protzel10, C.
Pettaway7, 1H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus,
Tampa, US, 2Vanderbilt University Medical Center, Nashville, US, 3Emory University -
Rollins School of Public Health, Atlanta, US, 4Winship Cancer Institute of Emory
University, Atlanta, US, 5University of Michigan Health System, Ann Arbor, US,
6University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, 7MD Anderson Cancer
Center, Houston, US, 8Mayo Clinic Cancer Center, Phoenix, US, 9St. Bartholomew's
Hospital - Barts Health NHS Trust, London, GB, 10Universitätsklinikum Rostock,
Rostock, DE

15:45 - 15:50 512MO - Outcomes of relapsed clinical stage I versus de novo metastatic
testicular cancer patients: An analysis of the IGCCCG Update database
S. Gillessen1, J. Lauritsen2, N. Sauvé3, A. Tryakin4, D.M. Jiang5, R. Huddart6, D. Heng7,

A. Terbuch8, E. Winquist9, M. Chovanec10, M. Hentrich11, C. Fankhauser12, J.
Shamash13, X. Garcia Del Muro14, D. Vaughn15, A. Heidenreich16, A. Jandari3, L.
Collette17, J. Beyer18, K.G. Daugaard2, 1Università della Svizzera Italiana (USI) and
Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH, 2Rigshospitalet,
Copenhagen, DK, 3EORTC AISBL/IVZW - European Organisation for Research and
Treatment of Cancer, Brussels, BE, 4National Medical Research Center of Oncology
named after N.N. Blokhin, Moscow, RU, 5University Health Network - Princess Margaret
Cancer Center, Toronto, CA, 6Institute of Cancer Research and Royal Marsden Hospital,
Surrey, GB, 7Tom Baker Cancer Centre - University of Calgary, Calgary, CA, 8LKH-
Universitaetsklinikum Graz - Universitaetsklinik für Innere Medizin (UKIM), Graz, AT,
9London Regional Cancer Program (LRCP) - London Health Science Center (LHSC),
London, CA, 10National Cancer Institute (Národny Onkologicky Ustav), Bratislava, SK,
11Rotkreuzklinikum München, Munich, DE, 12Luzerner Kantonsspital, Sursee, CH, 13St.
Bartholomew's Hospital - Barts Health NHS Trust, London, GB, 14ICO - Institut Català
d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES,
15Abramson Cancer Center - University of Pennsylvania, Philadelphia, US,
16Universitätsklinikum Köln (AöR), Köln, DE, 17International Drug Development Institute,
Louvain-la-Neuve, BE, 18University Hospital Inselspital Bern, Bern, CH

15:50 - 15:55 513MO - Risk and mortality of testicular cancer in patients with psychiatric or
neurodevelopmental disorders
A. Jansson1, J. Söderling2, J. Reutfors2, A. Thor3, C. Sköld1, G. Cohn-Cedermark2, O.

Ståhl4, K. Ekström Smedby2, A. Pettersson2, I. Glimelius1, 1University Hospital

Uppsala/Akademiska Sjukhuset, Uppsala, SE, 2Karolinska Institutet, Stockholm, SE,
3Karolinska Institutet, Huddinge, SE, 4Skåne University Hospital, Lund, SE

A.-K. Lalani, JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA


14:45 - 16:15 Type: Special session 7.3.H - Honfleur
Title: ESMO In collaboration with ASCO: The use of real- Auditorium
world data in guiding clinical practice
Chair(s): Solange Peters, CH; Eric Winer, US


14:50 - 15:05 How to use real-world data

J. Warner, Brown University, Providence, US

15:05 - 15:20 The perspective of the regulator
F. Pignatti, European Medicines Agency - Amsterdam, Amsterdam, NL

15:20 - 15:35 Statistical limitations and the perspective of the statistician
J. Bliss, ICR - Institute of Cancer Research, London, GB

15:35 - 15:50 Limitations of clinical trials, alternative trial designs and the perspective of the
clinician or patient
A. Partridge, Dana Farber Cancer Institute, Boston, US

M. Koopman1, P. Jänne2, 1UMC - University Medical Center Utrecht, Utrecht, NL, 2Dana

Farber Cancer Institute, Boston, US

Title: Rare head & neck cancer
Chair(s): Keith Hunter, GB; Lisa Licitra, IT

14:45 - 15:10 Pathology of salivary gland cancers and sino-nasal cancers
K. Hunter, University of Liverpool - School of Medicine, Liverpool, GB

15:10 - 15:35 Treatment algorithm for recurrent/metastatic salivary gland cancers
C. Van Herpen, Nijmegen, NL

15:35 - 16:00 Contemporary approach to the multidisciplinary management of sino-nasal
cancer
P. Bossi, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT



14:45 - 16:15 Type: Special session 7.3.M - Marseille
Title: Insights in clinical pharmacology to optimise systemic Auditorium
anti-cancer treatment in daily practice
Chair(s): Ron Mathijssen, NL; Emiliano Calvo, ES


Campal, Madrid, ES

14:50 - 15:05 Dosing anti-cancer therapy in patients with moderate and severe kidney and
liver dysfunction
N. Van Erp, LUMC - Leids Universitair Medisch Centrum, Leiden, NL

15:05 - 15:20 Dose individualisation of TKIs
J. Ciccolini, Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

15:20 - 15:35 The relevance of geno- and phenotyping cytochrome P450 prior to anticancer
treatment
C. Samer, Université de Genève (UNIGE) - Centre Médical Universitaire (CMU), Geneva,

CH

15:35 - 15:50 The relevance of endoxifen measurements in the adjuvant tamoxifen treatment
of breast cancer
S. Koolen, Erasmus MC - University Medical Center, Rotterdam, NL

15:50 - 16:10 The rationale behind selecting recommended dose and schedule in
immunotherapy ion

Campal, Madrid, ES

R. Mathijssen, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL


Title: ESMO Women for Oncology (W4O) Forum - Gender equity Auditorium
in oncology 2022: Challenges & opportunities
Chair(s): Cathy Smith, BE; Pilar Garrido Lopez, ES

14:45 - 14:50 Welcome
C. Smith, Speak-Easy Communications, Brussels, BE

14:50 - 14:55 Video contribution
S. Kyriakides, European Commission, Brussels, BE

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

15:02 - 16:15 Live discussion, Q&A, wrap-up
H. Linardou1, P. Garrido Lopez2, A. Cervantes3, C. Smith4, E. Mariamidze5,

1Metropolitan Hospital, Athens, GR, 2Hospital Universitario Ramon y Cajal, Madrid, ES,
3Hospital Clinico Universitario de Valencia, Valencia, ES, 4Speak-Easy Communications,
Brussels, BE, 5Todua Clinic, Tbilisi, GE

Title: Young Oncologist Masterclass: Clinical Trials Design and Auditorium
Development in the 21st Century
Chair(s): Teresa Amaral, DE; Anna Sophie Berghoff, AT

14:45 - 15:10 What is a well-designed clinical trial?


15:25 - 15:50 Addressing inequality in under-served populations in clinical trials
E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES


16:05 - 16:25 Coffee break

16:25 - 16:50 Insfrastructure and policies for global clinical trials: Opportunities and threats
C. Gomez-Roca, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR


17:05 - 17:30 How does the marketing authorization process work?
F. Pignatti, European Medicines Agency - Amsterdam, Amsterdam, NL


15:00 - 16:00 Type: Challenge your Expert 7.3.Q - Quimper
Title: Management of different glioma subtypes: Should all Auditorium
lower-grade gliomas be treated equally?
Chair(s): Lakshmi Nayak, US

M. Van Den Bent, Rotterdam, NL

L. Nayak, Dana Farber Cancer Institute, Boston, US


15:00 - 16:00 Type: Challenge your Expert 7.3.T - Toulouse Auditorium
Title: CNS metastases in metastatic breast cancer
Chair(s): Martine Piccart, BE; Priscilla Brastianos, US

N. Lin, Dana Farber Cancer Institute, Boston, US

M. Piccart, Institute Jules Bordet, Brussels, BE

Title: Janssen-Cilag International NV - Nursing Auditorium
Considerations with EGFR Inhibitors in NSCLC
Chair(s): Silvija Piskorjanac, HR

S. Piskorjanac, University Hospital Osijek, Osijek, HR

15:05 - 15:20 Targeted therapies for EGFR NSCLC - what's new?
S. Karabatic, KBC Zagreb - Clinic for Lung Diseases Jordanovac, Zagreb, HR

15:20 - 15:35 Understanding Targeted Therapy for NSCLC – cancer nurses knowledge, attitude
and practice

15:35 - 15:50 Diagnosing a person with a mutation positive lung cancer
K. Clayton, East Cheshire NHS Trust, Macclesfield, GB

15:50 - 16:05 What does a diagnosis mean
J. Vick, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

16:05 - 16:30 Discussion and Conclusion remarks

Title: Presidential Symposium II
Chair(s): Karin Jordan, DE; Florian Lordick, DE

16:30 - 16:45 LBA4 - Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO)
for localized renal cell carcinoma (RCC) at high risk of relapse after
nephrectomy: Results from the randomized, phase III CheckMate 914 trial
R. Motzer1, P. Russo1, V. Gruenwald2, Y. Tomita3, B. Zurawski4, O. Parikh5, S. Buti6, P.

Barthelemy7, J. Goh8, D. Ye9, A. Lingua10, J.-B. Lattouf11, B. Escudier12, S. George13, B.
Shuch14, B. Simsek15, J. Spiridigliozzi16, A. Chudnovsky16, A. Bex17, 1Memorial Sloan
Kettering Cancer Center, New York, US, 2West-German Cancer Center Essen, University

Hospital Essen, Essen, DE, 3Niigata University Graduate School of Medical and Dental
Sciences, Niigata, JP, 4Prof. Franciszek Łukaszczyk Oncology Centre, Bydgoszcz, PL,
5Lancashire Teaching Hospitals NHS Trust, Preston, GB, 6University Hospital of Parma,

University of Parma, Parma, IT, 7Institut de Cancérologie Strasbourg Europe, Strasbourg,
FR, 8Royal Brisbane and Women's Hospital, Herston, AU, 9Fudan University Shanghai
Cancer Center, Shanghai, CN, 10Instituto Médico Río Cuarto, Rio Cuarto, AR, 11CHUM -
Centre Hospitalier de l’Université de Montréal, Montreal, CA, 12Gustave Roussy - Cancer
Campus, Villejuif, FR, 13Roswell Park Comprehensive Cancer Center, Buffalo, US,
14University of California, Los Angeles, US, 15Bristol Myers Squibb, princeton, US,
16Bristol Myers Squibb, Princeton, US, 17Netherlands Cancer Institute, Amsterdam, NL

16:45 - 17:00 LBA5 - Primary results of the phase III KEYNOTE-412 study: Pembrolizumab
(pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally
advanced (LA) head and neck squamous cell carcinoma (HNSCC)
J.-P. Machiels1, Y. Tao2, B. Burtness3, M. Tahara4, D. Rischin5, G. Alves6, I. Lima7, B.

Hughes8, Y. Pointreau9, S. Aksoy10, S. Laban11, R. Greil12, M. Burian13, M. Hetnal14, L.
Licitra15, R. Swaby16, Y. Zhang16, B. Gumuscu16, B. Bidadi16, L. Siu17, 1Cliniques
Universitaires Saint-Luc (UCLouvain Saint-Luc) and Institut de Recherche Clinique et
Expérimentale (Pole MIRO), Woluwe-Saint-Lambert, BE, 2Institut Gustave Roussy,
Villejuif, Cedex, FR, 3Yale University School of Medicine - Yale Cancer Center, New
Haven, US, 4National Cancer Center Hospital East, Kashiwa, JP, 5Peter MacCallum
Cancer Centre, Melbourne, AU, 6Hospital Nossa Senhora da Conceicao, Porto Alegre, BR,
7CRIO Centro Regional Integrado de Oncologia, Fortaleza-CE, BR, 8Royal Brisbane and
Women's Hospital, Herston, AU, 9Centre Jean Bernard, Le Mans, FR, 10Hacettepe
University - Faculty of Medicine, Ankara, TR, 11University Hospital of Ulm - Ear, Nose
and Throat Medicine, Ulm, DE, 12Paracelsus Medizinische Privatuniversität, Salzburg,
AT, 13Ordensklinikum Linz Barmherzige Schwestern, Linz, AT, 14Andrzej Frycz
Modrzewski Krakow University, Amethyst Radiotherapy Centre, Rydygier Hospital,
Krakow, PL, 15Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 16Merck &
Co., Inc., Rahway, US, 17Princess Margaret Cancer Centre, Toronto, CA

17:00 - 17:15 LBA6 - Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV
melanoma (SWOG S1801)
S. Patel1, M. Othus2, V. Prieto1, M. Lowe3, E. Buchbinder4, Y. Chen5, J. Hyngstrom6, C.

Lao7, T.-G. Truong8, S. Chandra9, K. Kendra10, C. Devoe11, A. Hedge12, A. Mangla13, E.
Sharon14, L. Korde14, J. Moon2, V. Sondak15, A. Ribas16, 1The University of Texas MD
Anderson Cancer Center, Houston, US, 2Fred Hutchinson Cancer Research Center,
Seattle, US, 3Emory University, Atlanta, US, 4Dana Farber Cancer Institute, Boston, US,
5Cancer and Hematology Centers of Western Michigan / CRC West MI NCORP, Grand
Rapids, US, 6University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US,

7University of Michigan, Ann Arbor, US, 8Kaiser Permanente NCAL, Vallejo, US,
9Northwestern University, Chicago, US, 10Ohio State University Wexner Medical Center,
Columbus, US, 11Northwell Health Cancer Institute, Lake Success, US, 12The University
of Alabama at Birmingham, Birmingham, US, 13University Hospitals Seidman Cancer
Center, Cleveland, US, 14Cancer Therapy Evaluation Program, Bethesda, US, 15Moffitt
Cancer Center, Tampa, US, 16UCLA/Jonsson Comprehensive Cancer Center, Los Angeles,
US

17:15 - 17:30 LBA7 - Neoadjuvant immune checkpoint inhibition in locally advanced MMR-

deficient colon cancer: The NICHE-2 study
M. Chalabi1, Y. Verschoor2, J. Van Den Berg2, K. Sikorska1, G. Beets2, A. Lent3, M.C.

Grootscholten2, A. Aalbers2, N. Buller4, H. Marsman3, E. Hendriks5, P. Burger6, T.
Aukema7, S. Oosterling8, R. Beets-Tan 1, T. Schumacher2, M. Van Leerdam2, E. Voest2, J.
Haanen1, 1Netherlands Cancer Institute, Amsterdam, NL, 2NKI-AVL - Netherlands
Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, 3OLVG Hospital,
Amsterdam, NL, 4Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-
AVL), Amsterdam, NL, 5Tergooiziekenhuizen, Blaricum, NL, 6Catharina Hospital
Eindhoven, Eindhoven, NL, 7Hagaziekenhuis, Den Haag, NL, 8Spaarne Hospital
Hoofddorp, Hoofddorp, NL

17:30 - 17:45 Invited Discussant LBA4, LBA5, LBA6, LBA7 - The immunologist point of view

17:45 - 18:00 Invited Discussant LBA4, LBA5, LBA6, LBA7 - The medical oncologist point of
view
J. Larkin, The Royal Marsden Hospital - NHS Foundation Trust, London, GB


16:30 - 18:00 Type: Educational session 7.1.D - Dijon
Title: Minimizing some of the most distressing cancer and Auditorium
cancer treatment related symptoms
Chair(s): Karen Steindorf, DE; Florian Scotté, FR

16:30 - 16:55 Fatigue, cognitive dysfunction and emotional distress
K. Steindorf, German Cancer Research Center - National Center for Tumor Diseases

(NCT), Heidelberg, DE

16:55 - 17:20 Cachexia
J. Arends, Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für

Tumorbiologie, Freiburg im Breisgau, DE

17:20 - 17:45 Dyspnea and cough
D. Hui, Houston, TX, US


16:30 - 17:30 Type: Mini Oral session 7.3.G - Grenoble Auditorium
Title: Mini Oral session 2: Gynaecological cancers
Chair(s): Philipp Harter, DE; Antonio Jose Gonzalez Martin, ES

16:30 - 16:35 525MO - Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab
(pembro) vs treatment of physician’s choice (TPC) in patients (pts) with

advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
V. Makker1, N. Colombo2, A. Casado Herraez3, B. Monk4, H. Mackay5, A.D. Santin6, D.

Miller7, R. Moore8, S. Baron-Hay9, I. Ray-Coquard10, R. Shapira-Frommer11, K.
Ushijima12, K. Yonemori13, Y.M. Kim14, E.M. Guerra Alia15, U. Sanli16, J. Huang17, J.
Mckenzie17, G. Barresi18, D. Lorusso19, 1Memorial Sloan-Kettering Cancer Center, New
York City, US, 2University of Milan-Bicocca, European Institute of Oncology IRCCS,
Milan, IT, 3Hospital Clinico Universitario San Carlos, Madrid, ES, 4University of Arizona,
Creighton University, Phoenix, US, 5Odette Cancer Centre, Sunnybrook Health Sciences
Centre, Toronto, CA, 6Yale University School of Medicine, New Haven, US, 7University of
Texas Southwestern Medical Center, Dallas, US, 8University of Rochester Medical Center,
Rochester, US, 9Royal North Shore Hospital, St Leonards, AU, 10Centre Léon Bérard,
University Claude Bernard, GINECO Group, Lyon, FR, 11Sheba Medical Center, Ramat,
IL, 12Kurume University School of Medicine, Kurume, JP, 13National Cancer Center
Hospital, Chuo-ku, JP, 14Asan Medical Center, University of Ulsan, Seoul, KR, 15Hospital
Universitario Ramon y Cajal, Madrid, ES, 16Ege University, Izmir, TR, 17Eisai Inc., Nutley,
US, 18MSD - Austria, Vienna, AT, 19Fondazione Policlinico Universitario Agostino Gemelli
IRCCS and Catholic University of Sacred Heart, Rome, IT

16:35 - 16:40 526MO - Pathological assessment of sentinel lymph node in early-stage cervical
cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)
D. Cibula1, C. Köhler2, S. Bajsová3, S. Sebestova4, I. Zapardiel5, G. Di Martino6, L. Van

Lonkhuijzen7, B. Sehnal8, O. Arencibia Sánchez9, B. Gil Ibañez10, F. Martinelli11, J.
Presl12, L. Minář13, R. Marek14, P. Kascak15, P. Havelka16, M. Michal17, T. Van Gorp18, K.
Nemejcova19, R. Kocian1, 1General Teaching Hospital and The First Faculty of Medicine
of Charles University in Prague, CEEGOG (Central and Eastern European Gynecologic
Oncology Group), Prague, CZ, 2Asklepios Klinik Harburg, Hamburg, DE, 3University
Hospital Ostrava, CEEGOG, Ostrava, CZ, 4Masaryk University Faculty of Medicine, Brno,
CZ, 5IdiPAZ - Instituto de Investigacion Sanitaria del Hospital Universitario La Paz,
Madrid, ES, 6San Gerardo Hospital, Monza, IT, 7Academic Medical Center, University of
Amsterdam, Amsterdam, NL, 8University Hospital Bulovka, First Faculty of Medicine,

Charles University, CEEGOG, Prague, CZ, 9University Hospital of the Canary Islands, Las
Palmas de Gran Canaria, ES, 10Hospital Clinic of Barcelona, Barcelona, ES, 11National
Cancer Institute in Milan, Rome, IT, 12University Hospital Pilsen, Charles University,
CEEGOG, Plzen, CZ, 13Masaryk University, CEEGOG, Brno, CZ, 14Palacky University,
University Hospital Olomouc, CEEGOG, Olomouc, CZ, 15University Hospital Trencin,
CEEGOG, Trencin, SK, 16Krajska Nemocnice T. Bati, a.s. (T. Batas Regional Hospital),
CEEGOG, Zlin, CZ, 17Hospital Ceske Budejovice, CEEGOG, Ceske Budejovice, CZ,
18University Hospitals Leuven, BGOG (Belgium and Luxembourg Gynaecological
Oncology Group), Leuven, BE, 19Charles University and General University Hospital,
Prague, CZ

P. Harter, Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE

16:50 - 16:55 527MO - Rucaparib maintenance treatment in patients (pts) with newly
diagnosed ovarian cancer (OC): Defining benefit according to disease risk
subgroups within the phase 3 ATHENA–MONO study
R. Kristeleit1, S. Ghamande2, M.-C. Lim3, C. Parkinson4, M. Morgan5, M. Wilson6, A.

Oaknin7, J. Buscema8, P. Bessette9, D. Lorusso10, F. Ueland11, T. Safra12, J. Barlin13, F.
Marmé14, T. Herzog15, I. Mcneish16, S. Goble17, S. Hume17, K. Fujiwara18, B. Monk19,
1Guy's and St Thomas' NHS Foundation Trust, London, GB, 2Augusta University,
Augusta, US, 3National Cancer Center Korea, Goyang-si, Gyeonggi-do, KR,

4Addenbrooke’s Hospital, Cambridge, GB, 5University of Pennsylvania Health System,
Philadelphia, US, 6Auckland City Hospital, Auckland, NZ, 7Vall d’Hebron Institute of
Oncology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus,
Barcelona, ES, 8Arizona Oncology, Tucson, US, 9University of Sherbrooke, Sherbrooke,

CA, 10Fondazione Policlinico Universitario Gemelli IRCCS and Catholic University of
Sacred Heart, Rome, IT, 11Division of Gynecologic Oncology, College of Medicine,
University of Kentucky, Lexington, US, 12Tel Aviv Medical Center, and Sackler Faculty of
Medicine, Tel Aviv University, Tel Aviv, IL, 13Division of Gynecologic Oncology, Albany
Medical College, Albany, US, 14University Hospital Mannheim, Mannheim, DE,
15University of Cincinnati Cancer Center, Cincinnati, US, 16Imperial College London,
London, GB, 17Clovis Oncology, Inc., Boulder, US, 18Saitama Medical University
International Medical Center, Hidaka, Saitama, JP, 19HonorHealth Research Institute,
University of Arizona College of Medicine, Creighton University School of Medicine,
Phoenix, US

16:55 - 17:00 528MO - Is re-introduction or continuation of PARP inhibitors after local therapy
for oligo-metastatic progression in patients with relapsed ovarian cancer
relevant?
G. Thibault1, M. Kfoury2, D. Lorusso3, A. Floquet4, J. Ventriglia5, H. Salaun6, M.

Moubarak7, R. Rivoirard8, L. Polastro9, L. Favier10, B. You11, D. Berton-Rigaud12, T. De
La Motte Rouge13, L. Mansi14, C. Abdeddaim15, K. Prulhiere16, L. Lancry Lecomte17, M.
Provansal Gross18, C. Dalban19, I. Ray-Coquard19, 1Léon-Bérard Cancer Center, Lyon,
FR, 2Institut Gustave Roussy, Villejuif, Cedex, FR, 3Division of Gynecologic Oncology,
Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, IT, 4Institute Bergonié,
Bordeaux, FR, 5Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT,
6Institut Curie, Paris, FR, 7KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE, 8ICLN
- Institut de Cancérologie Lucien Neurwith, Saint-Priest-en-Jarez, Cedex, FR, 9Institute

Jules Bordet, Brussels, BE, 10Centre Georges Francois Leclerc, Dijon, FR, 11Institut de
Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO, Univ Lyon,
Université Claude Bernard Lyon 1, Pierre-Bénite, FR, 12ICO Institut de Cancerologie de
l'Ouest René Gauducheau, Saint-Herblain, FR, 13Centre Eugene - Marquis, Rennes, FR,
14CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, 15Centre Oscar Lambret, Lille,
FR, 16Polyclinique de Courlancy, Reims, FR, 17GHM - Groupe Hospitalier Mutualiste de

Grenoble, Grenoble, cedex, FR, 18Institute Paoli Calmettes, Marseille, FR, 19Centre Léon
Bérard, Lyon, FR

17:00 - 17:05 529MO - Phase II study of olaparib plus durvalumab with or without
bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-
germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
S. Banerjee1, M. Imbimbo2, P. Roxburgh3, J.-W. Kim 4, M.H. Kim5, R. Plummer6, S.

Stemmer7, B. You8, M. Ferguson9, R. Penson10, D. O'Malley11, K. Meyer12, H. Gao13, H.
Angell13, A. Tablante Nunes12, S. Domchek14, Y. Drew15, 1The Royal Marsden NHS
Foundation Trust and Institute of Cancer Research, London, GB, 2Lausanne University
Hospital, University of Lausanne, Lausanne, CH, 3Beatson West of Scotland Cancer
Centre, and Institute of Cancer Sciences, University of Glasgow, Glasgow, GB, 4Seoul
National University Hospital, Seoul, KR, 5Yonsei Cancer Centre, Yonsei University

College of Medicine, Seoul, KR, 6Northern Centre for Cancer Care, Newcastle upon Tyne

Hospitals NHS Foundation Trust, and Newcastle University, Newcastle upon Tyne, GB,
7Rabin Medical Center-Beilinson Campus, Petach Tikva, IL, 8Institut de Cancérologie des
Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO, Univ Lyon, Université Claude
Bernard Lyon 1, Pierre-Bénite, FR, 9Ninewells Hospital, NHS Tayside, Dundee, GB,
10Massachusetts General Hospital, Boston, US, 11The Ohio State University James
Comprehensive Cancer Center, Columbus, US, 12AstraZeneca, Gaithersburg, US,

13AstraZeneca, Cambridge, GB, 14University of Pennsylvania, Philadelphia, US,
15Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation
Trust and Newcastle University, Newcastle upon Tyne, GB

A.J. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES

Title: Proffered Paper session: Basic science & Auditorium
translational research
Chair(s): Federica Di Nicolantonio, IT; Sandra Demaria, US

16:30 - 16:40 903O - A prospective study of a multi-cancer early detection blood test
D. Schrag1, C. Mcdonnell Iii2, L. Nadauld3, C. Dilaveri4, E. Klein5, R. Reid6, C. Marinac7,

K. Chung8, M. Lopatin8, E. Fung8, T. Beer9, 1MSKCC - Memorial Sloan Kettering Cancer
Center, New York, US, 2Sutter Institute for Medical Research, Sacramento, US,
3Intermountain Healthcare - Intermountain Cancer Center of St George, St. George, US,
4Mayo Clinic, Rochester, US, 5Stanford Comprehensive Cancer Institute, Stanford, US,
6US Oncology, Inc., Thornton, US, 7Dana Farber Cancer Institute, Boston, US, 8GRAIL
LLC a subsidiary of Illumina Inc. currently held separate from Illumina Inc. under the
terms of the Interim Measures Order of the European Commission dated 29 October
2021, Menlo Park, US, 9OHSU - Center for Health & Healing Building 2, Portland, US

16:40 - 16:50 1696O - Genomic profiling and molecular targeting of lung cancer brain
metastases
H. Cheng1, M. Feng2, N. Fan2, E. Sokol3, F. Wang2, Y. Zou2, B. Farran2, J. Ross3, G.

Frampton3, T. Bhagat2, A. Verma1, R. Perez-Soler1, B. Halmos1, 1Montefiore Medical

Center/Albert Einstein College of Medicine, Bronx, US, 2Albert Einstein College of
Medicine, Bronx, US, 3Foundation Medicine, Inc, Cambridge, US

16:50 - 17:00 66O - MyPathway: A multiple target, multiple basket study of targeted
treatments in tissue-agnostic cohorts of patients (pts) with advanced solid
tumors
C. Friedman1, C. Swanton2, D. Spigel3, R. Bose4, H. Burris5, W. Yu6, Y. Wang7, J. Malato7,

R. Price7, W. Darbonne7, T. Szado7, K. Schulze7, C. Sweeney8, J. Hainsworth9, F. Meric-
Bernstam10, R. Kurzrock11, 1Memorial Sloan Kettering Cancer Center, and Weill Medical
College at Cornell University, New York, US, 2Francis Crick Institute, and UCL Hospitals,
London, GB, 3Sarah Cannon Research Institute, Cancer Centre, and Tennessee Oncology,
Nashville, US, 4Washington University School of Medicine, St. Louis, US, 5Sarah Cannon
Research Institute, and Tennessee Oncology, Nashville, US, 6Genentech, South San
Francisco, US, 7Genentech, Inc., South San Francisco, US, 8Dana Farber Cancer
Institute, Boston, US, 9TriStaCentennial Medical Center, Nashville, US, 10The University

of Texas MD. Anderson Cancer Center, Houston, US, 11Medical College of Wisconsin,
Milwaukee, US

F. Di Nicolantonio, University of Turin, Torino, IT

17:10 - 17:20 Q&A

17:20 - 17:30 1660O - Dual immune checkpoint blockade induces analogous alterations in the
intratumoral CD8+ T cell and Treg compartments
J. Traets1, A. Van Der Leun1, J. Vos1, J. Elbers2, S. Patiwael1, X. Qiao1, M. Machuca-

Ostos1, D. Thommen1, J. Haanen1, T. Schumacher1, C. Zuur3, 1NKI-AVL - Netherlands
Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, 2Erasmus
University Medical Center, Rotterdam, NL, 3Netherlands Cancer Institute, Amsterdam,
NL

17:30 - 17:40 67O - Quantifying poly(ADP-Ribose) polymerase (PARP1) in vivo using a non-
invasive PARP1 PET tracer
L. Lin, T. Daoud, T. Yap, F. Wong, The University of Texas M. D. Anderson Cancer Center,

Houston, US


17:50 - 18:00 Q&A


Title: The enigma of public policy in oncology: ESMO at Auditorium
the forefront
Chair(s): Ravindran Kanesvaran, SG; Rosa Giuliani, GB

R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

16:35 - 16:50 MCBS: The future of cost-effective care
F. Roitberg, ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR

16:50 - 17:05 GDPR in oncology: The EU experience
P.G. Casali, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

17:05 - 17:20 ESMO and Covid 19: The trials and tribulations
M. Garassino, University of Chicago Department of Medicine - Section of

Hematology/Oncology, Chicago, US

17:20 - 17:35 Onco-policy in Asia: ESMO to the fore

R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG




16:45 - 17:45 Type: Controversy session 7.2.F - Fécamp
Title: Stage III NSCLC: What defines resectability in the era of Auditorium
neoadjuvant chemo-IO v. PACIFIC?
Chair(s): Masahiro Tsuboi, JP

M. Tsuboi, National Cancer Center Hospital East, Kashiwa, JP


16:51 - 17:06 Pro: Stage III NSCLC: What defines resectability in the era of neoadjuvant
chemo-IO v. PACIFIC?

17:06 - 17:21 Contra: Stage III NSCLC: What defines resectability in the era of neoadjuvant
chemo-IO v. PACIFIC?
S. Senan, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL


17:22 - 17:42 Q&A

16:45 - 17:45 Type: Multidisciplinary session 7.3.Q - Quimper
Title: Young patients with newly-diagnosed multiple Auditorium
myeloma and severe complications
Chair(s): Evangelos Terpos, GR

E. Terpos, Athens, GR

16:52 - 17:09 Management of renal impairment
K. Weisel, Universitätsklinikum Tübingen, Tübingen, DE

17:09 - 17:26 Management of bone disease
E. Terpos, Athens, GR



Title: Supportive care and symptom management
Chair(s): Remziye Semerci, TR

16:45 - 17:00 Sexual wellbeing in cancer care
L. Grover, The London Clinic, London, GB

17:00 - 17:15 Malta: How cancer carers live with their own chronic conditions
D. Chircop, University of Malta - Msida Campus, Msida, MT

17:15 - 17:30 What really matters to you? A Delphi study on priority patient-reported
outcomes to evaluate when caring for people with advanced liver or advanced
renal cancer
C. Díez De Los Ríos De La Serna, Vall d'Hebron University Hospital, Barcelona, ES

17:30 - 17:40 CN60 - OptiBra study: An RCT, optimal postoperative bra support after breast
cancer surgery
M. Backman1, K. Fridblom2, M. Hassan- Nur3, H. Fredholm3, I. Fredriksson1,

1Karolinska Institute, Stockholm, SE, 2Tema Cancer, Karolinska University Hospital,
Solna, SE, 3Department of molecular medicine and surgery, stockholm, SE

17:40 - 17:50 CN59 - A scoping review to establish the utility of patient reported outcome
measures in blood cancer
S. Kirkpatrick1, K. Campbell2, 1North Bristol NHS Trust Clinical Research Centre,,

Bristol, GB, 2Edinburgh Napier University, Edinburgh, GB

17:50 - 18:00 CN62 - Patient and public involvement in cancer research: The needs and
perceptions of older adults living with and after cancer
A. Drury1, L. O'Connell2, A. O'Brien1, M. Harkin3, L. Rogers1, 1University College Dublin,

Dublin, IE, 2Tallaght University Hospital, Dublin, IE, 3Age and Opportunity, Dublin, IE

18:00 - 18:10 CN63 - Intervention pathways for low anterior resection syndrome after
sphincter-saving rectal cancer surgery: A systematic scoping review.
E. Pape1, J. Burch2, G. Van Ramshorst1, Y. Van Nieuwenhove1, C. Taylor2, 1UZ Gent -

Universitair Ziekenhuis Gent, Gent, BE, 2St Mark's Hospital, Harrow, GB



Title: Join us, learn, and share: Best practices across Auditorium
Europe
Chair(s): Petra Adamkova, CZ; Joanna Fratczak Kazana, PL

18:15 - 18:30 Setting the scene

18:30 - 18:45 The Gynecological Oncology Day: The world GO day
P. Adamkova, ESGO - European Society of Gynaecological Oncology, Prague, CZ

18:45 - 19:00 The impact of prostate cancer treatment on quality of life: EUPROMS study
A. Deschamps, Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE

19:00 - 19:15 iPoRaku (AfterCancer)
A. Kuna, Foundation Rak’n’Roll - Win a Life!, Warsaw, PL

19:15 - 19:30 Onko Ukraine


19:30 - 19:45 International Covid Blood Cancer Coalition
J. Pelouchova, Diagnoza leukemie, z.s, Prague, CZ



Title: Astellas - From landmark data to clinical excellence: Auditorium
Improving outcomes in LA/mUC
Chair(s): Ignacio Duran Martinez, ES

18:30 - 18:40 Making milestones: The evolving treatment landscape in LA/mUC
A. Merseburger, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck,

Lübeck, DE

18:40 - 18:55 Discovering the data: MoA and core clinical evidence
I. Duran Martinez, HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES

18:55 - 19:15 Defining the direction: Enfortumab vedotin eligibility and treatment initiation
R. Jones1, Y. Loriot2, 1MVLS - Medical, Veterinary and Life Sciences College - University

of Glasgow, Glasgow, GB, 2Institut Gustave Roussy, Villejuif, Cedex, FR

19:15 - 19:35 Practical tips for treatment: Optimising outcomes and managing adverse events
M.J. Juan Fita1, R. Jones2, 1IVO - Fundación Instituto Valenciano de Oncología, Valencia,
ES, 2MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow,
Glasgow, GB

19:35 - 19:45 Prioritising patients in practice: Evidence-driven care in the clinic
Y. Loriot, Institut Gustave Roussy, Villejuif, Cedex, FR

19:45 - 20:00 Pinpoints of interest: Panel discussion and Q&A
I. Duran Martinez1, R. Jones2, A. Merseburger3, Y. Loriot4, M.J. Juan Fita5, 1HUMV -

Hospital Universitario Marques de Valdecilla, Santander, ES, 2MVLS - Medical,
Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, 3UKSH -

Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, 4Institut Gustave
Roussy, Villejuif, Cedex, FR, 5IVO - Fundación Instituto Valenciano de Oncología,
Valencia, ES


Title: AstraZeneca - Cutting through complexity in NSCLC: How Auditorium
to navigate the patient journey
Chair(s): Michael Thomas, DE

18:30 - 18:34 Welcome and Intro
M. Thomas, Thoraxklinik Heidelberg gGmbH, Heidelberg, DE

18:34 - 18:47 Advances in systemic therapy for resectable NSCLC
J. Rotow, The Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute,

Boston, US

18:47 - 19:00 Evolving role of the surgeon in new treatment algorithms in resectable NSCLC

M. Thomas1, J. Rotow2, L. Payen3, J. Spicer4, 1Thoraxklinik Heidelberg gGmbH,

Heidelberg, DE, 2The Lowe Center for Thoracic Oncology at Dana-Farber Cancer

Institute, Boston, US, 3Hospices Civiles de Lyon, Lyon, FR, 4McGill University, Montreal,
CA

19:15 - 19:28 Future of metastatic NSCLC: Considerations for Optimizing Treatment

19:28 - 19:41 Comprehensive reflex biomarker testing for appropriate patient identification
L. Payen, Hospices Civiles de Lyon, Lyon, FR

M. Thomas1, J. Rotow2, L. Payen3, J. Spicer4, 1Thoraxklinik Heidelberg gGmbH,

Heidelberg, DE, 2The Lowe Center for Thoracic Oncology at Dana-Farber Cancer

Institute, Boston, US, 3Hospices Civiles de Lyon, Lyon, FR, 4McGill University, Montreal,
CA

19:56 - 20:00 Summary and Close


Title: GSK - Immune Checkpoint Inhibitors in Mismatch Repair Auditorium
Deficient Solid Tumors: Expert Interviews
Chair(s): Isabelle Ray-Coquard, FR

18:30 - 18:45 Clinical considerations for ICI treatment of dMMR endometrial cancer and other
dMMR solid tumors

18:45 - 19:10 Chair interview of Dr. Leary: Perspective on identifying patients with dMMR
endometrial cancer for ICI treatment
A. Leary, Institut Gustave Roussy, Villejuif, Cedex, FR

19:10 - 19:35 Chair interview of Dr. Cercek: Perspective on single-agent PD-1 blockade in
dMMR CRC/solid tumors
A. Cercek, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

19:35 - 19:55 Panel discussion: Considerations for ICI treatment of dMMR endometrial cancer
and CRC/solid tumors, expert perspectives
I. Ray-Coquard1, A. Leary2, A. Cercek3, 1Centre Léon Bérard, Lyon, FR, 2Institut Gustave
Roussy, Villejuif, Cedex, FR, 3Memorial Sloan Kettering Evelyn H. Lauder Breast Center,
New York, US

19:55 - 20:00 Q&A
I. Ray-Coquard1, A. Leary2, A. Cercek3, 1Centre Léon Bérard, Lyon, FR, 2Institut Gustave
Roussy, Villejuif, Cedex, FR, 3Memorial Sloan Kettering Evelyn H. Lauder Breast Center,
New York, US


Title: Servier - Understanding the treatment strategy in Honfleur
metastatic pancreatic cancer to improve patient outcomes Auditorium
Chair(s): Teresa Macarulla Mercade, ES; Thomas Seufferlein, DE

T. Seufferlein, University of Ulm, Ulm, DE

18:40 - 18:55 Treatment planning strategy in mPAC

18:55 - 19:10 Real-world data in mPAC
M. Peeters, UZA - University Hospital Antwerp, Edegem, BE

19:10 - 19:25 Insights from Japan in mPAC
M. Ikeda, National Cancer Center Hospital East, Kashiwa, JP

19:25 - 19:35 Long-term survivors
T. Macarulla Mercade, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center,

Barcelona, ES

T. Macarulla Mercade1, T. Seufferlein2, 1Vall d'Hebron Institute of Oncology (VHIO)-

Cellex Center, Barcelona, ES, 2University of Ulm, Ulm, DE

T. Seufferlein, University of Ulm, Ulm, DE


18:30 - 20:00 Type: Industry Satellite Symposium 7.3.O - Orléans Auditorium
Title: Merck - Evolution of SCCHN treatment
Chair(s): Ezra Cohen, US


18:35 - 18:47 Treatment options for cisplatin ineligible patients with LA SCCHN

18:47 - 18:59 Opportunities for novel combinations with radiation in LA SCCHN
K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London,

GB

18:59 - 19:11 Evolution of treatment sequencing in SCCHN
P. Szturz, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

19:11 - 19:23 New combinations in R/M SCCHN
A. Martins Ferreira Varges Gomes, Centro Hospitalar Universitário do Algarve - Hospital

de Faro EPE-SNS, Faro, PT

19:23 - 19:33 Summary of the data

19:33 - 19:55 Live discussion
E. Cohen1, S. Oosting2, K. Harrington3, A. Martins Ferreira Varges Gomes4, P. Szturz5,

1Moores Cancer Center - UC San Diego Health, La Jolla, US, 2 Groningen, NL, 3ICR -
Institute of Cancer Research - Chester Beatty Laboratories, London, GB, 4Centro

Hospitalar Universitário do Algarve - Hospital de Faro EPE-SNS, Faro, PT, 5CHUV -
Centre Hospitalier Universitaire Vaudois, Lausanne, CH



Title: MSD - Triple Negative Breast Cancer: An Evolving Auditorium
Treatment Landscape
Chair(s): Hope Rugo, US

18:30 - 18:35 Introduction and Objectives
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

18:35 - 18:55 Review of the Evolving Treatment Landscape in Early TNBC


18:55 - 19:15 Review of the Evolving Treatment Landscape in metastatic TNBC

R. Bartsch, Medizinische Universitaet Wien, Vienna, AT

19:15 - 19:35 PD-L1 testing for metastatic TNBC
G. Viale, IEO - Istituto Europeo di Oncologia, Milan, IT

19:35 - 19:45 Breast Cancer Patient Case Study

19:45 - 19:55 Q&A from Audience
H. Rugo1, R. Bartsch2, P. Schmid3, G. Viale4, 1UCSF Helen Diller Family Comprehensive

Cancer Center, San Francisco, US, 2Medizinische Universitaet Wien, Vienna, AT, 3Cancer

Research UK Barts Centre - Barts and The London School of Medicine and Dentistry,
London, GB, 4IEO - Istituto Europeo di Oncologia, Milan, IT

19:55 - 20:00 Closing


Title: Novartis - From clinical trial to real-world evidence: Auditorium
METex14 inhibitors in everyday practice
Chair(s): Alexis Cortot, FR

A. Cortot, CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR

18:33 - 18:48 Identifying MET-dysregulated NSCLC: the path to diagnosis
K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB

18:48 - 19:03 Expanding treatment options for patients with MET exon 14 skipping mutation
in NSCLC

19:03 - 19:28 MET inhibition for patients with METex14 NSCLC in the real world
A. Cortot1, K. Kerr2, M. Hochmair3, 1CHU Lille - Centre Hospitalier Régional

Universitaire de Lille, Lille, FR, 2Aberdeen Royal Infirmary - NHS Grampian, Aberdeen,

GB, 3Ludwig Boltzmann Institut Applied Diagnostics - Ludwig Boltzmann Gesellschaft
GmbH, Vienna, AT

19:28 - 19:48 MET inhibition: experience from clinical trials and beyond
M. Hochmair, Ludwig Boltzmann Institut Applied Diagnostics - Ludwig Boltzmann

Gesellschaft GmbH, Vienna, AT

19:48 - 19:58 Q&A with the audience
A. Cortot1, K. Kerr2, M. Hochmair3, 1CHU Lille - Centre Hospitalier Régional

Universitaire de Lille, Lille, FR, 2Aberdeen Royal Infirmary - NHS Grampian, Aberdeen,

GB, 3Ludwig Boltzmann Institut Applied Diagnostics - Ludwig Boltzmann Gesellschaft
GmbH, Vienna, AT

19:58 - 20:00 Meeting closure


Title: AstraZeneca - The Highs and Lows of Breast Cancer Auditorium
Treatment: An interactive case-based discussion
Chair(s): Judy King, GB

18:30 - 18:35 Welcome and introductions
J. King, UCLH - University College London Hospitals NHS Foundation Trust, London, GB

18:35 - 19:00 Rethinking TNBC: Treatment strategies and sequencing
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

19:00 - 19:30 Therapeutic strategies to maximise ET sensitivity and confront resistance
E. Hamilton, Sarah Cannon Research Institute-Cancer Centre, Nashville, US

19:30 - 19:55 The evolution of HER2-targeted treatments
V. Dieras, Centre Eugene - Marquis, Rennes, FR

19:55 - 20:00 Meeting Close
J. King, UCLH - University College London Hospitals NHS Foundation Trust, London, GB


12.09.2022
Title: Prostate-specific membrane antigen (PSMA) biology, Auditorium
diagnostics and treatment
Chair(s): Shahneen Sandhu, AU; Boris Hadaschik, DE


08:35 - 08:50 PSMA biology
N. Bander, New York, NY, US

08:50 - 09:05 PSMA for diagnosis and staging
D. Oprea-Lager, Amsterdam, NL

09:05 - 09:20 LU-PSMA for prostate cancer treatment
S. Sandhu, Peter MacCallum Cancer Centre, Melbourne, AU

09:20 - 09:35 T cell engagers



Title: Personalizing treatment for mCRC in 2022
Chair(s): Chiara Cremolini, IT; Pieter Tanis, NL

08:30 - 08:55 State-of-the art first-line therapy for mCRC
C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

08:55 - 09:20 Impact of locoregional treatments in the metastatic setting
P. Tanis, Erasmus MC Cancer Institute, Rotterdam, NL

09:20 - 09:45 Beyond first-line: Best practices and practical nuances
T. Price, The Queen Elizabeth Hospital - Emergency Department, Woodville, AU



08:30 - 10:00 Type: Mini Oral session 7.1.C - Cannes Auditorium
Title: Mini Oral session: Breast cancer, early stage
Chair(s): Prudence Francis, AU; Luca Malorni, IT; Aleix Prat, ES

08:30 - 08:35 135MO - HRQoL with neoadjuvant pembrolizumab + chemotherapy vs
placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo
for early-stage TNBC: Results from KEYNOTE-522
R. Dent1, J. Cortés2, L. Pusztai3, H. Mcarthur4, S. Kuemmel5, J. Bergh6, C. Denkert7, Y.H.

Park8, R. Hui9, N. Harbeck10, M. Takahashi11, M. Untch12, P.A. Fasching13, F. Cardoso14,
A. Haiderali15, L. Jia15, A. Nguyen15, W. Pan15, J. O'Shaughnessy16, P. Schmid17, 1Duke-
NUS Medical School, Singapore, SG, 2Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, ES, 3Yale University School of Medicine, New Haven, US, 4UT Southwestern
Medical Center, Dallas, US, 5Charité – Universitätsmedizin Berlin, Department of
Gynecology with Breast Center, Berlin, DE, 6Karolinska University Hospital, Karolinska
CCC, Solna, SE, 7Philipps University Marburg, Marburg, DE, 8Samsung Medical Center
Sungkyunkwan University School of Medicine, Seoul, KR, 9Westmead Hospital and the
University of Sydney, Sydney, AU, 10Dept. OB&GYN, LMU University Hospital, Munich,
DE, 11NKO Hokkaido Cancer Center, Sapporo, JP, 12Helios Klinikum Berlin-Buch, Berlin,
DE, 13Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, 14Champalimaud
Clinical Center/Champalimaud Foundation, Lisbon, PT, 15Merck & Co., Inc., Rahway, US,
16Texas Oncology, US Oncology, Dallas, US, 17Barts Cancer Institute, Queen Mary
University of London, London, GB

08:35 - 08:40 136MO - Differential benefit of low-dose cyclophosphamide and methotrexate
maintenance chemotherapy among TNBC subtypes in the context of the IBCSG
22-00 study
A. Joaquin Garcia1, M. Rediti1, D. Venet1, S. Majjaj1, R. Kammler2, M. Colleoni3, S. Loi4,

G. Viale3, M. Regan5, F. Rothé1, C. Sotiriou1, 1Institute Jules Bordet, Brussels, BE, 2ETOP
- European Thoracic Oncology Platform, Bern, CH, 3IEO - Istituto Europeo di Oncologia,
Milan, IT, 4Peter MacCallum Cancer Centre, Melbourne, AU, 5Dana Farber Cancer
Institute, Boston, US

08:40 - 08:45 137MO - Effect of peri-tumoral infiltration of local anaesthetic prior to surgery
on survival in early breast cancer
R. Badwe1, V. Parmar2, N. Nair2, R. Hawaldar3, S. Joshi4, S. Pawar5, G. Kadayaprath6, B.

Borthakur7, S. Rao8, S. Pandya9, S. B10, P. Chitale11, R. Neve12, C. Harris13, A.
Srivastava14, S. Siddique3, V. Vanmali2, A. Dewade4, V. Gaikwad4, S. Gupta3, 1Tata
Memorial Centre, Mumbai, IN, 2Tata Memorial Hospital - Tata Memorial Centre, mumbai,
IN, 3Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, 4Tata Memorial
Hospital - Parel, Mumbai, IN, 5Kolhapur Cancer Centre, Kolhapur, IN, 6Max Hospital
Delhi, Delhi, IN, 7B. Borooah Cancer Institute, Guwahati, Guwahati, IN, 8American
Cancer Hospital and Research Centre, Hyderabad, IN, 9GCRI - The Gujarat Cancer and
Research Institute, Ahmedabad, IN, 10Malabar Cancer Centre, Thalassery, IN, 11Shree
Siddhivinayak Ganapati Cancer Hospital, Miraj, IN, 12Sterling Multi-Speciality Hospital,
Pune, IN, 13NEIGRIHMS - North Eastern Indira Gandhi Regional Institute of Health and
Medical Sciences, Shillong, IN, 14AIIMS - All India Institute of Medical Sciences, New
Delhi, IN


P. Francis, Peter MacCallum Cancer Center, Melbourne, AU

09:00 - 09:05 139MO - Identification of biologically-driven HER2-positive breast cancer
subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO
trial
M. Rediti1, D. Venet1, A. Joaquin Garcia1, D. Agbor-Tarh 2, M. Maetens3, D. Vincent1, S.

Majjaj1, S. El-Abed4, M. Liu5, S. Di Cosimo6, M. Piccart1, L. Pusztai7, S. Loi8, R.
Salgado9, G. Viale10, F. Rothé1, C. Sotiriou1, 1Institute Jules Bordet, Université Libre de
Bruxelles, Brussels, BE, 2Frontier Science, Kincraig, GB, 3KU Leuven, Leuven, BE,
4Breast International Group - AISBL, Brussels, BE, 5Mayo Clinic, Rochester, US,
6Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 7Yale University School of
Medicine, New Heaven, US, 8Peter MacCallum Cancer Centre, Melbourne, AU, 9GZA-
ZNA Ziekenhuizen, Antwerp, BE, 10IEO - Istituto Europeo di Oncologia, Milan, IT

09:05 - 09:10 140MO - HER2DX genomic test in HER2-positive/hormone receptor-positive
(HER2+/HR+) breast cancer (BC) treated with neoadjuvant
trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA
trial
V. Guarneri1, M.V. Dieci1, G. Griguolo2, L. Pare Brunet3, M. Marin3, F. Miglietta2, M.

Bottosso2, C.A. Giorgi2, P. Blasco4, O. Castillo4, P. Galván4, P. Jares5, J. Puig-Butille6, A.
Vivancos7, P. Villagrasa Gonzalez3, J. Parker8, C. Perou9, P.F. Conte2, A. Prat5, 1University
of Padua, Padova, IT, 2IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, 3Reveal
Genomics, S.L., Barcelona, ES, 4IDIBAPS - August Pi i Sunyer Biomedical Research
Institute, Barcelona, ES, 5Hospital Clinic of Barcelona, Barcelona, ES, 6Hospital Clinic y
Provincial de Barcelona, Barcelona, ES, 7Vall d'Hebron University Hospital, Barcelona,
ES, 8UNC - Lineberger Cancer Center, Chapel Hill, US, 9UNC - Lineberger
Comprehensive Cancer Center, Chapel Hill, US

L. Malorni, Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato,
IT

09:25 - 09:30 138MO - Prognostic performance of Breast Cancer Index (BCI) in
postmenopausal women with early-stage HR+ breast cancer in the TEAM trial
J. Bartlett1, K. Xu1, J. Wong2, G. Pond3, Y. Zhang2, M. Spears1, R. Salunga2, E. Mallon4, K.

Taylor5, A. Hasenburg6, C. Markopoulos7, L. Dirix8, C. Seynaeve9, C. Van De Velde10, D.
Rea11, C. Schnabel2, K. Treuner2, J. Bayani1, 1Ontario Institute for Cancer Research,
Toronto, CA, 2Biotheranostics, A Hologic Company, San Diego, US, 3McMaster University
Medical Centre - Hamilton Health Sciences, Hamilton, CA, 4University of Glasgow,

Glasgow, GB, 5Cancer Research UK Edinburgh Centre, Edinburgh, GB, 6University
Center Mainz, Mainz, DE, 7National and Kapodistrian University of Athens, Athens, GR,
8Sint-Augustinus Cancer Center, Wilrijk-Antwerp, BE, 9Erasmus MC Cancer Institute,
Rotterdam, NL, 10Leiden University Medical Center, Amsterdam, NL, 11University of

Birmingham, Birmingham, GB

09:30 - 09:35 141MO - Pathological response and early survival data according to TNBCtype4
classifier in operable triple-negative breast cancer (TNBC) treated with
neoadjuvant carboplatin and docetaxel

I. Echavarria Diaz-Guardamino1, S. Lopez-Tarruella Cobo 2, M. Del Monte-Millan2, E.
Alvarez1, Y. Jerez1, F. Moreno Anton3, J.Á. García Saenz3, T. Massarrah2, I. Ocaña1, M.
Cebollero4, A.I. Ballesteros Garcia5, U. Bohn Sarmiento6, H. Gomez7, H. Fuentes8, B.
Herrero Lopez1, S. Gamez Casado1, O. Bueno4, M.J. Jiménez-Santos9, M. Roche-Molina1,
M. Martin Jimenez2, 1Hospital General Universitario Gregorio Marañon - Fundación
Investigación Biomedica, Madrid, ES, 2Hospital General Universitario Gregorio Marañon
- Fundación Investigación Biomedica, CIBERONC, Madrid, ES, 3Hospital Clinico
Universitario San Carlos, CIBERONC, Madrid, ES, 4Hospital General Universitario
Gregorio Maranon, Madrid, ES, 5Hospital Universitario de la Princesa, Madrid, ES,
6Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, ES,
7Oncosalud SAC, Lima, PE, 8INEN - Instituto Nacional de Enfermedades Neoplasicas,
Lima, PE, 9CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES


08:30 - 10:00 Type: Special symposium 7.2.E - Évry
Title: Leveraging biology and technology to improve symptoms Auditorium
and quality of life of cancer survivors
Chair(s): Ines Vaz Luis, FR; Justin Jeon, KR


08:35 - 08:50 The need for discovery science and biological basis in cancer cachexia
M. Jamal-Hanjani, UCL Cancer Institute - Paul O'Gorman Building, London, GB

08:50 - 09:05 Biological basis of exercise and physical activity on quality of life in cancer
survivors
J. Jeon, Yonsei University, Seoul, KR

09:05 - 09:20 Biological basis of behavioral interventions for cancer survivors: Focus on
mindfulness
J. Bower, Los Angeles, US

09:20 - 09:35 How do you use supportive technology to improve personalised care?
E. Minvielle, Institut Gustave Roussy, Villejuif, FR

J. Jeon, Yonsei University, Seoul, KR


08:30 - 09:40 Type: Mini Oral session 7.2.F - Fécamp
Title: Mini Oral session: Melanoma and other skin Auditorium

tumours
Chair(s): Teresa Amaral, DE; Dirk Schadendorf, DE

08:30 - 08:35 LBA41 - Phase II study SECOMBIT (sequential combo immuno and target
therapy study): 4-years OS data and preliminary biomarkers evaluation
P. Ascierto1, M. Mandala2, P.F. Ferrucci3, M. Guidoboni4, P. Rutkowski5, V. Ferraresi6,

A.M. Arance Fernandez7, M. Guida8, E. Maiello9, H. Gogas10, E. Richtig11, M.T. Fierro12,
C. Lebbe13, H. Helgadottir14, I. Melero15, G. Palmieri16, D. Giannarelli17, A. Grimaldi18,
R. Dummer19, V. Chiarion Sileni20, 1Istituto Nazionale Tumori - IRCCS - Fondazione
Pascale, Napoli, IT, 2University of Perugia and Papa Giovanni XXIII Cancer Center
Hospital, Perugia, IT, 3IEO - Istituto Europeo di Oncologia, Milan, IT, 4Istituto Scientifico
Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS S.r.l., Meldola, IT, 5Maria
Sklodowska Curie National Research Institute of Oncology, Warsaw, PL, 6IRCCS Istiuto
Nazionale Tumori Regina Elena (IRE), Rome, IT, 7Hospital Clinic y Provincial de

Barcelona, Barcelona, ES, 8IRCCS Istituto Tumori Giovanni Paolo II, Bari, IT, 9IRCCS
Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, 10Laiko General
Hospital of Athens, Athens, GR, 11Universitätsklinik für Dermatologie und Venerologie,
Graz, AT, 12Oncologia Medica, Torino, IT, 13Hopital Saint Louis AP-HP, Paris, FR,
14Karolinska University Hospital, Stockholm, SE, 15Clinica Universitaria de Navarra,
Pamplona, ES, 16University of Sassari, Sassari, IT, 17Fondazione Policlinico Universitario

Agostino Gemelli IRCCS, Rome, IT, 18A.O.R.N. San Pio, Benevento, IT,
19Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, 20IOV - Istituto
Oncologico Veneto IRCCS, Padova, IT

08:35 - 08:40 LBA42 - Combined nivolumab and ipilimumab with or without stereotactic body
radiation therapy for advanced Merkel cell carcinoma
S. Kim1, E. Wuthrick2, D. Blakaj3, Z. Eroglu2, C. Verschraegen3, R. Thapa2, M. Mills2, K.

Dibs3, C. Liveringhouse2, J. Russell4, J. Caudell1, A. Tarhini2, J. Markowitz2, D.-T. Chen 2,
T. Rose2, J. Messina2, V. Sondak2, K. Tsai2, N. Khushalani2, A. Brohl2, 1H. Lee Moffitt
Cancer Center University of South Florida, Tampa, US, 2H. Lee Moffitt Cancer Center &
Research Institute - Magnolia Campus, Tampa, US, 3OSUCCC - The Ohio State University
Comprehensive Cancer Center - James, Columbus, US, 4University of Utah Health -
Cancer Hospital, Salt Lake City, US

08:40 - 08:45 790MO - Phase I study of fianlimab, a human lymphocyte activation gene-3
(LAG-3) monoclonal antibody, in combination with cemiplimab in advanced
melanoma (mel)
O. Hamid1, A. Weise2, T.M. Kim3, M. Mckean4, N. Lakhani5, J. Kaczmar6, K.

Papadopoulos7, S. Chen8, J. Mani8, V. Jankovic8, G. Kroog8, T. Sims8, I. Lowy8, G. Gullo8,
1The Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, US,
2Henry Ford Hospital, Detroit, US, 3Seoul National University Hospital, Seoul, KR,
4Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, US, 5START
Midwest, Grand Rapids, US, 6MUSC Hollings Cancer Center, North Charleston, US,
7START San Antonio, San Antonio, US, 8Regeneron Pharmaceuticals, Inc., Tarrytown, US

08:45 - 09:00 Invited Discussant LBA41, LBA42 and 790MO


09:00 - 09:05 791MO - Clinical and tumor characteristics of patients (pts) with recurrence
after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab
(NIVO) in stage III melanoma
J. Versluis1, R. Elens1, I. Reijers1, A. Menzies2, A. Van Der Veldt3, E. Kapiteijn4, E.

Rozeman1, M. Klop1, W. Van Houdt5, R. Saw2, C. Zuur1, T. Pennington2, B. Van De Wiel5,
R. Scolyer2, A. Broeks1, A. Van Akkooi2, G. Long2, C. Blank1, 1Netherlands Cancer
Institute, Amsterdam, NL, 2Melanoma Institute Australia, Wollstonecraft, AU, 3Erasmus
MC - University Medical Center, Rotterdam, NL, 4Leiden University Medical Center
(LUMC), Leiden, NL, 5Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL

09:05 - 09:10 LBA43 - Intradermal IMO-2125 versus placebo as adjuvant treatment in patients
with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the
randomized phase II INTRIM study
J. Notohardjo1, S. Veenstra1, B. Koster1, V. Kandiah1, S. Van Der Velde1, A. Francken2, G.

Gooiker3, M.P. Van Den Tol1, M. Bekkenk4, K. In 'T Hof5, M. Straver6, B. Molenkamp7, R.
Vuylsteke8, B. Lissenberg-Witte 1, M. Labots1, S. Chunduru9, A. Van Akkooi10, F. Van Den
Eertwegh1, T. De Gruijl1, 1Amsterdam UMC - Location Vrije Universiteit, Amsterdam, NL,
2Isala Hospital, Zwolle, NL, 3Noordwest Ziekenhuisgroep - Alkmaar, Alkmaar, NL,

4Amsterdam UMC - Location University of Amsterdam, Amsterdam, NL, 5Flevo-
Ziekenhuis, Almere, NL, 6HMC - Haaglanden Medisch Centrum - Antoniushove,

Leidschendam, NL, 7Diakonessenhuis Utrecht, Utrecht, NL, 8Spaarne Gasthuis Haarlem
Zuid, Haarlem, NL, 9Idera pharmaceuticals, Exton, US, 10Netherlands Cancer Institute,
Amsterdam, NL

09:10 - 09:15 LBA44 - Pembrolizumab versus placebo after complete resection of high-risk
stage III melanoma: Long-term quality of life analysis results of the EORTC
1325-MG/Keynote-054 double-blinded phase III trial
A. Bottomley1, M. Kicinski1, G. Long2, M. Mandala3, V. Atkinson4, C. Blank5, A. Haydon6,

S. Dalle7, A. Khattak8, M. Carlino9, A. Meshcheryakov10, S. Sandhu11, S. Puig Sarda12, C.
Coens1, S. Suciu1, D. Grebennik13, C. Krepler13, P. Lorigan14, C. Robert15, A.
Eggermont16, 1European Organisation for Research and Treatment of Cancer, Brussels,
BE, 2The University of Sydney, and Royal North Shore and Mater Hospitals,
Wollstonecraft, AU, 3University of Perugia and Papa Giovanni XXIII Cancer Center
Hospital, Perugia, IT, 4Princess Alexandra Hospital, University of Queensland, Brisbane,
AU, 5NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL, 6Alfred Hospital, Melbourne, AU, 7HCL Cancer Institute, Cancer
Research Center of Lyon, Lyon University, Pierre Benite, FR, 8Fiona Stanley
Hospital/Edith Cowan University, Murdoch, AU, 9Westmead and Blacktown Hospitals,
Melanoma Institute Australia and the University of Sydney, Westmead, AU, 10N.N.
Blokhin National Medical Research Center of Oncology, Moscow, RU, 11Peter MacCallum
Cancer Centre, Melbourne, AU, 12Hospital Clinic de Barcelona, University of Barcelona
& CIBERER, Instituto de Salud Carlos III, Barcelona, ES, 13Merck & Co., Inc., Rahway,
US, 14Division of Cancer Sciences, University of Manchester and Christie NHS
Foundation Trust, Manchester, GB, 15Gustave Roussy Cancer Campus Grand Paris &
University Paris-Saclay, Villejiuf, FR, 16Comprehensive Cancer Center Munich (CCCM),
Munich, Germany, and University Medical Center Utrecht, Utrecht, NL

09:15 - 09:20 792MO - Neoadjuvant pepinemab in combination with nivolumab and/or
ipilimumab in resectable stage III melanoma
M. Lowe1, M. Yushak2, B. Olson2, A. Mokhtari1, A. Harutyunyan2, K. Delman1, D.
Parker1, E. Evans3, T. Fisher3, G. Lesinski2, R. Kudchadkar2, 1Emory University, Atlanta,

US, 2Winship Cancer Institute of Emory University, Atlanta, US, 3Vaccinex Inc.,
Rochester, US

09:20 - 09:35 Invited Discussant 791MO, LBA43, LBA44 and 792MO

Title: Mini Oral session 2: GU tumours, non- Auditorium
prostate
Chair(s): Guillermo Antonio De Velasco Oria, ES; Michiel van der Heijden, NL

08:30 - 08:35 1451MO - In-situ immune markers predict nivolumab (N) +/-ipilimumab
(I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key
ancillary analyses from the BIONIKK randomized trial
M. Meylan1, C.-M. Sun1, R.-T. Elaidi 2, M. Moreira1, A. Bougouin1, V. Verkarre3, M.

Bennamoun4, C. Chevreau5, D. Borchiellini6, P. Barthelemy7, D. Pannier8, D. Maillet9, M.
Gross Goupil10, C. Tournigand11, E. Braychenko2, L. Phan2, S. Oudard12, W.-H.
Fridman13, C. Sautes-Fridman1, Y.-A. Vano12, 1Centre de Recherche des Cordeliers,
INSERM, Université Paris Cité, Sorbonne Université, Paris, FR, 2ARTIC - Association
pour la Recherche de Thérapeutiques Innovantes en Cancérologie; Hôpital Européen
Georges Pompidou, APHP.Centre – Université Paris Cité, Paris, FR, 3Hôpital Européen
Georges Pompidou, APHP.Centre – Université Paris Cité, Paris, France, Paris, France,
Paris, FR, 4Institut Mutualiste Montsouris, Paris, FR, 5Institut Universitaire du Cancer -

Toulouse- Oncopole, Toulouse, FR, 6 Centre Antoine Lacassagne, Université Côte d'Azur,
Nice, FR, 7 Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, 8Centre Oscar
Lambret, Lille, FR, 9IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie
des Hospices de Lyon (IC-HCL), Pierre-Bénite, Pierre Benite, FR, 10Centre Hospitalier
Universitaire de Bordeaux - Hôpital Saint-André, Bordeaux, FR, 11Hôpital Henri-Mondor,
AP-HP - Université de Paris Est, Créteil France; INSERM, IMRB, F-94010 Creteil,,
Creteil, FR, 12Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM,
AP-HP.Centre – Université Paris Cité, Paris, FR, 13Centre de Recherche des Cordeliers,
INSERM, Université Paris Cité, Sorbonne Université, Paris, France,, Paris, FR

08:35 - 08:40 1452MO - Longitudinal analysis reveals gut microbiota shift during standard
therapies in metastatic renal cell carcinoma (mRCC)
C. Alves Costa Silva1, G. Piccinno2, L. Cerbone1, V. Iebba3, E. Colomba1, R. Flippot1, C.

Sow1, I. Darik1, A. Maltez Thomas2, N. Naoun1, A. Bernard-Tessier 1, A. Reni1, N.
Segata2, B. Escudier1, L. Zitvogel1, L. Albiges1, L. Derosa1, 1Gustave Roussy - Cancer
Campus, Villejuif, Cedex, FR, 2Università degli Studi di Trento, Trento, IT, 3University of
Trieste, Trieste, IT

08:40 - 08:45 LBA69 - Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL)
disease-associated neoplasms: 36 months of follow-up of the phase II
LITESPARK-004 study
R. Srinivasan1, O. Iliopoulos2, W.K. Rathmell3, V. Narayan4, B. Maughan5, S. Oudard6, T.

Else7, J. Maranchie8, S. Welsh9, A.B. Bøndergaard Iversen10, K. Chen11, R. Perini11, Y.
Liu11, W.M. Linehan1, E. Jonasch12, 1Center for Cancer Research, National Cancer

Institute, Bethesda, US, 2Massachusetts General Hospital Cancer Center and Harvard
Medical School, Boston, US, 3Vanderbilt University Medical Center, Nashville, US,
4University of Pennsylvania, Philadelphia, US, 5University of Utah, Salt Lake City, US,
6Georges-Pompidou Hospital, University of Paris, Paris, FR, 7University of Michigan, Ann
Arbor, US, 8University of Pittsburgh, Pittsburgh, US, 9Cambridge University Hospitals

NHS Foundation Trust, Cambridge, GB, 10Aarhus University Hospital, Aarhus, DK,
11Merck & Co., Inc., Rahway, US, 12The University of Texas MD Anderson Cancer Center,
Houston, US

G.A. De Velasco Oria, Hospital Universitario 12 de Octubre, Madrid, ES

09:00 - 09:05 1736MO - Pure or mixed basal/squamous tumours present decreased outcomes
after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial
C. Groeneveld1, V. Harter2, S. Culine3, C. Krucker1, V. Dixon1, A. De Reynies4, C. Pfister5,

F. Radvanyi1, Y. Allory1, 1Institut Curie, Paris, FR, 2François Baclesse Comprehensive

Cancer Center, Caen, FR, 3Hopital Saint Louis AP-HP, Paris, FR, 4Université de Paris,
Paris, FR, 5Hopital Charles-Nicolle - CHU de Rouen, Rouen, FR

09:05 - 09:10 1737MO - Tumor and immune features associated with disease-free survival with
adjuvant nivolumab in the phase III CheckMate 274 trial
A. Necchi1, D. Bajorin2, Y. Tomita3, D. Ye4, M. Agerbæk5, D. Enting6, A. Peer7, M.

Milowsky8, K. Kobayashi9, M.-O. Grimm10, F. Stenner-Liewen11, J. David12, J. Li12, S.
Chasalow12, F. Nasroulah12, A. Apfel12, K. Unsal-Kacmaz12, M. Galsky13, 1Vita-Salute
San Raffaele University, IRCCS San Raffaele Hospital, Milan, IT, 2Memorial Sloan
Kettering Cancer Center, New York, US, 3Niigata University Graduate School of Medical
and Dental Sciences, Niigata, JP, 4Fudan University Shanghai Cancer Center, Shanghai,

CN, 5Aarhus University Hospital, Aarhus, DK, 6Guy’s and St. Thomas’ NHS Foundation
Trust, London, GB, 7Rambam Health Care Center, Haifa, IL, 8University of North
Carolina School of Medicine, Chapel Hill, US, 9Sapporo Medical University, Sapporo, JP,
10Jena University Hospital, Jena, DE, 11University Hospital Basel, Basel, CH, 12Bristol
Myers Squibb, Princeton, US, 13Icahn School of Medicine at Mount Sinai, New York, US

M. Van Der Heijden, Netherlands Cancer Institute, Amsterdam, NL


Title: Early relapses in lymphoma: How to treat?
Chair(s): Catherine Thieblemont, FR; Marco Ladetto, IT

08:30 - 08:55 Follicular lymphoma
C. Thieblemont, Hopital Saint Louis AP-HP, Paris, FR

08:55 - 09:20 Mantle cell lymphoma
M. Ladetto, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT

09:20 - 09:45 Diffuse large B-cell lymphoma
M. Hutchings, Copenhagen, DK


08:30 - 10:00 Type: Mini Oral session 7.3.Q - Quimper
Title: Mini Oral session: NETs and endocrine Auditorium
tumours
Chair(s): Mauro Cives, IT; Hans Gelderblom, NL; Maria Cabanillas, US

08:30 - 08:35 1646MO - Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in
metastasized anaplastic and poorly differentiated thyroid carcinoma
C. Dierks1, J. Ruf2, J. Seufert2, M. Kreissl3, C. Klein2, C. Spitzweg4, M. Kroiss5, O.

Thomusch2, K. Lorenz6, A. Zielke7, C. Miething2, 1Martin Luther University Halle-
Wittenberg, Halle (Saale), DE, 2University Medical Center Freiburg, Freiburg im
Breisgau, DE, 3Klinikum Magdeburg GmbH, Magdeburg, DE, 4LMU Klinikum der
Universität München, Munich, DE, 5LMU - Ludwig Maximilians University of Munich,
Munich, DE, 6Department of Visceral, Vascular, and Endocrine Surgery,, halle, DE,
7Diakoniekrankenhaus Stuttgart, Stuttgart, DE

08:35 - 08:40 1647MO - BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics
and outcome under BRAF inhibitors and chemotherapy in real-life practice, a
multicentric retrospective study of the French ENDOCAN TUTHYREF network
C. De La Fouchardiere1, A. Jannin2, F. Giudici3, J. Wassermann4, C. Chougnet5, D. Drui6,

Y. Godbert7, F. Illouz8, S. Bardet9, N. Roudaut10, M. Batisse Lignier11, L. Groussin12, M.
Klein13, S. Zerdoud14, L. Lamartina15, E. Baudin15, F. Borson-Chazot16, C. Do Cao2, I.
Borget15, J. Hadoux15, 1Centre Léon Bérard, Lyon, FR, 2Centre Hospitalier Régional
Universitaire de Lille, Lille, FR, 3Institut Gustave Roussy, Villejuif, Cedex, FR, 4Hôpital
Pitié-Salpêtrière AP-HP, Paris, FR, 5Hopital Saint Louis AP-HP, Paris, FR, 6CHU de

Nantes, Hôtel Dieu, Nantes, FR, 7Bergonié Institute Cancer Center, Bordeaux, FR, 8CHU
Angers, Angers, Cedex, FR, 9Centre Francois Baclesse, Caen, Cedex, FR, 10Hôpital
Cavale Blanche (Brest), Brest, FR, 11Centre Jean Perrin, Clermont-Ferrand, FR, 12Hopital
Cochin - Site Port-Royal AP-HP, Paris, FR, 13CHRU Nancy, Nancy, FR, 14IUCT - Institut
Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, 15Institut Gustave Roussy,
Villejuif, FR, 16Hospices Civils de Lyon, Bron, FR

M. Cabanillas, Houston, US

08:55 - 09:00 888MO - Emergence of clonal hematopoiesis after peptide receptor radionuclide
therapy for neuroendocrine tumors
R. El Ferkh1, J. Hadoux2, L. Lamartina3, T. Kamoun3, L. Cysique-Foinlan1, G. Jepiral3, M.

Ducreux3, E. Baudin3, C. Marzac1, J. Baptiste Micol1, 1Institut Gustave Roussy, Villejuif,

Cedex, FR, 2Institut Gustave Roussy, Villejuif, FR, 3Gustave Roussy - Cancer Campus,
Villejuif, FR

09:00 - 09:05 889MO - Comparative expression of driver transcription factors in extra-
pulmonary small cell carcinoma
S. Puri1, A. Elliott2, H. Soares3, E. Lou4, B. Halmos5, C. Langer6, D. Uprety7, S. Darabi8,

P. Walker2, W. El-Deiry9, A. Vanderwalde10, T. Owonikoko11, S. Liu12, 1Huntsman Cancer
Institute, Salt Lake City, US, 2Caris Life Sciences - Headquarters, Irving, US, 3Huntsman
Cancer Institute at the University of Utah, Salt Lake City, US, 4Masonic Cancer Center -
University of Minnesota, Minneapolis, US, 5Montefiore Medical Center, New York City,

US, 6University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia,
US, 7Karmanos Cancer Institute, Detroit, US, 8Hoag Cancer Center, Newport Beach, US,
9Brown University, Providence, US, 10Caris Life Sciences, Phoenix, US, 11University of
Pittsburgh and Hillman Cancer Center, Pittsburgh, US, 12Lombardi Cancer Center
Georgetown University, Washington, US

09:05 - 09:10 890MO - Mutation spectrum in liquid versus solid biopsies from advanced
digestive neuroendocrine carcinoma patients
H. Sorbye1, S. Knappskog2, T. Grob3, A. Venizelos2, U. Amstutz3, G.O. Hjortland4, I.M.

Lothe5, C. Kersten6, E. Hofsli7, A. Sundlov8, H. Elvebakken9, H. Garresori10, A.
Couvelard11, J. Svensson12, A. Perren13, 1Haukeland Universitetssykehus, Bergen, NO,
2University of Bergen, Bergen, NO, 3Inselspital - University Hospital Bern -
Universitatsklinik fur Thoraxchirurgie, Bern, CH, 4Oslo University Hospital - The

Norwegian Radium Hospital, Oslo, NO, 5Oslo University Hospital - Ulleval Hospital, Oslo,
NO, 6Sorlandet Hospital, Kristiansand, NO, 7St. Olavs Hospital HF, Trondheim, NO,
8Skane University Hospital - Oncology Clinic, Lund, SE, 9Aalesund Hospital, Alesund,
NO, 10Helse Stavanger HF, Stavanger, NO, 11Beaujon Hospital APHP, Clichy, FR,
12Sahlgrenska University Hospital - Jubileumskliniken, Göteborg, SE, 13University of
Bern - Institute of Pathology, Bern, CH

09:10 - 09:15 496MO - Final overall survival results from the NICE-NEC trial (GETNE-T1913):
A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in
untreated advanced G3 neuroendocrine neoplasms (NENs) of
gastroenteropancreatic (GEP) or unknown (UK) origin
M.C. Riesco Martinez1, J. Capdevila Castillon2, V. Alonso3, P. Jimenez-Fonseca4, A. Teule5,

E. Grande6, I. Sevilla7, M. Benavent8, T. Alonso-Gordoa9, A. Custodio10, B. Antón
Pascual1, J. Hernando2, E. Polo3, O.A. Castillo Trujillo4, R. Garcia-Carbonero1, 1Hospital
Universitario 12 de Octubre, Imas12, UCM, Madrid, ES, 2Vall Hebron University
Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, 3Instituto Aragones
de Investigacion Sanitaria, Hospital Universitario Miguel Servet, Zaragoza, ES, 4Hospital
Universitario Central de Asturias, ISPA, Oviedo, ES, 5Institut Català d’Oncologia (ICO) -

IDIBELL, L’Hospitalet del Llobregat, ES, 6MD Anderson Cancer Center Madrid, Madrid,
ES, 7Investigación Clínica y Traslacional en Cáncer / Instituto de Investigaciones
Biomédicas de Málaga (IBIMA) / Hospitales Universitarios Regional y Virgen de la
Victoria de Málaga, Málaga, ES, 8University Hospital Virgen del Rocío, Instituto de
Biomedicina de Sevilla (IBIS), Seville, ES, 9Hospital Universitario Ramón y Cajal, Madrid,
ES, 10Hospital Universitario La Paz, Madrid, ES

09:15 - 09:20 LBA46 - Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in
patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE
41-BEVANEC randomized phase II study
T. Walter1, A. Lievre2, R. Coriat3, D. Malka4, F. El Hajbi5, F. Di Fiore6, O. Hentic Dhome7,

D. Smith8, V. Hautefeuille9, G. Roquin10, M. Perrier11, L. Dahan12, V. Granger13, I.
Sobhani14, L. Mineur15, P. Niccoli16, E. Assenat17, K. Le Malicot18, C. Lepage19, C.
Lombard Bohas20, 1Hospices Civiles de Lyon - HCL - Lyon University Hospital Center,
Lyon, FR, 2CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR, 3Hopital Cochin
AP-HP, Paris, FR, 4Institut Gustave Roussy, Villejuif, Cedex, FR, 5Centre Oscar Lambret,
Lille, FR, 6CHU de Rouen Normandie, Rouen, FR, 7Beaujon Hospital APHP, Clichy, FR,
8Hopital Haut Leveque, Pessac, FR, 9CHU Amiens-Picardie - Site Nord, Amiens, FR,
10CHU Angers, Angers, FR, 11Reims University Hospital, Reims, FR, 12AP-HM - CHU La
Timone Enfants, Marseille, FR, 13CHU Grenoble Alpes - Site Nord (La Tronche), La
Tronche, FR, 14CHU Henri Mondor, creteil, FR, 15Institut Ste Catherine, Avignon, FR,
16IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, 17ICM - Institut du Cancer de
Montpellier, Montpellier, Cedex, FR, 18Fédération Francophone de Cancérologie

Digestive, Dijon, FR, 19CHU Dijon, Dijon, FR, 20Hopital Edouard Herriot Pav. E bis, Lyon,
FR

09:20 - 09:35 Invited Discussant 888MO, 889MO, 890MO, 496MO and LBA46
M. Cives, Università degli Studi di Bari Aldo Moro, Bari, IT

09:35 - 09:40 1MO - An open-label, phase II trial of cabozantinib for advanced adrenocortical
carcinoma
M. Campbell1, C. Jimenez2, J. Long3, J. Varghese3, A. Shah3, M. Zhang4, G. Tamsen3, M.

Habra3, 1The M. D. Anderson Cancer Center, Houston, US, 2Banner MD Anderson

Cancer Center, Gilbert, US, 3The University of Texas M. D. Anderson Cancer Center,
Houston, US, 4MD Anderson Cancer Center, Houston, US

09:40 - 09:45 2MO - EO2401 (EO) therapeutic vaccine for patients (pts) with adrenocortical
carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP):
Phase I/II SPENCER study
E. Baudin1, S. Grisanti2, M. Fassnacht3, C. Menke-Van Der Houven Van Oordt 4, H. Haak5,

C. De La Fouchardiere6, V. Subbiah7, C. Jimenez7, J. Capdevila Castillon8, D. Granberg9,
K.G. Daugaard10, M. Kroiss11, D. Cosentini2, O. Kimpel3, L. Lamartina1, J. Hadoux1, J.-M.
Paillarse12, L. Chêne12, J. Fagerberg12, A. Berruti2, 1Institut Gustave Roussy, Villejuif,
FR, 2Università degli Studi di Brescia, Azienda Ospedaliera Spedali Civili, Brescia, IT,
3University Hospital, Würzburg, DE, 4Amsterdam UMC, Amsterdam, NL, 5Máxima

Medisch Centrum, Eindhoven, NL, 6Centre Léon Bérard, Lyon, FR, 7The University of
Texas MD Anderson Cancer Center (MDACC), Houston, US, 8Hospital Universitari Vall
d'Hebron, Barcelona, ES, 9Karolinska Institutet, Karolinska University Hospital,
Stockholm, SE, 10Rigshospitalet, Copenhagen, DK, 11LMU University Hospital, Ludwig-

Maximilians-Universität, Munich, DE, 12Enterome, Paris, FR

H. Gelderblom, LUMC - Leids Universitair Medisch Centrum, Leiden, NL

Title: ESMO meets pharma: Next frontiers in drug Auditorium
discoveries
Chair(s): Charles Swanton, GB; Fabrice André, FR


08:35 - 08:50 AI-driven drug discovery
J.-P. Rameau, Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR

08:50 - 09:05 Innovation drug discovery
S. Malek, NIBR - Novartis Institutes for BioMedical Research, Cambridge, US

09:05 - 09:20 Designing multispecific antibodies: ANKET for antigen-specific activation of NK
cells
E. Vivier, Aix-Marseille University - Faculté de Médecine - Timone, Marseille, FR

09:20 - 09:35 Cell therapy: Targeting clonal antigen



Title: Young Oncologist Forum: Going on a Research Journey: Auditorium
From grant writing, over PhD to team management
Chair(s): Alexios Matikas, SE; Kevin Punie, BE

08:30 - 08:50 How to write a grant/writing your grant application

08:50 - 09:10 Effective time management
R. Pihlak, The Christie NHS Foundation Trust, Manchester, GB

09:10 - 09:30 How to move between PhD and medical oncology

09:30 - 09:50 How to build and manage a research team in a competitive environment


Title: Professional and educational issues in cancer Auditorium
nursing
Chair(s): Grigorios Kotronoulas, GB

08:30 - 08:45 RN4CAST data about workforce issues
A.M. Rafferty, King's College London, London, GB

08:45 - 09:00 Professional and educational issues in cancer nursing in Eastern European
countries
Z. Vlaisavljevic, The University Clinical Center is in Belgrade, Belgrae, RS

09:00 - 09:15 ABC4Nurses: Education programme based on Delphi study outcomes
A. Drury, Trinity College Dublin, Dublin, IE

09:15 - 09:25 CN37 - Patient and public involvement in research: Reflections and experiences
of doctoral cancer nurse researchers in Europe
M. Tanay1, C. Díez De Los Ríos De La Serna2, V. Boland3, A. Lopes4, M. Dornan5, K.

Wingfield6, G. Yildiz7, D. Chircop8, G. Suchodolska9, B. Kurt10, S. Colomer-Lahiguera4,
1King's College London, London, GB, 2Barcelona University, Barcelona, ES, 3Trinity
College Dublin, Dublin, IE, 4Institute of Higher Education and Research in Healthcare -

IUFRS, CHUV, Lausanne, CH, 5Ulster University, Newtonabbey, GB, 6Cardiff University,
Cardiff, GB, 7Hacettepe University Faculty of Nursing, Ankara, TR, 8University of
Southampton, Southampton, GB, 9Medical University of Gdansk, Gdańsk, PL,
10Hacettepe University, Ankara, TR

09:25 - 09:35 CN39 - Development of a reference model for patient and public involvement in
oncology research in French-speaking Switzerland
S. Colomer-Lahiguera1, T. Corbière1, K. Soukup1, F. Reeb-Landry1, A. Addeo2, M.

Eicher3, 1Institute of Higher Education and Research in Healthcare - IUFRS, CHUV,

Lausanne, CH, 2HUG - Hopitaux Universitaires de Geneve, Geneva, CH, 3CHUV - Centre
Hospitalier Universitaire Vaudois, Lausanne, CH

09:35 - 09:45 CN43 - Addressing the professional and educational issues for the cancer
nursing and allied health professions workforce: A collaborative, strategic, UK-
wide approach
J. Armoogum (On Behalf Of Accend Steering Committee)1, D. Bell2, K. Bowles2, K.

Campbell3, J. Davis2, M. Fores4, M. Foulkes5, R. Hammond6, V. Lavender7, S. Lilley8, L.
Potter4, V. Taylor9, 1University of the West of England, Bristol, GB, 2Macmillan Cancer
Support, London, GB, 3Edinburgh Napier University, Edinburgh, GB, 4Health Education

England, x, GB, 5Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB, 6Circle
Health Group, London, GB, 7Guy's Cancer Academy - Guy’s Hospital, London, GB,
8Greater Manchester Cancer, Manchester, GB, 9University of Central Lancashire,
Preston, GB

09:45 - 09:55 CN38 - The effect of a mindfulness-based stress reduction program on the
pediatric hematology: Oncology nurses' professional quality of life and
perceived stress level
T. Pehlivan1, R. Semerci2, B.B. Çalışkan3, G. Yıldız4, N. Altınel4, M. Kapanci4, 1Istinye

University, Istanbul, TR, 2Trakya University Rektorlugu, Edirne, TR, 3Beykent University

- Beylikduzu Campus, Istanbul, TR, 4Medipol Mega Hospitals Complex (University
Hospital), Istanbul, TR


09:00 - 10:00 Type: Challenge your Expert 7.1.D - Dijon
Title: Manipulating the microbiome for clinical Auditorium
response
Chair(s): Jennifer Wargo, US

E. Elinav, Rehovot, IL

J. Wargo, Houston, TX, US


09:00 - 10:00 Type: Challenge your Expert 7.3.H - Honfleur Auditorium
Title: Challenges in the treatment of mesothelioma
Chair(s): Anne Tsao, US


A. Tsao, Houston, TX, US

09:00 - 10:00 Type: Challenge your Expert 7.3.T -
Title: How to select patients for immunotherapy-based therapy in Toulouse
the first-line treatment for recurrent/metastatic head and neck Auditorium
squamous cell cancer
Chair(s): Amanda Psyrri, GR



10:15 - 11:45 Type: Educational session 4.A - Antibes
Title: The current and future of immunotherapy for Auditorium
metastatic NSCLC
Chair(s): Natasha Leighl, CA; Pasi Jänne, US

10:15 - 10:40 Personalizing first-line immunotherapy: Beyond one size fits all

10:40 - 11:05 What’s next? Emerging next-generation immunotherapy in lung cancer

CA

11:05 - 11:30 Threading the needle: Considerations for immunotherapy in special populations



10:15 - 11:45 Type: Special symposium 4.B - Brest
Title: Evolving targets and treatment options in Auditorium
oesophagogastric cancer
Chair(s): Florian Lordick, DE


DE

10:20 - 10:35 Challenge of heterogeneity in gastric cancer
N. Van Grieken, Amsterdam, NL

10:35 - 10:50 Advances in HER2-targeted therapy or novel targeted therapies for HER2
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

10:50 - 11:05 Emerging molecular targeted therapies
V. Gambardella, Hospital Clinico Universitario de Valencia, Valencia, ES

11:05 - 11:20 Immunotherapy: Present and future

DE



10:15 - 11:45 Type: Proffered Paper session 7.1.C - Cannes
Title: Proffered Paper session 2: Melanoma and other Auditorium
skin tumours
Chair(s): Reinhard Dummer, CH; Teresa Petrella, CA

10:15 - 10:25 786O - Tumor biomarker analysis from COLUMBUS part 1: Encorafenib +
binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma
R. Dummer1, N. Pathan2, S. Deng3, C. Robert4, A.M. Arance Fernandez5, J.W. De Groot6,

C. Garbe7, H. Gogas8, R. Gutzmer9, I. Krajsova10, G. Liszkay11, C. Loquai12, M.
Mandala13, D. Schadendorf14, N. Yamazaki15, A. Di Pietro16, T. Xie3, P. Ascierto17, K.
Flaherty18, 1Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, 2Pfizer, La
Jolla, US, 3Pfizer, San Diego, US, 4Gustave Roussy and Paris-Saclay University, Villejiuf,
FR, 5Hospital Clinic y Provincial de Barcelona, Barcelona, ES, 6Isala Oncology Center,
Zwolle, NL, 7Universitaets-Hautklinik Tuebingen, Tuebingen, DE, 8National and
Kapodistrian University of Athens, Athens, GR, 9Johannes Wesling Medical Center, Ruhr

University Bochum Campus Minden, Minden, DE, 10University Hospital Prague, Prague,
CZ, 11National Institute of Oncology Hungary, Budapest, HU, 12University Medical
Center of the Johannes Gutenberg University Mainz, Mainz, DE, 13University of Perugia,

Perugia, IT, 14University Hospital Essen, West German Cancer Center and German
Cancer Consortium, Partner Site Essen, Essen, DE, 15National Cancer Center - Tsukiji
Campus, Chuo-ku, JP, 16Pfizer, Milan, IT, 17Istituto Nazionale Tumori - IRCCS -
Fondazione Pascale, Napoli, IT, 18MGH - Massachusetts General Hospital, Boston, US

10:25 - 10:35 788O - Association of pre-treatment ctDNA with disease recurrence and clinical
and translational factors in patients with stage IIIB-D/IV melanoma treated with
adjuvant immunotherapy (CheckMate 915)
G. Long1, K. Desai2, T. Tang3, J. Weber4, S. Dolfi2, C. Ritchings3, S.-P. Huang2, M.

Bolisetty3, M. Sausen5, M. Del Vecchio6, J. Larkin7, J. Baden3, D. Balli2, H. Chang3, J.
Loffredo8, N. Zhang9, M. Wind-Rotolo10, D. Tenney2, 1• The University of Sydney, and
Royal North Shore and Mater Hospitals, Wollstonecraft, AU, 2Bristol Myers Squibb,
Lawrenceville, US, 3Bristol Myers Squibb, Princeton, US, 4NYU Grossman School of

Medicine, New York City, US, 5PGDx - Personal Genome Diagnostics, Baltimore, US,
6Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 7The Royal Marsden
Hospital - NHS Foundation Trust, London, GB, 8Janssen Pharmaceutical Companies of

Johnson & Johnson, Spring House, US, 9Janssen Pharmaceutical Companies of Johnson &
Johnson, San Diego, US, 10Agios Pharmaceuticals, Inc., Cambridge, US

S. Patel, MD Anderson Cancer Center, Houston, US

10:45 - 11:00 Q&A

11:00 - 11:10 787O - Adjuvant immunotherapy with nivolumab (NIVO) versus observation in
completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS)
results from ADMEC-O, a randomized, open-label phase II trial
J.C. Becker1, S. Ugurel2, U. Leiter-Stoppke3, F. Meier4, R. Gutzmer5, S. Haferkamp6, L.

Zimmer2, E. Livingstone2, T. Eigentler7, A. Hauschild8, F. Kiecker9, J. Hassel10, P.
Mohr11, M. Fluck12, I. Thomas3, M. Garzarolli4, I. Grimmelmann13, K. Drexler6, S.
Eckhardt14, D. Schadendorf2, 1DKFZ - German Cancer Research Center and University
Hospital Essen, Essen and Heidelberg, DE, 2University Hospital Essen, Essen, DE,
3Universitaets-Hautklinik Tuebingen, Tuebingen, DE, 4Universitätsklinikum Carl Gustav
Carus Dresden, Dresden, DE, 5Johannes Wesling Medical Center Minden and Ruhr-
University Bochum, Minden, DE, 6UKR - University Hospital Regensburg, Regensburg,
DE, 7Charité – Universitätsmedizin Berlin, Berlin, DE, 8UK-SH Campus Kiel, Kiel, DE,
9Vivantes Klinikum Neukoelln, Berlin, DE, 10NCT - Nationales Zentrum für
Tumorerkrankungen, Heidelberg, DE, 11Elbe-Klinikum Buxtehude, Buxtehude, DE,

12Fachklinik Hornheide, Münster, DE, 13MHH - Medizinische Hochschule Hannover,
Hannover, DE, 14Alcedis GmbH, Giessen, DE

11:10 - 11:20 789O - Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0)
cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study
N. Gross1, D.M. Miller2, N. Khushanlani3, V. Divi4, E. Ruiz5, E. Lipson6, F. Meier7, Y.B.

Su8, P.L. Swiecicki9, J.L. Atlas10, J.L. Geiger11, A. Hauschild12, J.H. Choe13, B. Hughes14,
S.-Y. Yoo 15, K. Fenech15, M. Mathias15, H. Han15, M. Fury15, D. Rischin16, 1The
University of Texas M. D. Anderson Cancer Center, Houston, US, 2Beth Israel Deaconess

Medical Center, Boston, US, 3H. Lee Moffitt Cancer Center & Research Institute -
Magnolia Campus, Tampa, US, 4Stanford Cancer Institute, Palo Alto, US, 5Brigham and
Women’s Hospital, Harvard Medical School, Boston, US, 6Johns Hopkins Medicine - The
Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, 7University Hospital Carl
Gustav Carus, Dresden, DE, 8Nebraska Cancer Specialists, Omaha, US, 9University of
Michigan, Ann Arbor, US, 10Carolinas HealthCare System/Atrium Health, Charlotte, US,
11Cleveland Clinic, Sandusky, US, 12UK-SH, Campus Kiel, Kiel, DE, 13Duke Cancer
Institute, Durham, US, 14Royal Brisbane and Women's Hospital, Herston, AU,
15Regeneron Pharmaceuticals, Inc., Tarrytown, US, 16Peter MacCallum Cancer Centre,
Melbourne, AU

C. Blank, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,

Amsterdam, NL

11:30 - 11:45 Q&A

10:15 - 11:45 Type: Proffered Paper session 7.2.F - Fécamp Auditorium
Title: Proffered Paper session 2: GI, lower digestive
Chair(s): Myriam Chalabi, NL; Filippo Pietrantonio, IT

10:15 - 10:25 LBA24 - KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with
or without cetuximab in patients with advanced colorectal cancer (CRC)
harboring a KRASG12C mutation
S. Klempner1, J. Weiss2, M. Pelster3, A. Spira4, M. Barve5, S.-H. Ou6, T. Leal7, T. Bekaii-

Saab8, J. Christensen9, T. Kheoh9, K. Velastegui9, H. Der Torossian9, R. Yaeger10,
1Massachusetts General Cancer Center, Boston, US, 2University of North Carolina-
Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, US, 3Sarah Cannon
Research Institute, Nashville, US, 4Virginia Cancer Specialists, Fairfax, US, 5Mary
Crowley Cancer Research Center, Dallas, US, 6University of California Irvine, Chao
Family Comprehensive Cancer Center, Orange, US, 7Winship Cancer Institute, Emory
University, Atlanta, US, 8Mayo Clinic Cancer Center, Phoenix, US, 9Mirati Therapeutics,
Inc., San Diego, US, 10Memorial Sloan Kettering Cancer Center, New York, US

10:25 - 10:35 315O - Sotorasib in combination with panitumumab in refractory KRAS G12C-
mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
Y. Kuboki1, R. Yaeger2, M. Fakih3, J. Strickler4, T. Masuishi5, E. Kim6, C. Bestvina7, C.

Langer8, J. Krauss9, S. Puri10, P. Cardona11, E. Chan11, Q. Tran11, D.S. Hong12, 1National
Cancer Center Hospital East, Kashiwa, JP, 2Memorial Sloan Kettering Cancer Center,
New York, US, 3City of Hope Comprehensive Cancer Center, Duarte, US, 4Duke
University Medical Center, Durham, US, 5Aichi Cancer Center Hospital, Nagoya, JP, 6UC
Davis Comprehensive Cancer Center, Sacramento, US, 7University of Chicago, Chicago,
US, 8University of Pennsylvania, Philadelphia, US, 9University of Michigan, Ann Arbor,
US, 10Huntsman Cancer Institute, Salt Lake City, US, 11Amgen Inc., Thousand Oaks, US,
12University of Texas MD Anderson Cancer Center, Houston, US


M.E. Elez Fernandez, Vall d'Hebron University Hospital, Barcelona, ES

10:45 - 11:00 Q&A

11:00 - 11:10 LBA25 - FRESCO-2: A global phase III multiregional clinical trial (MRCT)
evaluating the efficacy and safety of fruquintinib in patients with refractory
metastatic colorectal cancer
N.A. Dasari1, S. Lonardi2, R. Garcia-Carbonero3, M.E. Elez Fernandez4, T. Yoshino5, A.

Sobrero6, J. Yao1, P. García-Alfonso7, J. Kocsis8, A. Cubillo Gracian9, A. Sartore Bianchi10,
T. Satoh11, V. Randrian12, J. Tomasek13, G. Chong14, Z. Yang15, W. Schelman15, M.
Kania15, J. Tabernero4, C. Eng16, 1The University of Texas MD Anderson Cancer Center,
Houston, US, 2Veneto Institute of Oncology IOV-IRCCS Padua, Padova, IT, 3Hospital
Universitario 12 de Octubre, lmas 12, UCM, Madrid, ES, 4Vall d’Hebron Institute of
Oncology, Barcelona, ES, 5National Cancer Center Hospital East, Kashiwa, JP, 6Azienda
Ospedaliera San Martino, Genova, IT, 7Hospital Universitario Gregorio Marañón, Madrid,
ES, 8Bács -Kiskun Megyei Oktatókórház, Kecskemét, HU, 9Hospital Universitario Madrid
Sanchinarro Centro Integral Oncológico Clara Campal, Madrid, ES, 10Università degli
Studi di Milano, Milan, IT, 11Graduate School of Medicine, Osaka University, Suita, JP,
12Poitiers University Hospital, Poitiers, FR, 13Masaryk Memorial Cancer Institute, Brno,
CZ, 14Austin Hospital, Heidelberg, AU, 15HUTCHMED International Inc., Florham Park,
US, 16Vanderbilt Ingram Cancer Center, Nashville, US

11:10 - 11:20 316O - Genomic mechanisms of acquired resistance of patients (pts) with BRAF
V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON
study
S. Kopetz1, D. Murphy2, J. Pu2, R. Yaeger3, F. Ciardiello4, J. Desai5, E. Van Cutsem6, H.

Wasan7, T. Yoshino8, B. Alkuzweny9, T. Xie2, X. Zhang10, J. Tabernero11, 1The University
of Texas M. D. Anderson Cancer Center, Houston, US, 2Pfizer, La Jolla, US, 3Memorial
Sloan Kettering Cancer Center, New York, US, 4University of Campania Luigi Vanvitelli,
Naples, IT, 5Peter MacCallum Cancer Centre, Melbourne, AU, 6University Hospital
Gasthuisberg and University of Leuven, Leuven, BE, 7Hammersmith Hospital, Imperial
College London, London, GB, 8National Cancer Center Hospital East, Kashiwa, JP, 9Pfizer,
San Diego, US, 10Pfizer Inc., New York, US, 11Vall d’Hebron University Hospital and Vall
d’Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, ES

F. Pietrantonio, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

11:30 - 11:45 Q&A


Title: Multidisciplinary updates in biomarkers in urinary Auditorium
cancers
Chair(s): Andres Acosta, US; Debbie Robbrecht, NL

D. Robbrecht, Erasmus MC Cancer Institute, Rotterdam, NL

10:20 - 10:35 What is new for the pathologist?
A. Acosta, Brigham and Women's Hospital, Boston, US

10:35 - 10:50 ctDNA in bladder and kidney cancers
L. Dyrskjot, Aarhus, DK

10:50 - 11:05 Latest imaging advances in PET and beyond translated to bladder and kidney
cancers

11:05 - 11:20 Microbiome
L. Derosa, , FR

A. Acosta, Brigham and Women's Hospital, Boston, US



10:15 - 11:45 Type: Special symposium 7.3.H -
Title: Personalized oncology in thyroid cancers: Moving from Honfleur
multi-targeted agents to tumor agnostic indications? Auditorium
Chair(s): Jaume Capdevila Castillon, ES; Marianne Pavel, DE

M. Pavel, Universitätsklinik Erlangen, Erlangen, DE

10:20 - 10:35 Current management of advanced thyroid cancer in the era of targeted agents
D. Führer, Essen, DE

10:35 - 10:50 Tumor agnostics in thyroid cancer: RET
J. Capdevila Castillon, Vall d'Hebron University Hospital, Barcelona, ES

10:50 - 11:05 Tumor agnostics in thyroid cancer: NTRK, mTOR and immunotherapy
L. Locati, ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano,

Milan, IT

11:05 - 11:20 Tumor agnostics in thyroid cancer: BRAF

M. Cabanillas, Houston, US

J. Capdevila Castillon, Vall d'Hebron University Hospital, Barcelona, ES



10:15 - 11:45 Type: Special symposium 7.3.O - Orléans
Title: Detection, characterisation and targeting of minimal Auditorium
residual disease
Chair(s): Katerina Politi, US; Sarah-Jane Dawson, AU


10:20 - 10:35 Persister cells: What are they, biology and heterogeneity
K. Politi, Yale University School of Medicine - Yale Cancer Center, New Haven, US

10:35 - 10:50 Modelling and targeting MRD in melanoma
R. Lee, The University of Manchester, Manchester, GB

10:50 - 11:05 Updates in circulating tumor cells for cancer monitoring, screening, metastasis
and resistance
N. Aceto, Zurich, CH

11:05 - 11:20 MRD and adjuvant clinical trial design


K. Politi, Yale University School of Medicine - Yale Cancer Center, New Haven, US



10:15 - 11:45 Type: Special symposium 7.3.T - Toulouse
Title: New developments in the management of Auditorium
recurrent/metastatic nasopharyngeal cancer
Chair(s): Brigette Ma, HK; Pierre Blanchard, FR

B. Ma, The Chinese University of Hong Kong, Sha Tin, HK

10:20 - 10:35 Recent advances in the development of 'liquid biopsy' in early detection and
therapeutic monitoring of nasopharyngeal cancer
W.K.J. Lam, Prince of Wales Hospital, Sha Tin, HK

10:35 - 10:50 Pivotal new phase III trials in the first-line setting: Incorporating IO into
management
D.W.-T. Lim, NCCS - National Cancer Centre Singapore, Singapore, SG

10:50 - 11:05 Second-line and beyond: New targets, new approaches
B. Ma, The Chinese University of Hong Kong, Sha Tin, HK

11:05 - 11:20 Impact of locoregional therapy in the management of recurrent/metastatic NPC
P. Blanchard, Institut Gustave Roussy, Villejuif, FR

P. Blanchard, Institut Gustave Roussy, Villejuif, FR



10:15 - 11:45 Type: Special session 7.3.M -
Title: In collaboration with the WHO: The impact of COVID-19 Marseille
on cancer services globally: Challenges and lessons learned Auditorium
Chair(s): Rosa Giuliani, GB; André Ilbawi, CH


10:20 - 10:40 Research and innovation in cancer: Understanding the landscape and impact of
pandemic
I. Soerjomataram, IARC - International Agency for Research on Cancer, Lyon, FR

10:40 - 11:00 Nearly three years into COVID: Projecting the impact and what we can do better

11:00 - 11:20 Cancer centres and networks: New ways of delivery care during and after the
pandemic

A. Ilbawi, WHO - World Health Organization, Geneva, CH



Title: Hard-to-treat cancers: What makes them special?
Chair(s): Nicholas McGranahan, GB; Fabrice André, FR

10:15 - 10:35 What defines “born to be bad” cancers?
N. Mcgranahan, UCL Cancer Institute - Paul O'Gorman Building, London, GB

10:35 - 10:55 Small cell lung cancer: How molecular insights have shed light on aggressive
clinical behaviour
C. Rudin, Memorial Sloan-Kettering Cancer Center, New York, US

10:55 - 11:15 Dissecting response to treatment in adult patients with a glioma
R. Verhaak, Jackson Laboratory for Genomic Medicine, Farmington, US

11:15 - 11:35 How can we accelerate drug discovery and development for patients with hard-
to-treat cancers?
E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES



Title: Empowering young cancer nurses academically, Auditorium
clinically and in career progression
Chair(s): Bethany Maynard, GB

10:15 - 10:30 Building resilience among young cancer nurses

10:30 - 10:45 Supporting young cancer nurses academically
R. Semerci, Trakya University Rektorlugu, Edirne, TR

10:45 - 11:00 Career progression among young cancer nurses
B. Maynard, The Royal South Hants Hospital - University Hospital Southampton NHS

Foundation Trust, Southampton, GB

11:00 - 11:10 CN41 - Comparison of professional quality of life, empathy and emotional
intelligence in cancer health care professionals: A study of cancer nurses,
radiation therapists and oncologists
P. Hunt1, M. Gooney1, A. Hennessy1, M. Keenleyside2, S. Denieffe1, 1South East

Technological University, Waterford, IE, 2St Patrick's Hospital, Waterford, IE

11:10 - 11:20 CN42 - The impact of an education WhatsApp group to support nurses working
in an acute oncology/haematology setting during the COVID-19 pandemic
R.G. Lawless, C. O'Shea, R. Fox, A. Elliott, A. Smullen, N. Anderson, Beaumont Hospital,
Dublin, IE

11:20 - 11:30 CN40 - Nurses’ experiences during the COVID-19 pandemic:
Multicenter mixed-methods study of coping and resilience strategies
L. Cadorin, S. Cedrone, J. Polesel, C. Mazzega Fabbro, Centro di Riferimento Oncologico

di Aviano (CRO) IRCCS, Aviano, IT

11:30 - 11:40 CN26 - Nurses caring for patients at the end of life report affected psychosocial
work environment when relocated during the COVID-19 pandemic: A cross-
sectional study
C. Olsson1, M. Dahlen Granrud2, M. Tillfors1, C. Bååth1, V. Abrahamsen Grøndahl3, A.K.

Helgesen3, I. Henoch4, C. Melin-Johansson5, J. Österlind6, M. Larsson1, 1Karlstad
University, Karlstad, SE, 2Inland Norway University of Applied Science, Elverum, NO,

3Østfold University College, Fredriksta, NO, 4University of Gothenburg - The
Sahlgrenska Academy, Göteborg, SE, 5Mid Sweden University, Östersund, SE, 6Marie
Cederschiöld University, Stockholm, SE



10:30 - 11:30 Type: Multidisciplinary session 7.2.E - Évry Auditorium
Title: Who should I test for genetics outside BRCA?


Cancro, Genova, IT

10:35 - 10:50 What and who to test
K. Punie, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

10:50 - 11:05 Systemic treatment implications
S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL

11:05 - 11:20 Surgical implications


10:30 - 11:45 Type: Multidisciplinary session 7.3.G - Grenoble
Title: What is the optimal therapeutic approach in high- Auditorium
risk endometrial cancer?
Chair(s): Alexandra Leary, FR


10:35 - 10:50 The role of surgery
C. Marth, Innsbruck Medical University, Innsbruck, AT

10:50 - 11:05 Can the molecular classification inform treatment?
J. Mcalpine, Vancouver, CA

11:05 - 11:20 What is the optimal adjuvant radiation for high-risk EC?
S. De Boer, LUMC - Universitair Medisch Centrum, Leiden, NL

11:20 - 11:35 Can the molecular classification guide adjuvant medical treatment?



Title: Management of brain metastases: Systemic Auditorium
treatment, radiosurgery or both?
Chair(s): Giuseppe Minniti, IT

G. Minniti, University of Siena, Siena, IT

10:35 - 10:50 Systemic treatment as first option
R. Bartsch, Medizinische Universitaet Wien, Vienna, AT

10:50 - 11:05 Do we need combined treatments?
S. Formenti, New York, US

11:05 - 11:20 Management of treatment-related neurological complications
E. Le Rhun, University Hospital Zürich, Zurich, CH


Title: Young Oncologist Brunch 3: Molecular Tumor Board: Auditorium
A luxury or a necessity?
Chair(s): Christoph Oing, GB

11:00 - 11:15 Molecular Tumor Board: A luxury or a necessity?
P. Aftimos, Institute Jules Bordet, Brussels, BE

C. Oing, Newcastle University, Newcastle upon Tyne, GB

12:00 - 12:30 Type: Keynote lecture 4.B - Brest Auditorium
Title: Breast cancer genetics: Where to now?
Chair(s): Charles Swanton, GB

C. Swanton, Francis Crick Institute, London, GB

12:05 - 12:30 Breast cancer genetics: Where to now?
J. Garber, Dana Farber Cancer Institute, Boston, US


Title: Baxter, Nutricia - Person-centred interprofessional Auditorium
practice in nutrition: Reality or a dream
Chair(s): Virpi Sulosaari, FI

12:00 - 12:05 Welcome
V. Sulosaari, Turku University of Applied Sciences, Turku, FI

12:05 - 12:15 Cancer nurses’ role and use of clinical guidelines in the nutritional care of
people with cancer (EONS)
S. Parreira, Hospital CUF Infante Santo, Lisbon, PT

12:15 - 12:25 Medical oncologists’ role and use of clinical guidelines in the nutritional care of
people with cancer (ESMO)
J. Arends, Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für

Tumorbiologie, Freiburg im Breisgau, DE

12:25 - 12:35 Oncology dietitians’ role and use of clinical guidelines in the nutritional care of
people with cancer (EFAD)
N. Erickson, LMU - Ludwig Maximilians University of Munich, Munich, DE

12:35 - 12:45 The use of clinical guidelines in multidisciplinary nutritional care of people with
cancer (ESPEN)
A. Laviano, Sapienza - Università di Roma, Rome, IT

12:45 - 12:55 Patient perspective: how can we provide a personalised response to address the
individual nutritional needs of people with cancer
R. Greene, HungerNdThirst Foundation, Amsterdam, NL

V. Sulosaari1, J. Arends2, R. Greene3, S. Parreira4, A. Laviano5, N. Erickson6, 1Turku

University of Applied Sciences, Turku, FI, 2Universitätsklinikum Freiburg - Klinik für
Innere Medizin I/Klinik für Tumorbiologie, Freiburg im Breisgau, DE, 3HungerNdThirst

Foundation, Amsterdam, NL, 4Hospital CUF Infante Santo, Lisbon, PT, 5Sapienza -
Università di Roma, Rome, IT, 6LMU - Ludwig Maximilians University of Munich, Munich,
DE



13:00 - 14:30 Type: Industry Satellite Symposium 7.2.F -
Title: Gilead and Kite Oncology - Break Expectations: Novel Fécamp
approaches in triple-negative and HR+/HER2- metastatic breast Auditorium
cancer
Chair(s): Martine Piccart, BE


13:05 - 13:20 Stepping into the emerging needs in metastatic breast cancer

13:20 - 13:40 Exploring current treatment approaches for triple-negative and HR+/HER2-
metastatic breast cancer
V. Dieras, Centre Eugene - Marquis, Rennes, FR

13:40 - 14:05 Expanding possibilities in triple-negative and HR+/HER2- metastatic breast
cancer


14:05 - 14:25 Audience Q&A
M. Piccart1, M. Kok2, V. Dieras3, P. Schmid4, 1Institute Jules Bordet, Brussels, BE,

2Netherlands Cancer Institute, Amsterdam, NL, 3Centre Eugene - Marquis, Rennes, FR,

4Cancer Research UK Barts Centre - Barts and The London School of Medicine and
Dentistry, London, GB



Title: Seagen - Expert Opinion: Considerations for Managing Auditorium
HER2+ Breast Cancer and Brain Metastases
Chair(s): Diana Lüftner, DE

D. Lüftner, MHB - Brandenburg Medical School Theodor Fontane - Institute of Social

Medicine and Epidemiology, Brandenburg an der Havel, DE

13:05 - 13:35 The HER2+ breast cancer pathway
D. Lüftner1, O. Tredan2, P.F. Conte3, I. Meattini4, 1MHB - Brandenburg Medical School

Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der
Havel, DE, 2Centre Léon Bérard, Lyon, FR, 3IOV - Istituto Oncologico Veneto IRCCS,
Padova, IT, 4AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT

13:35 - 13:55 Managing brain metastases
D. Lüftner1, P.F. Conte2, I. Meattini3, O. Tredan4, 1MHB - Brandenburg Medical School

Havel, DE, 2IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, 3AOUC - Azienda
Ospedaliero-Universitaria Careggi, Firenze, IT, 4Centre Léon Bérard, Lyon, FR

13:55 - 14:10 Brain metastases: challenging current perceptions
D. Lüftner1, I. Meattini2, O. Tredan3, P.F. Conte4, 1MHB - Brandenburg Medical School

Havel, DE, 2AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, 3Centre Léon
Bérard, Lyon, FR, 4IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

D. Lüftner, MHB - Brandenburg Medical School Theodor Fontane - Institute of Social

Medicine and Epidemiology, Brandenburg an der Havel, DE


Title: Myriad Genetics - Controversies in breast and Auditorium
ovarian cancer genetics
Chair(s): Peter Dubsky, CH; Jean-Marc Classe, FR

13:00 - 13:05 Controversies in breast and ovarian cancer genetics
J.-M. Classe, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain,

FR

13:05 - 13:20 Should we use genetic signatures for chemotherapy decisions in ER+/HER2-
premenopausal patients?

13:20 - 13:50 Roundtable discussion
L. Teixeira1, A. Constantinidou2, M. Untch3, 1Hopital Saint Louis AP-HP, Paris, FR, 2Bank
of Cyprus Oncology Centre, Nicosia, CY, 3Helios Klinikum Berlin-Buch, Berlin, DE

13:50 - 14:20 Are HRD tests interchangeable?
J.-M. Classe, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain,

FR

14:20 - 14:25 Q&A
P. Dubsky1, J.-M. Classe2, L. Teixeira3, M. Untch4, A. Constantinidou5, 1Onkozentrum

Luzern Hirslanden-Klinik St. Anna, Luzern, CH, 2ICO Institut de Cancerologie de l'Ouest

René Gauducheau, Saint-Herblain, FR, 3Hopital Saint Louis AP-HP, Paris, FR, 4Helios
Klinikum Berlin-Buch, Berlin, DE, 5Bank of Cyprus Oncology Centre, Nicosia, CY

14:25 - 14:30 Wrap-up


Title: Advanced Accelerator Application, a Novartis Company - From Honfleur
imaging to targeted treatments: Patient journey through the Auditorium
evolving landscape in mCRPC
Chair(s): Karim Fizazi, FR


13:05 - 13:25 Navigating the evolving treatment landscape: Therapy sequencing in
progressing mCRPC
B. Tombal, Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels,

BE

13:25 - 13:40 Patient journey in advanced prostate cancer: Unmet needs and quality of life
A. Morgans, Dana Farber Cancer Institute, Boston, US

13:40 - 13:55 The importance of imaging in managing patients with advanced prostate cancer
K. Herrmann, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

13:55 - 14:05 Multidisciplinary team: Addressing patients’ needs throughout the treatment
journey

14:05 - 14:15 Panel discussion: Treatment decisions in complex cases
K. Fizazi1, B. Tombal2, A. Morgans3, K. Herrmann4, 1Institut Gustave Roussy, Villejuif,

Cedex, FR, 2Cliniques Universitaires St. Luc - Université Catholique de Louvain,

Brussels, BE, 3Dana Farber Cancer Institute, Boston, US, 4University Hospital Essen
Westdeutsches Tumorzentrum, Essen, DE

14:15 - 14:30 Live and online Q&A
K. Fizazi1, B. Tombal2, A. Morgans3, K. Herrmann4, 1Institut Gustave Roussy, Villejuif,

Cedex, FR, 2Cliniques Universitaires St. Luc - Université Catholique de Louvain,

Brussels, BE, 3Dana Farber Cancer Institute, Boston, US, 4University Hospital Essen
Westdeutsches Tumorzentrum, Essen, DE


13:00 - 14:30 Type: ESMO Colloquium 7.3.O -
Title: ESMO Colloquium Supported by Daiichi-Sankyo and Orléans
AstraZeneca: Targeting HER2 in advanced breast cancer: Successes Auditorium
and perspectives
Chair(s): Giuseppe Curigliano, IT; Javier Cortés, ES

G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

13:10 - 13:30 Developments in the treatment algorithm of patients with metastatic HER2-
amplified/overexpressing breast cancer

13:30 - 13:50 The promise of novel ADC technologies for the management of patients with
HER2-low metastatic breast cancer
R. Greil, Paracelsus Medizinische Privatuniversität, Salzburg, AT

13:50 - 14:10 Novel ADC-based combinations with targeted agents for the continuum of HER2-
expressing advanced breast cancer
E. Hamilton, Sarah Cannon Research Institute-Cancer Centre, Nashville, US

14:10 - 14:25 Q&A and discussiond



Title: F. Hoffman-La Roche LTD - What, why and how: Expert Quimper
review and opinions on the potential of oral SERDs for our patients Auditorium
with HR+ BC
Chair(s): Nick Turner, GB


13:05 - 13:25 What are oral SERDs and why do our patients need them?
K. Jhaveri, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

13:25 - 13:45 What have we seen from oral SERDs and what could they mean for our patients
in future?

Boston, US

13:45 - 14:05 What’s next for oral SERDs and beyond for our patients with HR+ disease?

14:05 - 14:25 Q&A
N. Turner1, K. Jhaveri2, A. Bardia3, 1 London, GB, 2Memorial Sloan Kettering Evelyn H.

Lauder Breast Center, New York, US, 3Massachusetts General Hospital Cancer Center,
Harvard Medical School, Boston, US

14:25 - 14:30 Close


Title: Bristol Myers Squibb - The Evolving Treatment Landscape Toulouse
for Metastatic Melanoma: A Clinical Lens on Current Decision Auditorium
Making
Chair(s): Paolo Ascierto, IT


13:10 - 13:35 Emerging Data for the First-line Treatment of Metastatic Melanoma
N. Meyer, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR

13:35 - 14:00 Considerations for Treatment Selection: A Case-Based Panel Discussion
H. Tawbi, The University of Texas MD Anderson Cancer Center, Houston, US

14:00 - 14:25 The Melanoma Continuum of Care: Remaining Challenges and Unmet Needs




Title: Supporting Ukraine: The European cancer advocacy Auditorium
community responds
Chair(s): Kathy Oliver, GB

K. Oliver, IBTA - International Brain Tumour Alliance, Tadworth, GB

13:15 - 13:30 The conflict in Ukraine and its effect on healthcare inequalities in Europe
R. Sullivan, Institute of cancer policy, London, GB

13:30 - 13:45 My story
N. Hrad, Kyiv National Linguistic University, Kyiv, UA

13:45 - 14:00 Serving the adult cancer community of Ukrainian refugees
K. Rizvi, YCE - Youth Cancer Europe, Cluj-Napoca, RO

14:00 - 14:15 The Safer Ukraine Collaborative: Supporting Ukrainian children with cancer
affected by war
W. Mlynarski, Medical University of Lodz, Lodz, PL



Title: Sanofi and Regeneron - Decision-Making Discussions: Auditorium
IO in aNSCLC
Chair(s): Roy S. Herbst, US

R.S. Herbst, Yale University School of Medicine, New heaven, US

13:10 - 13:25 The role of biomarkers in selecting first-line therapy in aNSCLC

13:25 - 13:45 First-line therapy in aNSCLC - Clinical cases forum: A case with squamous
histology
W. Nassib William Junior, Beneficencia Portuguesa de Sao Paulo - BP Mirante, Sao Paulo,

BR

13:45 - 14:05 First-line therapy in aNSCLC – Clinical cases forum: A case of unresectable
locally advanced NSCLC, ineligible for surgical resection or definitive
chemoradiation
B. Besse, Institut Gustave Roussy, Villejuif, FR

14:05 - 14:25 First-line therapy in aNSCLC – Clinical cases forum: A case with brain
metastases at presentation
F. Fuchs, Universitätsklinik Erlangen, Erlangen, DE



Title: Roche - Cancer care: there is no place like Auditorium
home?
Chair(s): Mary Tanay, GB

M. Tanay, King's College London, London, GB

14:05 - 14:30 Unique national experimentation: Home care and monitoring of cancer patients
treated with immunotherapy
C. Galvez, Centre Léon Bérard, Lyon, FR

14:30 - 14:55 Roles and responsibilities of nurses in the delivery of cancer care and treatments
at home
G. Jones, The Christie NHS Foundation Trust, Manchester, GB

14:55 - 15:20 An oncology digital placement: preparing the nursing workforce in community
care
A. Sanneh, The Christie NHS Foundation Trust, Manchester, GB

15:20 - 15:30 Q&A and Conclusion remarks
M. Tanay, King's College London, London, GB


14:45 - 16:15 Type: Special session 4.A - Antibes
Title: Creating a new stage between early and metastatic Auditorium
cancers: Illustration with lung cancers
Chair(s): Mariam Jamal-Hanjani, GB; Pasi Jänne, US

P. Jänne, Dana Farber Cancer Institute, Boston, US

14:50 - 15:10 Novel technologies embracing blood-based biomarkers for early detection
A. Frankell, Francis Crick Institute, London, GB

15:10 - 15:30 Pushing the limit of detection for minimal residual disease
M. Diehn, Stanford, US

15:30 - 15:50 Tools and clinical application of ctDNA in the adjuvant setting

P. Jänne, Dana Farber Cancer Institute, Boston, US


Title: Cellular therapies for solid tumours
Chair(s): Inge-Marie Svane, DK; John Haanen, NL

14:45 - 15:10 TILs
I.-M. Svane, Herlev and Gentofte Hospital, Herlev, DK

15:10 - 15:35 Gene-engineered T cells
C. Quintarelli, Ospedale Pediatrico Bambino Gesù, Rome, IT

15:35 - 16:00 Alternative cell therapies
U. Kohl, Leipzig, DE


14:45 - 16:15 Type: Proffered Paper session 7.1.C - Cannes
Title: Proffered Paper session 2: GU tumours, non- Auditorium
prostate
Chair(s): Andre Fay, BR; Laurence Albiges, FR


14:45 - 14:55 LBA68 - Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the
investigator’s choice of sunitinib or cabozantinib in previously
untreated advanced renal cell carcinoma (RCC): Results from a phase III
randomized study (PIVOT-09)
N. Tannir1, M. Formiga2, N. Agarwal3, S. Pal4, D. Cho5, D. George6, W. Hong7, L. Tang7,

A. Qureshi8, M. Tagliaferri7, J. Zalevsky7, K. Penkov9, 1The M.D. Anderson Cancer Center,
Houston, US, 2A.C.Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE),
Sao Paulo, BR, 3University of Utah Health - Huntsman Cancer Institute, Salt Lake City,

US, 4City of Hope Comprehensive Cancer Center, Duarte, US, 5WMC Cancer Center,
Weirton, US, 6Duke University Medical Center, Durham, US, 7Nektar Therapeutics, San
Francisco, US, 8Bristol-Myers Squibb, Princeton, US, 9Private Medical Institution
"Euromedservice", Saint-Petersburg, RU

14:55 - 15:05 LBA73 - Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV)
monotherapy or in combination with pembrolizumab (P) in previously untreated
cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial
cancer (la/mUC)
J. Rosenberg1, M. Milowsky2, C. Ramamurthy3, N. Mar4, R.R. Mckay5, T. Friedlander6, C.

Ferrario7, S. Bracarda8, S. George9, H. Moon10, D. Geynisman11, D. Petrylak12, D.
Borchiellini13, E. Burgess14, J.P. Maroto Rey15, A.-S. Carret16, Y. Yu16, M. Guseva17, B.
Homet Moreno18, P. O'Donnell19, 1MSKCC - Memorial Sloan Kettering Cancer Center,
New York, US, 2University of North Carolina - Chapel Hill, Chapel Hill, US, 3University of
Texas Health Science Center San Antonio, San Antonio, US, 4UCI Health - University of
California Irvine, Orange, US, 5UC San Diego, La Jolla, US, 6UCSF - University of
California San Francisco, San Francisco, US, 7Jewish General Hospital, Montreal, CA,
8Azienda Ospedaliera Santa Maria, Terni, IT, 9Roswell Park Comprehensive Cancer
Center, Buffalo, US, 10Kaiser Permanente - Riverside Medical Center, Riverside, US,
11Fox Chase Cancer Center - Main Campus, Philadelphia, US, 12Yale University School of
Medicine, New Heaven, US, 13CENTRE ANTOINE LACASSAGNE, NICE CEDEX, FR,
14Levine Cancer Institute, Charlotte, US, 15Hospital de la Santa Creu I Sant Pau,
Barcelona, ES, 16Seagen Inc., Bothell, US, 17Astellas Pharma USA, Northbrook, US,
18Merck & Co., Inc., Rahway, US, 19The University of Chicago, Chicago, US


15:15 - 15:30 Q&A

15:30 - 15:40 1447O - Phase II study of belzutifan plus cabozantinib as first-line treatment of
advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003
T. Choueiri1, T. Bauer2, J. Merchan3, R. Figlin4, A. Roy5, R. Perini5, D. Vickery5, E.

Arrowsmith6, 1Dana-Farber Cancer Institute and Harvard Medical School, Boston, US,
2Sarah Cannon Research Institute and Tennessee Oncology, Nashville, US, 3University of

Miami Health System, Miami, US, 4Cedars Sinai Medical Center, Los Angeles, US,
5Merck & Co., Inc., Rahway, US, 6Tennessee Oncology, Chattanooga, US

15:40 - 15:50 1448O - Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) +
lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma
(nccRCC)
L. Albiges1, H. Gurney2, V. Atduev3, C. Suárez4, M.A. Climent Duran5, D. Pook6, P.

Tomczak7, P. Barthelemy8, J.-L. Lee9, T. Nalbandian10, V. Stus11, T. Ferguson12, P.
Wiechno13, E. Gokmen14, L. Lacombe15, C. Gedye16, R. Perini17, M. Sharma17, C. Li17,
C.-H. Lee18, 1Gustave Roussy, Villejuif, FR, 2Macquarie University, Sydney, AU, 3Volga
District Medical Center, Federal Medical-Biological Agency, Nizhny Novgorod, RU, 4Vall d
´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Vall d
´Hebron Barcelona Hospital Campus, Barcelona, ES, 5Instituto Valenciano de Oncología,
València, ES, 6Monash University, Melbourne, AU, 7Poznan University of Medical

Sciences, Poznan, PL, 8Institut de Cancérologie Strasbourg Europe, Strasbourg, FR,
9Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, 10Regional
Cancer Center, Kharkiv, UA, 11Dnipro State Medical University, Dnipro, UA, 12Fiona
Stanley Hospital, Perth, AU, 13Oncology Center-Institute Marii Sklodowskiej-Curie,
Warsaw, PL, 14Ege University Medical Faculty, Izmir, TR, 15Centre de Recherche du CHU
de Québec, Quebec, CA, 16University of Newcastle, Callaghan, AU, 17Merck & Co., Inc.,
Rahway, US, 18Memorial Sloan Kettering Cancer Center, New York, US

A. Fay, PUCRS - Escola de Medicina, Porto Alegre, BR

16:00 - 16:15 Q&A

14:45 - 16:15 Type: Proffered Paper session 7.2.E - Évry Auditorium

Title: Proffered Paper session: Head & neck cancer
Chair(s): Brigette Ma, HK; Paolo Bossi, IT

14:45 - 14:55 650O - A phase II study of nivolumab for high-risk oral leukoplakia
G. Hanna1, A. Villa2, R. Shi1, A. Oneill1, M. Liu1, C. Quinn1, R. Curtin3, M. Flynn3, N.

Treister1, H. Sroussi1, P. Vacharotayangul1, L. Goguen4, D. Annino4, E. Rettig1, V. Jo4, K.
Wong4, R. Uppaluri4, R. Haddad1, S.-B. Woo4, 1Dana Farber Cancer Institute, Boston, US,
2UCSF - University of California San Francisco, San Francisco, US, 3Dana Farber Cancer
Institute, BOSTON, US, 4Brigham and Women's Hospital, Boston, US

14:55 - 15:05 651O - Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel
(pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck
squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
M. Dzienis1, J. Cundom2, C. Fuentes3, A. Hansen4, M. Nordlinger5, A. Pastor6, P. Oppelt7,

A. Neki8, R. Gregg9, I. Lima10, F. Franke11, G. Da Cunha Junior12, J. Tseng13, T. Loree14,
A. Joshi15, J. Mccarthy16, N. Naicker17, Y. Sidi18, B. Gumuscu18, G. De Castro Jr.19, 1Gold
Coast University Hospital (GCUH), Southport, AU, 2IDIM Instituto de Diagnostico e
Investigaciones Metabolicas, Buenos Aires, AR, 3Fundacion Respirar, Buenos Aires, AR,
4Princess Margaret Cancer Centre, Toronto, CA, 5Thomas Jefferson University Hospital,
Philadelphia, US, 6Hospital Provincial del Centenario, Rosario, AR, 7Washington

University School of Medicine, St. Louis, US, 8Baptist MD Anderson Cancer Center,
Jacksonville, US, 9Cancer Centre of Southeastern Ontario at Kingston General Hospital,
Kingston, CA, 10Centro Regional Integrado de Oncologia, Fortaleza, Ceara, BR,
11Oncosite Centro de Pesquisa Clínica em Oncologia, Ijui, BR, 12CETUS Oncologia, Belo
Horizonte, Minas Gerais, BR, 13Orlando Health Cancer Institute, Orlando, US, 14Erie
County Medical Center, Buffalo, US, 15The Townsville University Hospital, Douglas, AU,
16Dr. H. Bliss Murphy Cancer Centre, St. John's, CA, 17MSD (UK) Limited, London, GB,
18Merck & Co., Inc., Rahway, US, 19Instituto do Cancer do Estado de Sao Paulo – ICESP,
Sao Paulo, BR


15:15 - 15:25 Q&A

15:25 - 15:35 652O - Randomized phase III VANCE study: Gemcitabine and carboplatin (GC)
followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-
CTL) versus the same chemotherapy as first-line treatment for advanced
nasopharyngeal carcinoma (NPC)
H.C. Toh1, M.-H. Yang2, H.-M. Wang3, C.-Y. Hsieh 4, I. Chitapanarux5, K.F. Ho6, R.-L.
Hong7, M.-K. Ang1, D. Colevas8, E. Sirachainan9, C. Lertbutsayanukul10, G.F. Ho11, J.
Samol12, Z. Huang13, C. Tan13, C. Ding13, A. Myo14, 1National Cancer Centre Singapore,
Singapore, SG, 2Taipei Veterans General Hospital, Taipei City, TW, 3Chang Gung
Memorial Hospital-Linkou, Taoyuan City, TW, 4China Medical University Hospital,
Taichung City, TW, 5Chiang Mai University, Chiang Mai, TH, 6Mount Miriam Cancer
Hospital, Tanjung Bungah, MY, 7National Taiwan University Hospital, Taipei, TW,
8Stanford University School of Medicine, Stanford, US, 9Ramathibodi Hospital, Mahidol
University, Bangkok, TH, 10King Chulalongkorn Memorial Hospital, Faculty of Medicine,

Chulalongkorn University, Bangkok, TH, 11Universiti Malaya Medical Centre, Kuala
Lumpur, MY, 12Tan Tock Seng Hospital Singapore, Singapore, SG, 13Tessa Therapeutics
Ltd, Singapore, SG, 14Tessa Therapeutics Ltd., Singapore, SG

15:35 - 15:45 653O - Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk
HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter
randomized phase II trial
H. Mirghani1, C. Even2, A. Larive3, H. Pere4, J. Fayette5, L. Geoffrois6, F. Clatot7, B.

Calderon8, Y. Tao2, T.V.F. Nguyen3, E. Fabiano4, S. Kreps4, D. Veyer4, J. Puech4, C.
Badoual1, F. Garic9, A. Auperin3, P. Blanchard3, 1European George Pompidou Hospital -
APHP, Paris, FR, 2Institut Gustave Roussy, Villejuif, Cedex, FR, 3Gustave Roussy - Cancer

Campus, Villejuif, FR, 4HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR,
5Centre Léon Bérard, Lyon, FR, 6Institut de Cancérologie de Lorraine - Alexis Vautrin,
Vandoeuvre-lès-Nancy, FR, 7Centre Henri Becquerel, Rouen, FR, 8Institut Sainte-

Catherine, Avignon, FR, 9Unicancer, Paris, Cedex, FR

L. Licitra, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:55 - 16:05 Q&A

14:45 - 15:55 Type: Mini Oral session 7.3.G - Grenoble Auditorium
Title: Mini Oral session: GI, lower digestive
Chair(s): Per Pfeiffer, DK; Pia Osterlund, FI; Clara Montagut Viladot, ES

14:45 - 14:50 LBA26 - BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab
(C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer
(mCRC)
J. Tabernero1, T. Yoshino2, T.W. Kim3, R. Yaeger4, J. Desai5, H. Wasan6, E. Van Cutsem7, F.

Ciardiello8, T. Maughan9, C. Eng10, J. Tie5, M.E. Elez Fernandez1, S. Lonardi11, X.
Zhang12, R. Chavira13, T. Usari14, E. Hahn15, S. Kopetz16, 1Vall d'Hebron University
Hospital, Barcelona, ES, 2National Cancer Center Hospital East, Kashiwa, JP, 3Asan
Medical Center - University of Ulsan College of Medicine, Seoul, KR, 4Memorial Sloan
Kettering Cancer Center, New York, US, 5Peter MacCallum Cancer Centre, Melbourne,
AU, 6Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, GB,
7University Hospital Gasthuisberg and University of Leuven, Leuven, BE, 8University of
Campania Luigi Vanvitelli, Napoli, IT, 9Oxford Institute for Radiation Oncology, Oxford,
GB, 10Vanderbilt Ingram Cancer Center, Nashville, US, 11Veneto Institute of Oncology
(IOV)-IRCCS, Padova, IT, 12Pfizer Inc., Groton, US, 13Pfizer Inc, New York, US, 14Pfizer
Inc, Milan, IT, 15Pfizer, Boulder, US, 16The University of Texas M. D. Anderson Cancer
Center, Houston, US

14:50 - 14:55 LBA27 - Additional analyses of MOUNTAINEER: A phase II study of tucatinib and
trastuzumab for HER2-positive mCRC
J. Strickler1, A. Cercek2, S. Siena3, T. André4, K. Ng5, E. Van Cutsem6, C. Wu7, A.

Paulson8, J. Hubbard9, A. Coveler10, C. Fountzilas11, A. Kardosh12, P. Kasi13, H.J. Lenz14,
K. Ciombor15, M.E. Elez Fernandez16, D. Bajor17, M. Stecher18, W. Feng19, T. Bekaii-
Saab20, 1Duke Cancer Center, Durham, US, 2Memorial Sloan Kettering Evelyn H. Lauder
Breast Center, New York, US, 3ASST Grande Ospedale Metropolitano Niguarda, Milan,
IT, 4Sorbonne University and Saint-Antoine Hospital, Paris, FR, 5Dana Farber Cancer
Institute, Boston, US, 6University Hospitals Gasthuisberg, Leuven & University of
Leuven, Leuven, BE, 7Mayo Clinic Cancer Center, Phoenix, US, 8Texas Oncology - Baylor
Charles A. Sammons Cancer Center, Dallas, US, 9Mayo Clinic, Rochester, US, 10Fred
Hutchinson Cancer Center/University of Washington, Seattle, US, 11Roswell Park
Comprehensive Cancer Center, Buffalo, US, 12OHSU - Oregon Health Science University,
Portland, US, 13Weill Cornell Medicine, New York, US, 14USC Norris Comprehensive
Cancer Center, Los Angeles, US, 15Vanderbilt Ingram Cancer Center, Nashville, US,
16Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Institute of Oncology (VHIO),
Universitat Autònoma de Barcelona, CIBERONC, Barcelona, ES, 17Case Western Reserve

University / University Hospitals, Cleveland, US, 18Seagen Inc., Seattle, US, 19Seagen
Inc., Bothell, US, 20Mayo Clinic, Scottsdale, US

P. Pfeiffer, OUH - Odense University Hospital, Odense, DK


15:05 - 15:10 317MO - Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients
with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials
C. Gallois1, Q. Shi2, J. Meyers2, T. André3, T. Iveson4, A. Sobrero5, S. Alberts2, A. De

Gramont6, J. Meyerhardt7, A. Shields8, T. Georges9, H.J. Schmoll10, I. Souglakos11, R.
Kerr12, S. Lonardi13, G. Yothers14, T. Yoshino15, R. Goldberg16, J. Taieb17, D.
Papamichael18, 1HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, 2Mayo
Clinic, Rochester, US, 3Hopital Saint-Antoine, Paris, FR, 4Southampton General Hospital,
Southampton, GB, 5IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul
Cancro, Genova, IT, 6Franco-britanique hospital, paris, FR, 7Dana Farber Cancer

Institute, Boston, US, 8Karmanos Cancer Institute, Detroit, US, 9UF - University of
Florida Health, Gainesville, US, 10UKH - Universitätsklinikum Halle (Saale), Halle
(Saale), DE, 11University General Hospital of Heraklion, Heraklion, GR, 12Churchill
Hospital, Oxford, GB, 13IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, 14University
of Pittsburgh, Pittsburgh, US, 15National Cancer Center Hospital East, Kashiwa, JP,
16West Virginia University, Morgantown, US, 17Hopital European George Pompidou,
Paris, FR, 18Bank of Cyprus Oncology Centre, Nicosia, CY

15:10 - 15:15 318MO - Circulating tumour DNA (ctDNA) dynamics, CEA and sites of
recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT)
guided by ctDNA analysis in stage II colon cancer (CC)
J. Tie1, J. Cohen2, K. Lahouel2, S. Lo3, Y. Wang2, R. Wong4, J. Shapiro5, S. Harris6, A.

Khattak7, M. Burge8, L. Horvath9, C. Karapetis10, J. Shannon11, M. Singh12, D. Yip13, N.
Papadopoulos2, C. Tomasetti2, K. Kinzler2, B. Vogelstein2, P. Gibbs14, 1Peter MacCallum
Cancer Centre, Melbourne, AU, 2Johns Hopkins Medicine - The Sidney Kimmel
Comprehensive Cancer Center, Baltimore, US, 3The University of Sydney School of Public
Health, Sydney, AU, 4Eastern Health - Box Hill Hospital - Main Entrance, Box Hill, AU,
5CabrinI Health - Malvern, Malvern, AU, 6Bendigo Health, Bendigo, AU, 7Fiona Stanley
Hospital, Murdoch, AU, 8Royal Brisbane and Women's Hospital, Herston, AU, 9Chris
O'Brien Lifehouse, Camperdown, AU, 10Flinders Centre for Innovation in Cancer, Bedford
Park, AU, 11Nepean Cancer Care Centre, Kingswood, AU, 12Barwon Health Andrew Love
Cancer Centre, Geelong, AU, 13The Canberra Hospital, Garran, AU, 14Walter and Eliza
Hall Institute of Medical Research, Parkville, AU

15:15 - 15:20 319MO - Real-world monitoring of circulating tumor DNA reliably predicts
cancer recurrence in patients with resected stages I-III colorectal cancer
S. Cohen1, P. Kasi2, V. Aushev3, D. Hanna4, G. Botta5, S. Sharif6, G. Laliotis3, S. Sharma3,

V. Sharma7, A. Alqahtani8, S. Chandana9, S. Kang10, S. Chakrabarti11, B. Somer12, A.
Kasi13, F. Dayyani14, M. Malla15, A. Jurdi3, A. Aleshin3, S. Kopetz16, 1University of
Washington and Fred Hutchinson Cancer Center, Seattle, US, 2Weill Cornell Medicine,
Englander Institute of Precision Medicine, New York Presbyterian Hospital, New York
City, US, 3Natera, Inc., Austin, US, 4USC - University of Southern California - Norris
Comprehensive Cancer Center, Los Angeles, US, 5UCSD Moores Cancer Center, La Jolla,
US, 6University of Iowa Holden Comprehensive Cancer Center, Iowa City, US, 7James
Graham Brown Cancer Center, Louisville, US, 8Ruesch Center for the Cure of
Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center - Georgetown
University Medical Center, Washington DC, US, 9Cancer and Hematology Centers of
Western Michigan, Grand Rapids, US, 10Winship Cancer Institute of Emory University,
Atlanta, US, 11Medical College of Wisconsin, Milwaukee, US, 12West Cancer Center,
Germantown, US, 13KUMC - University of Kansas Medical Center, Kansas City, US,

14University of California Irvine Chao Family Comprehensive Cancer Center, Orange, US,
15West Virginia University Cancer Institute, Morgantown, US, 16The University of Texas
M. D. Anderson Cancer Center, Houston, US

C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

15:35 - 15:40 320MO - A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN)
in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)
M. Fakih, J. Sandhu, D. Lim, S. Li, C. Wang, City of Hope Comprehensive Cancer Center,

Duarte, US

15:40 - 15:45 LBA28 - Prognostic effect of imaging and CEA follow-up in resected colorectal
cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD
phase III trial
C. Lepage1, J.M. Phelip2, L. Cany3, E. Barbier4, S. Manfredi5, P. Deguiral6, R. Faroux7, M.

Baconnier8, D. Pezet9, E. Terrebonne10, A. Adenis11, M. Ben Abdelghani12, J.F. Ain13, G.
Breysacher14, I. Boillot Benedetto15, A. Pelaquier16, A. Lievre5, P. Laurent Puig17, F.
Bibeau18, O. Bouche19, 1CHU Dijon, Dijon, FR, 2CHU Saint Etienne - Hopital Nord, Saint-
Étienne, FR, 3Clinique Francheville, Périgueux, FR, 4Fédération Francophone de
Cancérologie Digestive, Dijon, FR, 5CHU de Rennes - Hopital Pontchaillou, Rennes,
Cedex, FR, 6Clinique Mutualiste de l'Estuaire, Saint-Nazaire, FR, 7CHD Vendee - Hopital
Les Oudairies, La Roche-sur-Yon, FR, 8CH Annecy Genevois, Annecy, FR, 9CHU Estaing,
Clermont-Ferrand, FR, 10CHU Bordeaux - Hopital St. André, Bordeaux, FR, 11ICM -
Institut du Cancer de Montpellier, Montpellier, Cedex, FR, 12ICANS - Institut de
Cancérologie Strasbourg Europe, Strasbourg, FR, 13polyclinique val de saone, Macon,
FR, 14Hopital Louis Pasteur, Colmar, FR, 15Saint joseph-Saint Luc, Lyon, FR, 16Centre
Hospitalier Montelimar Service de Oncologie, Montelimar, FR, 17Paris Descartes
University, Paris, FR, 18CHU de Caen - Hopital Cote de Nacre, Caen, FR, 19CHU de
Reims - Hôpital Robert Debré, Reims, Cedex, FR

15:45 - 15:55 Invited Discussant 320MO and LBA28
P. Osterlund, Tampere University Hospital (Tays), Tampere, FI

14:45 - 16:15 Type: Mini Oral session 7.3.O - Orléans
Title: Mini Oral session: Non-metastatic NSCLC and other Auditorium
thoracic malignancies
Chair(s): Luis Paz-Ares, ES; Kersti Oselin, EE; Mariam Jamal-Hanjani, GB

14:45 - 14:50 1529MO - The genomic landscape of small cell lung cancer in never smoking
patients
M. Oh1, A. Barrett2, A. Ashok2, E. Mauer2, E. Garon1, A. Lisberg1, A. Cummings1, J.

Goldman1, 1UCLA - David Geffen School of Medicine, Los Angeles, US, 2Tempus Labs,
Inc., Chicago, US

14:50 - 14:55 930MO - PD-L1 expression and outcomes of pembrolizumab and placebo in
completely resected stage IB-IIIA NSCLC: Subgroup analysis of
PEARLS/KEYNOTE-091

S. Peters1, B. Besse2, S. Marreaud3, U. Dafni4, K. Oselin5, L. Havel6, E. Esteban
Gonzalez7, D. Isla8, A. Martinez-Marti9, M. Faehling10, M. Tsuboi11, J.-S. Lee12, K.
Nakagawa13, J. Yang14, S. Keller14, M. Mauer3, N. Jha3, R.A. Stahel15, L. Paz-Ares16, M.
O'Brien17, 1Lausanne University Hospital, Lausanne, CH, 2Institut Gustave Roussy,
Villejuif, FR, 3European Organisation for Research and Treatment of Cancer,
Headquarters, Brussels, BE, 4National and Kapodistrian University of Athens and
Frontier Science Foundation Hellas, Athens, GR, 5North Estonia Medical Centre, Tallinn,
EE, 6Charles University and Thomayer Hospital, Prague, CZ, 7Hospital Universitario
Central de Asturias, Oviedo, ES, 8University Hospital Lozano Blesa, IIS Aragon,
Zaragoza, ES, 9Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University
Hospital, Barcelona, ES, 10Klinikum Esslingen, Esslingen, DE, 11National Cancer Center
Hospital East, Kashiwa, JP, 12Seoul National University Bundang Hospital, Seoul National
University College of Medicine, Seongnam, KR, 13Kindai University Faculty of Medicine,
Osaka, JP, 14Merck & Co., Inc., Rahway, US, 15European Thoracic Oncology Platform,
Bern, CH, 16Hospital Universitario 12 de Octubre, CNIO & Universidad Complutense,
Madrid, ES, 17The Royal Marsden Hospital - Chelsea, London, GB

14:55 - 15:00 933MO - Longitudinal monitoring of circulating tumor DNA from plasma in
patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung
cancer
M.-J. Ahn1, H.A. Jung1, B.M. Ku2, Y.J. Kim2, S. Park1, J.-M. Sun1, S.-H. Lee1, J.S. Ahn1, J.H.
Cho2, H.K. Kim2, Y.S. Choi2, J. Kim2, 1Samsung Medical Center (SMC) - Sungkyunkwan
University School of Medicine, Seoul, KR, 2Samsung Medical Center (SMC), Seoul, KR

M. Jamal-Hanjani, UCL Cancer Institute - Paul O'Gorman Building, London, GB

15:15 - 15:20 LBA71 - First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy
(chemo) in patients (pts) with unresectable malignant pleural mesothelioma
(uMPM): 4-year update from CheckMate 743
G. Zalcman1, Y. Oulkhouir2, R. Cornelissen3, L. Greillier4, J. Rodriguez Cid5, J. Mazieres6,

P. Briggs7, A. Nowak8, A. Tsao9, N. Fujimoto10, S. Peters11, A. Mansfield12, S. Popat13, A.
Nassar14, J. Bushong14, N. Hu14, T. Spires14, D. Balli14, L. Eccles14, P. Baas15, 1Bichat-
Claude Bernard University Hospital, AP-HP, Université de Paris, Paris, FR, 2Hôpital Côte
de Nacre C H U Caen, Caen, FR, 3Erasmus MC Cancer Institute, Rotterdam, NL, 4Aix
Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, FR,
5Instituto Nacional de Enfermedades Respiratorias, Mexico City, MX, 6Service de

Pneumologie, Centre Hospitalier Universitaire de Toulouse - Hôpital Larrey, Université
Paul Sabatier, Toulouse, FR, 7Monash Medical Centre, Clayton, AU, 8University of
Western Australia and Department of Medical Oncology, Sir Charles Gairdner Hospital,
Perth, AU, 9MD Anderson Cancer Center, Houston, US, 10Okayama Rosai Hospital,
Okayama, JP, 11Lausanne University Hospital, Lausanne, CH, 12Mayo Clinic, Rochester,
US, 13Royal Marsden Hospital, London, GB, 14Bristol Myers Squibb, Princeton, US,
15Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, NL

15:20 - 15:25 931MO - Final overall survival analysis of phase III study of pemetrexed/cisplatin
versus vinorelbine/cisplatin for completely resected non-squamous non-small
cell lung cancer: The JIPANG Study
K. Yoh1, H. Kenmotsu2, N. Yamamoto3, T. Misumi4, T. Takahashi2, H. Saito5, S.

Sugawara6, K. Yamazaki7, K. Nakagawa8, K. Sugio9, T. Seto10, S. Toyooka11, H. Date12, T.
Mitsudomi13, I. Okamoto14, K. Yokoi15, H. Saka16, H. Okamoto17, Y. Takiguchi18, M.
Tsuboi1, 1National Cancer Center Hospital East, Kashiwa, JP, 2Shizuoka Cancer Center,
Shizuoka, JP, 3Wakayama Medical University, Wakayama, JP, 4National Cancer Center
Hospital East, Kashiwa, Japan, Kashiwa, JP, 5Kanagawa Cancer Center, Yokohama, JP,
6Sendai Kousei Hospital, Sendai, JP, 7National Hospital Organization Kyushu Medical

Center, Fukuoka, JP, 8Kindai University School of Medicine - Main Campus, Osaka, JP,
9Oita University, Yufu, JP, 10National Hospital Organization Kyushu Cancer Center,
Fukuoka, JP, 11Okayama University Graduate School of Medicine, Okayama, JP, 12Kyoto
University Graduate School of Medicine, Kyoto, JP, 13Kindai University - Faculty of
Medicine, Osaka, JP, 14Graduate School of Medical Sciences, Kyushu University, Fukuoka,
JP, 15Nagoya University, Graduate School of Medicine, Nagoya, JP, 16Matsunami General
Hospital, Gifu, JP, 17Yokohama Municipal Citizen's Hospital, Yokohama, JP, 18Chiba
University, School of Medicine, Chiba, JP


15:40 - 15:45 929MO - Platform study of neoadjuvant durvalumab (D) alone or combined with
novel agents in patients (pts) with resectable, early-stage non-small cell lung
cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA
(ctDNA) dynamics in the NeoCOAST study
J. Spicer1, T. Cascone2, G. Kar3, Y. Zheng4, J. Blando4, T.H. Tan5, M. Cheng4, R. Mager4,

O. Hamid4, Y. Soo-Hoo4, P. Forde6, W. Weder7, M.R. Garcia Campelo8, I. Grenga4, R.
Kumar4, L. Mcgrath3, 1McGill University, Montreal, CA, 2The University of Texas M. D.
Anderson Cancer Center, Houston, US, 3AstraZeneca, Waltham, US, 4AstraZeneca,
Gaithersburg, US, 5AstraZeneca, Munich, DE, 6Johns Hopkins University, Baltimore, US,
7Privatklinik Bethanien, Zurich, CH, 8Instituto de Investigación Biomédica de A Coruña
(INIBIC), A Coruña, ES

15:45 - 15:50 932MO - Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus
chemo as neoadjuvant treatment for resectable non-small cell lung cancer
(NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
E. Felip1, C. Wang2, T.-E. Ciuleanu3, G. Saylors4, F. Tanaka5, K.-N. Chen6, H. Ito7, N.

Girard8, S. Lu9, M. Provencio Pulla10, T. Mitsudomi11, M. Awad12, P. Forde13, R.
Lawrance14, F. Taylor15, G. Worthy16, S. Blum17, L. Vo17, J.L. Cai17, J. Spicer18, 1Vall
d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, ES,
2Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital,
Tianjin, CN, 3Institutul Oncologic Prof Dr Ion Chiricuta and University of Medicine and
Pharmacy Iuliu Hatieganu, Cluj-Napoca, RO, 4Charleston Oncology, Charleston, US,
5University of Occupational and Environmental Health, Kitakyushu, JP, 6Peking
University School of Oncology, Beijing Cancer Hospital, Beijing, CN, 7Kanagawa Cancer
Center, Yokohama, JP, 8Institut du Thorax Curie-Montsouris, Institut Curie, Paris, FR,
9Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University,
Shanghai, CN, 10Hospital Universitario Puerta de Hierro, Madrid, ES, 11Kindai University
Hospital, Osaka, JP, 12Dana-Farber Cancer Institute, Boston, US, 13Johns Hopkins Kimmel
Cancer Center, Baltimore, US, 14Adelphi Values, Macclesfield, GB, 15Adelphi Values,
Boston, US, 16Adelphi Values, Bollington, GB, 17Bristol Myers Squibb, Princeton, US,
18McGill University Health Center, Montreal, CA

15:50 - 15:55 LBA50 - Analysis of pathological features and efficacy outcomes with
neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for
resectable non-small cell lung cancer (NSCLC) in CheckMate 816
J. Deutsch1, A. Cimino-Mathews1, E.D. Thompson1, D. Wang1, R.A. Anders1, E.

Gabrielson1, P. Illei1, J. Jedrych1, L. Danilova1, J. Spicer2, M. Provencio Pulla3, P. Forde4,
D. Pandya5, M. Tran5, J. Fiore5, V. Devas5, T.R. Cottrell1, A.S. Baras1, J. Taube1, 1Johns

Hopkins University SOM, Baltimore, US, 2McGill University Health Centre, Montreal, CA,
3Hospital Universitario Puerta de Hierro, Madrid, ES, 4Bloomberg-Kimmel Institute for
Cancer Immunotherapy, Baltimore, US, 5Bristol Myers Squibb, Princeton, US

K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla),

Tallinn, EE

14:45 - 16:15 Type: Mini Oral session 7.3.T - Toulouse
Title: Mini Oral session: Haematological Auditorium
malignancies
Chair(s): Maria Gomes da Silva, PT; Irit Avivi, IL

14:45 - 14:50 623MO - Machine learning-based prediction of germinal center, MYC/BCL2
double protein expressor status, and MYC rearrangement from whole slide
images in DLBCL patients
C. Syrykh1, J.-B. Schiratti2, E. Brion2, C. Joubert3, M. Baia3, L. Marlot4, C. Maussion2, L.-

W. Danneaux2, S. Bologna5, J. Briere6, P. Dartigues7, P. Gaulard8, C. Haioun8, F. Jardin9, T.
Molina10, H. Tilly9, E. Gomez4, D. Sondaz4, C. Copie-Bergman11, C. Laurent1, 1IUCT
Oncopole, LYSA, Toulouse, FR, 2OWKIN, Paris, FR, 3LYSARC (The Lymphoma Academic
Research Organisation), Pierre-Bénite, FR, 4Institut CARNOT CALYM, Pierre-Bénite, FR,
5CHU Brabois, Vandoeuvre-lès-Nancy, FR, 6Hôpital St Louis, Paris, FR, 7INSTITUT
GUSTAVE ROUSSY, Villejuif, FR, 8Centre Hospitalier Universitaire Henri-Mondor AP-HP,

Créteil, FR, 9Centre Henri Becquerel, Rouen, FR, 10Institut Necker Enfant Malades,
Paris, FR, 11LYSA (The Lymphoma Study Association), Pierre-Bénite, FR

14:50 - 14:55 624MO - Retrospective analysis of clinical value of ctDNA in newly diagnosed
diffuse large B cell lymphoma
T. Guan, M. Zhang, L. Su, Shanxi Provincial Cancer Hospital, Taiyuan, CN

I. Avivi, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL

15:05 - 15:10 625MO - Combination of mitoxantrone hydrochloride liposome with
pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II
clinical trial
Y. Huang1, T. Wu1, Y. Hu1, Y. Li2, J. Ma3, Y. Guo4, H. Zhou5, R. Yang6, Y. Gong7, Q.Y.
Zhang8, L.E. Lin9, R. Zhou10, Y. Liu10, Z. Pan10, J. Xue11, D. Wang11, 1Affiliated Hospital
of Guizhou Medical University, Guiyang, CN, 2Henan Cancer Hospital/Affiliated Cancer
Hospital of Zhengzhou University, Zhengzhou, CN, 3The First Affiliated Hospital of
Guangxi Medical University, Nanning, CN, 4The First Affiliated Hospital of Henan

University of Science and Technology, Luoyang, CN, 5Hunan Cancer Hospital, Changsha,
CN, 6Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical
University & Yunnan Cancer Center, Kunming, CN, 7Chongqing University Cancer
Hospital, Chongqing, CN, 83rd Affiliated Hospital of Harbin Medical University, Harbin,
CN, 9Hainan General Hospital, Haikou, CN, 10CSPC Pharmaceutical Group Ltd.,
Shijiazhuang, CN, 11CSPC Zhongqi Pharmaceutical Technology Co., Ltd, Shijiazhuang,
CN

15:10 - 15:15 626MO - Incidence of cardiovascular disease in Swedish healthy blood stem cell
donors
S. Pahnke, H. Hägglund, G. Larfors, Unit of haematology, UPPSALA, SE

15:15 - 15:20 627MO - Orelabrutinib plus RCHOP for previously untreated non-germinal
center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with
extranodal disease
M. Wang, Q. Ke, Z. Li, D. Zhou, C. Liao, J. Sun, B. Guo, H. Cen, Guangxi Medical
University Affiliated Tumor Hospital and Oncology Medical Center, Nanning, CN

M. Gomes Da Silva, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil E.P.E.

(IPO Lisboa), Lisbon, PT

15:35 - 15:40 621MO - Preclinical study of DASH CAR-T cells manufactured in 48 hours
H. Wang, S.-T. Tsao, Q. Xiong, M. Gu, C. Fu, X. Li, M. Zhang, N. Li, H.-M. Hu, Hrain

Biotechnology Co., Ltd., Shanghai, CN

15:40 - 15:45 622MO - An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1
binding-dependent CD3 binding/activation and antitumor activity in acute
myeloid leukemia (AML) mouse model and leukemia blasts from AML patients
E. Lee1, Y. Lim1, S. Lee1, S. Park1, H. Park1, Y. Koh2, D. Shin2, J. Won1, 1ABL Bio, Inc.,

Seongnam, KR, 2SNUH - Seoul National University Hospital, Seoul, KR

I. Avivi, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL

14:45 - 16:15 Type: Mini Oral session 7.3.U - Urval Auditorium
Title: Mini Oral session: Sarcoma
Chair(s): Sebastian Bauer, DE; Herbert Ho Fung Loong, HK; Javier Martin-Broto, ES

14:45 - 14:50 1488MO - Initial results of phase II/III trial of AL102 for treatment of desmoid
tumors (DT)
M. Gounder1, R. Jones2, R. Chugh3, M. Agulnik4, A. Singh5, B. Van Tine6, V. Andelkovic7,

E. Choy8, J. Lewin9, R. Ratan10, J. Kaplan11, J. Yovell12, G. Gordon11, B. Kasper13,
1Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, 2The Royal
Marsden NHS Foundation Trust + Institute of Cancer Research, London, GB, 3University
of Michigan, Ann Arbor, US, 4City of Hope Comprehensive Cancer Center, Duarte, US,

5UCLA, Los Angeles, US, 6Washington University School of Medicine in St. Louis, St.
Louis, US, 7Gold Coast University Hospital (GCUH), Southport, AU, 8Massachusetts
General Hospital Cancer Center, Boston, US, 9Peter MacCallum Cancer Centre,
Melbourne, AU, 10MD Anderson Cancer Center, Houston, US, 11Ayala Pharmaceuticals,
Northbrook, US, 12Ayala Pharmaceuticals, Rehovot, IL, 13UMM - Universitaetsklinikum
Mannheim, Mannheim, DE

14:50 - 14:55 1489MO - A phase Ib/II study of selinexor as single agent and in combination
with imatinib in patients with advanced gastrointestinal stromal tumor (GIST):
SeliGIST/GEIS-41 trial
C. Serrano1, C.M. Valverde Morales2, J. Cruz Jurado3, J. Martinez Trufero4, J. Martinez-

Garcia5, S. Roche6, A. Redondo Sanchez7, M. Giuppi8, B. Suarez8, C. Romagosa6, V.
Martinez7, 1Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES,
2Vall d'Hebron University Hospital, Barcelona, ES, 3Hospital Universitario de Canarias,

San Cristobal de la Laguna, ES, 4Hospital Universitario Miguel Servet, Zaragoza, ES,
5Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, ES, 6Hospital
Universitario Vall d'Hebron, Barcelona, ES, 7Hospital Universitario La Paz, Madrid, ES,
8GEIS - Grupo Español de Investigación de Sarcomas, Madrid, ES

14:55 - 15:00 1486MO - The synovial and systemic pharmacokinetics and pharmacodynamics
of intra-articular administration of the CSF1 receptor antibody AMB-05X in a
phase II proof-of-concept trial in tenosynovial giant cell tumor
H. Gelderblom1, M. Huang2, M. Van De Sande3, T. Scharschmidt4, O. Kostogryz5, L.

Alani2, T. Huang2, L. Hsu2, K. Johnson2, 1LUMC - Leids Universitair Medisch Centrum,
Leiden, NL, 2AmMax Bio, Redwood City, US, 3Leiden University Medical Center, Leiden,
NL, 4Ohio State University Medical Center, Columbus, US, 5Institute of Traumatology
and Orthopedics of NAMS, Kiev, UA

S. Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

15:15 - 15:20 1490MO - CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT
PMO-1601)
M.-V. Teleanu 1, C. Heilig1, R. Hamacher2, S. Bauer2, R. Mayer-Steinacker3, V.I. Gaidzik3,

P. Horak1, L.-M. Lanz1, T. Muskatewitz1, H. Süsse1, A. Freitag1, M. Von Hornung1, L.
Wacker1, C. Von Kalle4, T. Barth3, S. Fröhling1, R. Schlenk1, 1German Cancer Research

Center - National Center for Tumor Diseases (NCT), Heidelberg, DE, 2West German
Cancer Center, University Hospital Essen, Essen, DE, 3Ulm University Hospital, Ulm, DE,
4Berlin Insitute of Health, Berlin, DE

15:20 - 15:25 1491MO - New benchmarks for designing clinical trials in advanced or
metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue
and bone sarcoma group meta-analysis
G. Kantidakis1, S. Litiere1, A. Neven2, M. Vinches3, I. Judson4, J.-Y. Blay 5, E.

Wardelmann6, S. Stacchiotti7, L. D'Ambrosio8, S. Marreaud1, W. Van Der Graaf9, B.
Kasper10, M. Fiocco11, H. Gelderblom11, 1EORTC Headquarters, Brussels, BE,
2Luxembourg Institute of Health, Strassen, LU, 3Institut du Cancer de Montpellier (ICM),
Montpellier, Cedex, FR, 4Institute of Cancer Research, London, GB, 5Centre Léon Bérard,

Lyon, FR, 6University Hospital Muenster-Gerhard Domagk Institute of Pathology,
Muenster, DE, 7Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT, 8IRCCS - Istituto
di Candiolo - FPO, Candiolo, IT, 9NKI-AVL - Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital, Amsterdam, NL, 10UMM - Universitaetsklinikum Mannheim,
Mannheim, DE, 11Leiden University Medical Center (LUMC), Leiden, NL

H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin,

HK

15:35 - 15:40 1487MO - A pan-sarcoma investigation of genetic alterations associated with
high telomeric content
R. Sharaf1, D. Jin1, J. Grady2, G. Frampton1, L. Albacker1, D. Thomas2, M. Montesion1,

1Foundation Medicine, Inc, Cambridge, US, 2Garvan Institute of Medical Research,
Darlinghurst, AU

15:40 - 15:45 1492MO - Immune and vascular biomarkers associated with efficacy and
mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in
leiomyosarcoma (LMS) and liposarcoma (LPS)
T.W.-W. Chen 1, C.-L. Hsu2, J.-C. Lee2, C.-C. Yen3, R.-L. Hong2, S.-C. Chen3, C.-W. Yu 2, M.-L.
Chen2, M.-C. Hsu2, T.-F. Kung3, A.-L. Cheng4, 1National Taiwan University Hospital-
College of Medicine, Taipei City, TW, 2National Taiwan University Hospital, Taipei City,
TW, 3Taipei Veterans General Hospital, Taipei City, TW, 4NTUH - National Taiwan
University Hospital, Taipei City, TW

15:45 - 15:50 1493MO - Peripheral immune biomarkers of survival in patients with resectable
dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic
sarcomas (UPS) treated with neoadjuvant nivolumab +/- ipilimumab
(neoICB)
E. Nassif1, E. Keung1, P. Jiang1, A. Reuben1, S. Crosby1, G. Mathew1, A. Lazar2, K.

Torres1, W.-L. Wang1, A. Guadagnolo1, A. Bishop1, K. Hunt1, J. Bird1, V. Lewis1, A.

Conley2, J. Wargo1, N. Somaiah2, C. Roland1, 1MD Anderson Cancer Center, Houston, US,
2The University of Texas M. D. Anderson Cancer Center, Houston, US

J. Martin-Broto, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

15:00 - 16:00 Type: Controversy session 7.2.F - Fécamp
Title: PD-L1 is a good predictive biomarker for anti-PD-1 Auditorium
therapy in oesophagogastric cancer
Chair(s): Elizabeth Smyth, GB



15:06 - 15:21 Pro: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in
Y. Janjigian, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

15:21 - 15:36 Contra: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in
R. Sundar, NUHS - National University Health System, Singapore, SG


15:37 - 15:57 Q&A


15:00 - 16:15 Type: Multidisciplinary session 7.1.D - Dijon Auditorium
Title: Management of oligometastatic prostate cancer
Chair(s): Nicholas James, GB

15:00 - 15:15 Definition and classification, plus presentation of case
N. James, ICR - Institute of Cancer Research, London, GB

15:15 - 15:30 Surgical treatment

15:30 - 15:45 Radiation
P. Ost, Ghent, BE

15:45 - 16:00 Systemic therapy
S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della

Svizzera Italiana (IOSI), Bellinzona, CH


15:00 - 16:00 Type: Multidisciplinary session 7.3.H - Honfleur
Title: Molecular tumor boards: Challenges in identifying Auditorium
personalised treatments for melanoma patients
Chair(s): Ryan Sullivan, US

O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US

15:05 - 15:20 The basic scientist’s perspective
R. Marais, Cancer Research UK Manchester Institute, Manchester, GB

15:20 - 15:35 The phase I perspective
R. Sullivan, MGH - Massachusetts General Hospital, Boston, US

15:35 - 15:50 The oncologist’s perspective
O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US



Title: Oligometastatic disease and oligoprogression in Auditorium
breast cancer
Chair(s): Carlos Barrios, BR

C. Barrios, Centro de Hematologia Oncologia E Transplante, Porto Alegre, BR

15:05 - 15:20 Radiotherapy
S. Rivera, Villejiuf, FR

15:20 - 15:35 Surgery
E. Mittendorf, Boston, MA, US

15:35 - 15:50 Systemic therapeutic options


15:00 - 16:00 Type: Challenge your Expert 7.3.M - Marseille
Title: How can we use ctDNA for early detection of Auditorium
cancer?
Chair(s): David Crosby, GB


D. Crosby, Cancer Research UK, London, GB


Title: EONS closing session
Chair(s): Virpi Sulosaari, FI

15:45 - 16:00 EONS Cancer Nursing Framework update

16:00 - 16:15 Introducing the European College of Cancer Nursing
W. Mcinally, Open University, Edinburgh, GB

16:15 - 16:20 CN36 - Informal caregivers’ contributions to self-care for patients treated with
oral anticancer agents: A qualitative study
S. Ucciero1, F. Sollazzo2, M. Di Nitto3, A. Durante4, F. Lacarbonara5, V. Biagioli6, F.

Torino7, R. Alvaro8, E. Vellone1, 1University of Rome Tor Vergata - School of Medicine
and Surgery, Rome, IT, 2Università degli Studi di Roma la Sapienza - Facoltà di Medicina,
Latina, IT, 3Istituto Superiore di Sanità, Rome, IT, 4Universidad de la Rioja, Logroño (La
Rioja), ES, 5University of Rome Tor Vergata, Rome, IT, 6Bambino Gesù Children's
Hospital IRCSS Rome, Firenze, IT, 7University of Rome Tor Vergata - School of Medicine
and Surgery, ROMA, IT, 8Università degli Studi di Roma Tor Vergata, Roma, IT

16:20 - 16:23 European Cancer Nursing Day 2022 Award
J. Barros Alfonso, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

16:23 - 16:24 European Cancer Nursing Day 2022 Winning Video

16:24 - 16:25 People's Choice Poster Award

16:25 - 16:30 Discussion & farewell


16:00 - 17:00 Type: Young Oncologist session 7.3.L -
Title: ON-SITE ONLY: Young Oncologist Clinical Case Discussion Lyon
sessions
Chair(s): Christoph Oing, GB; Kevin Punie, BE; Claudia Cardone, IT; Alexios Matikas, SE

16:00 - 16:00 Clinical case discussion in melanoma
C. Oing1, T. Amaral2, 1Newcastle University, Newcastle upon Tyne, GB, 2Skin Cancer

Clinical Trials Center, University of Tuebingen, Tübingen, DE

16:00 - 16:00 Breast cancer in pregnancy
L. Del Mastro1, K. Punie2, 1IRCCS Ospedale Policlinico San Martino, Genova, IT,
2University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:00 - 16:00 Genetic counselling (eg. Lynch family)
G. Evans1, C. Cardone2, 1The University of Manchester, Manchester, GB, 2Instituto

Nazionale Tumori—IRCCS Fondazione Pascale, Napoli, IT

16:00 - 16:00 Breast cancer
M. Oliveira1, A. Matikas2, 1Vall d'Hebron University Hospital, Barcelona, ES, 2Karolinska

Institutet, Huddinge, SE

Title: Presidential Symposium III
Chair(s): Andres Cervantes, ES; Charles Swanton, GB

16:30 - 16:45 LBA8 - Phase III study of cabozantinib (C) in combination with nivolumab (N)
and ipilimumab (I) in previously untreated advanced renal cell carcinoma
(aRCC) of IMDC intermediate or poor risk (COSMIC-313)
T. Choueiri1, T. Powles2, L. Albiges3, M. Burotto4, C. Szczylik5, B. Zurawski6, E. Yanez

Riuz7, M. Maruzzo8, A. Suarez Zaizar9, L. Fein10, F.A. Barros Schutz11, D. Heng12, F.
Wang13, F. Mataveli13, Y.-L. Chang13, M. Van Kooten Losio14, C. Suarez Rodriguez15, R.
Motzer16, 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, 2Barts
Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of
London, St. Bartholomew’s Hospital, London, GB, 3Institut Gustave Roussy, Université
Paris Saclay, Villejuif, FR, 4Bradford Hill Clinical Research Center, Santiago, CL,
5European Health Centre, Otwock, PL, 6Professor Franciszek Lukaszczyk Oncology

Center, Bydgoszcz, PL, 7James Lind Centro de Investigacion del Cancer, Temuco, CL,
8Istituto Oncologico Veneto, IOV – IRCCS, Padova, IT, 9Consultorio de Medicina
Especializada, Ciudad de Mexico, MX, 10Instituto de Oncología de Rosario, Rosario, AR,

11Beneficencia Portuguesa de Sao Paulo, Sao Paulo, BR, 12Tom Baker Cancer Center,
University of Calgary, Calgary, CA, 13Exelixis, Inc., Alameda, US, 14Bristol Myers Squibb,
Boudry, CH, 15Vall d’Hebron Institute of Oncology, Hospital Universitari Vall d’Hebron,
Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES, 16Memorial Sloan Kettering
Cancer Center, New York, US

S. Pal, City of Hope Comprehensive Cancer Center, Duarte, US

16:55 - 17:10 LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative
radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial
(ISRCTN40814031)
C. Parker1, N. Clarke2, A. Cook3, C. Catton4, W. Cross5, H. Kynaston6, J. Logue7, P.M.

Petersen8, P. Neville9, R. Persad10, H. Payne11, F. Saad12, A. Stirling13, W. Parulekar14,
M. Parmar3, M. Sydes15, 1The Royal Marsden Hospital (Sutton) - NHS Foundation Trust,
Sutton, GB, 2The University of Manchester, Manchester, GB, 3Institute of Clinical Trials
and Methodology-UCL, London, GB, 4Princess Margaret Cancer Center, Toronto, CA,
5University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB, 6Cardiff
& Vale UHB, Cardiff, GB, 7The Christie NHS Foundation Trust, Manchester, GB,

8Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, 9Medical Research
Council - MRC Clinical Trials Unit, London, GB, 10University Hospitals Bristol NHS
Foundation Trust, Bristol, GB, 11UCLH Foundation Trust, London, GB, 12Hospital St. Luc
du CHUM, Montreal, CA, 13MRC - Medical Research Council Clinical Trials Unit -
University College London (UCL), London, GB, 14Canadian Cancer Trials Group,
Kingston, CA, 15Medical Research Council Clinical Trials Unit, London, GB

S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della

Svizzera Italiana (IOSI), Bellinzona, CH

17:20 - 17:40 LBA10 - Sotorasib versus docetaxel for previously treated non-small cell lung
cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
M. Johnson1, J. De Langen2, D.M. Waterhouse3, J. Mazieres4, A.-M. Dingemans5, G.

Mountzios6, M. Pless7, J. Wolf8, M. Schuler9, H. Lena10, F. Skoulidis11, I. Okamoto12, S.-
W. Kim13, H. Linardou14, S. Novello15, Y. Chen16, B. Solomon17, C. Obiozor18, Y. Wang19,
L. Paz-Ares20, 1Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US,
2Netherlands Cancer Institute, Amsterdam, NL, 3US Oncology Research, Cincinnati, US,
4Centre Hospitalier Universitaire de Toulouse, Toulouse, FR, 5Erasmus MC Cancer
Institute, Rotterdam, NL, 6Henry Dunant Hospital Centre, Athens, GR, 7Kantonsspital
Winterthur, Winterthur, CH, 8University Hospital Cologne, Cologne, DE, 9University

Hospital Essen, Essen, DE, 10Centre Hospitalier Universitaire de Rennes, Hopital
Pontchaillou, Rennes, FR, 11The University of Texas M. D. Anderson Cancer Center,
Houston, US, 12Kyushu University Hospital, Fukuoka, JP, 13Asan Medical Center, Seoul,
KR, 14Metropolitan Hospital, Athens, GR, 15Università Degli Studi Di Torino – San Luigi
Hospital, Orbassano, IT, 16Cancer & Hematology Centers of Western Michigan, Grand
Rapids, US, 17Peter MacCallum Cancer Centre, Melbourne, AU, 18Amgen Inc., Thousand
Oaks, US, 19Amgen, Inc., Thousand Oaks, US, 20Hospital Universitario 12 de Octubre,
Madrid, ES

17:40 - 17:55 LBA11 - IPSOS: Results from a phase III study of first-line (1L) atezolizumab
(atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not
eligible for a platinum-containing regimen
S.M. Lee1, C. Schulz2, K. Prabhash3, B. Han4, A. Szczesna5, D. Cortinovis6, A.

Rittmeyer7, D. Vicente Baz8, R. Califano9, L. Tuan Anh10, G. Liu11, F. Cappuzzo12, J.
Reyes Contreras13, M. Reck14, Y. Hu15, S. Morris15, E. Hoeglander15, M. Connors16, H.K.
Vollan15, S. Peters17, 1University College London Hospitals NHS Foundation Trust, UCL

Cancer Institute and CRUK Lung Cancer Centre of Excellence, London, GB, 2University
Hospital Regensburg, Regensburg, DE, 3Tata Memorial Hospital, Mumbai, IN, 4Shanghai
Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, 5Mazowieckie Centrum
Leczenia Chorób Płuc i Gruźlicy, Warsaw, PL, 6AAST Monza San Gerardo Hospital,
Monza, IT, 7Lungenfachklinik Immenhausen, Immenhausen, DE, 8Hopsital Universitario
Virgen de la Macarena, Seville, ES, 9The Christie NHS Foundation Trust and Division of
Cancer Sciences, University of Manchester, Manchester, GB, 10Cho Ray Hospital, Ho Chi
Minh, VN, 11Princess Margaret Cancer Centre, Toronto, CA, 12National Cancer Institute
IRCCS Regina Elena, Rome, IT, 13Oncologico Potosino, San Luis Potosí, MX, 14Lung
Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research,
Grosshansdorf, DE, 15F. Hoffmann-La Roche Ltd, Basel, CH, 16Genentech, Inc, South San
Francisco, US, 17CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH


CA


16:30 - 18:00 Type: Special session 4.B - Brest Auditorium
Title: Emerging toxicities of new anticancer therapies
Chair(s): Jarushka Naidoo, IE; Erica Mayer, US

E. Mayer, Dana Farber Cancer Institute, Boston, US

16:40 - 16:55 Critical organ damage and late toxicities from anti-PD1

16:55 - 17:10 Late haematological malignancies of systemic anticancer therapies
J. Baptiste Micol, Institut Gustave Roussy, Villejuif, Cedex, FR

17:10 - 17:25 Chronic toxicities of targeted therapies and their implication on compliance:
Illustration with new endocrine therapies and CDK4 inhibitors
E. Mayer, Dana Farber Cancer Institute, Boston, US

17:25 - 17:40 Toxicities of CAR T cell and bispecific
C. Roddie, London, GB

17:40 - 18:00 Discussion: How to design better trial taking into account toxicities

Title: Proffered Paper session: NETs and endocrine Auditorium
tumours

Chair(s): Halfdan Sorbye, NO; Marcia Brose, US

16:30 - 16:40 LBA45 - Randomized open label phase III study comparing the efficacy and
safety of everolimus followed by chemotherapy (CT) with streptozotocin
(STZ)-5FU upon progression or the reverse sequence, in advanced progressive
panNETs: The SEQTOR study (GETNE 1206)
R. Salazar1, S. Tafuto2, M. Krogh3, A. Teule1, R. Garcia-Carbonero4, H.J. Klumpen5, B.

Cremer6, I. Sevilla7, B. Eriksson8, E. Tabaksblat9, J.-P. Metges10, N.S. Reed11, J.
Schrader12, V. Navarro1, V. Valentí1, J. Hernando13, A.M. Colao2, L. Vestermark3, C.
Carnaghi14, J. Capdevila13, 1Catalan Institute of Oncology (ICO), L’Hospitalet de
Llobregat, Barcelona, ES, 2Maria delle Grazie Hospital, Pozzuoli, IT, 3Odense University
Hospital, Odense, DK, 4Hospital 12 de Octubre, Imas12, UCM, Madrid, ES, 5Amsterdam
UMC, University of Amsterdam, Amsterdam, NL, 6Köln Universitätsklinikum Köln (AöR),
Köln, DE, 7Investigación Clínica y Traslacional en Cáncer / Instituto de Investigaciones
Biomédicas de Málaga (IBIMA) / Hospitales Universitarios Regional y Virgen de la
Victoria de Málaga, Malaga, ES, 8University Hospital, Uppsala, SE, 9Aarhus University
Hospital NET Centre, Aarhus, DK, 10Brest Hôpital Augustin Morvan, Institut de Cancero-
Hemato, Brest, FR, 11Beatson Oncology Centre, Glasgow, GB, 12Hamburg Medizinische
Klinik und Poliklinik, Hamburg-Eppendorf, DE, 13Vall Hebron University Hospital, Vall
Hebron Institute of Oncology (VHIO), Barcelona, ES, 14Humanitas Cancer Center,
Milano, IT

16:40 - 16:50 887O - First multicentric randomized phase II trial investigating the antitumor
efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate
(OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of
the OCLURANDOM trial
E. Baudin1, T. Walter2, A. Beron3, D. Smith4, J. Hadoux5, C. Lachachi6, D. Taieb7, C.

Ansquer8, L. Dierickx9, L. De Mestier Du Bourg10, E. Deshayes11, E. Quak12, L. Dahan13,
R. Guimbaud14, Y. Touchefeu15, M. Haissaguerre16, C. Do Cao17, C. Lombard Bohas18,
M. Attard1, S. Foulon1, 1Gustave Roussy - Cancer Campus, Villejuif, FR, 2Hospices Civiles
de Lyon - HCL - Lyon University Hospital Center, Lyon, FR, 3CHU Lille - Hopital Claude
Huriez, Lille, FR, 4Hopital Haut Leveque, Pessac, FR, 5Institut Gustave Roussy, Villejuif,
Cedex, FR, 6Hospices Civils de Lyon, Bron, FR, 7CHU de Marseille - Hôpital de la

Timone, Marseille, FR, 8Chu Nantes Hotel Dieu, Nantes, FR, 9Institut Claudius Regaud,
Toulouse, FR, 10Beaujon Hospital APHP, Clichy, FR, 11ICM - Institut régional du Cancer
de Montpellier, Val d'Aurelle, Montpellier, Cedex, FR, 12Centre François Baclesse, Caen,
FR, 13AP-HM - CHU La Timone Enfants, Marseille, FR, 14Centre Hospitalier Universitaire
de Toulouse - Hopital Rangueil, Toulouse, FR, 15CHU du Nantes - Hôtel-Dieu, Nantes,
Cedex, FR, 16CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, FR, 17Centre Hospitalier
Régional Universitaire de Lille, Lille, FR, 18Hopital Edouard Herriot Pav. E bis, Lyon, FR

J. Strosberg, H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus,

Tampa, US

17:00 - 17:15 Q&A


17:15 - 17:25 1644O - Donafenib in locally advanced/metastatic, radioactive iodine-refractory,
differentiated thyroid cancer: A randomized, double-blind, placebo-controlled,
multi-center phase III clinical trial (DIRECTION)
Y. Lin1, H. Yang2, F. Shi3, A. Yang4, X. Han5, B. Liu6, Z. Li7, Q. Ji8, L. Tang9, Z. Deng10, Y.
Ding11, W. Fu12, X. Xie13, L. Li14, X. He15, Z. Lv16, L. Wu17, L. Liu17, 1Peking Union
Medical College Hospital, Beijing, CN, 2The Affiliated Cancer Hospital of Zhengzhou
University, Zhengzhou, CN, 3Hunan Cancer Hospital, Changsha, CN, 4The First Affiliated
Hospital of Xi'an Jiaotong University, Xi' An, CN, 5The First Affiliated Hospital of
Zhengzhou University, Zhengzhou, CN, 6West China Hospital of Sichuan University,
Chengdu, CN, 7The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN, 8Fudan
University Shanghai Cancer Center, Shanghai, CN, 9The First Affiliated Hospital of
Nanjing Medical University, Nanjing, CN, 10Yunnan Cancer Hospital, Kunming, CN, 11The
Fifth Medical Center of Chinese PLA General Hospital, Beijing, CN, 12Affiliated Hospital
of Guilin Medical University, Guilin, CN, 13The First Affiliated Hospital of Fujian Medical
University, Fuzhou, CN, 14Zhejiang Cancer Hospital, Hangzhou, CN, 15Cancer Hospital
Chinese Academy of Medical Sciences, Beijing, CN, 16Shanghai Tenth People's Hospital,
Tongji University School of Medicine, Shanghai, CN, 17Suzhou Zelgen
Biopharmaceuticals Co., Ltd, Suzhou, CN

17:25 - 17:35 1645O - Durvalumab (D) plus tremelimumab (T) for the treatment of patients
with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-
T1812) trial
J. Capdevila Castillon1, M. Plana2, B. Castelo3, L. Iglesias4, J. Hernando1, R. Yaya Tur5, N.

Baste6, A. Carmona-Bayonas7, S. Ruiz8, J. Trigo8, I. Lorenzo-Lorenzo9, E. Grande10, D.
Lorente11, L. Ugidos12, G. Marquina13, A. García-Alvarez1, M. Taberna2, J. Villamayor14,
J. Molina-Cerrillo15, T. Alonso-Gordoa15, 1Vall Hebron University Hospital, Vall Hebron
Institute of Oncology (VHIO), Barcelona, ES, 2Catalan Institute of Oncology (ICO),
IDIBELL, L'Hospitalet de Llobregat, Barcelona, ES, 3University Hospital La Paz, Madrid,
ES, 4Hospital 12 de Octubre, Madrid, ES, 5IVO - Fundacion Instituto Valenciano de
Oncologia, Valencia, ES, 6Hospital Clínic de Barcelona, IDIBAPS, Barcelona, ES, 7UMU,
IMIB, Hospital Universitario Morales Meseguer, Murcia, ES, 8Hospitales Regional y
Universitario Virgen de la Victoria, IBIMA, UMA, Málaga, ES, 9Complejo Universitario
Hospitalario de Vigo (CHUVI) Álvaro Cunqueiro, Vigo, ES, 10MD Anderson Cancer Center
Madrid, Madrid, ES, 11Hospital Provincial de Castellón, Castellón de La Plana, ES,
12Centro Integral Oncológico "Clara Campal", Hospital Universitario HM Sanchinarro,
Madrid, ES, 13Hospital Clinico Universitario San Carlos. Department of Medicine, School
of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, ES, 14Clínica
Universidad de Navarra, Madrid, ES, 15Hospital Universitario Ramón y Cajal, Madrid, ES

M. Brose, Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, US

17:45 - 18:00 Q&A

16:30 - 18:00 Type: Mini Oral session 7.3.T - Toulouse Auditorium
Title: Mini Oral session: Developmental
therapeutics

Chair(s): Myung-Ju Ahn, KR; Ulrik Lassen, DK

16:30 - 16:35 455MO - NUC-7738 in patients with advanced solid tumours: Phase I results
from the NuTide:701 phase I/II study
S. Symeonides1, A. Skolariki2, N. Haris3, Z. Boh1, M. Myers4, E. Oelmann4, J. Bloss4, R.

Plummer3, S. Blagden2, 1Western General Hospital, Edinburgh, GB, 2Churchill Hospital,
Oxford, GB, 3Freeman Hospital, Newcastle-upon-Tyne, GB, 4NuCana plc, Edinburgh, GB

16:35 - 16:40 456MO - METEOR-1: A phase I study of the safety and efficacy of the protein
arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid
tumors
S. Postel-Vinay 1, A. Italiano2, P. Martin Romano3, P. Cassier4, L. Siu5, I. Lossos6, J.

Hilton7, M. Mckean8, J. Strauss9, G. Falchook10, M. De Jonge11, F. Opdam12, D. Rasco13,
J. Vermaat14, T. Crossman15, M. Zajac15, A. Hainline16, B. Kremer16, O. Barbash17, M.
Gounder18, 1Institut Gustave Roussy, Villejuif, FR, 2Institute Bergonié, Bordeaux, FR,
3Institut Gustave Roussy, Villejuif, Cedex, FR, 4Centre Léon Bérard, Lyon, FR, 5Princess
Margaret Cancer Centre, Toronto, CA, 6University of Miami Sylvester Comprehensive

Cancer Center, Miami, US, 7The Ottawa Hospital Regional Cancer Centre, Ottawa, CA,
8Sarah Cannon Research Institute, Nashville, US, 9Mary Crowley Cancer Research
Center, Dallas, US, 10Sarah Cannon Research Institute at HealthONE, Denver, US,
11Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL, 12NKI-AVL -
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL,

13South Texas Accelerated Research Therapeutics (START), San Antonio, US, 14Leiden
University Medical Center, Leiden, NL, 15GlaxoSmithKline UK - Stevenage, Stevenage,

GB, 16GlaxoSmithKline USA, Collegeville, US, 17GlaxoSmithKline, Philadelphia, US,
18Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

U. Lassen, Rigshospitalet, Copenhagen, DK

16:55 - 17:00 457MO - A phase I study of ATR inhibitor M1774 in patients with solid tumours
(DDRiver Solid Tumours 301): Part A1 results
T. Yap1, A. Tolcher2, R. Plummer3, J. Mukker4, M. Enderlin5, C. Hicking5, G. Locatelli5, Z.

Szucs6, I. Gounaris6, J. De Bono7, 1The University of Texas MD Anderson Cancer Center,
Houston, US, 2New Experimental Therapeutics (NEXT), San Antonio, US, 3Newcastle
Hospitals Trust, Newcastle-upon-Tyne, GB, 4EMD Serono Research & Development
Institute Inc., (an affiliate of Merck KGaA), Billerica, US, 5Merck Healthcare KGaA,
Darmstadt, DE, 6Merck Serono Ltd., (an affiliate of Merck KGaA), Feltham, GB, 7Royal
Marsden Hospital, Sutton, GB

17:00 - 17:05 458MO - Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and
capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers
(Ca) (MEDIPAC)
J. Lim1, R. Sundar1, A. Wong1, W.P. Yong1, R. Soo1, C.E. Chee1, S.C. Lee1, B.-C. Goh1, R.
Dent2, J. Chan2, K.Y. Wong3, S. D/o Nathan Jeraj1, L. Kwok1, G. Schiavon4, A. Foxley5,
D.S. Tan1, 1National University Cancer Institute, Singapore, Singapore, SG, 2NCCS -

National Cancer Centre Singapore, Singapore, SG, 3Icon Cancer Center SOC Singapore -
Gleneagles, Singapore, SG, 4AstraZeneca, Macclesfield, GB, 5AstraZeneca Academy

House, Cambridge, GB

I. Brana, Vall d'Hebron University Hospital, Barcelona, ES

17:20 - 17:25 459MO - Phase Ia study to evaluate GDC-6036 monotherapy in patients with
solid tumors with a KRAS G12C mutation
M. Patel1, J.-S. Lee2, M.J. De Miguel3, T. Burns4, A. Falcon Gonzalez5, T.W. Kim6, M.
Krebs7, H. Prenen8, E. Shacham Shmueli9, J. Desai10, P. Lorusso11, A. Sacher12, Y.
Choi13, N. Dharia13, M. Lin13, S. Mandlekar13, S. Royer-Joo13, J. Schutzman13, E.
Garralda14, 1Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, US,
2Seoul National University Bundang Hospital, Seongnam, KR, 3START MADRID, Hospital
Universitario HM Sanchinarro – CIOCC, Madrid, ES, 4UPMC Hillman Cancer Center,

Pittsburgh, US, 5Hospital Universitario Virgen del Rocio, Seville, ES, 6Asan Medical

Center - University of Ulsan College of Medicine, Seoul, KR, 7The Christie NHS
Foundation Trust and The University of Manchester, Manchester, GB, 8UZA - University
Hospital Antwerp, Edegem, BE, 9Chaim Sheba Medical Center, Ramat Gan, IL, 10Peter
MacCallum Cancer Centre, Melbourne, AU, 11Yale Smilow Cancer Center, New Haven,
US, 12Princess Margaret Cancer Centre, University Health Network, Toronto, CA,
13Genentech, Inc., South San Francisco, US, 14Vall d'Hebron University Hospital,
Barcelona, ES

17:25 - 17:30 460MO - Preliminary results from a phase I study using the bispecific, human
epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC)
zanidatamab zovodotin (ZW49) in solid cancers
K. Jhaveri1, H. Han2, E. Dotan3, D.-Y. Oh 4, C. Ferrario5, A. Tolcher6, K.-W. Lee 7, C.-Y.

Liao8, Y.-K. Kang9, Y.H. Kim10, E. Hamilton11, A. Spira12, N. Patel13, C. Karapetis14, S.Y.
Rha15, L. Boyken16, J. Woolery16, P. Bedard17, 1Memorial Sloan Kettering Cancer Center,
New York, NY, US, 2Moffitt Cancer Center, Tampa, US, 3Fox Chase Cancer Center,
Philadelphia, US, 4Seoul National University Hospital, Seoul, KR, 5Jewish General
Hospital, Montreal, CA, 6NEXT Oncology, San Antonio, US, 7Seoul National University
College of Medicine, Seoul National University Bundang Hospital, Seongnam, KR,
8University of Chicago Medicine, Chicago, US, 9Asan Medical Center, Seoul, KR, 10Korea
University Anam Hospital, Seoul, KR, 11Sarah Cannon Research Institute, Tennessee
Oncology, Nashville, US, 12Virginia Cancer Specialists, Fairfax, US, 13City of Hope,
Duarte, US, 14Flinders Medical Centre and Flinders University, Bedford Park, AU,
15Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, 16Zymeworks Inc.,
Vancouver, CA, 17Princess Margaret Cancer Centre, Toronto, CA


Medicine, Seoul, KR


16:30 - 18:00 Type: Mini Oral session 7.3.M - Marseille
Title: Mini Oral session: Policy and preventive Auditorium
strategies
Chair(s): Felipe Roitberg, BR; Daniel Goldstein, IL

16:30 - 16:35 1317MO - Non-OS endpoints in oncology: Strategies to bridge the gap in value
attribution by regulators, payors, oncologists, and patients
A. Fameli1, M. Glover2, B. Gutierrez2, A. Cimen3, L. Nelson2, S. Altimari3, T. Paulsson1,

1GSK, London, GB, 2GSK, Upper Providence, US, 3GSK, Zug, CH

16:35 - 16:40 1319MO - Actual patient access to innovative medicines in six European
countries
J. Vancoppenolle, N. Franzen, S. Koole, V. Retel, W. Van Harten, The Netherlands Cancer

Institute, Amsterdam, NL

16:40 - 16:45 1320MO - New oncologic drugs since 2010: Differences in approval and access
between the United States, Europe and Brazil
R. Barreto, A. Izidoro, A.B. Visentainer, R. Mireski, CEPON - Centro de Pesquisas

Oncológicas, Florianopolis, BR

D. Goldstein, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah

Tikva, IL

17:00 - 17:05 1321MO - Relevance index by cancer type: Trends and regional variation
analysis, 2016-2020, Republic of Korea
M. Ock1, J. Pyo2, H. Lee3, H. Jeong4, M.N. Lee5, 1Ulsan University Hospital, Ulsan, KR,
2Asan Medical Center - University of Ulsan, Seoul, KR, 3Korea Counseling Graduate

University, seoul, KR, 4University of Ulsan College of Medicine, Seoul, KR, 5korea
national open university, Seoul, KR

17:05 - 17:10 1322MO - Selection of a set of quality indicators (QIs) on the care pathway in
onco-hematology using a panel of experts
M. Di Palma1, M. Ferrua2, E. Minvielle3, 1Gustave Roussy - Cancer Campus, Villejuif, FR,

2CH d'Argenteuil, Villejuif, Cedex, FR, 3Institut Gustave Roussy, Villejuif, FR

17:10 - 17:15 1318MO - Time to diagnosis among patients with cancer in the US
M. Gitlin1, N. Mcgarvey1, N. Shivaprakash1, Z. Cong2, 1BluePath Solutions, Los Angeles,

US, 2*GRAIL LLC, a subsidiary of Illumina, Inc., *Currently held separate from Illumina

Inc. under the terms of the Interim Measures Order of the European Commission dated
29 October 2021, Menlo Park, US



Title: MSD - Advancements in Immuno-Oncology for Auditorium
Endometrial and Cervical Cancers
Chair(s): Robert Coleman, US

18:30 - 18:35 Introductions and Objectives

18:35 - 18:50 HPV Vaccination and Cervical Cancer: What Should an Oncologist Know
A. Giuliano, H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus,

Tampa, US

18:50 - 19:08 The role of immunotherapy in the management of cervical cancer
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

19:08 - 19:23 Panel Discussion – the role of oncologists in vaccination and the role of
immunotherapy in Gynecologic Cancer
A. Rodrigues1, R. Coleman2, I. Ray-Coquard3, A. Giuliano4, 1Faculdade de Medicina da

UFMG, Belo Horizonte, BR, 2US Oncology Research, The Woodlands, US, 3Centre Léon

Bérard, Lyon, FR, 4H. Lee Moffitt Cancer Center & Research Institute - Magnolia
Campus, Tampa, US

19:23 - 19:40 Treatment and management of advanced or recurrent endometrial cancer
A. Rodrigues, Faculdade de Medicina da UFMG, Belo Horizonte, BR

19:40 - 19:55 Q&A from audience
R. Coleman1, I. Ray-Coquard2, A. Rodrigues3, A. Giuliano4, 1US Oncology Research, The

Woodlands, US, 2Centre Léon Bérard, Lyon, FR, 3Faculdade de Medicina da UFMG, Belo

Horizonte, BR, 4H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus,
Tampa, US

19:55 - 20:00 Closing


Title: Novartis - Evidence-Based Practice in HR+/HER2− Advanced Auditorium
Breast Cancer: Illuminating the Treatment Path for Patients
Chair(s): Joseph Gligorov, FR

J. Gligorov, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital

Tenon, Paris, FR

18:35 - 19:00 First-Line Treatment of a Patient with HR+/HER2– ABC
S.X. Franco Millan, CTIC Centro de Tratamiento e Investigacion Sobre Cancer, Bogota,

CO

19:00 - 19:15 Round Table Discussion
J. Gligorov1, S. Chia2, S.X. Franco Millan3, 1Institut Universitaire de Cancérologie AP-HP.

Sorbonne Université, Hôpital Tenon, Paris, FR, 2BC Cancer Agency - Vancouver,
Vancouver, CA, 3CTIC Centro de Tratamiento e Investigacion Sobre Cancer, Bogota, CO

19:15 - 19:40 Second-Line Treatment of a Patient with HR+/HER2– ABC
S. Chia, BC Cancer Agency - Vancouver, Vancouver, CA

19:40 - 19:50 Round Table Discussion


19:50 - 20:00 Key Takeaways, Future Directions, and Live Q&A Session or Panel Discussion


Title: MSD - A Quantum Leap in Management of Auditorium
HNSCC with IO
Chair(s): Christophe Le Tourneau, FR


18:35 - 18:45 Current Management of HNSCC

18:45 - 19:05 Evolving Landscape in LA HNSCC
J.-P. Machiels, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE

19:05 - 19:25 Latest Updates in R/M HNSCC
D. Soulieres, CHUM - Centre Hospitalier de l’Université de Montréal, Montreal, CA

19:25 - 19:45 Case Discussions
C. Le Tourneau1, J.-P. Machiels2, D. Soulieres3, 1 Paris, FR, 2Cliniques Universitaires

Saint-Luc (UCLouvain Saint-Luc), Brussels, BE, 3CHUM - Centre Hospitalier de
l’Université de Montréal, Montreal, CA

19:45 - 20:00 Q&A and Closing Remarks
C. Le Tourneau1, J.-P. Machiels2, D. Soulieres3, 1 Paris, FR, 2Cliniques Universitaires

Saint-Luc (UCLouvain Saint-Luc), Brussels, BE, 3CHUM - Centre Hospitalier de
l’Université de Montréal, Montreal, CA


Title: Medscape Oncology Global - Targets of Antibody-Drug Honfleur
Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Auditorium
Future Prospects
Chair(s): Enriqueta Felip, ES

18:30 - 18:35 Personalizing Treatment in NSCLC: Recent Developments

18:35 - 18:55 Novel ADC Targets in NSCLC: Rationale and Diagnostic Considerations

18:55 - 19:20 Which Patients May Benefit From Emerging ADCs in NSCLC: Explaining the
Clinical Trial Data
E. Smit, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,

Amsterdam, NL

19:20 - 19:40 Preparing the Clinics and Future Prospects

19:40 - 19:58 Q&A Session
E. Felip1, M. Thomas2, E. Smit3, 1Vall d'Hebron University Hospital, Barcelona, ES,

2Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, 3NKI-AVL - Netherlands Cancer

19:58 - 20:00 Concluding Remarks


Title: Sanofi - ER+ / HER2- Breast Cancer: What’s next for Auditorium
patients & providers?
Chair(s): François Clément Bidard, FR


18:35 - 19:00 Opportunity to Improve on the Standard of Care in Adjuvant ER+/HER2- Breast
Cancer (BC)

19:00 - 19:20 Current Management Considerations in ER+/HER2- Metastatic BC

19:20 - 19:45 Oral SERDs & Novel ETs in ER+/HER2- Metastatic BC
A. Chan, Breast Cancer Research Centre BCRC - WA, Nedlands, AU

19:45 - 20:00 Live Q&A with the Panel
F.C. Bidard1, N. Harbeck2, A. Chan3, 1Institut Curie, Paris, FR, 2Ludwig Maximilians
University - Grosshadern, Munich, DE, 3Breast Cancer Research Centre BCRC - WA,
Nedlands, AU


Title: Astellas Pharma Europe Ltd - Navigating the evolving Quimper
landscape of locally advanced unresectable or metastatic G/GEJ Auditorium
adenocarcinoma
Chair(s): Hanneke van Laarhoven, NL

18:30 - 18:35 Welcome and introductions

18:35 - 18:55 The current landscape for locally advanced unresectable or metastatic G/GEJ
adenocarcinoma

18:55 - 19:20 Emerging treatments for locally advanced unresectable or metastatic G/GEJ
adenocarcinoma
E. Van Cutsem, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg,

Leuven, BE

19:20 - 19:40 Working together in an evolving therapeutic landscape
H. Van Laarhoven1, M. Iglesias2, E. Van Cutsem3, 1Academic Medical Center, University

of Amsterdam, Amsterdam, NL, 2IMIM - Institut Hospital del Mar d'Investigacions

Mediques, Barcelona, ES, 3UZ Leuven - University Hospitals Leuven - Campus
Gasthuisberg, Leuven, BE

19:40 - 19:55 Q&A session
H. Van Laarhoven1, M. Iglesias2, E. Van Cutsem3, 1Academic Medical Center, University

of Amsterdam, Amsterdam, NL, 2IMIM - Institut Hospital del Mar d'Investigacions

Mediques, Barcelona, ES, 3UZ Leuven - University Hospitals Leuven - Campus
Gasthuisberg, Leuven, BE

19:55 - 20:00 Meeting summary and close


Title: AstraZeneca - Navigating the real-world use of PARP Auditorium
inhibitors in BRCAm mCRPC: a practical discussion
Chair(s): Neal Shore, US

18:30 - 18:32 Chair’s welcome and introduction
N. Shore, Atlantic Urology Clinics, LLC, Myrtle Beach, US

18:32 - 18:42 Why are PARP inhibitors relevant in the treatment of prostate cancer?
N. Shore, Atlantic Urology Clinics, LLC, Myrtle Beach, US

18:42 - 18:52 What data support the clinical activity of PARP inhibitors in mCRPC?
N. Mehra, Radboud University Medical Center, Nijmegen, Nijmegen, NL

18:52 - 19:12 Case-based discussion 1: personalising patient care in BRCAm prostate cancer
N. Shore1, N. Mehra2, A. Armstrong3, 1Atlantic Urology Clinics, LLC, Myrtle Beach, US,
2Radboud University Medical Center, Nijmegen, Nijmegen, NL, 3Duke Cancer Center,
Durham, US

19:12 - 19:32 Case-based discussion 2: practical considerations for the real-world use of PARP
inhibitors in mCRPC
Durham, US

19:32 - 19:47 Evolving landscape of PARP inhibitors in mCRPC
A. Armstrong, Duke Cancer Center, Durham, US

19:47 - 20:00 Summary and Q&A
Durham, US


18:30 - 20:00 Type: Industry Satellite Symposium 7.3.U -
Title: Bristol Myers Squibb - Navigating the Integration of Immuno- Urval
Oncology Into the Perioperative Muscle-Invasive Urothelial Auditorium
Carcinoma Treatment Landscape
Chair(s): Andrea Necchi, IT

A. Necchi, IRCCS Ospedale San Raffaele, Milan, IT

18:35 - 18:50 The MIUC Treatment Landscape in 2022
M. Roupret, Sorbonne Université - Site Saint-Antoine, Paris, Cedex 12, FR

18:50 - 19:05 Opportunities for I-O Use in the Perioperative Setting
M. Retz, Bristol-Myers Squibb GmbH&Co. KGaA, Munich, DE

19:05 - 19:20 Optimising Patient Treatment: Perspectives on the Future Treatment Landscape

19:20 - 19:40 Interactive Multidisciplinary Team Meeting
A. Necchi1, M. Roupret2, M. Retz3, 1IRCCS Ospedale San Raffaele, Milan, IT, 2Sorbonne
Université - Site Saint-Antoine, Paris, Cedex 12, FR, 3Bristol-Myers Squibb GmbH&Co.
KGaA, Munich, DE

19:40 - 19:55 Q&A
A. Necchi1, M. Roupret2, M. Retz3, 1IRCCS Ospedale San Raffaele, Milan, IT, 2Sorbonne
Université - Site Saint-Antoine, Paris, Cedex 12, FR, 3Bristol-Myers Squibb GmbH&Co.
KGaA, Munich, DE

19:55 - 20:00 Summary and Close


13.09.2022
09:00 - 12:40 Type: Congress highlights 4.A - Antibes Auditorium
Title: Congress Highlights 1
Chair(s): Giuseppe Curigliano, IT; John Haanen, NL

09:00 - 09:20 Breast cancer, early stage
A. Bosch, Lund University - Faculty of Medicine, Malmo, SE

09:20 - 09:40 Breast cancer, metastatic
S. Dawood, Mediclinic City Hospital, Dubai, AE

09:40 - 10:00 Gynaecological cancers
C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU

10:00 - 10:20 CNS tumours
D. Brandsma, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,

Amsterdam, NL

10:20 - 10:40 Policy and preventive strategies

10:40 - 11:00 Break

11:00 - 11:20 Basic science & translational research
C. Ottensmeier, University of Liverpool - School of Medicine, Liverpool, GB

11:20 - 11:40 Developmental therapeutics
R. Baird, Addenbrooke's Hospital, Cambridge, GB

11:40 - 12:00 Genitourinary tumours, prostate
A. Omlin, OnkoZentrum Zürich, Zurich, CH

12:00 - 12:20 Genitourinary tumours, non-prostate
M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE

12:20 - 12:40 Investigational immunotherapy
I. Pires Da Silva, Melanoma Institute Australia, Wollstonecraft, AU


09:00 - 12:40 Type: Congress highlights 4.B - Brest Auditorium
Title: Congress Highlights 2
Chair(s): Amanda Psyrri, GR; Florian Lordick, DE

09:00 - 09:20 Melanoma and other skin tumours
T. Petrella, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA

09:20 - 09:40 Sarcoma
T.W.-W. Chen, NTU - National Taiwan University - College of Medicine, Taipei City, TW

09:40 - 10:00 Head and neck cancer
J.-P. Machiels, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE

10:00 - 10:20 Supportive and palliative care
C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

10:20 - 10:40 Haematological malignancies
I. Glimelius, Akademiska Sjukhuset Uppsala, Uppsala, SE

10:40 - 11:00 Break

11:00 - 11:20 Gastrointestinal tumours, lower digestive
M. Gerlinger, ICR - Institute of Cancer Research, London, GB

11:20 - 11:40 Gastrointestinal tumours, upper digestive

11:40 - 12:00 NETs and endocrine tumours

12:00 - 12:20 Non-metastatic NSCLC and other thoracic malignancies
M. Tsuboi, National Cancer Center Hospital East, Kashiwa, JP

12:20 - 12:40 NSCLC, metastatic
J. Lin, MGH - Massachusetts General Hospital, Boston, US


Final Programme Esmo2022 PDF

Uploaded by

Copyright:

Available Formats

Final Programme Esmo2022 PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Final Programme Esmo2022 PDF

Uploaded by

Copyright:

Available Formats

09.09.

F. Barlesi1, J. Naidoo2, S. Gadgeel3, 1Gustave Roussy - Cancer Campus, Villejuif, FR,

Last update: 09-09-2022 11:42:18am Programme

11:20 - 11:45 Discussion and conclusions

Last update: 09-09-2022 11:42:18am Programme

S. Lorenzen1, A. Adenis2, H. Van Laarhoven3, 1Klinikum Rechts der Isar - Technische

S. Lorenzen1, A. Adenis2, H. Van Laarhoven3, 1Klinikum Rechts der Isar - Technische

S. Lorenzen1, A. Adenis2, H. Van Laarhoven3, 1Klinikum Rechts der Isar - Technische

S. Lorenzen1, A. Adenis2, H. Van Laarhoven3, 1Klinikum Rechts der Isar - Technische

Last update: 09-09-2022 11:42:18am Programme

A. Prat1, P. Tarantino2, S. Modi3, 1Hospital Clinic y Provincial de Barcelona, Barcelona,

Last update: 09-09-2022 11:42:18am Programme

E. Samalin-Scalzi, ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR

Last update: 09-09-2022 11:42:18am Programme

J. Mazieres1, N. Leighl2, J. Vansteenkiste3, F. Länger4, 1Centre Hospitalier Universitaire

Last update: 09-09-2022 11:42:18am Programme

A. Psyrri, Attikon University Hospital, Haidari, GR

Last update: 09-09-2022 11:42:18am Programme

14:35 - 14:50 Immunomodulatory strategies for non-MSI-H metastatic colorectal cancer

Last update: 09-09-2022 11:42:18am Programme

I. Ray-Coquard1, A. Leary2, S. Pignata3, C. Cropet1, A.J. Gonzalez Martin4, G. Bogner5, H.

Ginecologia Oncologica - Fondazione Policlinico Universitario Gemelli Università

P. Disilvestro1, S. Banerjee2, N. Colombo3, G. Scambia4, B.-G. Kim5, A. Oaknin6, M.

Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, IT,

Cambridge, GB, 18AstraZeneca, Gaithersburg, US, 19Stephenson Oklahoma Cancer

A. Oza1, A. Lisyanskaya2, A. Fedenko3, A. De Melo4, Y. Shparik5, I. Bondarenko6, N.

J.E. Kurtz1, E. Pujade-Lauraine2, A. Oaknin3, L. Belin4, I. Tsibulak5, D. Cibula6, I.

department, Heilbronn, DE, 11Medical Oncology department, El Palmar, ES, 12Medicine

K. Fujiwara1, S. Nishio2, K. Yamamoto3, H. Fujiwara4, H. Itagaki5, T. Nagai6, H. Takano7,

Last update: 09-09-2022 11:42:18am Programme

Last update: 09-09-2022 11:42:18am Programme

Last update: 09-09-2022 11:42:18am Programme

S. Patel, MD Anderson Cancer Center, Houston, US

A. Brenner1, W. Phillips2, A. Bao3, M.H. Hedrick4, J. Michalek2, N. Lafrance4, T. Patel5, J.

J. Campian1, O. Butt2, J. Huang3, J. Luo3, Y. Tao3, R. Strowd4, D. Hissim4, S. Kizilbash1, C.

Last update: 09-09-2022 11:42:18am Programme

S. Cabezas-Camarero1, R. Pérez-Alfayate1, V. García-Barberán1, M. Gandía2, P. García-

P. Wen1, J. De Groot2, J. Battiste3, S. Goldlust4, D. Damek5, B. Ellingson6, J. Garner7, J.

University of California, Los Angeles, US

Last update: 09-09-2022 11:42:18am Programme

Last update: 09-09-2022 11:42:18am Programme

Last update: 09-09-2022 11:42:18am Programme

Last update: 09-09-2022 11:42:18am Programme

M. Lambertini1, A. Prat2, 1IRCCS AOU San Martino - IST-Istituto Nazionale per la

S. Turajlic1, A. Matikas2, 1The Royal Marsden Hospital - Chelsea, London, GB,

M.E. Elez Fernandez1, R. Sanchez Bayona2, 1Vall d'Hebron University Hospital,

C. Serrano1, K.H.J. Lim2, 1Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center,

A. Ilbawi1, E. Mariamidze2, 1WHO - World Health Organization, Geneva, CH, 2Todua

Last update: 09-09-2022 11:42:18am Programme

G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT

M. Goetz1, M. Toi2, J. Huober3, J. Sohn4, O. Tredan5, I.H. Park6, M. Campone7, S.C.

Last update: 09-09-2022 11:42:18am Programme

of China Medical University/Liaoning Cancer Hospital, Shenyang, CN, 5The First

Changchun, CN, 9Henan Breast Cancer Center/the affiliated Cancer Hospital of

H. Rugo1, A. Bardia2, F. Marmé3, J. Cortés4, P. Schmid5, D. Loirat6, O. Tredan7, E.

Medical School, Boston, US

Last update: 09-09-2022 11:42:18am Programme

A. Marra1, A. Gazzo1, A. Gupta1, P. Selenica1, E. Da Silva1, F. Pareja1, X. Pei1, Y. Zhu1, P.

L. Buisseret1, D. Loirat2, P. Aftimos3, K. Punie4, C. Maurer5, V. Debien1, A. Goncalves6, F.